Entries |
Document | Title | Date |
20080199524 | Eyedrops containing particulate agar - It is intended to prepare a composition which contains polysaccharide at a high concentration and yet remains in the state of a liquid having low viscosity to thereby provide drugs, eyedrops, foods, cosmetics, toiletry products having a novel texture or function. The composition in the state of a liquid having low viscosity is obtained by heating polysaccharide at a high concentration in a water-containing liquid and then cooling under applying a shear force, which enables the provision of the above-described drugs. The composition is usable as an aqueous drug vehicle which is free from gelling due to temperature changes during storage and easily applied without pouring and/or streaming down. Eyedrops containing agar have an effect of enhancing ocular drug penetration. Eyedrops containing particulate agar maintain a low viscosity and, achieve easy instillation and impart a favorable feel in instillation. | 08-21-2008 |
20080199525 | Micronized wood preservative formulations - The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component and an organic biocide, the inorganic component or the organic biocide or both are present as micronized particles. When compositions of the present invention are used for preservation of wood, there is minimal leaching of the metal and biocide from the wood. | 08-21-2008 |
20080206341 | Lipid Nanoparticles as Vehicles for Nucleic Acids, Process for Their Preparation and Use - The invention relates to solid lipid nanoparticles composed of lipid material and containing, as bioactive molecule, a nucleic acid, preferably an antisense oligonucleotide, preferably modified by chemical methods to achieve a greater resistance to endo- and exo-nucleases, and to the process for preparation of the nanoparticles. In the present invention, the efficiency of the delivery system represented by nanoparticles containing synthetic or natural polynucleotides allows the use of such system for transfection. The particles are especially effective in the treatment of diseases of the posterior segment of the eye (such as diabetic retinopathy, macular degeneration, etc.) and in angiogenesis. | 08-28-2008 |
20080206342 | Compositions and Methods For Increasing the Bioavailability of Pulmonarily Administered Insulin - A pharmaceutical composition suitable for pulmonary delivery includes insulin and EDTA. The presence of EDTA is effective to increase the relative pulmonary bioavailability of the insulin compared to the relative pulmonary bioavailability exhibited by a composition having the same components but absent the EDTA. The composition is in dry powder form. A method of treating or ameliorating diabetes or a related condition in a mammal includes administering by inhalation a pharmacologically effective amount of the composition. A method of improving the pulmonary bioavailability of an insulin composition includes adding EDTA to an insulin composition suitable for pulmonary delivery, wherein the composition is in dry powder form. | 08-28-2008 |
20080206343 | Hepatocytes and Chondrocytes from Adherent Placental StemCells; And CD34+ ,CD45- Placental Stem Cell-Enriched Cell Populations - Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34 | 08-28-2008 |
20080206344 | ENDOCYTOTIC PARTICLES - Endocytosis of an active agent into a cell having surface receptors can be enhanced by using particles that have a radius no less than an endocytotic threshold determined based on a surface density of the receptors, a surface density of the moieties and interaction parameters that include at least one of a receptor-moiety spring constant and a non-specific interaction strength. | 08-28-2008 |
20080206345 | Methods for Control of Soil-Dwelling Pests and/or Soil-Borne Diseases - A method for the control of soil-dwelling pests and/or soil-borne diseases comprising treating a plant propagation material with an effective amount of the pesticidal composition and/or applying an effective amount of a pesticidal composition to a locus where control is desired, provided that the composition comprises, as active ingredient, one or more pesticides (A) having a water solubility of at most 100 μg/litre, at 25° C. at neutral pH, and at least one formulation auxiliary, wherein the size of particles in the composition is in the range 3.60 μm to 0.70 μm at X | 08-28-2008 |
20080206346 | PREPARATION OF POWDER AGGLOMERATES - The invention relates to a method of producing an agglomerate of drug and solid binder. The process involves producing individual agglomerate particles and then converting the convertible amorphous content of same, following agglomeration, by the application of, for example, moisture. Agglomerates capable of conversion as well as the finished agglomerates and oral and nasal dosing systems including same are also contemplated. The process produces agglomerates which are rugged but which will produce an acceptable fine particle fraction during dosing. | 08-28-2008 |
20080213372 | Gel and Apparatus for Cleaning and Deodorizing Fluids - A gel for cleaning and deodorizing air includes an organic binder with ultraviolet light permeable polymeric molecules and particles of inorganic semi-conductors. The gel includes acrylic molecules, a polar diluent and an ultraviolet light inert charge including particles of silica, of rutile cristalline form of titanium oxide and/or of clay. | 09-04-2008 |
20080213373 | Particles for Treatment of Pulmonary Infection - Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration. Optionally, the nanoparticles are coated, such as with a surfactant or protein coating. The formulation may be administered as a powder or administered as a solution or via an enteral or non-pulmonary parenteral route of administration. The formulation is preferably administered as a pulmonary formulation. In the preferred embodiment for treatment of TB, the vaccine is a BCG vaccine that is stable at room temperature, or is an antibiotic effective against TB, such as capreomycin or PA-824, loaded at a very high percentage into the microparticles or nanoparticles. In one embodiment, a patient is treated with formulations delivering both antibiotic and vaccine. | 09-04-2008 |
20080213374 | NANOPARTICULATE SORAFENIB FORMULATIONS - The present invention is directed to compositions comprising a nanoparticulate sorafenib, or a salt, such as a sorafenib tosylate, or derivative thereof, having improved bioavailability. The nanoparticulate sorafenib particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of cancer, renal cancer, and related diseases. | 09-04-2008 |
20080213375 | Drying of Drug-Containing Particles - A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes, the secondary drying process utilizing a combination of vacuum, agitation, and a stripping gas. | 09-04-2008 |
20080213376 | Medicament that is Intended for Oral Administration, Comprising a Cyclooxygenase-2 Inhibitor, and Preparation Method Thereof - The invention relates to a medicament which is intended for oral administration, which comprises a cyclooxygenase-2 inhibitor and which has improved bioavailability, and to a method of preparing said medicament. The inventive medicament comprises an agglomerate based on inert solid particles based on at least one excipient, said agglomerate comprising a cyclooxygenase-2 inhibitor and at least one hydrophilic polymer. According to the invention, the agglomerate comprises a spray which is applied to the aforementioned particles, consisting of a solution or suspension of micronized grains of the inhibitor in said polymer(s), in order to agglomerate said particles. The inventive method essentially comprises the following steps, namely: (i) the preparation of a sprayable liquid that is based on the micronized grains of said inhibitor in solution or in suspension in at least one hydrophilic polymer; and (ii) the spraying of the liquid onto the solid particles, in order to obtain the agglomerate by means of wet granulation, said agglomerate comprising the grain solution or suspension spray. | 09-04-2008 |
20080213377 | Delivery of Nanoparticles and/or Agents to Cells - The present invention provides systems, methods, and compositions for targeted delivery of nanoparticles and/or agents to tissues, cells, and/or subcellular locales. In general, compositions comprise a nanoparticle (e.g. quantum dot, polymeric particle, etc.), at least one modulating entity (such as a targeting moiety, transfection reagent, protective entity, etc.), and at least one agent to be delivered (e.g. therapeutic, prophylactic, and/or diagnostic agent). The present invention provides methods of making and using nanoparticle entities in accordance with the present invention. | 09-04-2008 |
20080213378 | Nanoparticulate statin formulations and novel statin combinations - The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught. | 09-04-2008 |
20080220069 | Long Acting Injectable Crystal Formulations of Estradiol Metabolites and Methods of Using Same - The present invention provides sustained release formulations of estradiol metabolites whereby the in vivo pharmacokinetics are manipulated by a method selected from the group consisting of chemical modification, crystal packing formation, particle size or a combination thereof. Such compositions are useful in the long-term treatment of a wide variety of diseases. | 09-11-2008 |
20080220070 | Controlled release system and manufacturing method thereof - A controlled release system and manufacturing method thereof. The method comprises providing a first aqueous solution containing a hydrophilic drug and an alkaline agent, providing an organic solution containing a hydrophobic molecule, providing a second aqueous solution containing a hydrophilic surfactant, mixing the first hydrophilic solution with the organic solution to form a first emulsion, and mixing the first emulsion with a second aqueous solution to form a second emulsion containing delayed-release microsphere. | 09-11-2008 |
20080220071 | Aqueous Suspensions of Poorly Water-Soluble and Water-Insoluble Active Ingredients and Drying Powder Produced Therefrom - Aqueous suspensions comprising: (a) at least one sparingly water-soluble or water-insoluble active agent in the form of nanoparticulate particles; (b) at least one whey component selected from the group consisting of whey proteins, whey protein hydrolysates, and mixtures thereof; and (c) at least one sucrose fatty acid ester having an HLB value of 10 to 18; processes for preparing such aqueous suspensions; powders and oil-miscible compositions prepared therefrom and uses therefore. | 09-11-2008 |
20080220072 | BIOLOGIC MODULATIONS WITH NANOPARTICLES - Certain aspects of the invention relate to the use of small particles in biological systems, including the delivery of biologically active agents to cells or tissues using nanoparticles of less than about 200 nm in approximate diameter. Embodiments include collection of particles having a bioactive component, a surfactant molecule, a biocompatible polymer, and a cell recognition component, wherein the cell recognition component has a binding affinity for a cell recognition target. Compositions and methods of use are also set forth, including the use of antisense directed against Protein Kinase CK2, CK2alpha, CK2 alpha′, and CK2 beta. | 09-11-2008 |
20080220073 | The Treatment of Respiratory Diseases - A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours. | 09-11-2008 |
20080220074 | GAMMA RADIATION STERILIZED NANOPARTICULATE DOCETAXEL COMPOSITIONS AND METHODS OF MAKING SAME - Nanoparticulate compositions comprising docetaxel or a salt, derivative, conjugate or analogue thereof, wherein the compositions are terminally sterilized via gamma radiation, are described, as well as methods of making and using such compositions. | 09-11-2008 |
20080220075 | Nanoparticulate compositions of angiogenesis inhibitors - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions. | 09-11-2008 |
20080220076 | Active Agent Formulations, Methods of Making, and Methods of Use - Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof, are also disclosed. | 09-11-2008 |
20080220077 | MICROSPHERES FOR ACTIVE EMBOLIZATION - The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) for use in embolization drug therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions. | 09-11-2008 |
20080226727 | Water-In-Silicone Oil Emulsion for Use as a Sunscreen Product - A water-in-silicone oil emulsion contains (i) in the range from 0.1 to 25% by weight of particles of metal oxide having a median particle volume diameter in dispersion in the range from 18 to 32 nm, (ii) 5 to 60% by weight of silicone oil, and (iii) greater than 20% by weight of water. The metal oxide particles are preferably incorporated into the emulsion in the form of an aqueous dispersion. The emulsion exhibits good skin feel, effective UV protection, stability and improved transparency. | 09-18-2008 |
20080226728 | Antimicrobial Nanoparticulate Additives Forming Non-Leachable Sustained Antimicrobial Polymeric Compositions - The present invention provides a particle comprising at least one aliphatic polymer having anti-microbially active quaternary ammonium groups chemically bound thereto. The particle of the invention may be used to inhibit populations of microorganisms and biofilms. Also provided are methods for the preparation of such particles and uses thereof for the inhibition of microorganisms. | 09-18-2008 |
20080226729 | STABLE POWDER FORMULATIONS OF ALUM-ADSORBED VACCINES - The present invention is directed to methods for preparing a stable powder formulation of an alum-adsorbed vaccine. The methods comprise atomizing a liquid formulation comprising an immunogen adsorbed onto an aluminum adjuvant to produce an atomized formulation, freezing the atomized formulation to produce frozen particles, and drying the frozen particles to produce dried powder particles. Pharmaceutical compositions comprising a stable powder formulation of an alum-adsorbed vaccine are also disclosed herein. The pharmaceutical compositions are stable at high temperatures and can be reconstituted in a pharmaceutically acceptable carrier to produce a reconstituted liquid vaccine that exhibits little or no particle agglomeration and retains immunogenicity. Methods of using the alum-adsorbed vaccine compositions for preventing and treating a disease in a subject, wherein the disease is associated with the particular immunogen, are further provided. | 09-18-2008 |
20080226730 | PARTICLES FOR INHALATION HAVING RAPID RELEASE PROPERTIES - The invention generally relates to formulations having particles comprising phospholipids, bioactive agent and excipients and the pulmonary delivery thereof. Dry powder inhaled insulin formulations are disclosed. Improved formulations comprising DPPC, insulin and sodium citrate which are useful in the treatment of diabetes are disclosed. Also, the invention relates to a method of for the pulmonary delivery of a bioactive agent comprising administering to the respiratory tract of a patient in need of treatment, or diagnosis an effective amount of particles comprising a bioactive agent or any combination thereof in association, wherein release of the agent from the administered particles occurs in a rapid fashion. | 09-18-2008 |
20080226731 | Pharmaceutical Compositions Comprising I Matinib and a Release Retardant - Sustained release pharmaceutical compositions that contain imatinib or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions further contain a release retardant, for example a water soluble, a water swellable and/or a water insoluble polymer. The present invention also features a particularly useful process of making such sustained release pharmaceutical compositions by using an extruder. | 09-18-2008 |
20080226732 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions. | 09-18-2008 |
20080226733 | SPATIAL ARRANGEMENT OF PARTICLES IN A DRINKING DEVICE FOR ORAL DELIVERY OF PHARMACEUTICALS - The present invention relates to spatially arranging a plurality of particles in a device for the oral delivery of a pharmaceutical. In particular, the plurality of particles is utilized for the oral delivery of a pharmaceutical to a subject via the drinking device. | 09-18-2008 |
20080226735 | RARE EARTH METAL COMPOSITIONS FOR TREATING HYPERPHOSPHATEMIA AND RELATED METHODS - Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water. | 09-18-2008 |
20080226736 | Inhalatory Pharmaceutical Compositions in Form of Dry Powders, Solutions or Suspensions Obtained From the Same and Process for their Preparation - Inhalatory pharmaceutical composition comprising a drug, a soluble excipient and a surfactant, characterized by: said soluble excipient is present in an amount between 10% and less than 100% by weight; —the weight ratio between said surfactant and said drug is between 0.01 and 10; —the particle size of at least 50% of the particles of said powder is below 5 μm; —the bulk density d | 09-18-2008 |
20080226737 | Use of Calcitonin For the Treatment of Ra - The present invention relates to a novel use of calcitonin in rheumatoid arthritis, and to methods of treating and/or preventing rheumatoid arthritis and conditions associated therewith in mammals, particularly humans. In particular, a method is provided of preventing or/and treating rheumatoid arthritis in a patient in need thereof comprising administering to said patient a therapeutically effective amount of calcitonin, e.g. salmon calcitonin in free form or salt form, in a pharmaceutically acceptable oral delivery form, wherein the therapeutically effective amount of a calcitonin is delivered orally in a composition comprising the calcitonin and a delivery agent for calcitonin. | 09-18-2008 |
20080233196 | INJECTABLE STERILE PHARMACEUTICAL COMPOSITION WITH PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM AS ACTIVE PRINCIPLES - A sterile pharmaceutical composition having as its active principles piperacillin sodium and tazobactam sodium of substantially the same density, mixed with sodium bicarbonate. The mixture is soluble in water to give injectable reconstituted solutions having high stability with time. | 09-25-2008 |
20080241251 | Method of Producing Microparticles - A method of producing microparticles having a median diameter up to 100 μm and the microparticles so produced are described. The method includes the steps of providing a solvent having a bioactive dispersed or dissolved therein and a vehicle dissolved therein, carrying out an emulsification in a non-solvent phase to produce an emulsion containing the bioactive and the vehicle in a solvent phase, and evaporating the solvent to leave the microparticles, wherein a mixture of at least two surfactants is employed to stabilize the emulsion and wherein the mixture has a hydrophilic-lipophilic balance (HLB) of up to 8. | 10-02-2008 |
20080241252 | METHODS AND COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION TO TREAT OCULAR CONDITIONS - Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include TKI component solutions or particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps. | 10-02-2008 |
20080241253 | Formulations for Spray-Drying Large Porous Particles - Particles having a tap density less than about 0.4 g/cm3 are formed by spray drying from a colloidal solution including a carboxylic acid or salt thereof, a phospholipid, a divalent salt and a solvent such as an aqueous-organic solvent. The colloidal solution can also include a therapeutic, prophylactic or diagnostic agent. Preferred carboxylic acids include at least two carboxyl groups. Preferred phospholipids include phosphatidylcholines, phosphatidylethanolamines, phosphatidylglycerols, phophstidylserines, phosphatidylinositols and combinations thereof. The particles are suitable for pulmonary delivery. | 10-02-2008 |
20080241254 | PHARMACEUTICAL COMPOSITION COMPRISING ATOVAQUONE PARTICLES - The present invention relates to atovaquone particles having d | 10-02-2008 |
20080241255 | DEVICE AND METHOD FOR DELIVERY OF A MEDICAMENT - The disclosure relates to a method of enhancing nicotine or other medicament concentrations in a gaseous carrier. The methods are adaptable to the delivery of nicotine or other medicaments for therapeutic effect in various diseases, in particular nicotine for tobacco product use cessation, substitution and/or harm reduction. The disclosure further relates various devices and device design principles for practicing these methods. | 10-02-2008 |
20080241256 | TARGETED ACTIVE AGENT DELIVERY SYSTEM BASED ON CALCIUM PHOSPHATE NANOPARTICLES - Calcium phosphate nanoparticle active agent conjugates are described. Specifically, anticancer agent conjugates are prepared which are suitable for targeted active agent delivery to tumor cells and lymphatics for the treatment of cancer and the treatment or prevention of cancer metastasis. | 10-02-2008 |
20080241257 | Biodegradable Nanoparticles Incorporating Highly Hydrophilic Positively Charged Drugs - Nanoparticles of a biodegradable polymer containing a hydrophilic, cationic drug, like streptomycin, and preparations containing the same, are disclosed. Pharmaceutical preparations containing the nanoparticles are administered, preferably orally, to individuals suffering from a disease or condition, and the nanoparticles release the drug, in vivo, to treat the disease or condition. | 10-02-2008 |
20080241258 | TREATMENT OF DISEASES WITH NANOPARTICLES HAVING A SIZE-DEPENDENT CYTOTOXICITY - The present invention relates to the use of at least one gold nanocluster compound in the manufacture of a pharmaceutical composition or medicament for the prophylactic and/or therapeutic (curative) treatment of a disease, especially a tumor and/or cancer disease. The gold nanocluster compound having a defined particle size, especially a defined size of the core of said gold nanocluster compound, the size ranging from 0.5 nm to 10 nm, the outer limits of this range being included. Especially, the gold nanocluster compounds used possess size-dependent cytotoxic properties, stimulating or inducing cellular death when treating and/or contacting respective cells, especially tumor and/or cancer cells, with the gold nanocluster compounds either via apoptosis or via necrosis, depending on the respective gold cluster size or core size. | 10-02-2008 |
20080241259 | Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof - The present invention relates to a method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of:
| 10-02-2008 |
20080241260 | Compositions for Enhanced Absorption of Biologically Active Agents - The present invention relates to a novel pharmaceutical composition comprising polymeric nanoparticles with one or more biologically active agent/s for mucosal and or oral administration. Said polymeric nanoparticles further comprise of an agent that enhances absorption of said biologically active agent/s. The compositions are formulated as powders, sprays, suspension, freeze dried powders for reconstitution, tablets, capsules, pellets, wafers, patches, films, rods, pessaries, suppositories, aerosols, bioadhesive gels, creams. | 10-02-2008 |
20080241261 | PROCESS FOR PRODUCING SOLID ORAL DOSAGE FORMS WITH SUSTAINED RELEASE OF ACTIVE INGREDIENT - The present invention relates to a process for producing solid oral dosage forms with sustained release of active ingredient, comprising at least one active ingredient, a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone, where appropriate, water-soluble polymers or lipophilic additives and, where appropriate, other conventional excipients, wherein this mixture or parts of this mixture are granulated by heating to from 40° C. to 130° C., and the granules are, after admixture with conventional excipients, subsequently tabletted. | 10-02-2008 |
20080248118 | METHOD AND COMPOSITION FOR INHIBITING REPERFUSION INJURY IN THE BRAIN - The present invention relates to a method for inhibiting reperfusion injury in the brain. The method involve injecting via the carotid artery or jugular vein an antioxidant-loaded nanoparticle. A nanoparticle formulation containing an inert plasticizer is also provided for sustained release of an active agent. | 10-09-2008 |
20080248119 | Production method of drug containing composite particle - A strong pressure and a strong shearing force are exerted to a mixture, constituted of two kinds or more of powder materials including a drug powder, while causing the mixture to pass between a press section ( | 10-09-2008 |
20080248120 | Aerosol Composition and Method - A method of dispensing periodic metered doses of a single phase aerosol composition wherein: the aerosol composition comprises a propellant and at least one active component selected from the group comprising fragrances, perfumes, air fresheners, deodorants and sanitisers; the metered dose spray rate is between 0.1 and 2 g/s of aerosol composition; and the mean particle size of each dose of the aerosol composition is between 1 μm and 40 μm. | 10-09-2008 |
20080248121 | MULTIPLE EMULSION CONTAINING A TENSIONING AGENT - The present invention relates to a W/O/W multiple emulsion containing an inner aqueous phase, an oily phase and an outer aqueous phase, the emulsion containing at least one tensioning agent present at least in the inner aqueous phase of the emulsion. The invention also relates to compositions containing the emulsion and to the cosmetic use of these compositions and emulsions for, e.g., smoothing out wrinkles and fine lines and/or for restoring tautness to the skin. | 10-09-2008 |
20080254126 | Composition comprising nanoparticle ginkgo biloba extract with the effect of brain function activation - To supply the | 10-16-2008 |
20080254127 | Inhalation particles incorporating a combination of two or more active ingredients - Crystalline spherical inhalation particles incorporating a combination of two or more different active ingredients and a process for the preparation thereof. The particles have a narrow particle size distribution, rough surfaces and improved stability. The inhalation particles of the invention are particularly useful in the administration of a combination medicament, e.g. a combination of an anti-inflammatory agent and a bronchodilator, by inhalation in the treatment of asthma and other respiratory disorders. | 10-16-2008 |
20080254128 | Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same - The present invention provides a method of continuous precipitation and isolation of an amorphous solid particulate form of 3-[2-(3-tert-Butyl-ureido)-3,3-dimethyl-butyryl]-6,6-dimethyl-3-aza-bicyclo[3.1.0]hexane-2-carboxylic acid (2-carbamoyl-1-cyclobutylmethyl-2-oxo-ethyl)-amide having controlled physical properties. The present invention provides also pharmaceutical formulations comprising the precipitated compound. | 10-16-2008 |
20080254129 | Use of avian anti-methanogen antibodies for reduction of methane production - Herein, it is shown that strong specific anti-methanogen avian antibodies can be produced when chickens are immunized with an optimal dose of methane producing bacterial antigen (methanogen) formulated with an appropriate adjuvant. The antibodies can in turn be used to reduce methane gas production from an animal by administering an effective amount of the anti-methanogen antibodies to the animal, thereby reducing methane gas evolved by the animal compared to an untreated or mock treated control animal of similar age and condition. | 10-16-2008 |
20080254130 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction - The present invention relates to a topical method of treatment for dysfunction of certain dermal enzymes, and the treatment of skin condition or disorder caused by said dysfunction. The said method of treatment consists of (i) an extra-cellular, matrix metalloprotease regulating agent, and (ii) an intra-cellular ubiquitin—proteasome regulating agent, and (iii) an epidermal melanocyte-regulating agent; and, wherein, said extra-cellular agent, said intracellular agent, and said epidermal agent can, surprisingly and unexpectedly, be a single multi-function compound having chemical formula (I). Additionally, the method of the present invention provides treatment of skin condition or disorder caused by dysfunction of said dermal enzymes; wherein said skin disorder is skin aging, skin wrinkles, dark skin, age spots, acne, skin inflammation, loss of cellular antioxidants, loss of collagen, loss of skin pliability, loss of skin suppleness, oily skin, or a combination thereof: | 10-16-2008 |
20080260838 | GLUCAGON-LIKE PEPTIDE 1 (GLP-1) PHARMACEUTICAL FORMULATIONS - A composition is disclosed comprising glucagon-like peptide 1 (GLP-1) particles in combination with diketopiperazine (DKP) that is stable both in vitro and in vivo. The composition has utility as a pharmaceutical formulation for treating diseases such as diabetes, cancers, and obesity but is not limited to such diseases or conditions. In particularly, the composition has utility as a pharmaceutical formulation for pulmonary delivery. | 10-23-2008 |
20080260839 | Pulmonary Formulation - The use of microparticles of silicon and particularly resorbable and/or photoluminescent silicon in the preparation of a medicament for nasal or pulmonary delivery. Aerosol formulations and their preparation are also described and claimed. These formulations may be used for example as carriers for pharmaceutical compounds as well as having diagnostic applications. | 10-23-2008 |
20080260840 | Suspension formulations of insulinotropic peptides and uses thereof - A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described. | 10-23-2008 |
20080260841 | Micronized wood preservative formulations - The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component and an organic biocide, the inorganic component or the organic biocide or both are present as micronized particles. When compositions of the present invention are used for preservation of wood, there is minimal leaching of the metal and biocide from the wood. | 10-23-2008 |
20080268058 | PARTICLES - Particles, such as particles including a polymer including vinyl formal monomer units, and related compositions and methods, are disclosed. | 10-30-2008 |
20080268059 | IMMOBILIZING PARTICLES ONTO SURFACES - A method for immobilizing micro-particles, nano-particles or combinations thereof onto a surface is disclosed. The method includes distributing the micro-particles, nano-particles or combinations thereof onto the surface. The surface and the particles are exposed to thermal treatment, vapor treatment or combinations thereof, thereby adhering at least some of the micro-particles, nano-particles or combinations thereof to the surface. Materials including such immobilized micro-particles, nano-particles or combinations thereof are also disclosed herein. | 10-30-2008 |
20080268060 | Methods and apparatus for producing nanoscale particles - Liquid nanoscale particle precursor materials for generating nanoscale particles include at least one high volatility carrier and a second component. A nanoscale particle generating device generates nanoscale particles by passing a liquid nanoscale particle precursor material through a flow passage heated to convert the carrier into a vapor and the second component into nanoscale particles. The nanoscale particles preferably consist essentially of the second component and can consist essentially of dry, solid particles. The particle generator can be incorporated in a hand held inhaler, and can be delivered to a targeted portion of the lung using the inhaler. Composite controlled release particles of micron or nanoscale size can be produced by flowing a solution of medicament, control release agent and carrier liquid through a capillary heater. | 10-30-2008 |
20080274193 | Retinoic Acid-Containing Antidiabetic Agent - The present invention aims to provide a novel agent for treating and/or preventing diabetes which agent can not only control a blood sugar level but also fundamentally treat a patient with type I diabetes suffering from destruction of β cells and a patient with type II diabetes suffering from dysfunction in insulin secretion. The present invention provides an agent for treating and/or preventing diabetes, the agent containing retinoic acid as an active ingredient. Retinoic acid incorporated as an active ingredient may be all-trans retinoic acid, an isomer thereof, a derivative thereof, a salt thereof or a prodrug thereof. Retinoic acid may be incorporated singly. Alternatively, composite particles of retinoic acid and an appropriate inorganic or organic substance are prepared, and the retinoic acid composite particles may be incorporated. | 11-06-2008 |
20080274194 | Stabilized Hme Composition With Small Drug Particles - A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients. A hydrophilic polymer, such as hydroxypropyl methylcellulose (HPMC E15), polyvinyl alcohol (PVA), or poloxamer, and/or a surfactant, such as sodium lauryl sulfate (SLS), can be included in the composition. A process for preparing the extrudate is conducted at a temperature approximating or above the softening or melting temperature of the matrix and below the point of solubilization of drug-containing particles in the carrier system, and below the recrystallization point in the case of amorphous fine drug particles. | 11-06-2008 |
20080274195 | Compositions and Methods for Making and Using Nanoemulsions - The present invention discloses an improved nanoemulsion comprising a uniform and discrete range of very small particle nano-sized diameters. This uniformity results in improved bioavailability of incorporated compounds (i.e., pharmaceuticals or nutraceuticals) as reflected in various pharmacokinetic parameters including, but not limited to, decreased T | 11-06-2008 |
20080274196 | Oral Pharmaceutical Suspension Compositions Of Fexofenadine - An oral, pharmaceutical suspension composition of Fexofenadine. Fexofenadine is a mixture of compacted Fexofenadine and plain fexofenadine in a ratio of 0.01:0.99 to 0.99 to 0.01 having a mean particle size of fexofenadine particles in the range of 10μ and 250 μ.An oral, pharmaceutical suspension composition of Fexofenadine, which is bioequivalent to a tablet dosage form of fexofenadine marketed under the trade name of Allegra®. Bioequivalence between a suspension formulation and the commercially tablet formulation of fexofenadine i.e. ‘Allegra®’ is achieved by the use of a mixture of compacted Fexofenadine. | 11-06-2008 |
20080274197 | LYOPHILIZED FORMULATION - For clinical application of cis[((1R,2R)-1,2-cyclohexanediamine-N,N′)bis(R | 11-06-2008 |
20080274198 | USE OF MULTILAYERED PIGMENTS IN THE FOOD AND PHARMACEUTICALS SECTOR - The present invention relates to the use of multilayered pigments based on platelet-shaped substrates for colouring food and pharmaceutical products. | 11-06-2008 |
20080274199 | CONTROLLED RELEASE CERAMIC PARTICLES, COMPOSITIONS THEREOF, PROCESSES OF PREPARATION AND METHODS OF USE - Controlled release ceramic particles, processes for their preparation, controlled release ceramic particles prepared by such processes, compositions comprising such controlled release ceramic particles and methods of using controlled release ceramic particles are described. In one form each of the controlled release ceramic particles has an active material(s) substantially homogeneously dispersed throughout the particles, wherein the active material(s) is capable of being released from said particles, and the active material(s) in said particles is substantially protected from degradation until release of the active material(s) from the particles. | 11-06-2008 |
20080279946 | METHODS AND COMPOSITIONS FOR INCREASING INFRARED ABSORPTIVITY OF A TARGET - Disclosed herein are compositions and methods for increasing the infrared absorptivity of a therapeutic target. Also disclosed are methods for detecting or ablating a therapeutic target that include providing a nanoparticle composition for increasing the infrared absorptivity of the therapeutic target. Subsequently, the therapeutic target having increased infrared absorptivity is exposed to a therapeutically effective dose of infrared irradiation to effect its detection or ablation. In addition, a method is disclosed for treating a subject suffering from a tumor by providing to the tumor a nanoparticle composition for increasing its infrared absorptivity. The tumor having increased infrared absorptivity is then heated by exposing it to a therapeutically effective dose of infrared irradiation. | 11-13-2008 |
20080279947 | Menthol-Containing Solids Composition - A menthol-containing solids composition comprising or consisting of
| 11-13-2008 |
20080279948 | Treatment of Asthma and Copd Using Triple-Combination Therapy - A medicament comprising, separately or together (A) a compound of formula I | 11-13-2008 |
20080279949 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS - Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions. | 11-13-2008 |
20080279950 | NANO-PARTICLES COMPRISING CUCURBITURIL DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND PROCESS FOR THE PREPARATION THEREOF - Provided are nanoparticles prepared by the aggregation of cucurbituril derivatives and having a particle size of 1 to 1,000 nm, a pharmaceutical composition in which a pharmaceutically active substance is loaded into the nanoparticles, and preparation methods thereof. | 11-13-2008 |
20080286361 | Gene Delivery - The present invention relates to a method of delivery of a therapeutic agent to a target cell the method comprising targeting particles comprising the therapeutic agent to the cell using magnetic means to apply a magnetic force to said particles so as to tend to move said particles towards said magnetic means and at the same time moving said magnetic means. | 11-20-2008 |
20080286362 | Compositions Exhibiting Improved Flowability - Powder compositions exhibiting improved flow properties. The compositions generally contain a bulk solid material in the form of a powder and surface-modified nanoparticles. Methods of improving the flow of powder compositions and devices and articles made using such compositions are also disclosed. | 11-20-2008 |
20080286363 | Pharmaceutical Compositions for the Treatment of Inflammatory and Obstructive Airways Diseases - A medicament comprising, separately or together (A) a compound of formula I | 11-20-2008 |
20080286364 | EXTERNAL DERMATOLOGIC PREPARATION - An object of the present invention is to provide an external dermatologic preparation which comprises nanoparticles consisting of proteins that can exhibit desirable effects via regulation of particle diameters. The present invention provides an external dermatologic preparation which comprises protein nanoparticles containing an active ingredient and having an average particle size of 200 to 500 nm. | 11-20-2008 |
20080286365 | Method For Producing Solid-Lipid Composite Drug Particles - A method of producing solid composite lipid/drug nanoparticles that includes the steps of: (1) dissolving a lipid and a drug in a suitable organic solvent to form a solution; (2) emulsifying the solution in a liquid to form an emulsion having a discontinuous phase of micelles comprising the organic solvent, the drug and the lipid, and a continuous phase comprising the liquid; and (3) contacting the emulsion with a supercritical fluid under conditions suitable to keep the supercritical fluid in a supercritical state, whereby the supercritical fluid extracts the organic solvent from the micelles, causing them to precipitate as organic-solvent free solid composite lipid/drug nanoparticles suspended or dispersed in the liquid. | 11-20-2008 |
20080286366 | Delivery of micro- and nanoparticles with blood platelets - The invention is directed to platelets containing micron or nanometer size particles wherein the micron or nanometer sized particles comprises an active agent. The invention is also directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the above platelets. The invention is further directed to methods of delivering the micron or nanometer size particles containing an active agent to a site of interest in a patient. | 11-20-2008 |
20080286367 | Compositions containing benefit agent composites pre-emulsified using colloidal cationic particles - A cleansing or a surface-conditioning composition comprising a mixture of (i) and (ii) in water: i) a surfactant selected from the group consisting of anionic, non-ionic, zwitterionic, cationic, and mixtures thereof; and ii) a hydrophobic benefit agent in a particulate form having a mean particle size in the range of 1-1,000 micron, and a specific gravity of ≧1, not encapsulated within a film or a capsule-like enclosure, the particulate hydrophobic benefit agent comprising: a) a physically-modified form of the hydrophobic benefit agent; and b) a deposition-aid material bonded to the surface of the physically-modified benefit agent material, wherein the bonding between the two said materials is achieved prior to addition to i), wherein said deposition-aid material is not a surfactant having a weight average molecular weight of less than 5,000 Dalton. | 11-20-2008 |
20080286368 | Pharmaceutical composition for the treatment of acute disorders - A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders. | 11-20-2008 |
20080292709 | KITS FOR DHEA AND DHEA-SULFATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Kits for treating or preventing chronic obstructive pulmonary disease (COPD) by using as active agent a non-glucorticoid steroid, analogue thereof, such as dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S), or their salts, in an amount effective for preventing or treating COPD. | 11-27-2008 |
20080299204 | Dosage forms for movement disorder treatment - The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual. | 12-04-2008 |
20080299205 | Particulate Constructs For Release of Active Agents - Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments. | 12-04-2008 |
20080299206 | Ophthalmic preparations - The present invention provides ophthalmic formulations containing cyclosporine, methods for preparing the formulation, and methods for using the formulation. | 12-04-2008 |
20080299207 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF OXYBUTYNIN - Administration of Oxybutynin in nebulized dry powder form directly to a patient's lungs for treating urinary incontinence or respiratory disease. | 12-04-2008 |
20080305171 | PYRROLOPYRAZINE, FORMULATIONS, METHODS OF MANUFACTURE, AND METHODS OF USE THERE - Disclosed herein is a pyrrolopyrazine COMPOUND I having defined amounts of R isomer, particle size, and stability. Also disclosed are pyrrolopyrazine oral dosage forms comprising the described COMPOUND I material as well as methods of treating disorders amenable to therapy using COMPOUND I. | 12-11-2008 |
20080305172 | OPHTHALMIC DEPOT FORMULATIONS FOR PERIOCULAR OR SUCONJUNCTIVAL ADMINISTRATION - The present invention relates to ophthalmic depot formulations comprising an active agent, e.g. embedded in a pharmacologically acceptable biocompatible polymer or a lipid encapsulating agent, e.g. for periocular or subconjunctival administration. | 12-11-2008 |
20080311206 | Anti-Chafing Compositions Comprising Boron Nitride - The invention in one aspect relates to an anti-chafing composition with improved efficacy, in one embodiment, comprising an effective amount of boron nitride suspended in a dermatologically acceptable carrier vehicle. Another embodiment relates to an anti-chafing composition in the form of a powder or a stick containing boron nitride. The present invention also relates to a method of inhibiting or reducing chafing to the skin by topically applying an effective amount of such anti-chafing composition to the skin or to a surface to be in contact with the skin. | 12-18-2008 |
20080311207 | Micelles and Nanoemulsions for Preventive and Reactive Treatment of Atherosclerosis - The subject invention is directed to microemulsion-based (ME) nanoparticles and methods of using same. The ME nanoparticles of the subject invention encompass self-assemblies of oil in water emulsions in the presence of at least two emulsifiers. One of the emulsifiers is a salt of a fatty acid, and the combined concentration of the at least two emulsifiers is sufficiently large to produce micelles, wherein the oil droplets are the hydrophobic core of the micelles. The subject invention also contemplates methods of modifying lipids, high density lipoprotein (HDL), and low density lipoprotein (LDL) in blood by contacting the blood with the ME nanoparticles of the subject invention. Another aspect concerns methods for treating atherosclerosis by administering the ME nanoparticles of the subject invention to a patient in need thereof. | 12-18-2008 |
20080311208 | Pharmaceutical Formulations Useful in the Treatment of Insomnia - There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles. | 12-18-2008 |
20080311209 | TOPICAL COMPOSITIONS COMPRISING NANOPARTICLES OF AN ISOFLAVONE - The present invention is directed to topical compositions, comprising isoflavone nanoparticle compositions. The isoflavone nanoparticle compositions contain isoflavone in the form of nanoparticles and preferably a carrier. In the topical compositions recrystallization of the isoflavone to bigger particles is avoided. | 12-18-2008 |
20080311210 | PHARMACEUTICAL COMPOSITION FOR USE AS A LAXATIVE - The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds ( | 12-18-2008 |
20080311211 | Easily Dispersible Lipidic Phase - The present invention relates to the use of a lipidic phase comprising an oil and a lipophilic additive (LPA), which is suitable to make an oil-in-water emulsion by application of low energy or a manual operation. The lipidic phase contains a Lipophilic Additive (LPA) which forms self-assembly structures inside the emulsion oil droplets. The aqueous phase contains a hydrophilic emulsifier and the lipidic and aqueous phases are mixed without using classical high shearing devices or homogenisers. | 12-18-2008 |
20080311212 | CRYSTALLINE ISOXAZOLE DERIVATIVE AND PHARMACEUTICAL PREPARATION THEREOF - Crystalline 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-{[amino(morpholin-4-yl)methylene]amino}-isoxazole that exhibits the following angle of diffraction (2θ) and relative intensity in a powder X-ray diffraction pattern, is very easy to handle and stable in a process of its formulation into a pharmaceutical preparation. | 12-18-2008 |
20080317862 | Organic Compounds Comprising a Glycopyrrolium Salt - Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases. | 12-25-2008 |
20090004277 | Nanoparticle dispersion containing lactam compound - Disclosed is a nanoparticle dispersion comprising nanoparticles dispersed in an aqueous medium in the presence of at least one stabilizer. The nanoparticles comprise at least lactam compound of formula I: | 01-01-2009 |
20090004278 | Enzymatically Crosslinked Protein Nanoparticles - It is an object of the present invention to provide highly safe nanoparticles made from highly biocompatible materials without the use of a surfactant or synthetic polymer. The present invention provides a protein nanoparticle which is obtained by enzymatic crosslinking during and/or after the formation of protein nanoparticle. | 01-01-2009 |
20090004279 | Method For Improvement Of Tolerance For Therapeutically Effective Agents Delivered By Inhalation - A method for improvement of tolerance for therapeutically effective agents delivered by inhalation comprising a pretreatment of a patient with a nebulized lidocaine or a lidocaine-like compound administered immediately or up to about thirty minutes before administration of the primary therapeutically effective agent. The pretreatment of the patient with the nebulized lidocaine or a lidocaine-like compound improves airway tolerance and deposition of the agent in the lungs and makes such deposition more safe, efficacious, controllable and predictable. The method of the invention is especially useful for enhancement of deposition of immunosuppressive agents in the lung(s) of transplant patients, improved tolerance of the drugs by reducing cough, and improving pulmonary drug deposition. | 01-01-2009 |
20090004280 | KIT FOR CARING FOR THE SKIN INTENDED TO SOFTEN CUTANEOUS SIGNS OF AGEING - A kit for skin care intended to soften cutaneous signs of ageing, contains in separate packagings, a microdermabrasion composition, a peeling composition, a soothing composition and an anti-ageing composition. | 01-01-2009 |
20090011029 | COLORLESS AND TRANSPARENT ANTIBIOTIC MATERIAL INCLUDING SILVER, AND A METHOD FOR THE PREPARATION OF IT - Disclosed herein is a colorless and transparent antibiotic material including silver and a method of preparing the same. Specifically, the current invention pertains to a method of preparing a colorless and transparent antibiotic material including silver (Ag), which includes a) reacting a salt including a silver ion (Ag+) with a salt including a sulfate anion, to prepare a silver (Ag)-sulfate complex; and b) diluting the silver (Ag)-sulfate complex prepared in a) with water, and to an antibiotic material prepared using the method. Further, the current invention pertains to an antibiotic material including silver, which is harmless to the human body and exhibits disinfecting and antibiotic activities, and as well, is colorless and transparent and does not easily form colored oxides, unlike conventional silver-based antibiotic materials, and to a method of preparing such an antibiotic material. Thus, the colorless and transparent antibiotic material of this invention can be widely applied to manufacture industrial goods, such as nonwoven fabrics, packaging materials, etc., living goods, such as clothes, bedclothes, etc., and fiber goods. | 01-08-2009 |
20090011030 | BREAKTHROUGH PAIN MANAGEMENT - The present invention is directed to a powdered formulation comprising an analgesic, preferably fentanyl, for use in pulmonary inhalation administration for the rapid analgesic titration of pain, in particular breakthrough pain. Upon administration, the powdered formulation is able to provide a narrower titration range in patients suffering from pain, as well as effective analgesic amounts of fentanyl in a shorter time and at lower dose levels of administered fentanyl when compared to fentanyl administered by an oral transmucosal route. | 01-08-2009 |
20090011031 | Delivery of oral drugs - Disclosed is a system for delivery of a drug comprising a multiple unit dosing device comprising a chousing and an actuator, said device containing multiple doses of multiparticulates comprising drug particles, said device upon actuation delivering a unit dose of said multiparticulates, said drug particles having a mean diameter of greater than 10 μm to about 1 mm such that an effective dose of said drug cannot be delivered into the lower lung of a human patient. Also disclosed are novel methods, devices and dosage forms for delivering a drug. | 01-08-2009 |
20090017122 | Drug Forms Having Controlled Bioavailability - The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and have controlled bioavailability, and to processes for their preparation. | 01-15-2009 |
20090017123 | DERMAL REGENERATION ENHANCER - An object of the present invention is to provide a novel dermal regeneration enhancer. In accordance with the present invention, there is provided a dermal regeneration enhancer as a novel pharmaceutical use of lyotropic liquid crystal which has been utilized as a basic material for pharmaceutical preparations for external application and for cosmetics, and the dermal regeneration enhancer of the present invention achieves an excellent suppressive effect to aging of the skin, generation of spots, etc. | 01-15-2009 |
20090017124 | Nucleic Acid Microparticles for Pulmonary Delivery - The present disclosure is related to microparticle compositions, in which the microparticles are made of nucleic acids and non-polymeric cations, which are suitable for administration to moist or aqueous target locations (e.g., the lung tissue), where the substantially spherical nucleic acid microparticles release the nucleic acids through dissolution, allowing the released nucleic acids to freely interact with the target cells. | 01-15-2009 |
20090022806 | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed. | 01-22-2009 |
20090028947 | USING OF NANOSILVER IN POULTRY, LIVESTOCK AND AQUATICS INDUSTRY - Nanosilver material is disclosed. Said material is nano silver based disinfectant and disease preventer for poultry, livestock and aquatics. The material contains silver nano particle and pure water and can be used as a surface disinfectant, water disinfectant and therapentic material for poultry, livestock and aquatic disease caused by bacteria's viruses, fungi and other monocellular microorganism. | 01-29-2009 |
20090028948 | NANOPARTICLE COMPOSITION AND METHODS OF SYNTHESIS THEREOF - The present invention relates to improved therapeutically active nanocomposite microstructure compositions, including nanoparticle compositions and nanoparticle preparations. Preferred embodiments include nanoparticle compositions comprising nanoparticles of a therapeutically active agent dispersed in a carrier matrix. The invention also relates to a method for preparing said compositions and preparations using solid-state mechanochemical synthesis. Further, it relates to therapeutic products produced using said compositions and to methods of treatment using the compositions. | 01-29-2009 |
20090028949 | CALCIUM PHOSPHATE-BASED ADHESIVE FORMULATION FOR BONE FILLING WITH SWELLING PROPERTIES - The present invention relates to a calcium phosphate-based formulation for bone filling, comprising at least one adjuvant giving adhesion properties, said at least one adjuvant can be selected from the sugar and sugar derivative group. | 01-29-2009 |
20090028950 | GRANULE DISPERSION COMPOSITION, PROCESS FOR PRODUCING THE SAME, AND GRANULAR MATERIAL AND MEDICINE - The subject matter of the present invention is to provide a new particulate material dispersion composite in which a material poorly soluble in water is micronized and dispersed. For the above purpose, a particulate material dispersion composite is produced in the present invention, wherein a particulate material containing a specific material which is poorly soluble in water, a polymer and a lipid is dispersed in water, the mean diameter of said particulate material is 1 μm or less, and the ratio of the combined weight of said polymer and said lipid to the weight of said specific material is 1.5 or larger. | 01-29-2009 |
20090028951 | Compositions for Oral Administration of Sustained Release Glutathione, Methods for Their Production and Uses Thereof - A composition suitable for oral administration for sustained-release of glutathione, the composition having from about 50% by weight to about 90% by weight glutathione; from about 0% by weight to about 10% by weight binder; from about 10% by weight to about 50% by weight of at least one sustained release agent; and a granule size of from about 850 μm to about 5000 μm, is provided. Methods for preparing such compositions are also provided. Uses and methods of medical treatment by orally administering a composition for sustained release of glutathione to a patient suffering from or at risk of suffering from a neurological disorder are also provided. | 01-29-2009 |
20090028952 | Hydroxy sulfonate of quinone compounds and their uses - The present invention provides sodium 6-hydroxy-2,2-dimethyl-5-oxo-3,4,5,6-tetrahydro-2H-benzo(h)chromene-6-sulfonate, and its synthesis and uses in the treatment of cancer. | 01-29-2009 |
20090028953 | METHOD OF TREATMENT USING MICROPARTICULATE BIOMATERIAL COMPOSITION - Compositions of microspheres formed of stabilized hyaluronic acid are disclosed. The unique biological properties of hyaluronic acid provide for very inert properties when exposed to tissues. Microsphere formulations of hyaluronic acid have medical utility due to the resultant properties of flowability, physical stability, and degradability. High concentration formulations of the microspheres have utility when injected to form a localized mass within tissues by providing physical stability and anti-fibrotic biological activity, especially suitable for certain surgical reconstructions. Low concentration formulation of the microspheres of the appropriate size range have utility when injected into the blood system to delivery diagnostic and therapeutic compounds. | 01-29-2009 |
20090028954 | PRECURSOR FOR THE PREPARATION OF A PASTY BONE REPLACEMENT MATERIAL BY ADMIXTURE OF A LIQUID - The precursor is used for the preparation of a pasty bone replacement material by admixture of a liquid. The precursor comprises a biocompatible substance swellable by the action of water or of an aqueous solution thereby forming a hydrogel; and solid particles made of a substance which is suitable as a bone replacement material. The swellable substance is in the form of discrete particles having a mean dimension in the range of 18 μm to 2000 μm. | 01-29-2009 |
20090035378 | NANOSTRUCTURED BIOACTIVE MATERIALS PREPARED BY DUAL NOZZLE SPRAY DRYING TECHNIQUES - Nano-particles of calcium and phosphorous compounds are made in a highly pure generally amorphous state by spray drying a weak acid solution of said compound and evaporating the liquid from the atomized spray in a heated column followed by collection of the precipitated particles. Hydroxyapatite (HA) particles formed by such apparatus and methods are examples of particle manufacture useful in bone and dental therapies. Dual nozzle spraying techniques are utilized for generally insoluble compounds. | 02-05-2009 |
20090035379 | Fenofibrate compositions - The invention provides fenofibrate compositions comprising granulates, where the granulates comprise micronized fenofibrate. | 02-05-2009 |
20090041847 | METHOD OF QUENCHING ELECTRONIC EXCITATION OF CHROMOPHORE-CONTAINING ORGANIC MOLECULES IN PHOTOACTIVE COMPOSITIONS - The photostabilizing electronic excited state energy—particularly singlet state energy from a UV-absorbing molecule has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds of formulas (I) and (V) having an alkoxy radical preferably in the four (para) position (hereinafter methoxycrylenes) on one or both of the phenyl rings: | 02-12-2009 |
20090041848 | SKIN ANTI-AGING AGENT FOR EXTERNAL USE - It is an object of the present invention to provide a skin anti-aging agent for external use which comprises highly safe protein nanoparticles having high transparency due to the small particle size and high permeability into skin. The present invention provides a skin anti-aging agent for external use, which comprises protein nanoparticles containing an active ingredient. | 02-12-2009 |
20090041849 | DISSOLUTION AIDS FOR ORAL PEPTIDE DELIVERY COMPRISING A BIGUANIDE - A pharmaceutical composition comprising a mixture of: (c) an active macromolecular principle; (d) an aromatic alcohol absorption enhancer chosen from propyl gallate, butylated hydroxy toluene (BHT), butylated hydroxy anisole (BHA) and analogues and derivatives thereof, or mixtures thereof; and (d) a biguanide or a pharmaceutically acceptable salt thereof, capable of increasing the solubility of the aromatic alcohol absorption enhancer in an aqueous medium, wherein the aromatic alcohol absorption enhancer is present in an amount by weight greater than or equal to that of the active principle. | 02-12-2009 |
20090047351 | Processes For Making Lactose Utilizing Pre-Classification Techniques And Pharmaceutical Formulations Formed Therefrom - A process for forming lactose suitable for use in a pharmaceutical formulation comprises providing a plurality of lactose particles containing no more than 10% w/w of lactose particles having a volume average particle size of about 70 microns or less; milling the plurality of lactose particles to yield a plurality of milled lactose particles with an average particle size, (D50), ranging from about 50 microns to about 100 microns; and classifying the plurality of milled lactose particles into at least two fractions comprising a fine fraction and a coarse fraction wherein the fine fraction has an average particle size, (D50), ranging from about 3 microns to about 50 microns, and the coarse fraction has an average particle size, (D50), ranging from about 40 microns to about 250 microns. | 02-19-2009 |
20090047352 | Colourant Compositions and Their Use - A fibre colourant and an ink composition are provided which comprise monodisperse particles capable of forming a colloidal crystal that diffracts light having a wavelength in a range that corresponds to the wavelength of visible light. The use of such compositions in colouring substrates is also provided. | 02-19-2009 |
20090047353 | CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES WITH ADJUVANTS - The invention seeks to avoid components in split vaccines that could cause an excessive Th2 response. Thus the invention provides an immunogenic composition comprising a split influenza virus antigen and a Th1 adjuvant, wherein the antigen is preferably prepared from a virus grown in cell culture (e.g., it is free from egg proteins). | 02-19-2009 |
20090047354 | PROCESS FOR THE PREPARATION OF 5-(2-(4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL) ETHYL)-6-CHLORO-1, 3-DIHYDRO-2H-INDOL-2-ONE HYDROCHLORIDE (ZIPRASIDONE HYDROCHLORIDE) AND ITS INTERMEDIATE - The present invention relates to improved processes for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one and its hydrochloride, which is known as Ziprasidone hydrochloride of Formula (I) and 5-(2-Chloro acetyl)-6-chloro oxindole of Formula (IV), which is an intermediate for the preparation of 5-(2-chloro ethyl)-6-chloro oxindole of Formula (V). Ziprasidone hydrochloride of Formula (I) of the present invention is depicted by the following structure. | 02-19-2009 |
20090047355 | PROCESS FOR PRODUCING PULVERULENT PHYTOSTEROL FORMULATIONS - A process for the production of pulverulent phytosterol formulations, includes preparing an aqueous solution, suspension or dispersion of the phytosterol in an aqueous molecular dispersion or colloidal dispersion of a protective colloid and drying. | 02-19-2009 |
20090053314 | SUBMICRONIZATION OF PROTEINS USING SUPERCRITICAL FLUIDS - An apparatus and a method for the submicronization of proteins using supercritical fluids is provided for feeding the supercritical fluid and feeding a protein solution using a precipitation vessel with a taper shape at its lower part, in which the precipitation vessel accommodates the supercritical fluid and the protein solution to generate submicroparticles of the protein, and a spray nozzle with coaxial arrangement having an outer nozzle for spraying the supercritical fluid and an inner nozzle for spraying the protein solution. | 02-26-2009 |
20090053315 | Thermo-Kinetic Mixing for Pharmaceutical Applications - Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding. | 02-26-2009 |
20090053316 | NANOCLUSTERS FOR DELIVERY OF THERAPEUTICS - The present invention discloses a nano-cluster that includes a plurality of nano-particles, wherein the nano-particles can disperse in response to an environmental cue. Also disclosed is a method of preventing, treating, or diagnosing a disease or condition in a subject comprising administering a therapeutically effective amount of a composition comprising nano-clusters of the present invention. | 02-26-2009 |
20090061001 | SUNSCREEN AEROSOL SPRAY - A sunscreen formulation and a method of dispensing the sunscreen formulation is described in which the sunscreen formulation in the form of an emulsion includes one or more sunscreen agents and one or more propellants contained within an aerosol can such that the sunscreen composition is dispensed from the aerosol can by the propellant(s) in the form of a fine mist spray or fog allowing a uniform film of the sunscreen composition to be applied to the skin of a person to provide a uniform form of protection so as to overcome the harmful effects of the suns rays on the skin. | 03-05-2009 |
20090061002 | CALCIUM PHOSPATE BASED DELIVERY OF GROWTH AND DIFFERENTIATION FACTORS TO COMPROMISED BONE - Resorbable calciumphosphate (CaP) based compositions comprising growth and differentiation factors (GDF) and their uses in bone regeneration and preventive treatment, in particular of osteoporotic bone, are disclosed. | 03-05-2009 |
20090061003 | CARRIERS FOR DRUG DELIVERY - The present invention relates to chemically bonded ceramic precursor material of aluminates and silicates exhibiting a controlled release rate and properties that make the material suitable as a carrier material used in drug delivery. According to the invention, this is accomplished by selecting a microstructure based on pre-reacted phases and/or reacting phases, which contains the drugs. The present invention also relates to a cured ceramic material and a method of manufacturing said cured material. The precursor and the cured ceramic material according to the present invention can suitably be used for different types of drug intake and delivery. | 03-05-2009 |
20090061004 | Leave-In Hair Styling Product with Particles for Improving Hair Volume - The present invention relates to a leave-in hair styling product that improves the volume of a hair-do. More specifically, it relates to a leave-in composition in the form of aerosol mousse, pump mousse, gel, spray-gel, aerosol hairspray, pump spray, hair wax, hair styling cream or hair setting lotion. The leave-in compositions according to the present invention comprise solid particles of spherical, ellipsoid or oval shape and at least one film-forming ingredient. | 03-05-2009 |
20090061005 | Paliperidone Polymorphs - Described herein are novel polymorphic forms of paliperidone, processes for preparing the novel forms and use thereof. Also provided are processes for the preparation of novel polymorphic forms of paliperidone and the use thereof in the preparation of pharmaceutical compositions. | 03-05-2009 |
20090068271 | EMBOLIZATION PARTICLES - Embolic particles, embolic particle chains, and methods for making embolic particles and embolic particle chains are described. | 03-12-2009 |
20090068272 | MESOPOROUS CALCIUM SILICATE COMPOSITIONS AND METHODS FOR SYNTHESIS OF MESOPOROUS CALCIUM SILICATE FOR CONTROLLED RELEASE OF BIOACTIVE AGENTS - Mesoporous calcium silicate compositions for controlled release of bioactive agents and methods for producing such compositions are disclosed herein. In one embodiment, mesoporous calcium silicate is synthesized by acid modification of wollastonite particles using hydrochloric acid. A hydrated silica gel layer having abundant Si—OH functional groups can be formed on the surface of wollastonite after acid modification. Bruhauer-Emmett-Teller (BET) surface area increased significantly due to acid modification and, in one arrangement, reached over 350 m | 03-12-2009 |
20090068273 | Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases - The invention provides inhalation devices comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof, inhalation devices comprising formulations and combinations of the compound or a salt or solvate thereof, and methods for the treatment or prophylaxis of a clinical condition in a mammal by employing the inhalation devices | 03-12-2009 |
20090068274 | HIGHLY EFFICIENT DELIVERY OF A LARGE THERAPEUTIC MASS AEROSOL - A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm | 03-12-2009 |
20090068275 | Process for the Manufacture of Powders of Inhalable Medicaments - The invention relates to an improved process for the production of powders of an inhalable medicament by crystallization from a supersaturated fluid containing said medicament, the method comprising passing along a tubular reactor
| 03-12-2009 |
20090074870 | Alteration of cell membrane for new functions - Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the proteins and polypeptides embodying these sequences are disclosed for modulating the immune system. The modulations include down-regulation, up-regulation and apoptosis. | 03-19-2009 |
20090074871 | Composition for filling bone defects - The invention is directed toward an improved formable bone composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone particles ranging from about 100 to 850 microns. The bone particles are mixed in an excipient carrier combination containing carboxymethylcellulose, sodium hyaluronate, and a sodium phosphate saline buffer, the carboxymethylcellulose component of the carrier ranging from about 5.0 to about 11.0% of the composition and the sodium hyaluronate component of the carrier ranging from about 0.3 to about 0.7% of the composition, the composition having a pH between 6.5-7.5. | 03-19-2009 |
20090074872 | Active Agent Formulations, Methods of Making, and Methods of Use - Stable fenofibrate suspensions are disclosed herein. A fenofibrate composition includes fenofibrate nanoparticles having an average particle size of less than 500 nm, and a particle sequestrant, wherein the average particle size of the nanoparticulate suspension changes by less than 50% after standing at room temperature for 21 or more days. | 03-19-2009 |
20090074873 | Nanoparticulate beclomethasone dipropionate compositions - There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble therapeutic or diagnostic agent particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment and diagnosis using the aerosol. | 03-19-2009 |
20090081297 | Use of surface tension reducing agents in aerosol formulations - The present disclosure describes aerosol formulations that are particularly effective for pulmonary aerosol delivery. The aerosol formulations comprise an aqueous dispersion of active agent particles, said aqueous dispersion having an excess of a surface tension reducing agent. As a result of the reduced surface tension of the aqueous dispersion, the resulting aerosol droplets formed have a particle size less in one embodiment of than 10 microns in size or in an alternate embodiment of less than 6 microns in size. The present disclosure also provides for a method for forming an aerosol from said aerosol formulation, a method of treating a mammal in need of said treatment using said aerosol formulation, and a method of diagnosing a mammal in need of such diagnosis using said aerosol formulation. | 03-26-2009 |
20090081298 | SUSTAINED RELEASE OF APO A-I MIMETIC PEPTIDES AND METHODS OF TREATMENT - A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I. | 03-26-2009 |
20090081299 | SUSTAINED RELEASE OF APO A-I MIMETIC PEPTIDES AND METHODS OF TREATMENT - A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I. | 03-26-2009 |
20090081300 | AGENT FOR USE IN THE CASE OF FRUCTOSE INTOLERANCE - The present invention refers to an agent for use in the case of fructose intolerance and any form of impairment and affliction of health and well being which is caused by the administration of fructose or fructose containing foodstuffs or by the release of fructose in the digestive tract of humans or animals from other substances, such as e.g. sucrose. The agent according to the invention comprises | 03-26-2009 |
20090081301 | MICROPARTICLE DISPERSION LIQUID MANUFACTURING METHOD AND MICROPARTICLE DISPERSION LIQUID MANUFACTURING APPARATUS - In a dissolving step, a poorly soluble drug and a dispersion stabilizer are dissolved in a volatile organic solvent. In a fixing step, the organic solvent, contained in a solution obtained in the dissolving step, is removed by evaporation, pellet-form residues | 03-26-2009 |
20090081302 | PULMONARY DELIVERY OF POLYENE ANTIFUNGAL AGENTS - The present invention provides spray-dried polyene compositions for oral inhalation to the lung. The polyene antifungal compositions demonstrate superior aerosol properties, do not exhibit appreciable degradation of the polyene upon spray-drying, and are useful in the treatment and prophylaxis of both pulmonary and systemic fungal infections. | 03-26-2009 |
20090081303 | PHARMACEUTICAL FORMULATION FOR CONTRACEPTION AND HORMONE-REPLACEMENT THERAPY - The present invention provides slow release estradiol-progesterone formulations that can be used in either contraception or hormone replacement therapies. The formulations comprise shaped particles of estradiol that is in a hemicrystalline form that exhibits especially low dissolution rates. The shaped particles comprise estradiol compounded in a 1:1 molar ratio with cholesterol, and are administered in combination with progesterone. The slow release formulations of the present invention afford the dual advantages of a low dose estradiol formulation with a low frequency administration regimen. The formulations can be parenterally administered once a month or less often. | 03-26-2009 |
20090087491 | METHOD FOR PREPARING PARTICLES FROM AN EMULSION IN SUPERCRITICAL OR LIQUID CO2 - The present invention relates to a method for preparing particles, notably particles encapsulating an active substance. It also relates to particles obtainable by this process, dispersion thereof, and their use as a vehicle for pharmaceutical, cosmetic, diagnostic, veterinary, phytosanitary active substances or processed foodstuff. | 04-02-2009 |
20090087492 | Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use - The present invention relates to a process, for the production of crystalline particles of an active organic compound The process includes the steps of generating a micro-seed by a wet-milling process and subjecting the micro-seed to a crystallization process. The resulting crystalline particles have a mean particle size of less than about 100 μm. The present invention also provides for a pharmaceutical composition which includes the crystalline particles produced by the method described herein and a pharmaceutically acceptable carrier. | 04-02-2009 |
20090092671 | Cerium Oxide Nanoparticles for Treatment and Prevention of Alzheimer's Disease, Parkinson's Disease, and Disorders Associated with Free Radical Production and/or Mitochondrial Dysfunction - Cerium oxide nanoparticles (CeONP) can be used to treat or prevent neurodegenerative diseases, including for example Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, AIDS-related dementia, ALS, progressive supranuclear palsy, and encephalitis, as well as mitochondrial diseases and diseases associated with mitochondrial damage. In particular, CeONP having an average size of about 2 nm to about 100 nm can be administered in an amount sufficient to block production of hydroxyl or superoxide radicals, block free radical production by Aβ | 04-09-2009 |
20090098205 | pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES - The present invention provides a pH sensitive nanoparticulate delivery system for the administration of peptide hormones and drugs. In particular it provides a pH sensitive nanoparticulate for oral insulin administration. The nanoparticles developed by this process are fatty acid nanoparticles and a polymer is used as a stabilizer and also to incorporate pH sensitivity so that these particles shrink in the gastric acidic pH thereby protecting the incorporated insulin. These particles being also hydrophobic in nature and by virtue of their small size get absorbed through the intestinal cell wall and Peyer's patches. These nanoparticles are novel and unique in the sense that polymer content is only 0.03-0.06 g/g product and the polymer is hydrophilic in nature. | 04-16-2009 |
20090098206 | Particulate Metal Oxide - A particulate metal oxide having a median volume particle diameter in the range from 24 to 42 nm, a photogreying index in the range from 0.05 to 3 and/or and a yellowing index of less than 6. The dispersion can be used in a sunscreen product which is transparent, exhibits effective UV protection, reduced photoactivity, and reduced yellowing in combination with organic UV absorbers. | 04-16-2009 |
20090098207 | Technology for the Preparation of Microparticles - Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions. | 04-16-2009 |
20090098208 | PHARMACEUTICAL COMPOSITIONS BASED ON POROUS ZEOLITES AS RELEASE MEANS OF PHARMACOLOGICALLY ACTIVE MOLECULES AND RELATIVE USE - The present invention relates to pharmaceutical compositions for the oral administration of pharmacologically active molecules, comprising a release means consisting of porous zeolite in powder form, incorporating pharmacologically active molecules inside the pores and/or on its surface, the relative use for the preparation of drugs for oral administration, in particular for the treatment of inflammatory pathologies at an intestinal level and the preparation process of these compositions. | 04-16-2009 |
20090098209 | PHARMACEUTICAL COMPOSITIONS CONTAINING WATER-SOLUBLE DERIVATIVES OF PROPOFOL AND METHODS OF ADMINISTERING SAME VIA PULMONARY ADMINISTRATION - The present invention is directed to methods of delivering propofol derivative compounds via pulmonary administration to a mammal in order to induce or maintain anesthetized, sedated and sub-hypnotic states. | 04-16-2009 |
20090098210 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 04-16-2009 |
20090104268 | Nanoparticles Comprising Antigens and Adjuvants, and Immunogenic Structures - Nanoparticles comprising adjuvants and antigens, such as tumour and pathogen antigens, are disclosed and their use in a range of applications such as for the treatment of cancer and infectious diseases. Immunogenic structures based on nanoparticles or antibodies with carbohydrate ligands, and their use for therapeutic and prophylactic purposes, and for the isolation and detection of antibodies directed against the carbohydrate structures. | 04-23-2009 |
20090104269 | Nanoformulations - Methods, and the products thereof, for producing nanoparticles that in some embodiments are at least partially encapsulated by an encapsulant; and methods, and products thereof, for producing nanoformulations that are suspensions of nanoparticles in a liquid formulation. Typically the nanoparticles include agrochemicals, pharmaceuticals, catalysts, and other active ingredients. | 04-23-2009 |
20090104270 | Film delivery system for tetrahydrolipstatin - The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including tetrahydrolipstatin, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided. | 04-23-2009 |
20090104271 | Use of microparticles combined with submicron oil-in-water emulsions - Compositions are provided which include biodegradable microparticles with entrapped or adsorbed antigens, in combination with submicron oil-in-water emulsions. Also provided are methods of immunization which comprise administering to a vertebrate subject (a) a submicron oil-in-water emulsion, and (b) a therapeutically effective amount of a selected antigen entrapped in a microparticle. | 04-23-2009 |
20090104272 | INHALED HYPERTONIC SALINE DELIVERED BY A HEATED NASAL CANNULA - The invention described herein is directed to method of treating chronic obstructive pulmonary disease, comprising administering an effective amount of an osmolyte by at least one nasal cannula to a subject in need thereof. Also provided is a nasal cannula system for delivering an osmolyte, comprising a nebulizer and tubing having two ends, where the first end of the tubing is connected to the nebulizer and the second end of the tubing is tapered to fit in the nostril of a subject. | 04-23-2009 |
20090104273 | Novel nifedipine compositions - The present invention is directed to nanoparticulate compositions comprising nifedipine. The nifedipine particles of the composition have an effective average particle size of less than about 2 microns. | 04-23-2009 |
20090110736 | ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent. | 04-30-2009 |
20090110737 | Orally Disintegrating Powder Comprising Cilostazol and Mannitol - The present invention provides an orally disintegrating powder comprising cilostazol as an active ingredient and mannitol in an amount of 70% by weight or more, which can be taken without water and can be disintegrated in oral cavity. Said powder is suitable for patients to whom cilostazol is applied, especially for aged patients and patients suffering from dysphagia. | 04-30-2009 |
20090117193 | Compositions Comprising an Active Agent - The present invention provides a highly dispersible formulation comprising an active agent and a dipeptide or tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided are a method for (i) increasing the dispersibility of an active-agent containing formulation for administration to the lung, and (ii) delivery of the composition to the lungs of a subject. | 05-07-2009 |
20090123548 | Device for administering aromatherapy - A device for administering aromatherapy to a subject and the method of using the device are disclosed. The device comprises an aromatherapy composition housed within a container. The container has at least one opening or aperture through which the subject may breathe in or inhale the aromatic and volatile components of the aromatherapy composition through the mouth and/or nose. The aromatherapy composition comprises a particulate component comprising one or more irregularly- or regularly-shaped particles, granules, beads or the like. In addition, the aromatherapy composition has a volatile component comprising an amount of an essential oil-containing composition. The volatile component is that portion of the essential oil-containing composition that is retained by the particulate component after contacting the particulate component with the essential oil-containing composition and removal of the portion that is not retained by the particulate component. | 05-14-2009 |
20090123549 | Pharmaceutical Compositions - A composition comprising a pharmaceutically acceptable group (2, 4, 12, 13 or 14) metal compound for the treatment of a dermatological condition involving an abnormal decrease in the cell-to-cell adhesion between epithelial cells in the epidermal barrier. | 05-14-2009 |
20090123550 | CORTICOSTEROID COMPOSITIONS - Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 05-14-2009 |
20090123551 | GASTROINTESTINAL DELIVERY SYSTEMS - Provided herein are compositions suitable for the delivery of therapeutic agents to the gastrointestinal tract. Also provided herein are methods for treating, preventing or alleviating disorders of the gastrointestinal tract, for example, those involving the esophagus, by orally administering compositions described herein. | 05-14-2009 |
20090130214 | Gemcitabine derivatives nanoparticles - The invention concerns a 2′,2′-difluoro-2′-deoxycytidine derivative of general formula (I), wherein: R | 05-21-2009 |
20090130215 | GRANULAR PREPARATION CONTAINING BIGUANIDE COMPOUND - A granular preparation containing a biguanide compound and a solidification-preventive agent does not solidify during storage and can avoid the difficulty in dosing. | 05-21-2009 |
20090130216 | MULTIMODAL PARTICULATE FORMULATIONS - Multimodal particulate formulations of medicaments and methods for their use, e.g. by nasal or pulmonary administration for the treatment of various medical conditions, are provided. | 05-21-2009 |
20090130217 | Cosmetic Composition Containing Nanoparticulate a-Alumina - Cosmetic or dermatological preparations which contain modified or unmodified nanocrystalline a-alumina having particle sizes of from 10 to 100 nm and d50 values of from 30 to 60 nm are described. | 05-21-2009 |
20090136577 | Intestinal Absorptive Anti-Tumor Agent - An objective of the present invention is to provide intestinal absorptive antitumor agents with an excellent intestinal absorptive effect by using injectable antitumor agents. In the intestinal absorptive pharmaceutical agents of the present invention, antitumor components that can be used only as injections are supported by hydroxyapatite particles. | 05-28-2009 |
20090136578 | Pharmaceutical Composition Comprising Perindopril or Its Salts - The present invention relates to a stable pharmaceutical composition of the ACE inhibitor perindopril or its salts having a defined particle size distribution. | 05-28-2009 |
20090136579 | Nanoparticles Comprising a PDGF Receptor Tyrosine Kinase Inhibitor - The present invention relates to nanoparticles comprising a platelet-derived growth factor (PDGF) receptor tyrosine kinase inhibitor, especially a PDGF receptor tyrosine kinase inhibitor having a water-solubility at 20° C. between about 2.5 g/100 ml and 250 g/100 ml, more specifically nanoparticles comprising an N-phenyl-2-pyrimidine-amine derivative of formula I, | 05-28-2009 |
20090136580 | PREFERENTIAL KILLING OF CANCER CELLS AND ACTIVATED HUMAN T CELLS USING ZnO NANOPARTICLES - Here we disclose the response of normal human cells to ZnO nanoparticles under different signaling environments and compare it to the response of cancerous cells. ZnO nanoparticles exhibit a strong preferential ability to kill cancerous T cells (˜28-35X) compared to normal cells. Interestingly, the activation state of the cell contributes toward nanoparticle toxicity as resting T cells display a relative resistance while cells stimulated through the T cell receptor and CD28 costimulatory pathway show greater toxicity in direct relation to the level of activation. The novel findings of cell selective toxicity towards potential disease causing cells indicate a potential utility of ZnO nanoparticle in the treatment of cancer and/or autoimmunity. | 05-28-2009 |
20090136581 | Copper-Based Fungicide/Bactericide - The present invention discloses an improved copper-based fungicide/bactericide composition. The improved composition offers higher biological activity over typical copper-based products, while requiring significantly less copper in the composition. The present invention also discloses methods of making the improved copper-based fungicide/bactericide composition. The present invention further discloses methods of using the improved copper-based fungicide/bactericide composition. | 05-28-2009 |
20090142401 | Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release - Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed. | 06-04-2009 |
20090142402 | MICROPARTICLES, MICROPARTICLE DISPERSION AND METHOD AND APPARATUS FOR PRODUCING THE SAME - A method and an apparatus enabling manufacture of a microparticle dispersion liquid at high efficiency in a short time while suppressing drug degradation, etc., are provided. In a dissolving step, a poorly soluble drug and a dispersion stabilizer are dissolved in a volatile organic solvent in a container | 06-04-2009 |
20090142403 | ORGAN REGENERATION DEVICE - An organ regeneration device adapted to be used by placing it into a defective portion of an organ to regenerate the organ is provided. The organ regeneration device has a base body having a shape corresponding to a shape of the defective portion of the organ. The organ regeneration device also has particles carried on the base body, wherein the particles are composed of a different material from that of the base body. The organ regeneration device also has a growth-related substance contained in the organ regeneration device for growth and differentiation of cells around the defective portion. The growth-related substance contains an angiogenesis factor. Further, the growth-related substance contains nucleic acid containing a base sequence coding for amino-acid sequence of a growth factor different from the angiogenesis factor. Furthermore, the nucleic acid is introduced into a host cell. | 06-04-2009 |
20090148530 | METHOD FOR PREVENTION AND TREATMENT OF REFLUX INJURY IN THE AERODIGESTIVE TRACT AND LARYNGOPHARYNX CAUSED BY PEPSIN - A method for treating or preventing disorders, diseases, and symptom of reflux, that is laryngopharyngeal reflux (LPR), in the laryngopharynx caused by pepsin comprises orally administering to the laryngopharynx of a patient an effective amount of cellulose powder. A method for treating or preventing damage to the lining membranes of at least some of the aerodigestive tract, the damage caused by pepsin, comprises coating at least some of the lining membranes with an effective amount of a cellulose powder. Upon inhalation of the powder, the powder coats the lining membranes. Upon coating the lining membranes, the powder becomes a gel. The gel prevents the pepsin from binding with the lining membranes, thereby preventing damage caused by pepsin in laryngopharyngeal reflux or in extra-esophageal reflux. | 06-11-2009 |
20090148531 | RATE-CONTROLLED PARTICLES - Rate-controlled particles, comprising compounds of the formula | 06-11-2009 |
20090155367 | Occlusion of Fallopian Tubes - The present invention provides a method for inducing Fallopian tube blockage as a means for female contraception. The method comprises contacting the inner surface tissue of a Fallopian tube with a silver nitrate bearing substrate, delivering an amount of silver nitrate to the tissue sufficient to induce blockage of the Fallopian tube. Preferably, the substrate is a bead. In one embodiment, at least one silver nitrate bearing bead is introduced through the uterine opening of the Fallopian tube by use of a catheter or other device suitable for manipulating the bead. Alternatively, a plurality of beads can be introduced into the Fallopian tube. In a preferred embodiment, one or more silver nitrate bearing beads are arranged on a string to facilitate later removal of the beads. The method of the present invention delivers an amount of silver nitrate to the tissue sufficient to cause tissue necrosis and blockage of the Fallopian tube. The silver nitrate is delivered to the tissue by the substrate in a controlled and localized manner. | 06-18-2009 |
20090155368 | Pharmaceutical compositions - The present invention relates to crosslinked polyamine particles and/or pharmaceutical compositions comprising, at least in part, crosslinked polyamine particles and aggregates of such particles (including cured aggregates of crosslinked polyamine particles). The compositions may be in the form of tablets comprising, for example, particles larger than 500 μm, and used for treating patients, for example, patients with hyperphosphatemia. | 06-18-2009 |
20090162440 | SODIUM ALGINATE MICROSPHERE VASCULAR EMBOLUS CONTAINING WATER-SOLUBLE DRUG AND PREPARATION AND APPLICATION THEREOF - The present disclosure relates to a kind of sodium alginate microsphere vascular embolus that contains water-soluble drug and preparation and application thereof. The embolus preparation falls into dry microsphere type and wet one that are made of degradable materials. The drug carrier can be sodium alginate, human serum albumin, chitosan or sodium hyalurate, solidifying and forming microsphere together with calcium ion solution under presence of static charge. The microsphere can have a diameter in the range of 20-1000 μm and can be divided into a wide variety of sizes in case of need. The present disclosure adopts raw materials that are good at mechanical strength, bio-compatibility, bio-degradability and stability. In vitro experiments, animal trials and clinical observations reveal that this embolus is a good targeting medication for embolism treatment and immunochemotherapy, which is safe, effective for the treatment of solid tumors including primary liver cancer, lung cancer, renal tumors, bladder cancer, uterine cancer, ovary cancer, colon carcinoma and rectal cancer. | 06-25-2009 |
20090162441 | PULMONARY DELIVERY IN TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM - A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm | 06-25-2009 |
20090162442 | MULTI-PHASIC, NANO-STRUCTURED COMPOSITIONS CONTAINING A COMBINATION OF A FIBRATE AND A STATIN - The present invention discloses a pharmaceutical formulation containing a multi-phasic pharmaceutical composition in an oral dosage form. The multi-phasic pharmaceutical composition contains: (a) a fibrate, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (b) a statin, or a pharmaceutically acceptable salt, ester, hydrate, or prodrug thereof; (c) a solvent; (d) a non-miscible liquid; (e) a stabilizer; and (f) water. The fibrate or the statin or both is in a particulate state and/or a solubilized state. Such pharmaceutical formulations are capable of reducing the fed/fast variability and improving oral bioavailability to which a number of active pharmaceutical ingredients are susceptible. The pharmaceutical formulations of the invention, therefore are bioequivalent in fed and fasted states and have improved oral bioavailability. | 06-25-2009 |
20090162443 | COMPOSITIONS AND METHODS FOR REDUCING OR PREVENTING WATER LOSS FROM THE SKIN - Moisturizing compositions comprising microspheres for the purpose of preventing or reducing moisture loss from the skin. | 06-25-2009 |
20090162444 | RALOXIFENE COMPOSITION - A pharmaceutical composition comprising raloxifene or a pharmaceutically acceptable salt thereof, a mixed cellulose excipient, and a disintegrant can be conveniently made. | 06-25-2009 |
20090162445 | Composition for Repair of Defects in Osseous Tissues - Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form. | 06-25-2009 |
20090162446 | ABSORBENT ARTICLE HAVING A STABLE SKIN CARE COMPOSITION - The present invention relates to an absorbent article having a stable skin care composition disposed on its skin-contacting surface. The skin care composition is readily transferable to the skin via normal contact, wearer motion, and/or body heat. Importantly, the skin care composition contains at least one skin care ingredient imparting visible skin benefits to the skin upon transfer to the skin and at least one theological agent for stabilizing the composition such that agglomeration, stratification and/or settling of the composition are minimized. The present invention also relates to a process for making the absorbent articles having a stable skin care composition disposed thereon. | 06-25-2009 |
20090169629 | MICELLAR COMPOSITIONS WITH OPHTHALMIC APPLICATIONS - This invention relates to micellar compositions comprising at least one pharmaceutically active substance and a mixture of n-alkyl dimethyl benzyl ammonium chlorides, wherein the mixture comprises more than 30% n-alkyl dimethyl benzyl ammonium chlorides having a chain length superior or equal to C | 07-02-2009 |
20090169630 | Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications - Methods and compositions for the controlled and sustained release of peroxides or oxygen to aqueous environments (e.g. a patient's body or circulatory system, or for other applications) or non-aqueous environments, include a material coating or encapsulating hydrogen peroxide, inorganic peroxides or peroxide adducts. In the case of peroxide adducts, and particularly in one type of embodiment, the peroxide adducts should be able to permeate the material, but water, hydrogen peroxide and inorganic peroxides should be able to permeate the material. The methods and compositions that allow the release of oxygen, H | 07-02-2009 |
20090175947 | PHARMACEUTICAL COMPOSITION FOR INJECTIONAL PARTICULARLY TARGETED LOCAL ADMINISTRATION - The invention relates to a pharmaceutical composition for injectional, in particular targeted local administration, characterized in that it comprises a sterile suspension of platinum complex of general formula (I), wherein A and A′ independently of one another are an NH | 07-09-2009 |
20090186090 | Oral Care Composition to Reduce or Eliminate Dental Sensitivity - The invention includes an oral care composition that reduces and/or eliminates the perception of tooth sensitivity. The composition includes an adherent material and includes, in part, particles having a particle size of 2-5 microns. Also included within the scope of the invention are methods comprising the use of such compositions, such as methods of reducing dental sensitivity. | 07-23-2009 |
20090186091 | Methods of Treating Cardiovascular Disorders Associated with Atherosclerosis - Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material alone and in combination with other cholesterol-reducing agents in an amount effective to reduce hypercholesteremia in said mammal. Also provided are methods of treating a cardiovascular disorder associated with atherosclerosis in a mammalian subject comprising administering to the subject a layered phyllosilicate material in an amount effective to reduce atherosclerotic lesion formation in the subject. | 07-23-2009 |
20090191272 | Use of vegetable fine grain sized fibres for preparing a nutritional composition for reducing mycotoxin bioavailability - The invention relates to using substantially insoluble vegetable fibres embodied in the form of microparticles at least 90% in weight of which has a size less than 700 μm as ingredients for preparing a nutritional composition for reducing a mycotoxin bioavailability in a human being or an animal during ingestion of a food contaminated by said mycotoxins. | 07-30-2009 |
20090191273 | Metal Oxide Dispersion - A dispersion contains particles of metal oxide having a median volume particle diameter in the range from 24 to 42 nm which are dispersed in a medium which includes a mixture of at least one polar material having an interfacial tension of less than 30 mNm | 07-30-2009 |
20090196929 | Silica Wetcake Treatment Method - New methods of treating silica wetcake during precipitated silica materials manufacturing are provided. Such methods permit a significant increase in high solids content processing while simultaneously reducing high viscosity of the resultant particles for transport facilitation. The resultant precipitated silica wetcake is treated with a borate-containing dispersant to impart the necessary low viscosity characteristics thereto. Such a dispersant accords not only such a viscosity result, but will not char or otherwise discolor the silica particles during evaporation of the liquids within the wetcake itself. Furthermore, such a dispersant, if left on the surfaces of such particles, will not deleteriously affect the abrasivity, fluoride compatibility, or other dentifrice properties of the precipitated silica materials themselves. Also encompassed within this invention are the resultant precipitated silica particles exhibiting borate residues and dentifrices including such materials. | 08-06-2009 |
20090196930 | AEROSOLIZED NITRITE AND NITRIC OXIDE -DONATING COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described. | 08-06-2009 |
20090196931 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS - Methods are provided for inhibiting or treating stenosis or restenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective amount of a therapeutic agent via a catheter. Also provided is a catheter adapted for administering a therapeutically effective amount of a therapeutic agent to a mammalian host for inhibiting or treating stenosis or restenosis. | 08-06-2009 |
20090196932 | PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN - A dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof, as well as a dry-granulated pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof in combination with at least one other active drug, methods for preparing said compositions, kits for containing such compositions, and a method of treating hypercholesterolemia and/or hyperlipidemia, osteoporosis, benign prostatic hyperplasia (BPH), and Alzheimer's disease using a therapeutically effective amount of the pharmaceutical composition. | 08-06-2009 |
20090202643 | Oil-in-water emulsions containing lignan-class compounds and compositions containing the same - An object of the present invention is to increase the rate at which lignan-class compounds are absorbed into the body, namely, to provide fast-acting lignan-class compounds. | 08-13-2009 |
20090202644 | FUNCTIONAL NANOPARTICLE FILLED CARBON NANOTUBES AND METHODS OF THEIR PRODUCTION - Carbon nanotubes filled with a suspension or colloidal solution of functional nanoparticles and methods for production of carbon nanotubes loaded with functional nanoparticles are provided. | 08-13-2009 |
20090202645 | INTRASYNOVIAL FORMULATIONS OF STANOZOLOL - Disclosed are intrasynovial formulations comprising stanozolol and a suitable carrier. | 08-13-2009 |
20090202646 | Method For Preparing Nano-Scale Particle of Active Material - Disclosed herein is a method for preparing nanoscale particles of active material with using a gas of a supercritical fluid, by dissolving an active material into a solvent which is in solid phase at room temperature, to produce nanoscale particles of the active materials which can be advantageously used in medicine, cosmetics, functional foods or the like. | 08-13-2009 |
20090202647 | SOLID FORM OF RACEMIC ROTIGOTINE - Disclosed herein are solid state forms, amorphous and crystalline forms, of racemic rotigotine having high purity, adequate stability, good flowability and good dissolution properties, a process for preparation, and pharmaceutical compositions comprising amorphous racemic rotigotine. | 08-13-2009 |
20090202648 | AGRICULTURAL COMPOSITIONS - Compositions have been discovered that are suitable for forming a stable dispersion. The compositions comprise an agriculturally active compound and a multivalent metal oligomeric or polymeric compound having a molecular weight of from about 150 to about 15,000 Daltons. | 08-13-2009 |
20090208580 | Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles - The present invention relates to compositions comprising functionalized dendrimer-stabilized nanoparticles (DSNPs), functionalized dendrimer-encapsulated nanoparticles (DENPs) (e.g., metal DENPs), and methods of generating and using the same. | 08-20-2009 |
20090208581 | FORMULATIONS LIMITING SPREAD OF PULMONARY INFECTIONS - Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as vital infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be a surfactant and, optionally, a carrier. The formulation may be administered as a powder where the particles consist basically of the material altering surface tension. The carrier may be a solution, such as an alcohol, although an aqueous solution may be utilized, or a material mixed with the material altering surface tension to form particles. These may include proteins such as albumin or polysaccharides such as dextran, which also has surface active properties, or polymers such as polyethylene oxide (PEO) or biodegradable synthetic polymers which can be used to encapsulate or deliver the materials to be delivered. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation. | 08-20-2009 |
20090208582 | Templated Open Flocs of Anisotropic Particles for Enhanced Pulmonary Delivery - The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery. | 08-20-2009 |
20090214655 | Method and Device for Obtaining Micro and Nanometric Size Particles - The invention relates to a method and device for obtaining micro and nanometric particles in a controlled, reproducible manner. The aforementioned particles have a spherical shape and a very narrow, uniform size distribution. More specifically, the invention relates to a novel method of forming emulsions and to the application thereof in micro and nanoencapsulation techniques involving the extraction/evaporation of the solvent. In particular, the invention relates to the encapsulation of the fluorescent compounds and the subsequent application thereof. | 08-27-2009 |
20090214656 | ITRACONAZOLE COMPOSITIONS WITH IMPROVED BIOAVAILABILITY - A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>ΔH | 08-27-2009 |
20090214657 | Orally Absorbed Pharmaceutical Formulation and Method of Administration - A pharmaceutical formulation for absorption through oral mucosae comprising an effective amount of (a) a pharmaceutical agent in mixed micellar form, (b) at least one micelle-forming compound selected from the group comprising an alkali metal alkyl sulfate and a polyoxyethylene sorbitan monooleate, (c) a block copolymer of polyoxyethylene and polyoxypropylene, (d) at least one additional micelle-forming compound, and (e) a suitable solvent. The invention also provides a metered dose dispenser (aerosol or non-aerosol) containing the present formulation and a method of administering insulin using the metered dose dispenser comprising administering split doses of a formulation containing insulin before and after each meal. | 08-27-2009 |
20090214658 | Inorganic sorbent copolymer - A medicinal preparation useful for treating viral diseases and for prophylaxis of various diseases—including zoonotic diseases—along with methods of using the same, is described. The preparation comprises a fine crystalline antimony silicate-based sorbent of the compositional formula xA | 08-27-2009 |
20090214659 | MINERAL COMPOSITION - The invention relates to a mineral composition for improving well-being and fitness of living beings in general as well as in the presence of equipment emitting non-ionising electromagnetic radiation, comprising a layered phyllosilicate comprising paramagnetic ions and having a conductivity, measured in non-conductive water at a concentration of 1 wt. % of the mineral clay composition relative to the total weight of the non-conductive water and the mineral clay composition, of at most 20 μS/cm. | 08-27-2009 |
20090220609 | PROCESS TO CONTROL PARTICLE SIZE - A multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of: passing the pharmaceutical substance through a first stage of a particle size reduction process with a first set of particle size control parameters to obtain a feedstock of reduced median particle size and lesser distribution of median particle size for a second stage of a particle size reduction process; passing the feedstock, through a second stage of a particle size reduction process with a second set of particle size control parameters; optionally, using the product of the second stage or subsequent stages as a feedstock in further stages of a multi-stage particle size reduction process with a set of particle size control parameters for each stage; and collecting a pharmaceutical substance with a median particle size greater than 10 μm and with a narrow, reproducible distribution of median particle sizes. | 09-03-2009 |
20090220610 | Suspension Comprising Benzimidazole Carbamate and a Polysorbate - This invention is directed to a pharmaceutical composition for drinking water administration comprising benzimidazole carbamate particles having an effective average particle size of less than 450 nm and a TWEEN-type surfactant; a method for making the composition; use of the composition to make a medicament for controlling parasites; and a method for protecting an animal from a parasitic infection. | 09-03-2009 |
20090232892 | Cellooligosaccharide-Containing Composition - Disclosed is a cellooligosaccharide composition comprising, as the main ingredient, at least one cellooligosaccharide selected from the group consisting of cellobiose, cellotriose, cellotetraose, cellopentaose and cellohexaose, which is in the powdery form having an average L/D value of 3.0 or lower, a bulk density of 0.80 g/mL or lower and an angle of repose of 60° or lower. | 09-17-2009 |
20090232893 | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION - The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-143, using miR-143 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA. | 09-17-2009 |
20090232894 | Process for Stabilizing an Adjuvant Containing Vaccine Composition - The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form. | 09-17-2009 |
20090232895 | PROCEDURE AND DEVICES FOR THE CONTROLLED OBTAINING OF DRY SALINE AEROSOLS WITH THERAPEUTIC EFFECT - The patent refers to a procedure and devices for the generation of dry aerosols, continuously, by mechanic self-erosion, by average stirring in air or air-oxygen feed, of some crystals with special structure obtained by controlled crystallization processes. There can be also used other salts known to have physiological effects or mixtures of saline crystals with capacities close to the micro-particle generation. The devices can be for human or veterinary individual use, in intensive therapies or for producing aerosols with therapeutic or preventive effect in public rooms. | 09-17-2009 |
20090238876 | BISPHOSPHONATES FOR TREATING ENDOMETRIOSIS - A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject. | 09-24-2009 |
20090238877 | Agent For Improving Fine Wrinkles - An agent for improving fine wrinkles contains an oil based preparation for external use for skins, the oil based preparation containing: (i) 50% by mass to 95% by mass of an oil constituent, which contains 10% by mass to 100% by mass of a solid or semisolid oil constituent, and (ii) 5% by mass to 50% by mass of particles, the oil based preparation having occlusion characteristics of at least 50%. A beauty culture method for improving fine wrinkles comprises applying the oil based preparation for external use for skins onto a skin. | 09-24-2009 |
20090238878 | Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances With Reduced Ostwald Ripening - The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry. The present invention provides novel pharmaceutical compositions composed of solid nanoparticles dispersed in aqueous medium of substantially water insoluble pharmaceutical substances such as docetaxel with reduced Ostwald ripening. | 09-24-2009 |
20090238879 | DELIVERY SCAFFOLDS AND RELATED METHODS OF USE - The present invention relates to delivery systems. In particular, the present invention provides microporous scaffolds having thereon agents (e.g., extracellular matrix proteins, exendin-4) and biological material (e.g., pancreatic islet cells). In some embodiments, the scaffolds are used for transplanting biological material into a subject. In some embodiments, the scaffolds are used in the treatment of diseases (e.g., type 1 diabetes), and related methods (e.g., diagnostic methods, research methods, drug screening). | 09-24-2009 |
20090238880 | PHOSPHOLIPID-BASED PHARMACEUTICAL FORMULATIONS AND METHODS FOR PRODUCING AND USING SAME - Pharmaceutical formulations and methods of producing and using the same are described and claimed. The formulations are dispersions of phospholipids and one or more pharmacologically active compounds, pharmaceutically acceptable salts thereof, or prodrugs thereof. In specific embodiments, the pharmaceutically active compounds are ansamycins and the overall formulation is substantially devoid of medium and long chain triglycerides. | 09-24-2009 |
20090238881 | IONOPHORE ANTIBIOTIC FORMULATIONS - The invention relates to an ionophore antibiotic composition capable of diluting with water to a substantially stable dispersed form in all water than present, said composition comprising or including:—at least one ionophore antibiotic (preferably monensin) of a mean particle size of less than 20 microns,—and at least one dispersing agent. A method of preparing the ionophore antibiotic composition is also disclosed. | 09-24-2009 |
20090238882 | Carbon-substituted diketopiperazine delivery systems - Compositions useful in the delivery of active agents are provided. These delivery compositions include (a) an active agent; and (b) a carrier of at least one mono-C-substituted or di-C-substituted diketopiperazine. Methods for preparing these compositions and administering these compositions are also provided. | 09-24-2009 |
20090246281 | Soft steroid compositions for use in dry powder inhalers - A medicament and a method of producing a medicament are disclosed. The medicament contains a soft steroid and is suitable for administration via a dry powder inhaler. | 10-01-2009 |
20090246282 | RECOMBINANT GELATIN PARTICLES FOR CELL ADHESION - The present invention relates to cell carrier particles prepared from recombinantly produced gelatins comprising at least two outer lysine residues which are separated by at least 25 percent of the total number of amino acids in the recombinant gelatin polypeptide. The invention is also directed at applications in which such cell carriers are used, for example as injectable cell carrier, for tissue augentation or cosmetic surgery or as microcarrier in in vitro cell cultivation. | 10-01-2009 |
20090246283 | Repeat Sequence Protein Polymer Nanoparticles Optionally Containing Active Agents and Their Preparation - A nanocomposite of a repeat sequence protein polymer, such as a copolymer of silk and elastin, is produced by Supercritical Antisolvent Precipitation with Enhanced Mass Transfer (SAS-EM). The nanocomposite may include an active agent, such as a protein or hormone, that is releasably bound to the repeat sequence protein polymer. | 10-01-2009 |
20090246284 | O-desmethylvenlafaxine Cocrystals - Disclosed herein are co-crystals comprising O-desmethylvenlafaxine and succinic acid, process for the preparation, pharmaceutical compositions, and method of treating thereof. | 10-01-2009 |
20090252801 | Process for the Preparation of Micronised Sterile Steroids - The present invention relates to a process for the preparation of micronised sterile steroids, comprising sterilisation of the steroids in crystalline form by means of irradiation with gamma or beta rays, and subsequent sterile micronisation. | 10-08-2009 |
20090252802 | Compositions Including Relatively Water Insoluble/Unwettable Drugs And Methods For Using Same - Compositions including therapeutic components and surfactant components which enhance the utility of the therapeutic components and methods of using such compositions are provided. | 10-08-2009 |
20090252803 | GLYCYRRHETINIC ACID-MEDIATED NANOPARTICLES OF HEPATIC TARGETED DRUG DELIVERY SYSTEM, PROCESS FOR PREPARING THE SAME AND USE THEREOF - Disclosed are a hepatic targeted drug delivery system and a process for preparing the same. Also disclosed is a method for treating liver cancer. | 10-08-2009 |
20090252804 | MEDICAL DEVICES WITH AN ANTIBACTERIAL POLYURETHANEUREA COATING - The present invention relates to a medical device which has at least one coating which is obtained starting from an aqueous dispersion, the aqueous dispersion comprising at least one nonionically stabilized polyurethaneurea and at least one silver-containing constituent. | 10-08-2009 |
20090258068 | Titanium Oxide-Zinc Oxide Aggregate Powder And Production Method Thereof - The present invention provides a powder that can display excellent protection ability in both UV-A and UV-B regions. The titanium oxide-zinc oxide aggregate powder comprises an aggregate formed by the aggregation of porous titanium oxide particles and zinc oxide particles, and said porous titanium oxide particle is an aggregate of primary fine particles of titanium oxide. The production method of the titanium oxide-zinc oxide aggregate powder comprises the steps of: (a) hydrolyzing, with heating, an aqueous solution containing a titanium salt and an aliphatic alcohol; (b) adding a water-soluble zinc salt to a suspension of a precipitate obtained by the hydrolysis with heating in step (a), and then neutralizing the suspension with an alkali; and (c) calcining a precipitate obtained by the neutralization in step (b). | 10-15-2009 |
20090258069 | Delivery of LFA-1 antagonists to the gastrointestinal system - The present invention provides compositions and methods for treating disorders and diseases by delivery of LFA-1 antagonists to the gastrointestinal system. Methods include delivery of LFA-1 antagonists to effect localized treatment. | 10-15-2009 |
20090258070 | Topical LFA-1 antagonists for use in localized treatment of immune related disorders - This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for topical delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 topical formulations of the present invention. | 10-15-2009 |
20090258071 | COMPOSITIONS AND METHODS FOR PH TARGETED DRUG DELIVERY - The invention provides compositions and methods for the targeted, in particular, pH targeted, delivery of pharmaceutically active agents in mammals. The compositions comprise pH sensitive diblock copolymers, which permit the release of the pharmaceutically active agent when exposed to an environment having a particular pH. The compositions are particularly useful for the oral delivery of water insoluble pharmaceutically active agents. | 10-15-2009 |
20090258072 | LARGE ULTRAVIOLET ATTENUATING PIGMENTS - Large particle sunscreen powders useful as ingredients in cosmetic compositions and in dispersions for incorporation into cosmetic compositions comprise a UV shielding agent in a matrix material. The macroparticle powders can be used in a wide range of cosmetic formulations, including sunscreens, eyeshadow, mascara, foundation, blusher, toner, lipstick and other compositions requiring ultraviolet protection. | 10-15-2009 |
20090258073 | MAGNETIC CARRIER AND MEDICAL PREPARATION FOR CONTROLLABLE DELIVERY AND RELEASE OF ACTIVE SUBSTANCES, METHODS OF THEIR PRODUCTION AND METHODS OF TREATMENT USING THEREOF - The present invention relates to magnetic carriers and medical preparations for controllable delivery and release of active substances. The carrier for active substances comprises material A, which is magnetically or electrically sensible, and material B capable of controlling the retention/release rate of the said active substance from the said carrier, the said retention/release rate being temperature dependent; wherein the material B is in thermal contact with material A, and wherein the material A has magnetocaloric or electrocaloric effect sufficient to substantially vary the said retention/release rate of the active substance from the carrier. The invention further provides methods for controllable delivery and release of active substances in a predetermined place and at a predetermined time, and methods of treatment using these carriers. Methods of production of magnetic carriers are also proposed. | 10-15-2009 |
20090263485 | Targeted hollow gold nanostructures and methods of use - Provided are novel nanostructures comprising hollow nanospheres and nanotubes for use as chemical sensors and molecular specific photothermal coupling agents. The nanostructures can be used in laser-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are of particular use in the fields of clinical diagnosis, clinical therapy, clinical treatment, and clinical evaluation of various diseases and disorders, manufacture of compositions for use in the treatment of various diseases and disorders, for use in molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof. The hollow gold nanospheres have a unique combination of spherical shape, small size, and strong, tunable, and narrow surface plasmon resonance absorption covering the entire visible to near IR region. | 10-22-2009 |
20090263486 | NANOPARTICLE-STABILIZED CAPSULE FORMULATION FOR TREATMENT OF INFLAMMATION - A formulation for the delivery of an anti-inflammatory agent to a subject is described. In one particular application of the invention, the formulation comprises oil-based or aqueous droplets comprising indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetic acid) or celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl) pyrazol-1-yl] benzenesulfonamide) stabilised by nanoparticles, particularly silica nanoparticles. | 10-22-2009 |
20090263487 | Bubble drink provided by bubbling engineering progress - A bubble drink as a health food, which is produced by imparting a catalytic function for gas escaping to an adsorptive fine food powder to allow the fine food powder to be dispersed in a colloidal solution reverse vessel, and reacting the dispersion with a gas-saturated solution to generate foam (a bubbling engineering process), whereby the food is converted into foam having a three-state composite structure of gas, liquid and solid states suitable to be ingested within a digestive system. | 10-22-2009 |
20090263488 | PRESSURISED METERED DOSE INHALERS CONTAINING SOLUTIONS OF BETA-2 AGONISTS - The present invention relates to a pharmaceutical formulation for use in the administration of 2(1H)-quinolinone derivatives long-acting β | 10-22-2009 |
20090269408 | Aqueous formulations of imidoalkanepercarboxylic acids - Liquid formulations of imidoalkanepercarboxylic acids, in the form of aqueous dispersions comprising, in percentages by weight relative to the total weight of the composition: A) from ≧7% to 40% and preferably from 10% to 20% of imidoalka-nepercarhoxylic acids having the general formula (I), the said imidoalkanepercarboxylic acids being in the β form and having a dissolution time, determined via the test of the rate of dissolution at a temperature of 40° C. or 18° C., of not more than 5 minutes when determined at 40° C. or 15 minutes when determined at 18° C., for an amount of dissolved acid equal to 99% of the theoretical amount; B) from 0.001% to 0.9% of a nonionic surfactant; the said dispersions having a viscosity of not more than 2000 mPa·sec at 25° C. by applying a shear rate of 20 s | 10-29-2009 |
20090269409 | PHARMACEUTICAL COMPOSITIONS COMPRISING ESZOPICLONE - Pharmaceutical compositions comprising eszopiclone, including its pharmaceutically acceptable salts, hydrates, clathrates, solvates, polymorphs, and mixtures thereof. The invention also relates to processes for preparing the compositions and their methods of use. | 10-29-2009 |
20090269410 | Inhibition of Neovascularization by Cerium Oxide Nanoparticles - The present invention provides methods for reducing, reversing or inhibiting neovascularization in a tissue of a mammalian subject having a pathological condition involving neovascularization by administration in vivo of nanoceria particles (cerium oxide nanoparticles) to the subject. The method of the invention is useful, for example, for reducing, treating, reversing or inhibiting neovascularization in ocular tissue such as the retina, macula or cornea; in skin; in synovial tissue; in intestinal tissue; or in bone. In addition, the method of the invention is useful for reducing or inhibiting neovascularization in a neoplasm (tumors), which can be benign or malignant and, where malignant, can be a metastatic neoplasm. As such, the invention provides compositions, which contain nanoceria particles and are useful for reducing, treating, reversing or inhibiting angiogenesis in a mammalian subject. | 10-29-2009 |
20090274763 | IMMUNOADJUVANT - An immunoadjuvant comprising one kind or two or more kinds of immunostimulating substances carried separately by two or more kinds of different microparticle immunostimulating substance carriers, and comprising at least a combination of (a) an inorganic substance such as microparticle calcium phosphate having a size phagocytizable by cells, and (b) precipitates of a soluble protein and a mucopolysaccharide formed by coacervation as the microparticle immunostimulating substance carriers, which is highly safe and can exhibit potent immunoadjuvant activity. | 11-05-2009 |
20090274764 | Hollow Foam Beads for Treatment of Glioblastoma - Compositions and methods for the treatment of tumors are disclosed. Specifically, the present invention provides hollow foam beads having a chemotherapeutic agent incorporated therein. A method of making such beads is disclosed. In addition, a method for treating a glioblastoma tumor and other types of tumors with the compressible hollow foam beads is disclosed. | 11-05-2009 |
20090280184 | PHARMACEUTICAL COMPOSITION, METHOD OF PREPARATION AND METHODS OF TREATING ACHES/PAINS - Provided are methods and compositions useful for treating/aches and/or pains. The compositions comprise an herbal therapeutic agent and an analgesic agent, wherein the composition is effective when delivered to the mucosal membrane. | 11-12-2009 |
20090280185 | Particulate wood preservative and method for producing the same - A wood preservative includes injectable particles comprising one or more sparingly soluble copper salts. The copper-based particles are sufficiently insoluble so as to not be easily removed by leaching but are sufficiently soluble to exhibit toxicity to primary organisms primarily responsible for the decay of the wood. Exemplary particles contain for example copper hydroxide, basic copper carbonate, copper carbonate, basic copper sulfates including particularly tribasic copper sulfate, basic copper nitrates, copper oxychlorides, copper borates, basic copper borates, and mixtures thereof. The particles typically have a size distribution in which at least 50% of particles have a diameter smaller than 0.25 μm, 0.2 μm, or 0.15 μm. At least about 20% and even more than 75% of the weight of the particles may be composed of the substantially crystalline copper salt. Wood or a wood product may be impregnated with copper based particles of the invention. | 11-12-2009 |
20090285898 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH AN ANTICHOLINERGIC BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anticholinergic bronchodilator for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. | 11-19-2009 |
20090285899 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A METHYLXANTHINE DERIVATIVE FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a methylxanthine derivative for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. | 11-19-2009 |
20090285900 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A BETA-AGONIST BRONCHODILATOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a β2-agonist bronchodilator for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. | 11-19-2009 |
20090285901 | Polyamino acid for use as adjuvant - Use of a polyamino acid as an adjuvant; an application of a polyamino acid as an adjuvant in the production of a vaccine; a vaccine comprising a polyamino acid as an adjuvant; a biodegradable nanoparticle having a virus antigen immobilized thereon; and a vaccine comprising the biodegradable nanoparticle. | 11-19-2009 |
20090285902 | DIETARY SUPPLEMENT COMPOSITION FOR BLOOD LIPID HEALTH - A human or animal dietary supplement composition comprising one or more long chain (C24-C36) primary alcohols (policosanols) dispersed in food-grade oils or fats where the policosanol particle size is substantially less than ten (10) microns. The composition (Nanocosanol™) is effective and convenient for supporting blood lipid health. | 11-19-2009 |
20090285903 | METHODS FOR DENDRITIC CELL THERAPY USING PHARMACOLOGICALLY ACTIVE MICROCARRIERS - Monocytes and dendritic cells are grafted to the surface of microparticles for use as a therapeutic device for stimulating a post-injection immune response in vivo. Various embodiments include an injectable composition, an apparatus for grafting cells to the surface of polymer microspheres, and methods of facilitating activation and delivery of an injectable therapeutic device are disclosed. | 11-19-2009 |
20090291141 | METHOD OF QUENCHING ELECTRONIC EXCITATION OF CHROMOPHORE-CONTAINING ORGANIC MOLECULES IN PHOTOACTIVE COMPOSITIONS - The photostabilizing electronic excited state energy—particularly singlet state energy from a UV-absorbing molecule has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds of formulas (I) and (V) having an alkoxy radical preferably in the four (para) position (hereinafter methoxycrylenes) on one or both of the phenyl rings: | 11-26-2009 |
20090291142 | NANOPARTICULATE BICALUTAMIDE FORMULATIONS - The present invention is directed to compositions comprising an acylanilide, such as bicalutamide, having improved solubility in water. The bicalutamide particles of the composition have an effective average particle size of less than about 2000 nm, and are useful in the treatment of prostate cancer. | 11-26-2009 |
20090291143 | Combination of Azelastine and Steroids - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 11-26-2009 |
20090291144 | Therapeutic and Prophylactic Compositions Including Catalytic Biomimetic Solids and Methods to Prepare and Use Them - The invention discloses therapeutic and prophylactic compositions based on synthetic solid catalysts such as zeolites, clays, silicates, silicas and double hydroxides. These solids can be used to treat numerous disease conditions such as diabetes, arthritis and other autoimmune diseases, cancer, skin diseases, microbial infections etc. The invention also describes methods to produce such products and use them independently or in combination with other pharmaceutically and biologically active ingredients. Such catalysts are designed so to imitate biological catalytic systems (enzymes, antigen presenting cells, delayed active component release, cell organeles, etc.) and are, therefore, biomimetic. | 11-26-2009 |
20090297608 | BONE MARROW-DIRECTING DRUG DELIVERY MATERIALS AND THEIR APPLICATIONS - The present invention pertains to a bone marrow-directing drug delivery material that includes at least one fine particle, wherein the fine particle includes an anionic moiety on a surface of the particle. Also disclosed are uses of the material set forth herein for the prevention, treatment, or diagnosis of a disease of bone, cartilage, bone marrow, or a joint. Also disclosed are methods of preventing, treating, or diagnosing a disease of bone, cartilage, bone marrow, or a joint in a subject, involving administering to the subject a pharmaceutically effective amount of the material of the present invention. | 12-03-2009 |
20090297609 | Method of Biomolecule Immobilization On Polymers Using Click-Type Chemistry - The present invention provides a method for the covalent immobilization of biomolecules on polymers for delivery of the biomolecules, which has the advantage of being simple, highly efficient, environmentally friendly and free of side products relative to traditional immobilization techniques. The invention provides a modified micro/nanoparticle system, which uses a functionalized polymer formed into micro or nanoparticles to bind a molecule to the particles using uses facile chemistry, the Diels-Alder cycloaddition between a diene and a dienophile with the polymer being functionalized with one of them and the molecule with the other, or the Huisgen 1,3-dipolar cycloaddition between a terminal alkyne and an azide to bind the molecule to the particle. The molecules and/or other therapeutic agents may be encapsulated within the polymer particles for intravenous therapeutic delivery. The invention also provides a novel synthetic biodegradable polymer, a furan/alkyne-functionalized poly(trimethylene carbonate) (PTMC)-based polymer, whose composition can be designed to meet the defined physical and chemical property requirements. In one example, the particle system self-aggregates from functionalized PTMC-based copolymers containing poly(ethylene glycol) (PEG) segments. The composition of the copolymers can be designed to meet various particle system requirements, including size, thermodynamic stability, surface PEG density, drug encapsulation capacity and biomolecule immobilization capacity. | 12-03-2009 |
20090297610 | Composition and system to promote wound healing - An externally applied non-absorbent composition applied to a wound to promote the healing of skin. The composition contains a plurality of granulated minerals to provide a protective cover and to mask the wound. The composition, together with similar compositions, may be assembled as a system and layered above the wound to better bar undesired particles from contaminating the wound and to camouflage the wound site. The compositions of the system may each be applied via a dispensing brush which retains the composition in a reservoir and dispenses the composition to the skin through the brush bristles, preventing contamination of the composition from the wound. | 12-03-2009 |
20090297612 | HOMOGENEOUS, INTRINSIC RADIOPAQUE EMBOLIC PARTICLES - The invention is directed to embolic material comprising spherical, homogeneous and substantially non-porous radiopaque polymer particles based on at least one hydrophilic monomer and at least one radiopaque monomer according to general formula | 12-03-2009 |
20090304796 | Nanoparticle suitable for delivery of a biomolecule into or out of a membrane enclosed cell or cell organelle - A nano sized particle for in vitro or ex vivo biomolecule delivery to cell cultures through heat induced endosomal release comprising a superparamagnetic core coated in a heat sensitive coating, comprising membrane disruptive components and binding sites for attachment of biomolecules and markers to be delivered is provided. A method is provided for introducing the release effect of a plurality of said biomolecule and endosomal disrupture molecules by applying an alternating field to a cell culture harbouring the particle described by the invention. | 12-10-2009 |
20090304797 | Process for the Preparation of Micronized Valsartan - The present invention relates to process for preparing micronized Valsartan with particle size distribution of d | 12-10-2009 |
20090304798 | Methods and compositions for therapeutic use of RNA interference - The present invention provides methods and compositions for attenuating expression of a target gene in vivo. In general, the method includes administering RNAi constructs (such as small-interfering RNAs (i.e., siRNAs) that are targeted to particular mRNA sequences, or nucleic acid material that can produce siRNAs in a cell), in an amount sufficient to attenuate expression of a target gene by an RNA interference mechanism, e.g., in a sequence-dependent, PKR-independent manner. In particular, the subject method can be used to alter the growth, survival or differentiation of cells for therapeutic and cosmetic purposes. | 12-10-2009 |
20090304799 | NANOEMULSION INFLUENZA VACCINE - The present invention relates to methods for inducing an immune response to influenza in a subject comprising administering a nanoemulsion vaccine composition comprising an influenza immunogen or protein. | 12-10-2009 |
20090311326 | Pulmonary Insulin Crystals - The present invention provides methods and compositions for treating diabetes by administering insulin or an insulin analog via a pulmonary route, wherein the insulin or insulin analog is in crystalline form with a diameter below 10 microns when recovered from a solution having a pH between 7.0 and 9.5. The insulin or insulin analog may be in the form of a dry. The present invention provides methods and compositions for treating diabetes by administering acylated insulin or an acylated insulin analog via a pulmonary route. The insulin or insulin analog may be in the form of a dry powder or a solution. | 12-17-2009 |
20090311327 | Oral Therapeutic Compound Delivery System - The present, invention provides an oral delivery system for a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof with pharmacological, physiological or biochemical activity. The present invention particularly provides a swallow formulation comprising a therapeutic compound that is an acid, a salt of an acid or an unionized compound or a proactive form thereof which facilitates the rapid delivery of the therapeutic compound to the circulatory system. | 12-17-2009 |
20090311328 | Bulking of Soft Tissue - A soft tissue bulking material includes a plurality of particles. Each particle comprises a rounded polymeric shell defining an internal cavity and having a maximum outer dimension of 50 μm-250 μm. A port or opening is provided in the shell. The port or opening thus provides access to the cavity. The port or opening has a size or dimension that ranges from one tenth of the particle's outer dimension up to the particle's outer dimension. | 12-17-2009 |
20090311329 | CASEIN MICELLES FOR NANOENCAPSULATION OF HYDROPHOBIC COMPOUNDS - The present invention relates to the field of food technology and delivery of hydrophobic biologically active compounds, particularly nutrients, via food products and beverages. In particular the present invention provides isolated casein micelles useful for the encapsulation of hydrophobic nutrients, therapeutic and cosmetic compounds, compositions thereof and methods of preparing the micelles. | 12-17-2009 |
20090311330 | LIQUID ORAL COMPOSITIONS - A suspension which is suitable for oral administration, comprising simvastatin, at least one suspending agent, and at least one preservative, wherein at least 90 wt % of the particles of simvastatin are less than 100 μm in diameter. The present invention also includes uses of the suspension and methods of making the suspension. | 12-17-2009 |
20090311331 | Pellet Formulation Comprising Colloidal Silicon Dioxide - The present invention provides a pellet formulation comprising colloidal silicon dioxide (CSD) and one or both of a surfactant and a plasticiser. A process for the production of 5 said formulation is also provided. | 12-17-2009 |
20090311332 | Method for forming mesoporous silica nanoparticles, mesoporous silica nanopartices, and applications thereof - A method for synthesizing a mesoporous silica nanoparticle, a mesoporous silica nanoparticle, and applications thereof are provided. The method includes fractionating a mesoporous silica nanoparticle suspension to produce size-fractionated mesoporous silica nanoparticle. The method further includes etching the size-fractionated mesoporous silica nanoparticle to produce synthesized mesoporous silica nanoparticle having a hollow, porous morphology configured to receive one of a therapeutic agent and an imaging material. The etching includes differential etching of silica from areas of low polymeric density within the mesoporous silica nanoparticle and re-depositing of the silica in areas of higher polymeric density existing near the surface of the mesoporous silica nanoparticle. A target material is loaded into the synthesized mesoporous silica nanoparticle and a controlled released of the target material is provided by decreasing the physiological pH of the surface of the mesoporous silica nanoparticle. | 12-17-2009 |
20090311333 | FEED OR FOOD PRODUCT COMPOSITION - The present invention relates to a feed or food product composition which comprises a mixture of bovine colostrum, comprising bioactive components, and organic particulate matter having a size between 0.3 and 7 mm in diameter. The composition is especially adapted to deliver the mixture of bioactive bovine colostrum components to the digestive tract of a mammal. | 12-17-2009 |
20090317475 | COMBINATION ANTITUMOR THERAPIES - Improved methods of treating cancers that are characterized by unwanted angiogenesis employ combinations of therapies designed to inhibit the VEGF mediated angiogenesis pathway with therapies designed to inhibit the bFGF-mediated angiogenesis pathway. | 12-24-2009 |
20090317476 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LEUKOTRIENE RECEPTOR ANTAGONIST FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a leukotriene receptor antagonist for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. | 12-24-2009 |
20090317477 | COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A GLUCOCORTICOSTEROID FOR TREATMENT OF ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE OR ALLERGIC RHINITIS - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a glucocorticosteroid for the treatment of asthma, chronic obstructive pulmonary disease, allergic rhinitis, or any other respiratory disease. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or any other respiratory disease. | 12-24-2009 |
20090324723 | Method of prophylaxis of infection - A method for prophylaxis of infection of the respiratory tract of a subject by pathogenic airborne bacteria the method comprising administering to the subject by inhalation binding proteins directed against the bacteria. the pathogenic bacteria is a bacteria which survives inside phagocytes and the binding proteins are directed against said bacteria which survives inside phagocytes. The binding proteins comprise antibodies or antibody fragments directed against said bacteria which survives inside phagocytes. The binding proteins are selected from the group consisting of polyclonal antibodies, monoclonal antibodies, F(ab) fragments, F(ab′) | 12-31-2009 |
20090324724 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS - The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers. | 12-31-2009 |
20090324725 | PEG-MODIFIED HYDROXYAPATITE, PHARMACEUTICAL USING THE SAME AS BASE MATERIAL AND PRODUCTION PROCESS THEREOF - The present invention provides a PEG-modified HAP having a high degree of safety and novel functions by modifying the surface of hydroxyapatite particles with a polyethylene glycol derivative, applications thereof, and a production process of the same. The PEG-modified HAP of the present invention is a substance in which hydroxyapatite having a particle diameter of 50 μm to 10 nm is bonded to a polyethylene glycol derivative having a carboxyl group as a terminal functional group through —O(CO) bonds, and the carbon content thereof is 10 to 0.1%. In addition, the present invention is a substance composed of this substance and a pharmaceutical active ingredient or pharmaceutical additive, in which the weight ratio of the pharmaceutical active ingredient is 1 to 30%, and the substance is obtained by treating hydroxyapatite having a particle diameter of 50 μm to 10 nm and an active ester of polyethylene glycol derivative having a carboxyl group as a terminal functional group in an anhydrous organic solvent. | 12-31-2009 |
20090324726 | Non-Viral Gene Therapy Using Chitosan-Containing Nanoparticles - The present invention concerns a new drug delivery system and more particularly, a non-viral drug delivery system comprising a polymer according to the following formula and useful for treating a disease characterized by over-expression of folic acid receptors on the cell surface. | 12-31-2009 |
20090324727 | NANOEMULSION - The present invention relates to a nanoemulsion comprising at least one aqueous component and a carrier, wherein the carrier comprises at least one lipophilic component, at least one surfactant and at least one alcohol, characterised in that at least one alcohol has at least three carbon atoms. The present invention further relates to a composition comprising said nanoemulsion and an active agent. In particular, the composition is present as a gel and the active agent is 5-aminolevulinic acid, a derivative, precursor and/or metabolite thereof. The invention further relates to the preparation of said nanoemulsion and/or composition and to their use for the treatment of dermatological diseases, virus-associated diseases as well as diseases associated with cell proliferation, in particular, tumor diseases and/or psoriasis. The present invention is further directed to the use of said nanoemulsion in cosmetics. | 12-31-2009 |
20090324728 | PHARMACEUTICAL COMPOSITIONS COMPRISING AMORPHOUS BENZIMIDAZOLE COMPOUNDS - Compositions comprising amorphous substituted benzimidazole compounds. | 12-31-2009 |
20100003330 | ANTIMICROBIAL NANOEMULSION COMPOSITIONS AND METHODS - The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs. | 01-07-2010 |
20100003331 | SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE - A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier. | 01-07-2010 |
20100003332 | Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug - A powder comprising nanoparticles of a sparingly water-soluble drug prepared in accordance with the present invention exhibits enhanced bioavailability without generating adverse side effects caused by impurities, while the nano-particle size of the drug remains unchanged when administered. Accordingly, the powder can be useful for the development of a formulation of a sparingly water-soluble drug for oral and parenteral administration. | 01-07-2010 |
20100003333 | COMPOSITIONS AND METHODS FOR TREATING DIGESTIVE DISORDERS - Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating digestive disorders or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said digestive disorders by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions. | 01-07-2010 |
20100003334 | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use - This invention relates to formulations for topical use comprising antibiotics in combination with anti-inflammatory steroids for treating ophthalmic infections and attendant inflammation. More specifically, this invention relates to pharmaceutical ophthalmic formulations comprising a pH stabilizing amount of tobramycin and the soft steroid loteprednol etabonate. | 01-07-2010 |
20100008993 | Compositions and Methods for Increasing Bioavailability of Topical Ophthalmic Drugs - An ophthalmic composition comprises an ophthalmic drug that has a low solubility in water and a surfactant, wherein the ophthalmic drug is present at a concentration from about 3 to about 7000 times the solubility of the drug in water. A volume of about 1-15 microliter is administered topically to an eye of a subject to treat or control a condition for which the drug is effective. | 01-14-2010 |
20100008994 | ELECTROSPUN STRUCTURES AND METHODS FOR FORMING AND USING SAME - The present invention relates to structures that contain one or more fiber and/or nanofiber structures where such structures can be formed on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.). In one embodiment, the present invention relates to a process for forming one or more fibers, nanofibers or structures made therefrom on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.). In another embodiment, the present invention relates to a process for forming one or more fibers, nanofibers or structures made therefrom on a wide variety of structures or surfaces (e.g., asperities, flat surfaces, angled surface, hierarchical structures, etc.) where such fibers and/or structures are designed to sequester, carry and/or encapsulate one or more substances. In still another embodiment, the present invention relates to structures that contain one or more fiber and/or nanofiber structures on asperities where the nanofiber and/or fiber structures are designed to sequester, carry and/or encapsulate one or more substances. | 01-14-2010 |
20100008995 | Processes for preparing pharmaceutical compositions - A process for the production of a composition comprising a water-insoluble triptan which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble triptan, ii) a water soluble carrier, and iii) a solvent for each of the triptan and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the triptan in the carrier. | 01-14-2010 |
20100008996 | INHALATIVE AND INSTILLATIVE USE OF SEMIFLUORINATED ALKANES AS AN ACTIVE SUBSTANCE CARRIER IN THE INTRAPULMONARY AREA - A medical aid for the direct transport of at least one drug into lung regions of a patient, wherein provided as the carrier for at least one active substance is at least one semifluorinated alkane in which the at least one active substance is purely physically dissolved in a homogeneous phase. | 01-14-2010 |
20100008997 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS - Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent. | 01-14-2010 |
20100008998 | SUBMICRON NANOPARTICLE OF POORLY WATER SOLUBLE CAMPTOTHECIN DERIVATIVES AND PROCESS FOR PREPARATION THEREOF - The present invention relates to a nanoparticle composition comprising a camptothecin derivative, solid polyethyleneglycol and an anti-associative agent, and the process for preparing the same. Specifically, the present invention provides a composition comprising a nanoparticle of the camptothecin derivative, which is prepared by solid-dispersing the poorly water soluble camptothecin derivative in polyethyleneglycol and dissolving the solid dispersions in an aqueous solution containing an anti-associative agent. The composition of the present invention stabilizes the camptothecin derivative lactone form in body fluid for effective anticancer activity. | 01-14-2010 |
20100008999 | COMPOSITIONS FOR ORAL ADMINSTRATION OF ACTIVE PRINCIPLES REQUIRING MASKING OF TASTE - Composition intended for the oral administration of active principles with unacceptable taste, which comprises from about 15% to about 30% of organoleptically unpleasant active ingredient (principle) that is mixed with from about 60% to about 80% of an ester of glycerol or of a fatty acid, to which a wax is optionally added and to which a surfactant is added, and in that it is prepared by a spray-cooling process which can produce a particle size of less than 350 μm. | 01-14-2010 |
20100015232 | NANOPARTICLES FOR NUCLEIC ACID DELIVERY - The present invention provides chitosan/RNA nanoparticles that are useful as research tools or medicaments. Preferably, the RNA part of the nanoparticle is a siRNA capable of modulating the expression of a target mRNA. The invention also provides methods for the preparation of chitosan/RNA nanoparticles. | 01-21-2010 |
20100015233 | anti-parasitic compositions - The present invention relates to nanodisperse antiparasitics and provides a composition comprising at least one water insoluble anti-parasitic drug and a water-soluble carrier material, wherein the water-insoluble anti-parasitic drug (preferably an Artemisinin-type drug or a quinine type drug) is dispersed through the carrier material in nano-disperse form having a peak diameter of the nano-disperse form below 1000 nm. The invention further provides an aqueous dispersion of a water insoluble anti-parasitic drug and a water-soluble carrier material, wherein the anti-parasitic drug is in nano-disperse form having a peak diameter of the nano-disperse form below 1000 nm, the invention further subsists in a process for preparing an anti-parasitic composition comprising a water insoluble anti-parasitic agent and a water-soluble carrier, which comprises the steps of either: a) providing an emulsion comprising a solution of the anti-parasitic agent in a water-immiscible solvent for the same, and an aqueous solution of the carrier, or providing a mixture comprising at least one non-aqueous solvent optional water a water-soluble carrier material soluble in the mixture and a water-insoluble anti-parasitic agent soluble in the mixture, and, b) drying the emulsion (preferably by spray drying) to remove water and the water-immiscible solvent to obtain a substantially solvent-free nano-dispersion of the anti-parasitic agent in the carrier. | 01-21-2010 |
20100015234 | Pharmaceutical preparations and their manufacture - A method for making a composition comprising active particles comprising an active substance comprises the steps of a) providing an emulsion having a dispersed phase comprising a solution of the active substance in a solvent and b) inducing the formation, in the emulsion, of solid particles comprising the active substance. The particles may be isolated from the emulsion. Active particles having a normalized kurtosis of at least 5 and a mean diameter of less than 100 μm are provided. | 01-21-2010 |
20100015235 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 01-21-2010 |
20100015236 | PESTICIDE NANOPARTICLES OBTAINED FROM MICROEMULSIONS AND NANOEMULSIONS - The present invention provides a redispersible powder and aqueous dispersions of nanoparticles of water insoluble organic pesticides. The invention further provides methods for preparing the redispersible powder and the aqueous dispersion, wherein the methods include preparation of an oil-in-water nanoemulsion or microemulsion and solvent removal. The present invention also provides pesticidal compositions of the redispersible powder or aqueous dispersions, and their agricultural use in combating pests. | 01-21-2010 |
20100015237 | NSAID Delivery from Polyarylates - This invention provides biodegradable, sustained-release pharmaceutical compositions of non-steroidal, anti-inflammatory drugs (NSAIDs) formulated with biocompatible, biodegradable tyrosine-derived polyarylates. The compositionsare particularly suitable for localized delivery of NSAIDs for various disease states. For example, implantation of the compositions at the site of surgery leads to relatively high local concentrations of the NSAID to reduce or alleviate post-surgical pain. Long term zero order release of certain NSAIDs can also be provided by with certain polymer formulations. | 01-21-2010 |
20100021546 | CONTROLLED-RELEASE IMMUNOGENIC FORMULATIONS TO MODULATE IMMUNE RESPONSE - Single-dose controlled-release immunogenic formulations, such as vaccines, based on bioerodible polyanhydride copolymer or homopolymer microparticles for the control of immune response mechanisms are provided. The copolymer or homopolymer microparticles degrade by surface-erosion from in vivo hydrolysis of anhydride linkages at the surface of the microparticle, which results in controlled release of immunogen(s) to a patient. | 01-28-2010 |
20100021547 | PHARMACEUTICAL COMPOSITION FOR PIPERIDINOALKANOL COMPOUNDS - The invention provides a pharmaceutical composition in solid unit dosage form, comprising, a) a therapeutically effective amount of a piperidinoalkanol compound or a pharmaceutically acceptable salt thereof; and, b) at least one inert ingredient. | 01-28-2010 |
20100021548 | USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE RESPONSES - The use of poly(lactide) or poly(lactide-co-glycolide) microparticles with adsorbed antigen is disclosed. The microparticles are useful for enhancing CTL responses to a selected antigen. | 01-28-2010 |
20100028439 | Nanoparticulate stabilized anti-hypertensive compositions - The present invention is directed to anti-hypertensive compositions comprising a nanoparticulate temocapril, or a salt or derivative thereof, having improved bioavailability. The nanoparticulate temocapril particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of hypertension and related diseases. | 02-04-2010 |
20100028440 | DRYING OF DRUG-CONTAINING PARTICLES - A secondary drying process is disclosed for removing residual solvent from drug-containing particles that have been formed by solvent-based processes. | 02-04-2010 |
20100028441 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 02-04-2010 |
20100028442 | METHODS OF THERAPEUTIC TREATMENT OF EYES - Provided are electrokinetically-altered aqueous fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating an irritation, infection or inflammatory eye condition, comprising administering to, by contacting the eye of a subject in need thereof a therapeutically effective amount of an electrokinetically-altered aqueous fluid. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids) and therapeutic compositions for use in treating eye conditions. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids to treat a cosmetic and/or therapeutic symptom related to eye conditions and/or diseases. | 02-04-2010 |
20100028443 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION - Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions. | 02-04-2010 |
20100028444 | USE OF WATER-DISPERSIBLE CAROTENOID NANOPARTICLES AS TASTE MODULATORS, TASTE MODULATORS CONTAINING WATER-DISPERSIBLE CAROTENOID NANOPARTICLES, AND, METHOD FOR TASTE MODULATION - Use of at least one type of water-dispersible carotenoid nanoparticles as taste modulators in compositions of matter; process for taste modulation of compositions of matter in which at least one type of water-dispersible carotenoid nanoparticles is added to compositions of matter; and also taste modulators for compositions of matter comprising | 02-04-2010 |
20100028445 | POLYMER - The invention provides compositions comprising a polyamidoamine (PAA) polymer comprising a pendant disulphide, sulphydryl, or activated sulphydryl moiety, and methods for their manufacture. The invention extends to the use of such polyamidoamine polymers to form cross-linked compositions, and hydrogels comprising the same, and the use of such compositions in various biological and non-biological applications, such as the delivery of biomolecules to target sites, and for tracking fluid flows. The invention also provides carrier particles, which may be used to deliver biomolecules, and to methods of treatment. The invention also provides a fluid tracking system for monitoring fluid flow. | 02-04-2010 |
20100028446 | TRANSPORT OF DRUGS VIA THE BLOOD-BRAIN BARRIER BY MEANS OF APOLIPOPROTEINS - Combination preparations comprising at least one apolipoprotein as one component, and a medicinal agent to be transported via the blood-brain barrier to the central nervous system as a further component. The components are administered simultaneously, separately or sequentially. A method for administering a medicinal agent to the central nervous system is also provided. | 02-04-2010 |
20100028447 | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs - The present invention generally relates to pharmaceutical compositions for the intranasal, buccal, or sublingual administration of metanicotine analogs. | 02-04-2010 |
20100028448 | IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism. | 02-04-2010 |
20100034884 | LUMINESCENT CONDUCTING NANO-DRUG CRYSTAL ULTRA-THIN FILM SELF-ASSEMBLY AND USES - This invention involves two fields of photoelectron information materials and pharmaceuticals, especially refers to the self-assembly of conducting photoluminescence nanomedicine crystals and thin films and their preparation processes. In the invention, self-assembling unitary, binary, ternary and quaternary complexes of an antioxidase antioxidant, an agonist of the β-adrenergic receptors, an agonist of the P | 02-11-2010 |
20100034885 | FORMULATIONS CONTAINING GLIMEPIRIDE AND/OR ITS SALTS - The invention relates, in general, to new formulations and dosage units containing glimepiride of defined particle size and/or salts thereof that are useful for the therapeutic treatment (including prophylactic treatment) of mammals, including humans, without the need for micronizing any excipients together with the glimepiride that advantageously saves time, energy and resources and a process for making the same. In particular, the invention can be useful for the treatment of diabetes. | 02-11-2010 |
20100034886 | Polyglutamic Acids Functionalised by Histidine Derivatives and Hydrophobic Groups and the Uses Thereof, in Particular for Therapeutic Purposes - The invention relates to novel biodegradable materials based on modified polyamino acids and suitable, in particular, for vectoring active substance(s) (AS). Said invention also relates to novel pharmaceutical, cosmetic, dietary or plant protective compositions which are based on said polyamino acids. | 02-11-2010 |
20100034887 | Bursting Pellets - In the present invention, a new pharmaceutical formulation of bursting pellets comprising in the core a high dose of a low potency active substance which is poorly soluble in water is described. Release of the active substance from the core takes place within minutes. | 02-11-2010 |
20100034888 | GRANULATE CONTAINING A PHARMACEUTICALLY ACTIVE SUBSTANCE AND METHOD FOR ITS MANUFACTURE - One aspect of the present invention relates to a granulate having a volume weighted mean diameter of 1-200 m and containing: at least 0.1 wt. % of a pharmaceutically active substance; at least 10 wt. % of emulsifier 0-89.9 wt. % of a water-dispersible saccharide; the combination of the pharmaceutically active substance, the emulsifier and the water-dispersible saccharide together representing at least 60 wt. % of the granulate; wherein the granulate is monophasic or wherein the granulate comprises a dispersed phase containing the pharmaceutically active substance, said dispersed phase having a volume weighted mean diameter of less than 300 nm. Another aspect of the invention relates to a process for the preparation of said granulate containing a pharmaceutically active substance, which process employs. | 02-11-2010 |
20100034889 | EFFERVESCENT TABLETS/GRANULES - This invention provides an effervescent solid form that dissolves in cold water quickly enough to not disappoint consumers yet not so quickly that the visual interest generated during the effervescent reaction is lost. This performance is achieved by forming effervescent particles that are dense enough to retard dissolution and small enough to not take too long to dissolve. The aim of this invention is to provide a beverage in solid effervescent form that takes between about 30 and about 120 seconds to dissolve in warm water. The granules may carry functional additives such as flavors, vitamins, minerals, sweeteners, colors and drugs. The granules may also be compounded of materials intended to provide relief from skin or topical discomfort, as in the form of a wash or bath additive. The granules may also be formulated to provide cleaning agents, such as ceramic cleaners and denture cleaners. | 02-11-2010 |
20100034890 | COMBINATIONS OF FORMOTEROL AND FLUTICASONE PROPIONATE FOR ASTHMA - A pharmaceutical composition comprising (A) formoterol or a pharmaceutically acceptable salt thereof or a solvate of formoterol or said salt and (B) fluticasone propionate, suitable for use in the treatment of inflammatory or obstructive airways diseases. | 02-11-2010 |
20100040691 | PHARMACEUTICAL COMPOSITIONS COMPRISING METHOTREXATE - The present invention relates to pharmaceutical compositions and their uses in therapy. In particular, the invention relates to compositions comprising methotrexate, preferably wherein the compositions are for administration via the inhaled or intranasal route. | 02-18-2010 |
20100040692 | TWO PHASE BIOACTIVE FORMULATIONS - The present invention relates to two-phase systems of a bioactive ingredient in particle form that has limited or no solubility in a liquid medium, which provides stability to the active ingredient that is similar to the active ingredient when in the solid state. The active ingredient may be capable of therapeutically treating for the presence of a cholinesterase inhibitor. | 02-18-2010 |
20100040693 | SILICA CAPSULES HAVING NANO-HOLES OR NANO-PORES ON THEIR SURFACES AND METHOD FOR PREPARING THE SAME - The present invention relates to silica capsules having nano-holes or nano-pores on the surface thereof, and preparation methods thereof. More specifically, relates to silica capsules having holes with a size ranging from a few nanometers (nm) to a few hundreds of nanometers (nm), on the surface thereof, multifunctional silica capsules containing magnetic nanoparticles and optical nanoparticles, and preparation methods thereof. According to the present invention, the silica capsules having holes on the surface thereof can be prepared by making an emulsion system using two fluids having different surface tensions, and selectively evaporating only one fluid of the two fluids during a process of forming a silica layer. In addition, the multifunctional silica capsules containing magnetic nanoparticles and optical nanoparticles can be prepared by loading various multifunctional nanoparticles into the two fluids. | 02-18-2010 |
20100040694 | LOW-MOLECULAR WEIGHT, WATER-SOLUBLE CHITOSAN NANOPARTICLE FOR GENE DELIVERY WITH FOLIC ACID CONJUGAED THERETO AS TARGET LIGAND AND PREPARATION METHOD THEREOF - Disclosed are low-molecular weight, water-soluble chitosan nanoparticles with folic acid conjugated thereto as a target ligand and a preparation method thereof. The nanoparticles can be simply prepared since the strong reactivity of the chitosan allows folic acid to be readily introduced thereinto. Also, the folic acid-conjugated, low-molecular weight, water-soluble chitosan nanoparticles can be useful as gene carriers because they are of low or zero-toxicity, have sizes suitable for use as gene carriers, can readily form complexes with DNA, allow high gene expression rates, and are excellent in targeting tumor cells which are rich in folic acid receptors. | 02-18-2010 |
20100047352 | COMPOSITIONS AND METHODS FOR TREATING EXCESSIVE BLEEDING - The inventive material is a unique family of externally used wound sealants based upon a binding agent of reactive submicron silica particles that, when hydrated, agglomerate in the form of a supramolecular cross-linked network serving as the structural framework facilitating clot formation. A thrombolytic cascade accelerant can be provided, optionally with additional clotting factors, to further accelerate the clotting process. | 02-25-2010 |
20100047353 | HAIR CARE COMPOSITION - A hair care composition which comprises a plurality of cross-linked polymer particles, said polymer being the polymerization product of at least two monomer units selected from the group consisting of monoalkenyl aromatic compounds, alkyl esters derived from a saturated alcohol and acrylic or methacrylic acid, and vinyl esters of an aliphatic carboxylic acid is useful for controlling sebum on hair without providing undue whiteness to the hair. | 02-25-2010 |
20100047354 | COMBRETUM LAURIFOLIUM MART. EXTRACT AND METHODS OF EXTRACTING AND USING SUCH EXTRACT - A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of | 02-25-2010 |
20100055187 | NANOVITAMIN SYNTHESIS - Stable nanoparticulate vitamin compositions are prepared from agglomerated or larger sized vitamin particles of at least one vitamin compound by breaking down and/or solubilizing the agglomerated or larger sized vitamin particles and associating the particles with a surface modifying agent. | 03-04-2010 |
20100055188 | NANO-VALVES FOR SMALL-MOLECULE DRUG DELIVERY - A system for drug delivery including a plurality of molecular-valves that are responsive to an exterior stimulus so as to selectively open in response to the stimulus. A quantity of a drug is initially contained within the molecular-valves. The molecular-valves are associated with the surface (e.g., both the exterior surface, as well as within the internal pore structure) of the substrate. Upon exposure to a selected stimulus, the molecular-valves open, resulting in release of the drug molecules. | 03-04-2010 |
20100055189 | Nanoparticles for immunotherapy - Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described. | 03-04-2010 |
20100055190 | Sterol-Containing Compositions - The invention relates to a powder formulation containing sterol in the form of a super-cooled melt from sterols and sterol esters, provided that the sterol ester content is at least 30 wt % in relation to the content of the powder. The introduced sterol ester is a fatty acid ester having a chain length of 2 to 24, preferably 8 to 12 carbon atoms. As the sterol preparations are wettable and melt easily without the use of complex equipment, they can easily be incorporated into food, and produce, in particular, good organoleptic and sensory properties, in particular, in drinks. | 03-04-2010 |
20100055191 | POWDER COMPOSITION, METHOD FOR PRODUCING THE SAME, AND FOOD COMPOSITION, COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - A powder composition of a functional oil material is obtained by drying an emulsion composition comprising at least one functional oil component and (i) at least one water-soluble encapsulating agent selected from saccharide containing at least two sugar units including a fructose unit or (ii) at least one water-soluble encapsulating agent selected from saccharides containing at least one galactose unit and one fructose unit. Food compositions, cosmetic compositions and pharmaceutical compositions are provided which contain the powder composition described above. | 03-04-2010 |
20100055192 | MICRONIZED PARTICLES OF LOW-DOSAGE STRENGTH ACTIVE AGENTS FOR POWDER FORMULATIONS FOR INHALATION - Micronized particles of a low-dosage strength active ingredient, to be used in dry powder formulations for inhalation, with particular properties can easily and homogenously disperse in a dry powder formulation to be administered by means of a dry powder inhaler device. | 03-04-2010 |
20100055193 | Stable powder formulation containing an anticholinergic agent - The invention relates to a spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which X | 03-04-2010 |
20100055194 | PHARMACEUTICAL FORMULATIONS CONTAINING MICROPARTICLES OR NANOPARTICLES OF A DELIVERY AGENT - This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent. | 03-04-2010 |
20100062067 | COMPOSITIONS COMPRISING MACROMOLECULAR ASSEMBLIES OF LIPID AND SURFACTANT - A composition comprising lipid and surfactant, characterised in that the lipid and surfactant are in the form of macromolecular assemblies of less than 100 nm in diameter. The surfactant can have a HLB number of less than 20, or be an ether or ester surfactant, or be ionic. | 03-11-2010 |
20100062068 | CISTUS EXTRACTS - The present invention relates to the use of a nasal spray made from | 03-11-2010 |
20100062069 | PROCESS FOR PREPARING PARTICLES CONTAINING AN ANTIVIRAL - A process for preparing a particle comprising a co-precipitate surrounding a neutral hydrophilic carrier, said process comprising spraying an organic solution on a neutral hydrophilic carrier, said solution comprising at least one triazine or pyrimidine active ingredient having HIV inhibiting properties, one surface active agent, and one hydrophilic polymer, wherein the spraying of whole of the solution occurs in at least two separate steps, each of these steps followed by a grinding step of the product obtained at the end of the preceding step. | 03-11-2010 |
20100062070 | Pulverzed crystals of olmesartan medoxomil - An olmesartan medoxomil having a particle diameter at 90% cumulative volume of 75 μm or less, which provides an improved dissolution property. The olmesartan medoxomil is advantageously used to treat or prevent hypertension or a disease caused by hypertension. | 03-11-2010 |
20100062071 | Particle Formulations and Uses Thereof - Aqueous dispersions of chemically and physically stable particles for use in delivery of active pharmaceutical ingredients and processes for their production and use to enhance a biological response to an active pharmaceutical ingredient and prophylactically or therapeutically treat a subject are provided. Vaccines, wherein the active pharmaceutical ingredient is a solution of subunit vaccine antigen mixed with a colloidal dispersion of electrically charged particles and use of such vaccines in immunization are also provided. | 03-11-2010 |
20100062072 | Method for the delivery of a biologically active agent - A method of manufacturing a stable nanosuspension for delivery of a biologically active agent into the bloodstream of a subject is disclosed. A microfluidizable mixture is initially formed and processed via a microfluidization process to form the stable nanosuspension, which may be administered via the buccal mucosa or other suitable routes of administration. This product demonstrates increased bioavailability, enhanced period of onset, and enhanced stability for a controlled-release product. | 03-11-2010 |
20100068282 | Preparation of pharmaceutical compositions - A process for the production of a composition comprising a water-insoluble paracetamol or NSAID which comprises the steps of: a) providing a mixture comprising: i) a water-insoluble paracetamol or NSAID, ii) a water soluble carrier, and iii) a solvent for each of the paracetamol or NSAID and the carrier, and b) spray-drying the mixture to remove the or each solvent and obtain a substantially solvent-free nano-dispersion of the paracetamol or NSAID in the carrier. | 03-18-2010 |
20100068283 | Ex VIVO modifiable particle or polymeric material medicament carrier - Described embodiments include a final dosage form, an article of manufacture, and method. A final dosage form for administering a medicament to an animal is described. The final dosage form includes the medicament. The final dosage form also includes a particle or polymeric material carrying the medicament in a first medicament-release state wherein the medicament is available to the animal in a first bioavailability if the final dosage form is administered to the animal. The particle or polymeric material is modifiable ex vivo by an exposure to a stimulus to carry the medicament in a second medicament-release state wherein the medicament is available to the animal in a second bioavailability if the final dosage form is administered to the animal. In an embodiment, the final dosage form further includes a transport medium suitable for delivering the particle or polymeric material binding the medicament to the animal. | 03-18-2010 |
20100068284 | Stable Fixed Dose Topical Formulation - The present invention relates to stable fixed dose topical formulations comprising an antiacne agent and an antibiotic, which exhibit storage stability at a temperature of about 40° C. and relative humidity of about 75% for a period of at least 3 months. Particularly, the present invention relates to stable fixed dose topical formulations comprising therapeutically effective amounts of (a) adapalene-containing microspheres and (b) clindamycin, a process for their preparation thereof and their use for the treatment of acne. | 03-18-2010 |
20100068285 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. Other aspects of the invention include methods of making such nanoparticles. | 03-18-2010 |
20100068286 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. | 03-18-2010 |
20100068287 | Process for Preparation of a Stable Dispersion of Solid Amorphous Submicron Particles in an Aqueous Medium - The invention relates to a process for the preparation of a stable dispersion of particles, particularly sub-micron particles in an aqueous medium and to a stable dispersion of particles in a liquid medium. The sub-micron dispersion provided exhibit reduced or substantially no particle growth during storage and reduced crystallisation rate of the substantially water insoluble active compound. | 03-18-2010 |
20100068288 | MIXTURES OR ORGANIC COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES - A medicament comprising, separately or together, (A) a compound of formula (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, for simultaneous, sequential or separate administration in the treatment of an inflammatory or obstructive airways disease, the molar ratio of (A) to (B) being from 100:1 to 1:300. | 03-18-2010 |
20100074958 | METHODS AND COMPOSITIONS FOR TARGETING FENESTRATED VASCULATURE - Targeting of a fenestrated vasculature at a body site by micro or nanoparticles can be increased by using particles that have a radius substantially equal to a critical radius of a normal vasculature at the body site. The particles can be used for treating or monitoring a physiological condition responsible for the fenestrated vasculature. A method of improving an ability of micro or nanoparticles to target fenestrated blood vessels in a body site by selecting particles from a population of the micro or nanoparticles, where the selected particles have a radius that permits enhanced delivery into the fenestrated blood vessels. | 03-25-2010 |
20100074959 | LIPID GROWTH FACTOR FORMULATIONS - The present invention is directed to novel formulations and methods for the improved delivery and administration of hydrophobic therapeutic compounds that are substantially insoluble and/or susceptible to precipitation in aqueous solution at physiological pH, including, e.g., growth and differentiation factor-5 and related proteins. Many therapeutic compounds are hydrophobic at physiological pH levels. | 03-25-2010 |
20100080849 | PELLETS CONTAINING A PHARMACEUTICAL SUBSTANCE, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME - The invention relates to pellets containing a pharmaceutical substance with a breaking strength of more than 0.001 newton, method of production thereof and pharmaceutical preparations based on said pellets. | 04-01-2010 |
20100080850 | POLYPEPTIDE LIGANDS FOR TARGETING CARTILAGE AND METHODS OF USE THEREOF - Ligands that specifically bind to articular cartilage tissues are disclosed, including uses for targeting therapeutics towards articular cartilage tissue and new materials for articular cartilage. The ligands are effective in vivo to target therapeutic materials to articular cartilage. | 04-01-2010 |
20100086601 | Modified Calcium Phosphate Nanoparticle Formation - The present disclosure relates to non-aggregating nanoparticles and their associated methods of preparation. The nanoparticles may have a surface and a size range of 1 nm to 999 nm, along with a zeta potential of −50 to 50 millivolts. A polycation and/or polyanion may be disposed on the nanoparticle surface. In addition, an active ingredient may be encapsulated within the nanoparticles or associated with the polycation or polyanion on the nanoparticle surface. | 04-08-2010 |
20100086602 | PHARMACEUTICAL COMPOSITION CONTAINING STATIN-ENCAPSULATED NANOPARTICLE - The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization. | 04-08-2010 |
20100086603 | COMPOSITION FOR PHOTOPROTECTION - The present invention relates to a method for improving the lifetime of compounds that are prone to photo-degradation by containing the compounds in microcapsules, which have light protecting particles bonded chemically to the capsule walls. In particular, the present invention relates to a microcapsule comprising a biologically active compound inside the microcapsule and light protecting particles which are chemically bonded to the microcapsule wall material; to the use of such a microcapsule; to a process for preparing such a microcapsule; and to surface-modified light protecting particles and their use in such a microcapsule. | 04-08-2010 |
20100086604 | ABSORBANT SUPERHYDROPHOBIC MATERIALS, AND METHODS OF PREPARATION AND USE THEREOF - The present invention relates to coated, absorbent, freestanding assemblies comprising inorganic nanowires, articles of manufacture comprising the same, processes of producing the same and methods of use thereof. The assemblies of this invention are useful in various applications, including removal of organics or hydrophobic materials, and waterproofing applications. | 04-08-2010 |
20100086605 | MATERIAL, ITEM AND PRODUCTS COMPRISING A COMPOSITION HAVING ANTI-MICROBIAL PROPERTIES - A coating product composition has the general formula AO | 04-08-2010 |
20100086606 | Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same - Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications. | 04-08-2010 |
20100086607 | Self-Assembled Biodegradable Nanoparticles for Medical and Biological Applications - A method for forming a biodegradable composition that self-assembles into nanoparticles is provided. The method includes reacting N,N′-Disuccinimidyl carbonate with hydroxyl end-groups of poly(lactide-co-fumarate) to form a composition comprising succinimide-terminated poly(lactide-co-fumarate). | 04-08-2010 |
20100086608 | Methods and Devices for Detecting Binding Events via Zeta-Potential and Pharmacologically Active Compounds and Delivery Systems Identified Thereby - Methods, devices and arrays for measuring a change in zeta-potential of a surface indicative of a binding event are provided. Pharmacologically active compounds and delivery systems for active pharmaceutical ingredients determined to be pharmacologically active or optimized for pharmacological activity or determined to be useful for delivery of the active pharmaceutical ingredient to a target via measurement of a change in zeta-potential of the compound, ingredient or delivery system are also provided. | 04-08-2010 |
20100086609 | Methods and Compositions for Delivering Peptides - Methods are provided for purifying peptides and proteins by incorporating the peptide or protein into a diketopiperazine or competitive complexing agent to facilitate removal one or more impurities, from the peptide or protein. Formulations and methods also are provided for the improved transport of active agents across biological membranes, resulting for example in a rapid increase in blood agent concentration. The formulations include microparticles formed of (i) the active agent, which may be charged or neutral, and (ii) a transport enhancer that masks the charge of the agent and/or that forms hydrogen bonds with the target biological membrane in order to facilitate transport. In one embodiment, insulin is administered via the pulmonary delivery of microparticles comprising fumaryl diketopiperazine and insulin in its biologically active form. This method of delivering insulin results in a rapid increase in blood insulin concentration that is comparable to the increase resulting from intravenous delivery. | 04-08-2010 |
20100092563 | Methods for the Preparation of Biologically Active Compounds in Nanoparticulate Form - A method for producing a composition comprising nanoparticles of a biologically active compound. | 04-15-2010 |
20100092564 | Composition of and Method for Preparing Orally Disintegrating Tablets - An improved orally dissolving tablet (ODT) and method of manufacture is provided. The improved ODT disclosed herein are prepared by direct compression of a mixture of pharmaceutical excipients including at least one water-insoluble hydrophobic inorganic salt in combination with at least one water-insoluble inorganic salt with less hydrophobicity compared to the water-insoluble hydrophobic inorganic salt component. These components may be formed into granules, and may include other commonly used excipients. In an illustrative embodiment, the granules are formed into tablets by direct compression, optionally using a lubricant. The fast disintegrating tablets prepared using these components exhibit desirable performance properties such as sufficient hardness, low friability, quick disintegration time and good mouth-feel when compared to conventional ODT. A further advantage is that the improved ODT may be manufactured using commonly available manufacturing equipment for granulation, blending and tableting. | 04-15-2010 |
20100092565 | PHARMACEUTICAL COMPOSITION COMPRISING MICROPARTICLE OILY SUSPENSION - A pharmaceutical composition comprising a suspension of medicinally-active ingredient microparticles having a mean particle diameter of 20 μm or smaller in a base oil which can achieve extremely high intestinal absorption and bioavailability especially when the medicinally-active ingredient is hardly water-soluble. | 04-15-2010 |
20100092566 | Highly concentrated drug particles, formulations, suspensions and uses thereof - Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability. | 04-15-2010 |
20100092567 | IMMUNOSTIMULATORY NANOPARTICLES AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Provided herein are immunostimulatory nanolipoprotein particles and related compositions methods and systems. | 04-15-2010 |
20100092568 | DRUG MICROPARTICLES - Provided are microparticles of active pharmaceutical ingredients, drug delivery vehicles comprising same, and methods for making them. | 04-15-2010 |
20100098765 | Powder Makeup Compositions And Methods - An anhydrous powder composition wherein the ratio of platelet to non-platelet particulates is greater than about 5 to 1 respectively, which is preferably talc-free, oil-free, paraben-free, and fragrance-free; and a method for preparing the powder composition of the invention. | 04-22-2010 |
20100098766 | USE OF AN AQUEOUS MICRO-EMULSION FOR THE PREPARATION OF A FORMULATION FOR THE TREATMENT OF ADIPOSE DISEASES - Use of a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and good release behaviour of active substances. | 04-22-2010 |
20100098767 | CONVECTION ENHANCED DELIVERY APPARATUS, METHOD, AND APPLICATION - An embodiment of the invention is directed to a microfabrπcated, silicon-based, Convection Enhanced Delivery (CED) device The device comprises a silicon shank portion, at least one individual parylene channel disposed along at least a part of an entire length of the shank, wherein the channel has one or more dimensioned fluid exit ports disposed at one or more respective locations of the channel and a fluid (drug) input opening The fluid input opening may be configured or adapted to be connected to a fluid reservoir and/or a pump and/or a meter and/or a valve or other suitable control device(s) or apparatus that supplies and/or delivers fluid (e g, a drug) to the microfabricated device The device may have multiple channels disposed side by side or in different surfaces of the device | 04-22-2010 |
20100098768 | Method of neuroprotection from oxidant injury using metal oxide nanoparticles - A metal oxide nanoparticle composition including a cerium oxide nanoparticle and a metal adapted to enhance the neuroprotective activity of the cerium oxide nanoparticle. The metal can include noble metals such as platinum, and rare earth metals such as gadolinium, samarium, titanium, yttrium, zirconium, and a combination thereof Another metal oxide nanoparticle composition including a cerium oxide nanoparticle and a surface modifier, such as polyethylene oxide, polyethylene imine, dextran, polylactic acid, chitosan, alginate, and a combination thereof is provided. A method of using the metal oxide nanoparticle compositions as neuroprotective agents for the inactivation of reactive oxygen species in nervous tissues is also provided. More specifically, a neuroprotective method using the metal oxides such as ceria, yttria, or mixed ceria and yttria (or any of the other referenced metal oxide nanoparticle compositions) before, during, or after an ischemic event. | 04-22-2010 |
20100104644 | Compositions and Methods for Treating or Preventing Ophthalmic Disease - Methods are disclosed for treating or preventing ophthalmic conditions related to a toxic visual cycle product. Compounds and compositions useful in these methods, either alone or in combination with other therapeutic agents, are also described, along with methods of screening for new agents useful in said the therapeutic and prophylactic methods of the invention. | 04-29-2010 |
20100104645 | METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES - This application provides methods of making nanoparticles using pre-functionalized poly(ethylene glycol) (also referred to as PEG) as a macroinitiator for the synthesis of diblock copolymers. These diblock copolymers comprise a poly(ethylene glycol) block bearing a targeting agent at its terminus and a second biocompatible and biodegradable hydrophobic polymer block (e.g. a poly(ester)). The poly(ethylene glycol) is hetero-bifunctional with a targeting moiety (agent) covalently bound to its α terminus and a polymerization initiating functional group (e.g., a hydroxyl group) present on its ω terminus. Ring opening polymerization yields the desired poly(ester)-poly(ethylene glycol)-targeting agent polymer that is used to impart targeting capability to therapeutic nanoparticles. This “polymerization from” approach typically employs precursors of the targeting agent wherein the reactivity of functional groups of the targeting agent is masked using protecting groups. Also described is a “coupling to” that utilized the poly(ethylene glycol)-targeting agent conjugate where the targeting agent remains in its native un-protected form. This method uses “orthogonal” chemistry that exhibit no cross reactivity towards functional groups typically found within targeting agents of interest. Nanoparticles produced according to the disclosed methods as well as their use in the treatment of various diseases are also provided. | 04-29-2010 |
20100104646 | NANOPARTICLE COMPOSITION FOR PREVENTION OF HAIR LOSS AND PROMOTION OF HAIR GROWTH - A nanoparticle composition is provided for preventing hair loss and promoting hair growth. It is based on herbal materials and thus has no harmful side effects on the body. When applied to the scalp, the nanoparticle composition deeply infiltrates into the dermis to promote blood circulation therein and provide nutrients thereto. Accordingly, the nanoparticle composition stimulates and activates hair follicles to thus promote the metabolism of hairs. Also, the nanoparticle composition exerts antioxidant activity on the scalp to thus inhibit depilation and aid in hair regrowth. | 04-29-2010 |
20100104647 | HOLLOW MICROPARTICLES - The invention provides a process for making hollow microparticles. The process comprises providing a dispersion having a continuous aqueous phase and a discontinuous organic phase and polymerising a monomer in the dispersion to form hollow polymeric microparticles. The continuous aqueous phase of the dispersion comprises a stabiliser and the discontinuous organic phase of the dispersion comprises the monomer and an organic liquid. The monomer has two or more polymerisable groups per molecule. Prior to the step of polymerising the monomer, the discontinuous organic phase does not contain a polymer. | 04-29-2010 |
20100104648 | TREATMENT OF INFLAMMATORY AND/OR BACTERIAL CONDITIONS WITH PARTICLES OF MICROSTRUCTURE - The present invention refers to a method for treatment of an inflammatory and/or bacterial condition, wherein particles of microstructure comprising titanium, titanium alloy, at least one titanium oxide or a combination thereof, and having a surface with at least a substantial part consisting of at least one type of titanium oxide, are brought into contact with at least one infected site in a human or animal body by insertion, injection or implantation, which at least one infected site exhibits the inflammatory and/or bacterial condition. Moreover, the present invention refers to an injectable suspension comprising the particles according to the invention and a fluid vehicle for use as a medicament. Finally, the present invention also defines use of the particles of microstructure according to the invention for the manufacture of a medicament in the form of an injectable suspension. Examples of conditions being treated with the injectable suspension according to the present invention are periodontitis, periimplantitis, and osteitis. | 04-29-2010 |
20100104649 | Lercanidipine Hydrochloride Polymorphs and an Improved Process for Preparation of 1,1,N-Trimethyl-N-(3,3-Diphenylpropyl)-2-Aminoethyl Acetoacetate - Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of substantially pure Lercanidipine intermediate, 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate. The intermediate is useful for preparing Lercanidipine, or a pharmaceutically acceptable salt thereof, in high yield and purity. The present invention further provides a novel crystalline form of Lercanidipine hydrochloride and a process for its preparation. The present invention also provides a process for the preparation of amorphous form of Lercanidipine hydrochloride. | 04-29-2010 |
20100104650 | CHARGED MESOPOROUS SILICA NANOPARTICLE-BASED DRUG DELIVERY SYSTEM FOR CONTROLLED RELEASE AND ENHANCED BIOAVAILABILITY - A charged mesoporous silica nanoparticle (MSN)-based drug delivery system for controlled release and enhanced bioavailability is disclosed. The system comprises a positively charged MSN, which has a silica matrix and an array of pores and/or nanochannels in the matrix. The entire substance of the matrix, all the surfaces and the pores and/or nanochannels comprise a plurality of silanol (Si—OH) and quaternary ammonium functional groups. The bioavailability of a negatively charged bioactive compound can be increased by loading it into the pores and/or nanochannels. The silanol (Si—OH) functional groups on the surfaces lining the walls of the pores and/or nanochannels are free to deprotonate in a fluid having pH above the pI of the positively charged MSN and lead to a sustained release of the negatively charged drug from the pores and/or nanochannels, and thereby enhance the bioavailability of the drug. | 04-29-2010 |
20100104651 | Pharmaceutical Compositions Containing Diacerein - A once-daily controlled-release formulation of diacerein for treating inflammatory or autoimmune diseases or their complications, with reduced adverse side effects and methods of treating such diseases are disclosed. | 04-29-2010 |
20100112066 | Prostaglandin fat emulsion, method for producing the same, method for stabilizing the same, and emulsifying agent - A fat emulsion comprises a prostaglandin as an active ingredient, the fat emulsion comprising a phospholipid that comprises phosphatidylcholine (PC) and phosphatidylglycerol (PG) and has a ratio of PC to PG (PC:PG) of 85:15 to 99.7:0.3. | 05-06-2010 |
20100112067 | Compositions and methods for biological remodeling with frozen particle compositions - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100112068 | Compositions and methods for biological remodeling with frozen particle compositions - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 05-06-2010 |
20100112069 | Flowable Carrier Matrix - A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site. | 05-06-2010 |
20100112070 | Composition and dosage form comprising a particle formulation and suspending vehicle - A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent. | 05-06-2010 |
20100112071 | POLYPEPTIDES AND POLYNUCLEOTIDES FOR ENHANCING IMMUNE REACTIVITY TO HER-2 PROTEIN - Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided. | 05-06-2010 |
20100119608 | Synthesis of pH-sensitive, Acid-Stable Metal-Binding Nanoparticles - Among natural mechanisms of cell deaths, disease or toxicity, one of the most common method is through overloading of certain biological metals such as calcium, iron and zinc. We propose to utilize this natural mechanism of cell death against cancer by utilizing the well known phenomenon of enhanced permeation and retention effect (EPR effect) and metal-binding nanoparticle moieties that can self-degrade under certain biological conditions such as pH. More specifically, we show that one can form nanoparticles that consist of polymerized citric acid and various different types of metals including, but not limited to, iron, calcium, zinc, silver and magnesium, displaying acid-stability and self-degradation leading to constituent metal release when pH rises closer to the neutral pH of 7 or higher. We also show that these nanoparticles with different metal compositions have distinct cytotoxicity against various different types of cancer cell lines, including B16F10 melanoma, H460 human lung cancer, T98G kidney cancer, Ramos leukemic cancer, etc. in vitro. We also show evidence of in vivo anti-cancer activity of our nanoparticles containing various different metals using mouse model studies. | 05-13-2010 |
20100119609 | METHODS, COMPOSITIONS, AND FORMULATIONS FOR THE TREATMENT OF THYROID EYE DISEASE - Compositions, formulations, methods, and systems for treating thyroid eye disease and related conditions (e.g., Grave's Ophthalmopathy). The methods described herein include administering, to a patient in need, systemic or local beta adrenergic agonists (e.g., as an extended release crystalline microparticle suspension). The methods can further include administering a compound for reducing beta adrenergic receptor desensitization (e.g., a corticosteroid) prior to administering or coadministered with the beta adrenergic agonist. The methods can also include locally administering to the eye an immunosuppressant agent (e.g., rapamycin) prior to administering a beta adrenergic agonist. The compositions described herein include ophthalmic pharmaceutical formulations of beta adrenergic agonists in the form of extended release crystalline microparticle suspensions or mixtures of the crystalline microparticle suspensions with beta adrenergic agonist solutions. The compositions also include ophthalmic formulations of a compound for reducing beta adrenergic receptor desensitization in the form of extended release crystalline microparticle suspensions. | 05-13-2010 |
20100124571 | Use of pH-sensitive, Acid-Stable Metal-Binding Nanoparticles - Methods of preventing and/or treating cancer are disclosed. The methods comprise administering to the patient a pharmaceutically effective amount of a water-soluble, acid-stable organometallic nanoparticles, optionally in combination with another therapeutic agent. In particular, nanoparticles that consist of polymerized citric acid and various different types of metals including, but not limited to, iron, calcium, zinc, silver and magnesium. These nanoparticles are acid-stability and self-degradation leading to constituent metal release when pH rises closer to the neutral pH of 7 or higher. | 05-20-2010 |
20100129453 | EMULSIONS COMPRISING RUBBER ARABICUM - The invention relates to micelles, micellar solutions and pre-concentrates of emulsions comprising active ingredient and Gum Arabic; products comprising such micelles or pre-concentrates of emulsions, respectively; processes for manufacturing micelles, pre-concentrates of emulsions and products. | 05-27-2010 |
20100129454 | ABSORBENT COMPOSITION FOR SURFACE TREATMENT - The invention concerns an absorbent composition comprising: (a) at least 50 wt.-% of the overall composition have a particle size of less than 150 μm and are comprised of at least one absorbent component; and (b) at least 1.0 wt.-% of the overall composition have a particle size of at least 250 μm and are comprised of at least one particulate component, and its preferred uses. | 05-27-2010 |
20100129455 | NANOPARTICLE-DISPERSED FINE GLASS BEADS HAVING A CAVITY THEREIN, AND METHOD OF PRODUCING THE SAME - The present invention provides fine silicon-containing glass beads each having one or more cavities therein and containing nanoparticles in a glass phase of each of the silicon-containing glass beads, and a method of producing such glass beads, and also provides silicon-containing glass beads containing nanoparticles, which may be identical to or different from the nanoparticles in the glass phase, and a functional material such as pharmaceutical molecules (e.g., materials having fluorescent properties, magnetic properties, drug effects, etc.), and a method of producing such glass beads. | 05-27-2010 |
20100129456 | SUSTAINED-RELEASE NANOPARTICLE CONTAINING LOW-MOLECULAR-WEIGHT DRUG WITH NEGATIVELY CHARGED GROUP - A nanoparticle containing a low-molecular-weight drug having a negatively charged group is provided that is effectively targeted to an affected site, is capable of sufficiently sustained release of the drug, and has a reduced tendency to accumulate in the liver to cause reduced side effects. The nanoparticle containing a low-molecular-weight drug having a negatively charged group is obtained by hydrophobicizing the low-molecular-weight drug having a negatively charged group with a metal ion, and reacting the hydrophobicized drug with poly L-lactic acid or poly(L-lactic acid/glycolic acid) copolymer and poly DL- or L-lactic acid-polyethylene glycol block copolymer or poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer. | 05-27-2010 |
20100129457 | Nanodiamond Enhanced Drugs | 05-27-2010 |
20100136115 | Pharmaceutical Titanium Dioxide Composite Allowing Disappearance of Drug Efficacy By Light Irradiation - Disclosed is a titanium dioxide composite material which can be dispersed in an aqueous solvent stably and can be administered to a living body in a simple manner and in which the pharmacological effect of a therapeutic compound carried on the composite material can be eliminated by irradiation with light. Also disclosed is a dispersion product of the composite material. The composite material comprises titanium dioxide which has a photocatalytic activity and a therapeutic compound attached to the titanium dioxide through a hydrophilic polymer. The composite material is stable in an aqueous solvent and can be administered to a living body in a simple manner. After the composite material is administered to a living body, a site on the living body where the pharmacological effect of the therapeutic compound is not needed to be developed can be irradiated with light to induce the light excitation of titanium dioxide at the site, thereby decomposing the therapeutic compound to reduce any adverse side effect of the therapeutic compound. | 06-03-2010 |
20100136116 | NOVEL HYDRATED FORM OF ERLOTINIB FREE BASE AND A PROCESS FOR PREPARATION OF ERLOTINIB HYDROCHLORIDE POLYMORPH FORM A SUBSTANTIALLY FREE OF POLYMORPH FORM B - The present invention provides a novel and stable hydrated form of erlotinib free base, and a process for its preparation thereof. The present invention also provides a process for preparation of erlotinib hydrochloride crystalline polymorph A substantially free of polymorph B. The present invention further relates to erlotinib hydrochloride crystalline particles having mean particle size (D | 06-03-2010 |
20100136117 | HYDROXYAPATITE TISSUE FILLER AND ITS PREPARATION AND USE - The invention pertains to a biocompatible composition, suitable for use in soft or hard tissue augmentation, wherein the composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than 15 &mgr;m and an augmentation fraction of ceramic particles of at least 20 &mgr;m. The ceramics typically comprise calcium phosphate. The composition is a may be used in soft tissue repair as well as hard bone replacement. It advantageously avoids the need for foreign body materials which are conventionally applied to stabilize augmentation suspensions. | 06-03-2010 |
20100136118 | CALCIUM ABSORPTION ENHANCER - The present invention provides a calcium absorption enhancer that places no burden on the body of a human or a domestic animal to which a calcium compound is administered and can increase the efficiency with which a calcium content is absorbed into the body by supplying calcium ions in the stomach or the like of the human or the domestic animal in a sustained-release manner after administration of the calcium compound. The calcium absorption enhancer of the present invention contains, as an active ingredient, water-soluble calcium particles that can release calcium ions in an aqueous solution in a sustained-release manner. | 06-03-2010 |
20100136119 | CONTROLLED-RELEASE PREPARATION CONTAINING CILOSTAZOL AND PROCESS FOR THE PREPARATION THEREOF - A controlled release preparation which comprises particles containing cilostazol or its pharmaceutically acceptable salt dispersed in a solubilizing agent and an erodible material encasing said particles which is capable of forming a hydrogel, can maintain a constant level of cilostazol in the blood through its slow release during its prolonged residence time in the stomach and intestines, thereby minimizing adverse effects caused by rapid release of the drug or solubilizing agent. | 06-03-2010 |
20100136120 | COMPOSITIONS AND METHODS FOR FORMING AND STRENGTHENING BONE - Compositions are provided which stimulate bone growth. Also provided are methods for utilizing the compositions for filling in bone defects, promoting rapid fusion of bone fractures, grafts, and bone-prostheses, and promoting strengthening of osteoporotic bones. | 06-03-2010 |
20100136121 | MEDICAMENTS - There is described a bimodal pharmaceutical composition comprising effective amounts of a first active ingredient which substantially comprises a coarse fraction and a second active ingredient which substantially comprise a fine fraction characterized in that the coarse fraction possesses a greater mass median aerodynamic diameter than the fine fraction. There is also described a method of delivering a therapeutically effective amount of a substantially fine active ingredient to the lung of a patient by co-administration with a substantially coarse active ingredient. | 06-03-2010 |
20100143479 | METHOD OF MAKING SUSTAINED RELEASE MICROPARTICLES - Various embodiments of a method of preparing sustained release microparticles are described. In one embodiment, the method includes the steps of forming a dispersed phase of an active agent in a polymer and combining the dispersed phase with a continuous phase to form a microparticle dispersion. The method further includes the step of adding a measured amount of a dilution composition to the microparticle dispersion. It has been found herein that the various embodiments for preparing sustained release microparticles using various amounts of the dilution composition alters the release rate of the sustained microparticle for the specific active agent. | 06-10-2010 |
20100143480 | TRICALCIUM PHOSPHATE COARSE PARTICLE COMPOSITIONS AND METHODS FOR MAKING THE SAME - Methods for preparing a tricalcium phosphate coarse particle composition are provided. Aspects of the methods include converting an initial tricalcium phosphate particulate composition to hydroxyapatite, sintering the resultant hydroxyapatite to produce a second tricalcium phosphate composition and then mechanically manipulating the second tricalcium phosphate composition to produce a tricalcium phosphate coarse particle composition. The subject methods and compositions produced thereby find use in a variety of applications. | 06-10-2010 |
20100143481 | METHOD OF PREPARING SOLID DOSAGE FORMS OF MULTI-PHASIC PHARMACEUTICAL COMPOSITIONS - Pharmaceutical formulations comprising a multi-phasic pharmaceutical composition, and an adsorbent carrier, where the pharmaceutical formulation is a solid dosage form. Methods for preparing such pharmaceutical compositions are described. | 06-10-2010 |
20100151030 | Use of MgO Doped with a Divalent or Trivalent Metal Cation for Removing Arsenic from Water - Systems and methods for use of magnesium hydroxide, either directly or through one or more precursors, doped with a divalent or trivalent metal cation, for removing arsenic from drinking water, including water distribution systems. In one embodiment, magnesium hydroxide, Mg(OH) | 06-17-2010 |
20100151031 | DISCRETE SIZE AND SHAPE SPECIFIC ORGANIC NANOPARTICLES DESIGNED TO ELICIT AN IMMUNE RESPONSE - The presently disclosed invention is broadly directed to therapeutic micro- and/or nanoparticles designed to target an immune cell with an active agent. More particularly, the particles have a predetermined geometry and a broadest dimension of less than about 10 μm. The immune cell-targeted micro and/or nanoparticles may additionally comprise a biocompatible polymer. | 06-17-2010 |
20100151032 | Silver and Zinc Containing Body Care Agent - The invention relates to a body care agent containing metal particles which release zinc and silver ions in said body care agent by contacting body liquid or body humidity and whose metallic silver content at least equal or greater than 99 % (m/m). | 06-17-2010 |
20100159014 | POLYMERIC MICELLAR CLUSTERS AND THEIR USES IN FORMULATING DRUGS - Polymeric micellar clusters formed from amphiphilic carbohydrate polymers and their uses in formulating drugs is disclosed, and in particular the finding that amphiphilic carbohydrate polymers are capable of self assembling to form micellar clusters in which the carbohydrate amphiphiles aggregate into hierarchically organised micellar clusters of individual aggregates. The micellar clusters may be transformed into stable nanoparticles with drugs, especially hydrophobic drugs that have poor aqueous solubility, and may improve the transfer of hydrophobic drugs across biological barriers. | 06-24-2010 |
20100159015 | Systems and Methods to Treat Pain Locally - Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NFκB family of transcription factors. | 06-24-2010 |
20100159016 | PAIN RELIEF COMPOSITION COMPRISING PARAMAGNETIC SILVER NANOPARTICLES - The present invention relates to a pain relief composition comprising paramagnetic silver nanoparticles. More specifically, the composition is characterized in that it comprises from 0.03 to 0.05% by weight of paramagnetic silver nanoparticles having specific properties that were not revealed by conventional diamagnetic silver nanoparticles. The pain relief composition according to the present invention shows excellent effect of relieving pain of arthritis due to antibiotic property and anti-toxicity of paramagnetic silver nanoparticles. By using the paramagnetic silver nanoparticles having small particle size, the composition is rapidly absorbed into cells upon being applied to skin. In addition, by virtue of using silver (Ag), no complication such as skin coloration or edema was observed. According to the present invention, pain is relieved by simple application, so that the usage is easy as compared to surgical treatment such as arthroscopic operation to provide high satisfaction to a patient. | 06-24-2010 |
20100166868 | Filmy Compositions - Washing with conventional filmy soaps cannot bring about clean detergent effect because of the remaining sliminess due to the ingredient essential for forming soap into films. Further, when moisture adheres to conventional filmy compositions, the water-soluble polymer or other ingredients contained in the compositions dissolve in the moisture to cause the blocking of filmy compositions, which makes it impossible to take out the filmy compositions one by one. Detergent effect without sliminess and the antiblocking of filmy compositions can be attained by incorporating a granular component into a filmy composition containing a water-soluble polymer. The filmy compositions of the invention are used as filmy facial masks, whitening masks, sheet soap, cleansing sheets, sheet shampoos, sheet rinses, sheet bath additives, and so on. | 07-01-2010 |
20100166869 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION - The present invention features methods for treating, stabilizing, preventing, and/or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and/or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and/or nanoparticles that comprise a carrier protein and a taxane (e.g. paclitaxel) or a derivative thereof. | 07-01-2010 |
20100172992 | PATHOGENIC ATTENUATION VIA THE ADMINISTRATION OF AN EQUILIBIOTIC COMPOUND - A pharmaceutical preparation comprising as an active ingredient micron-sized sulphur particles [−(300 microns]. The pharmaceutical preparation further comprises an excipient, i.e. a sodium lignin sulphate or other suitable agents. The preparation is used for the prevention and treatment of pathogenic disorders in humans and animals, in a nutritional and/or supplemental regime, as well as, to improve feed and reproductive performance. A variety of conditions were treated including: pneumonia, arthritis, ulcers, diabetes mellitus, GI cancer, lupus, herpes, psoriasis and early menopause. | 07-08-2010 |
20100172993 | PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF - The present invention discloses compositions having particles comprising, inorganic element; one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms. | 07-08-2010 |
20100172994 | Nanoparticles for Protection of Cells from Oxidative Stress - The present invention concerns metal oxide semiconductor nanoparticles with free radical scavenging activity, compositions comprising such nanoparticles, methods for their use, and methods for their production. In one aspect, the invention concerns a method for enhancing the survival or viability of transplanted cells, comprising administering an effective amount of metal oxide semiconductor nanoparticles to a target anatomical site of a subject before, during, or after administration of transplant cells to the subject. Preferably, the metal oxide nanoparticle is a cerium oxide (ceria) nanoparticle. | 07-08-2010 |
20100172995 | Process For Preparing A Solid Pharmaceutical Composition - The invention relates to a process for preparing a solid pharmaceutical composition of perindopril or a salt thereof which avoids a wet granulation step and results in very stable pharmaceutical compositions, like tablets. | 07-08-2010 |
20100172996 | Chain-End Functionalized Methoxy Poly(Ethylene Glycol) and Metal Nano-Particles Using the Same - Disclosed is a chain-end functionalized methoxy poly(ethylene glycol) (mPEG), a process of preparing the same, a living methoxy poly(ethylene glycol) for preparing the functionalized methoxy poly(ethylene glycol), a nano-particles of transition metal or metal salt encapsulated in the micelle structure formed by the chain-end functionalized methoxy poly(ethylene glycol), and a method for preparing the nano-particles of transition metal or metal salt. | 07-08-2010 |
20100172997 | GOLD, SILVER, AND COPPER NANOPARTICLES STABILIZED IN BIOCOMPATIBLE AQUEOUS MEDIA - The present invention includes metal nanoparticles composition and methods of making and using the same by converting a metal (I) to a metal (0) and forming one or more metal nanoparticles from the metal (0). The one or more metal nanoparticles are stabilized with one or more biocompatible stabilizers to prevent agglomeration and make them amenable for biomedical applications. | 07-08-2010 |
20100178347 | Method of treating traumatic brain injury - This invention provides for methods of treating a subject suffering from central nervous system injury, including traumatic brain injury, comprising administering to the subject an amount of a perfluorocarbon. This invention also provides for use of a perfluorocarbon in the manufacture of a medicament for treating a subject suffering from central nervous system injury including traumatic brain injury. This invention further provides for a pharmaceutical composition comprising a perfluorocarbon for use in treating a subject suffering from central nervous system injury, including traumatic brain injury. | 07-15-2010 |
20100178348 | Myostatin Inhibition for Enhancing Muscle and/or Improving Muscle Function - The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy and/or increasing endurance, force and/or strength). The methods involve delivering genes to cells using gene delivery in order to inhibit myostatin. Examples of genes to be delivered are genes encoding’ proteins such as Follistatin, Follistatin-related gene-1 (FLRG-I), growth differentiation factor associated protein-1 (GASP-I) and myostatin precursor propeptide. The genes are delivered using a recombinant Adeno-associated virus (rAAV) lacking rep and cap DNA capable of infecting the cells. Following introduction, the genes are expressed in the cell body of the infected cell and the encoded proteins are secreted systemically. In other methods-of the invention expression of proteins such as activin lib and myostatin is inhibited by oligonucleotide techniques to effect muscle enhancement. All the methods have applications in the treatment of musculoskeletal and neurodegenerative disorders among others, as well as enhancing muscle in livestock. | 07-15-2010 |
20100178349 | PHARMACEUTICAL FORMULATION FOR THE PRODUCTION OF RAPIDLY DISINTEGRATING TABLETS - Pharmaceutical formulation in the form of agglomerates comprising
| 07-15-2010 |
20100178350 | AMINO-ACID-CONTAINING MEDICINAL GRANULAR PREPARATION HIGHLY EASY TO TAKE - The present invention aims to provide an amino acid-containing granule preparation improved in the ease of taking medication than conventional products, which disintegrates rapidly. The amino acid-containing granule preparation of the present invention containing granules having a maximum particle size of substantially not more than 1000 μm and a bulk density of not less than 0.57 g/mL markedly improves ease of taking medication without impairing disintegration property, as compared to conventional amino acid-containing granule preparations. | 07-15-2010 |
20100183725 | MULTIPLE ACTIVE PHARMACEUTICAL INGREDIENTS COMBINED IN DISCRETE INHALATION PARTICLES AND FORMULATIONS THEREOF - The present disclosure describe inhalation particles where each discrete unagglomerated inhalation particle comprising 2 or more active pharmaceutical ingredients. In one embodiment, the inhalation particles comprise a first and a second API where the second API covers, at least partially, and protects the first API from degradation or instability. Inhalation particles comprising a first and a second API as described herein have many advantages over present means of delivering two or more APIs. Formulations comprising such inhalation particles are also described. | 07-22-2010 |
20100183726 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DACARBAZINE NANOEMULSIONS - A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent, such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of anti-cancer agents. As a nanoemulsion, dacarbazine has a greater anti-cancer efficacy than when applied as a free solution. | 07-22-2010 |
20100183727 | Immunonanotherapeutics that Provide IgG Humoral Response Without T-Cell Antigen - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides synthetic nanocarriers capable of eliciting an immune system response in the form of antibody production, wherein the nanocarriers lack any T cell antigens. In some embodiments, the invention provides nanocarriers that comprise an immunofeature surface, which provides high avidity binding of the nanocarriers to antigen presenting cells. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 07-22-2010 |
20100183728 | NANOPARTICLE COMPRISING RAPAMYCIN AND ALBUMIN AS ANTICANCER AGENT - The present invention features methods for treating, stabilizing, preventing, and/or delaying cancer by administering nanoparticles that comprise rapamycin or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof. The invention further provides combination therapy methods of treating cancer comprising administering to an individual an effective amount of nanoparticles that comprise rapamycin or a derivative thereof and a second therapy. | 07-22-2010 |
20100183729 | Novel Process - The invention relates to a stable pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD) and a novel micronisation process for manufacturing a stable formulation for formoterol or its enantiomers and a carrier/diluent comprising a carbohydrate such as lactose. | 07-22-2010 |
20100189796 | CRYSTALLINE FORM OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]-AMINO]-2-PYRIMIDINYL]AMINO- ]BENZONITRILE - This invention concerns polymorph I of TMC278, its use and preparation. It further concerns pharmaceutical formulations comprising this polymorph. | 07-29-2010 |
20100196483 | METHOD FOR TREATMENTOF SEVERE AND UNCONTROLLABLE ASTHMA - A method for treatment of severe and uncontrollable asthma by providing means for delivery of high doses of a suitable inhalable corticosteroid directly to the small airways of the lower lungs with substantial decrease in need for simultaneous administration of oral corticosteroids and with a significant reduction in undesirable secondary side effects in an oropharyngeal area. The method utilizes devices allowing individualization of treatment parameters in asthmatic patients having compromised breathing pattern due to severe and uncontrollable asthma. | 08-05-2010 |
20100196484 | Use of expanded amorphous mineral particles for increasing the tenacity of a fragrance, scenting composition and method for treating body odours - The subject-matter of the invention is a cosmetic method for scenting a human keratinous substance which consists in applying, to the said substance, a scenting composition comprising, in a cosmetically acceptable medium, at least 0.3% by weight of at least one scenting substance and at least particles of an expanded amorphous mineral material and in particular of an expanded amorphous mineral material resulting from at least one volcanic rock and more particularly expanded perlite particles. | 08-05-2010 |
20100196485 | RARE EARTH METAL COMPOUNDS, METHODS OF MAKING, AND METHODS OF USING THE SAME - Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water. | 08-05-2010 |
20100196486 | METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION - Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10 μm, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension. | 08-05-2010 |
20100196487 | COMPOSITION WITH ANTIMICROBIAL EFFECT - A composition with antimicrobial efficacy has at least one or more polymers; or polymerizable or crosslinkable monomers; or polymerizable or crosslinkable prepolymers; or polymerizable or crosslinkable polymers; and porous glass particles which contain an antimicrobial silver additive. | 08-05-2010 |
20100196488 | Pharmaceutical Formulation - The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant. | 08-05-2010 |
20100196489 | BONE GROWTH PARTICLES AND OSTEOINDUCTIVE COMPOSITION THEREOF - A biocompatible synthetic bone growth composition comprising a fibrillar collagen component and a calcium phosphate component. The composition is formed into particles, and then formed into a unitary article that may be provided at the site of a skeletal defect. An osteoinductive component may be further added, either before or after forming the unitary article. The composition may be formulated as a paste or putty and facilitates bone growth and/or repair. | 08-05-2010 |
20100196490 | COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS - The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. The human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The invention also provides methods for reducing one or more side effects of administration of the pharmaceutical composition, methods for inhibiting microbial growth and oxidation in the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell. | 08-05-2010 |
20100203143 | SYSTEMS AND METHODS FOR NANOMAGNETIC ACTUATION OF MOLECULAR CELL SIGNALING - The present invention relates to signaling mechanisms that transduce magnetic inputs into physiological cellular outputs. More particularly, the present invention relates to systems and methods for non-invasively controlling cellular signaling functions and behaviors by harnessing receptor-mediated and intracellular molecular-mediated signal transduction using nanomagnetic cellular switches. | 08-12-2010 |
20100203144 | Immobilized Metallic Nanoparticles as Unique Materials for Therapeutic and Biosensor Applications - The present invention relates to compositions and methods by which surface modification techniques can be used to modify wide range polymeric or metal substrates using metal nanoparticles. | 08-12-2010 |
20100203145 | CONTINUOUS PROCESS FOR MICROSPHERES PRODUCTION BY USING EXPANDED FLUIDS - The invention concerns a process for the continuous treatment of an emulsion and/or a micro-emulsion assisted by an “expanded liquid” for the production of micro- and/or nano-particles or micro- and/or nano-spheres containing one or more active ingredients. In particular, a liquid solvent expanded by compressed or supercritical CO | 08-12-2010 |
20100203146 | INTERMITTENT DOSING STRATEGY FOR TREATING RHEUMATOID ARTHRITIS - The present invention provides methods of treating rheumatoid arthritis. The methods generally involve an intermittent dosing strategy for administering Atiprimod alone or in combination with a second therapeutic agent wherein the second therapeutic agent is selected from the group consisting of Methotrexate, gold compounds, antimalarials, cyclosporine A, leflunomide, azathioprine, sulfasalazine d-penicillamine, aurothioglucose, auranofin, or a TNF inhibitor. | 08-12-2010 |
20100209512 | Particle size-structured parenteral dispersions - A Drug/Adjuvant Delivery System (D/A DS), and associated method, are disclosed. An exemplary D/A DS system includes a liquid carrier; and a particle-size structured dispersion of solid and/or liquid particles suspended in the liquid carrier. | 08-19-2010 |
20100209513 | PHARMACEUTICAL COMPOSITION CONTAINING MICRONIZED PARTICLES OF NAPHTHOQUINONE-BASED COMPOUND - Provided is a pharmaceutical composition having excellent in vivo absorption properties by increasing solubility and absorption rate of a sparingly-soluble naphthoquinone-based compound via incorporation of micronized particles of a certain naphthoquinone-based compound. | 08-19-2010 |
20100215750 | ORAL PREPARATION COMPRISING SPECIFIC ORGANIC ACID, AND METHOD FOR IMPROVEMENT IN ELUTION PROPERTY AND CHEMICAL STABILITY OF ORAL PREPARATION - A chemically stable oral preparation with an excellent dissolution property comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof is disclosed. The oral preparation according to the present invention comprises a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof as an effective ingredient and an organic acid, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C. The method for improving dissolution property and chemical stability of an oral preparation according to the present invention comprises incorporating an organic acid in the oral preparation comprising as an effective ingredient a specific morphinan derivative or a pharmaceutically acceptable acid addition salt thereof, wherein 1 g of said organic acid requires not less than 30 mL of water to dissolve in at 20° C. | 08-26-2010 |
20100215751 | METHODS AND COMPOSITIONS FOR TREATING RECURRENT CANCER - The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein. | 08-26-2010 |
20100215752 | POLICOSANOL NANOPARTICLES - The present invention provides nanoparticulate policosanol, formulations including these particles, as a well as methods of using the particles and formulations for treatment and prophylaxis of various diseases and conditions. | 08-26-2010 |
20100215753 | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose - A solid dosage form is provided which includes an active agent and silicified microcrystalline cellulose, the dosage form formed by a) combining a wetted active agent with dry silicified microcrystalline cellulose in a dryer to form agglomerated particles; and b) incorporating the agglomerated particles into the solid dosage form. In certain preferred embodiments, step b comprises combining said silicified microcrystalline cellulose, said active agent, and colloidal silicon dioxide in a dryer. Preferably, the dryer is a spray dryer, and, in certain embodiments, the active agent may be an herbal extract. | 08-26-2010 |
20100215754 | Delivery System for Functional Compounds - A delivery system for various functional compounds is disclosed. The delivery system incorporates a composition containing alumina. Various functional materials containing particular moieties may be adsorbed onto the alumina and used as desired. The functional compounds can be, for instance, pharmaceuticals, xenobiotics, anti-microbial agents, anti-viral agents, UV absorbers, odor control agents, fragrances, and the like. In one particular embodiment, for instance, certain dyes can be adsorbed onto the alumina surfaces. Once the dye is adsorbed onto the alumina surface, the resulting particles can be combined with a liquid vehicle for use in any suitable printing process. | 08-26-2010 |
20100215755 | Resveratrol Ferulate Compounds, Compositions Containing The Compounds, And Methods Of Using The Same - The present invention relates to methods of using topical or cosmetic compositions containing resveratrol ferulates for skin lightening and anti-aging applications and method of synthesizing resveratrol ferulates. | 08-26-2010 |
20100221344 | Functionalized Nanoceria Composition For Ophthalmic Treatment - The invention provides a composition comprising a plurality of nanoceria particles, a sufficient amount of at least one inhibitor of human carbonic anhydrase II associated with said plurality of nanoceria particles, and a pharmaceutically acceptable carrier containing said plurality of nanoceria particles with associated inhibitor. One preferred inhibitor of human carbonic anhydrase II comprises 4-carboxybenzene sulfonamide. The disclosed composition is useful in treatment of glaucoma. | 09-02-2010 |
20100221345 | OSTEOGENIC BIOMATERIAL CONTAINING OSTEOGENESIS PROMOTING SUBSTANCE AND NANOGEL - An object of the present invention is to provide an osteogenic biomaterial which achieves long-term sustained release and localized functional expression of a substance which promotes the formation of bone tissue. The present inventors have found out that a nanogel efficiently encloses an osteogenesis promoting substance to suppress the substance from diffusion into blood, and that the nanogel functions as a carrier for local administration of the osteogenesis promoting substance. Furthermore, they have found out that the osteogenesis promoting substance-containing nanogel can be cross-linked with a water-soluble polymer to allow sustained release of the osteogenesis promoting substance at a local area over a long period of time. Based on these findings, the present invention was completed. The osteogenic biomaterial of the present invention which contains the osteogenesis promoting substance and the nanogel shows osteogenesis promoting activity over a long period of time, and can be used as a preventive and therapeutic agent against bone diseases. | 09-02-2010 |
20100221346 | Method For Transfecting Cells Using A Magnetic Field - Described is a method for transfecting a cell comprising bringing a complex comprising vector(s) and magnetic particle(s) in contact with a cell by applying a magnetic field and methods of treatment using said method. Furthermore, described is such a complex as well as methods for making it. Finally, pharmaceutical compositions, uses of such complexes and a kit are described. The method described is particularly useful where automatizable high-throughput transfection is required for large scale screening processes. | 09-02-2010 |
20100221347 | ENHANCING SOLUTE TRANSPORT WITHIN A TISSUE SCAFFOLD - This document provides materials and methods related to tissue scaffolds for use in replacing or augmenting various tissues in the body. For example, flexible tissue scaffolds with controlled pore geometry and methods of enhancing solute transport using rhythmic compression (e.g., 1.0 Hz) of tissue scaffolds are provided | 09-02-2010 |
20100221348 | THERAPEUTIC USES OF DUNALIELLA POWDER - A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating to a subject an effective amount of crude | 09-02-2010 |
20100226989 | Nanoparticulate megestrol formulations - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm. | 09-09-2010 |
20100226990 | Method of Producing Porous Microparticles - A method of preparing porous microparticles comprises the steps of combining one or more organic compounds with a volatile system, and drying the system thus formed to provide substantially pure porous microparticles of the organic compound or composite porous microparticles of combinations of organic compounds. Organic compounds used in the method may be one or more of a bioactive, a pharmaceutically acceptable excipient, a pharmaceutically acceptable adjuvant or combinations thereof. The invention also relates to porous microparticles produced by such a method, and pharmaceutical compositions comprising such porous microparticles. | 09-09-2010 |
20100226991 | SOLID INORGANIC/ORGANIC HYBRID WITH MODIFIED SURFACE - The invention relates to solid organometallic hybrids with modified surface. Said solid may be used for example for the encapsulation and vectoring of molecules of interest such as active pharmaceutical agents, compounds of interest in cosmetics and markers, for example, contrast agents. Said solids show good results in terms of loading capacity in medicament agents and in biocompatibility. | 09-09-2010 |
20100226992 | Pharmaceutical Composition for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye - The present invention relates to development of efficacious pharmaceutical compositions in the form of intraocular suspensions comprising an anti-angiogenic compound in a therapeutically effective amount and a polyethylene glycol having a molecular weight of at least 2000, preferably at least 3000. | 09-09-2010 |
20100226993 | COMPOSITION FOR REGENERATIVE TREATMENT OF CARTILAGE DISEASE - A composition for regenerative treatment of cartilage disease, which comprises a PDE4 inhibitor as an active ingredient, specifically a composition comprising a PDE4 inhibitor and a biocompatible and biodegradable polymer is provided, which composition, when formulated into a form suited to administer locally to affected cartilage region, such as microsphere preparation, can provide a pharmaceutical composition showing an excellent effect in regenerative treatment of cartilage. | 09-09-2010 |
20100233268 | POWDER FORMULATIONS FOR INHALATION CONTAINING ENANTIOMERICALLY PURE BETA-AGONISTS - The present invention relates to powder formulations for inhalation containing enantiomerically compounds of general Formula (I) wherein the groups R | 09-16-2010 |
20100233269 | MINERALIZED POLYMER PARTICLES AND THE METHOD FOR THEIR PRODUCTION - A process for mineralizing a particulate organic material includes providing particles of a non-porous, swellable organic material, and contacting the particles with a solution containing at least one cation and a solution containing at least one anion, thereby obtaining the mineralized particulate organic material. | 09-16-2010 |
20100233270 | Delivery of Oligonucleotide-Functionalized Nanoparticles - The present invention relates to compositions and methods for delivering an oligonucleotide-functionalized nanoparticle. | 09-16-2010 |
20100233271 | SLOW RELEASE OF ORGANIC SALTS OF LOCAL ANESTHETICS FOR PAIN RELIEF - Particles of an organic acid salt of an amino acid amide or ester local anesthetic are employed as agents for the improved alleviation of pain. Particularly, the particles find use with surgically created wounds, where the particles may be administered directly into the bed of the wound or topically for transdermal transport. | 09-16-2010 |
20100233272 | DOSAGE FORMS COMPRISING CELECOXIB PROVIDING BOTH RAPID AND SUSTAINED PAIN RELIEF - A pharmaceutical dosage form comprising celecoxib and a pharmaceutically acceptable carrier, the dosage form when initially administered to at least 12 human patients in the fasted state in a crossover study providing: (a) a mean blood plasma concentration of celecoxib within 0.5 hour after administration (C | 09-16-2010 |
20100233273 | POLYMER COMPOSITIONS WITH BIOACTIVE AGENT, MEDICAL ARTICLES, AND METHODS - A polymer composition that includes a hydrophilic polymer, an optional secondary organic polymer, and a bioactive agent distributed therein, wherein the bioactive agent is selected from the group consisting of a silver compound, a copper compound, a zinc compound, and combinations thereof. | 09-16-2010 |
20100239674 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND PREVENTION OF DISEASES INVOLVING IMPOTENCE - Disclosed is a pharmaceutical composition for the treatment and/or prevention of erectile dysfunction, comprising (a) a therapeutically effective amount of a compound represented by Formula 1 or 2, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. | 09-23-2010 |
20100239675 | PLASMON MEDIATED PHOTOINDUCED SYNTHESIS OF SILVER TRIANGULAR BIPYRAMIDS - A method of preparing silver triangular bipyramids having a high shape selectivity and low edge length variation is disclosed. Also disclosed are silver triangular bipyramids prepared by this method. | 09-23-2010 |
20100239676 | Stable Aerosolizable Suspensions of Proteins in Ethanol - Stable suspensions of a biologically active protein are disclosed that are suited for aerosol delivery to the lungs of a patient in need of treatment, which comprise particles of biologically active protein suspended in ethanol. In a preferred embodiment, the invention describes a stable suspension of insulin useful for aerosol delivery to the lungs of a patient in need of treatment comprising particles of a pharmaceutically effective amount of insulin suspended in ethanol. A method of delivering a therapeutically effective amount of a protein to the respiratory tract of a patient is described which comprises producing an aerosol of a stable liquid suspension of a protein using an electrohydrodynamic spraying means wherein the liquid suspension comprises particles of the protein suspended in ethanol. The stable ethanol suspensions of the invention may optionally contain up to about 20% (V/V) of a pharmaceutically acceptable formulation additive such as glycerol, propylene glycol and polyethylene glycol as well as minor amounts (from about 0.05% to about 5.0% W/V) of a pharmaceutically acceptable excipient. | 09-23-2010 |
20100239677 | NONAEROSOL/AEROSOL DISPENSING OF SUNSCREEN SPRAYS COMPRISING SILICA MICROPARTICLES - Nonaerosol/atomizer pumps or aerosol dispensers comprise (A) a reservoir confining at least one vaporizable sunscreen composition suited for UV-photoprotecting the skin and/or hair against the damaging effects of UV radiation, the at least one vaporizable sunscreen composition comprising (1) a UV-photoprotecting amount of at least one UV-sunscreen and (2) an SPF-enhancing amount of generally spherical silica microparticles, formulated into (3) a topically applicable, cosmetically acceptable carrier therefor, and (B) at least one agent for pressurizing the at least one vaporizable sunscreen composition into a spray of fine sunscreen particles. | 09-23-2010 |
20100239678 | IONICALLY FUNCTIONALIZED NANODIAMONDS - The present invention is directed to attaching drugs | 09-23-2010 |
20100247653 | NANOPARTICLES CONTAINING NICOTINE AND/OR COTININE, DISPERSIONS, AND USE THEREOF - The present invention relates to nanoparticles containing nicotine and/or cotinine. The present invention further relates to dispersions containing these nanoparticles. The invention relates in particular to corresponding novel transdermal pharmaceuticals containing nicotine and cotinine in nanoparticulate form, and use thereof for smoking cessation. | 09-30-2010 |
20100247654 | STABLE MICELLES FORMED WITH DIBLOCK COPOLYMERS OF CRITICAL MICELLE CONCENTRATION COPOLYMER AND TEMPERATURE-SENSITIVE COPOLYMER - A novel class of mixed micelles formed with critical micelle concentration (Cmc) character's diblock copolymer, and temperature-sensitive character's diblock copolymer were disclosed. The mixed micelles possess complementary effects in adjusting external temperature shift (storage vs. body temperature) and concentration change (dilution after intravenous injection). The mixed micelles of the present invention can serve as a potential injectable drug delivery system for anticancer drugs, such as doxorubicin and many others. | 09-30-2010 |
20100247655 | Synthesis of Small Particles - The invention provides an apparatus for forming fine particles of a substance in a precipitation chamber, in which the apparatus has means to convey the fine particles from the precipitation chamber to at least one particle collection chamber, downstream of the precipitation chamber, the particle collection chamber having an inlet and an outlet separate from the inlet. The invention also provides a method of forming fine particles of a substance, the method comprising contacting a non-gaseous fluid containing the substance with a dense fluid to expand the non-gaseous fluid in a precipitation chamber, conveying a resulting mixture of fluid and the fine particles from the precipitation chamber to a collection chamber, the collection chamber having an inlet and an outlet separate from the inlet. | 09-30-2010 |
20100247656 | Method for in situ Generation of Molecular Iodine on Mucus Membranes Using Nanoparticles - Nano-particles created using a biodegradable chemical backbone structure suitably designed to permit creation of at least two populations of nano-particles that contain chemical compositions. A first population of particles can contain iodide (I | 09-30-2010 |
20100247657 | TELOMERASE REVERSE TRANSCRIPTASE VARIANT - The present invention relates to nucleic and amino acid sequences of a novel variant of the telomerase reverse transcriptase. More particularly, the present invention is directed to a novel variant of human telomerase reverse transcriptase, which displays properties distinct from those of wildtype telomerase reverse transcriptase, and methods of use thereof. | 09-30-2010 |
20100247658 | ORGANIC COMPOUNDS - A process for reducing the tendency of a drug substance to aggregate and/or agglomerate during storage. The process involves micronising the drug substance to give a mean particle size of less than about 10 μm, and exposing the micronised drug substance to a dry environment at an elevated temperature between 40° C. and 120° C. for at least six hours. | 09-30-2010 |
20100255102 | STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION - The present invention relates to methods for sterilization of dispersions of one or more nanoparticulate active agents via gamma irradiation. | 10-07-2010 |
20100255103 | Mesoporous Silica Nanoparticles for Biomedical Applications - A submicron structure includes a silica body defining a plurality of pores that are suitable to receive molecules therein, the silica body further defining an outer surface between pore openings of said plurality of pores; and a plurality of anionic molecules attached to the outer surface of the silica body. The anionic molecules provide hydrophilicity to the submicron structure and are suitable to provide repulsion between other similar submicron structures, and the submicron structure has a maximum dimension less than one micron. | 10-07-2010 |
20100255104 | PHARMACEUTICAL FORMULATION OF TAXANE - A pharmaceutical formulation of taxane to be administered to mammals, preferably humans, including two compositions which are combined prior to their administration, forming a transparent solution free from precipitates and essentially free from foam, wherein said compositions comprise a solid composition of taxane and a solubilizing composition of said solid taxane composition comprising a tensoactive and an antifoam agent. A kit for such a formulation of injectable taxane includes a prefilled syringe. Also there is a pharmaceutical taxane perfusion solution. | 10-07-2010 |
20100255105 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING METOPROLOL SUCCINATE - An extended release pharmaceutical composition comprising metoprolol succinate and at least two pharmaceutically acceptable excipients, wherein the first pharmaceutically acceptable excipient is an extended release agent; the second pharmaceutically acceptable excipient is selected from a binder, a diluent and mixtures thereof; and metoprolol succinate is in a crystalline form having a D50 ranging from 5 to 16 microns and a D90 below 50 microns. | 10-07-2010 |
20100255106 | BENZOTHIOPHENES, FORMULATIONS CONTAINING SAME, AND METHODS - This invention provides compounds of formula I | 10-07-2010 |
20100260851 | Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium - The present invention provides a novel polymorphic form of atorvastatin calcium, designated as form Al, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention further provides a process for the preparation of highly pure amorphous atorvastatin calcium using the novel atorvastatin calcium form Al. The present invention also relates to novel amorphous form of atorvastatin tert-butyl ester, chemically known as [R-(R*,R*)]-2-(4-fluorophenyl)-[β],[δ]-dihydroxy -5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl-1H-pyrrole-1-heptanoicacid tert-butyl ester, process for the preparation, and its application for preparing highly pure atorvastatin and its pharmaceutically acceptable salts thereof. The present invention also relates to use of the novel amorphous atorvastatin tert-butyl ester and novel atorvastatin calcium form al for preparing amorphous atorvastatin calcium. | 10-14-2010 |
20100260852 | LAXATIVE AGENT - A laxative agent comprising composite magnesium oxide particles represented by the following formula (1) as an effective component: | 10-14-2010 |
20100260853 | COMPOSITIONS FOR PULMONARY DELIVERY - The present invention relates to methods of direct pulmonary delivery of polypeptides e.g. of domain antibodies, and to particular polypeptide compositions suitable for direct pulmonary delivery. The invention also relates to use of such compositions in medicine, e.g. for the treatment and diagnosis of lung disease, for example for treating Chronic Obstructive Pulmonary Disease (COPD) and asthma. | 10-14-2010 |
20100260854 | GRANULATE FOR THE FORMULATION OF ORODISPERSIBLE TABLETS - This invention relates to a granulate comprising mannitol and sorbitol in a weight ratio of between 70:30 and 97:3. This invention also relates to the use of the said granulate in the preparation of orodispersible tablets, to the orodispersible tablets obtained with the said granulate and to a process of production for obtaining the said granulate. | 10-14-2010 |
20100260855 | DELIVERY OF AS-OLIGONUCLEOTIDE MICROSPHERES TO INDUCE DENDRITIC CELL TOLERANCE FOR THE TREATMENT OF AUTOIMMUNE TYPE 1 DIABETES - AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to prevent an autoimmune diabetes condition in NOD mice in vivo and in situ. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations. | 10-14-2010 |
20100266694 | Chitosan/Carbon Nanotube Composite Scaffolds for Drug Delivery - A novel composite for internal application within wounds, incisions, and the like, for the prevention of biofilm growth therein is provided. Such a composite includes an antibiotic introduced within a sponge-like chitosan delivery product with electrically conductive nanomaterials present. Such a delivery product is also lyophilized subsequent to nanomaterial introduction but prior to antibiotic inclusion. The inventive lyophilized composite permits delivery of needed antibiotics internally within a patient with the simultaneous exposure to a sufficiently strong electrical current to permit a synergistic effect of increased antibiotic efficacy. In such a manner, relatively low amounts of antibiotic may be utilized to reduce the propensity of biofilm formation and/or growth within a wound or incision, or on the surface of an implant. Additionally, the lyophilized chitosan/nanomaterial composite allows for a maximum amount of antibiotic to be introduced with maximum elution therefrom as well. Lastly, the chitosan degrades over time within the subject's body, thereby avoiding any further invasive removal procedures. The method of such a manner of delivering improved antibiotic efficacy for biofilm prevention is encompassed within this invention as well. | 10-21-2010 |
20100266695 | MULTIVALENT CLUSTERING TARGETING STRATEGY FOR DRUG CARRIERS - The present invention provides clustered ligand vehicles for the delivery of a nucleic acid therapeutic agent to a target expressing a receptor. The invention further provides methods for treating a disease state by targeting a nucleic acid therapeutic agent to a target expressing a receptor using clustered ligand vehicles. | 10-21-2010 |
20100266696 | Organic Compounds - A process of preparing a particulate and substantially crystalline drug substance. The process involves suspending a substantially crystalline drug substance in an anti-solvent to give a suspension, homogenising the suspension at elevated pressure to give drug particles that have a mean particle size of less than about 10 μm, and drying the drug particles to remove any residual anti-solvent. | 10-21-2010 |
20100266697 | MIXED LIGAND SURFACE-MODIFIED NANOPARTICLES - A composition comprises surface-modified nanoparticles of at least one amphoteric metal oxide or oxyhydroxide. The nanoparticles bear, on at least a portion of their surfaces, a surface modification comprising (i) at least one surface modifier selected from lactate, thiolactate, and mixtures thereof, and (ii) at least one surface modifier selected from halide, nitrate, acetate, carbonate, formate, propionate, sulfate, bromate, perchlorate, tribromoacetate, trichloroacetate, trifluoroacetate, carboxylate comprising from one to about four alkyleneoxy moieties, chlorate, and mixtures thereof. | 10-21-2010 |
20100266698 | USE OF INSULIN FOR THE TREATMENT OF CARTILAGINOUS DISORDERS - The present invention relates to methods for the treatment and repair of cartilage, including cartilage damaged by injury or cartilaginous disorders, including arthritis, comprising the administration of insulin and/or insulin variants. Optionally, the administration may be in combination with a cartilage agent (e.g., peptide growth factor, catabolism antagonist, osteo-, synovial, anti-inflammatory factor), in an extended- or sustained-release form. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of insulin and/or insulin in combination with standard surgical techniques. Alternatively, the method provides for the treatment and repair of cartilage damaged by injury or cartilaginous disorders comprising the administration of chondrocytes previously treated with an effective amount of insulin and/or insulin variant. | 10-21-2010 |
20100266699 | Pharmaceutical Suspensions and Related Methods - A pharmaceutical suspension having a therapeutically effective amount of phenylephrine and a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener; an effective amount of water; and an effective amount of a suspending system; wherein the pharmaceutical suspension has a pH of from about 4 to about 6 and is substantially free of a reducing sugar and related methods. | 10-21-2010 |
20100266700 | USE OF ADSORBENT CARBON MICROSPHERES FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME - Adsorbent carbon microspheres are administered to treat irritable bowel syndrome or symptoms associated with irritable bowel syndrome. | 10-21-2010 |
20100272811 | COMPLEX OF TROSPIUM AND PHARMACEUTICAL COMPOSITIONS THEREOF - The invention is directed to a complex of trospium and saccharin. In one embodiment, the complex is a crystalline form. In another embodiment, the complex is a monohydrate form. The invention also encompasses methods of preparing the the saccharin complex of trospium and to pharmaceutical compositions thereof. | 10-28-2010 |
20100272812 | RGD-MODIFIED ALGINATE MICROPARTICLES AS A DRUG RELEASE SYSTEM - The object of the present invention is to provide particles of a polymeric material containing cells therein, wherein said particles have a strength that is substantially greater than the microcapsules known in the state of the art. Said strength is achieved by means of functionalizing the polymeric material forming the microcapsule with a peptide which can bind to the adhesion proteins of the cell membrane, such that the cells act as cross-linking agents of the matrix resulting in an improvement of the mechanical properties of the matrixes | 10-28-2010 |
20100272813 | NANOPARTICLE-MEDIATED TREATMENT FOR INFLAMMATORY DISEASES - The present invention provides nanoparticles for treatment of inflammatory diseases. The nanoparticles preferably comprise chitosan and a siRNA targeting a mRNA encoding a pro-inflammatory cytokine, such as e.g. tnf-alfa. A preferred route of administration of the nanoparticles is by injection intraperitoneally. | 10-28-2010 |
20100272814 | METHOD AND MEANS FOR PRODUCING BRONCHORELAXATION - A method of producing bronchorelaxation in the lungs of a human or animal affected by airway obstruction comprises administration of a pharmacologically effective amount to the body or to the intestine of said human or animal of an agent capable of binding mercury in elemental, ionic and/or organic form present in the body or in the intestinal lumen to enhance its excretion via the feces and/or the urine. A corresponding use of the agent and its use for the manufacture of a medicament are also disclosed. | 10-28-2010 |
20100272815 | AMORPHOUS FORM OF TAPENTADOL HYDROCHLORIDE - Disclosed herein is a novel and stable amorphous form of tapentadol hydrochloride, a process for the preparation, pharmaceutical compositions, and a method of treating thereof. Disclosed also herein is a stable amorphous co-precipitate of tapentadol hydrochloride with pharmaceutically acceptable excipients, a method for the preparation, pharmaceutical compositions, and a method of treating thereof. Advantageously, the amorphous co-precipitates of tapentadol hydrochloride have improved physiochemical characteristics that assist in the effective bioavailability. | 10-28-2010 |
20100278919 | Dendritic cell targeting compositions and uses thereof - The present invention provides compositions and methods for targeting dendritic cells of the immune system. In particular, the compositions comprise carbon nanoparticles, optionally magnetic carbon nanoparticles comprising iron, which are preferentially endocytosed by dendritic cells compared to macrophages when contacted with a biological sample. The nanoparticles of the present invention may be functionalized to enhance delivery of biomolecules to dendritic cells. | 11-04-2010 |
20100278920 | Polyacrylate Nanoparticle Drug Delivery - Drug delivery of resistance reversal agents by polyacrylate nanoparticles for treatment of drug (e.g. chloroquine) resistant malaria. Also provided are drug delivery by polyacrylate nanoparticles of ciprofloxacin for treatment of anthrax. | 11-04-2010 |
20100278921 | SOLID ORAL FORMULATION OF ABT-263 - An orally deliverable pharmaceutical composition comprises (a) a pharmaceutically acceptable acid addition salt of ABT-263 in solid particulate form, and (b) a plurality of pharmaceutically acceptable excipients including at least a solid diluent and a solid disintegrant; wherein the salt is formed from more than one equivalent of acid per equivalent of ABT-263. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 11-04-2010 |
20100278922 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF INSULIN - The present invention provides a pharmaceutical composition formulated for oral delivery of insulin, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and insulin suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of insulin. | 11-04-2010 |
20100285135 | Nanoparticles For Use In Immunogenic Compositions - Disclosed herein are sterile-filtered lyophilized nanoparticle compositions which contain at least one biodegradable polymer, at least one surfactant, at least one cryoprotective agent and at least one antigen. Also disclosed are methods of making and using such compositions and kits supplying such compositions. | 11-11-2010 |
20100285136 | SYSTEM COMPRISING BACTERIOPHAGES AND PARTICLES THAT CONTAIN ACTIVE SUBSTANCES - The present invention concerns a system, comprising bacteriophages and particles comprising active agents, in which a first additional peptide is fused to proteins of the bacteriophage, the first additional peptide adheres to the surface of the particle and furthermore a second additional peptide is fused to proteins of the bacteriophage. The second additional peptide can adhere on substrate surfaces. The present invention furthermore concerns the use of the system for delayed release of active agents and also a method for production of the system. The present invention furthermore concerns a method for the selection of phage species from a combinatorial phage population. | 11-11-2010 |
20100285137 | ANTIBIOTIC/BONE MORPHOGENIC PROTEIN FORMULATION AND METHOD OF TREATMENT - A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time. | 11-11-2010 |
20100285138 | COMPOSITIONS COMPRISING NANOPARTICLES AND APOPTOTIC AGENTS AND METHODS OF USE - Compositions comprising nanoparticles, such as silver or gold nanoparticles or carbon nanotubes (CNTs), and apoptotic agents are described. The nanoparticles can significantly enhance the cancer chemotherapeutic effects of the apoptotic agents. In particular, a highly increased anti-tumor activity has been demonstrated for the combination of etoposide and CNTs against HeLa cells compared to the administration of either etoposide alone or nanoparticles alone. Data provided by flow cytometry, Caspase 3 and other methods, suggest a strong interaction between the nanoparticles and the cellular structure, which can result in the improved effectiveness of chemotherapeutic agents. These findings provide potential new cancer therapies by carefully selecting the right combination of cytostatic drugs and nanostructural materials which synergistically provide significantly greater curative rates. | 11-11-2010 |
20100285139 | PHARMACEUTICAL COMPOSITION FOR THE PROPHYLAXIS AND/OR SYMPTOMATIC TREATMENT OF CYSTIC FIBROSIS - A pharmaceutical composition for prophylaxis and/or treatment of infections and/or infectious diseases occurring in cystic fibrosis includes at least one antidepressant; at least one dispersant; and at least one pharmaceutically tolerable carrier material. | 11-11-2010 |
20100285140 | ANTIMICROBIAL AGENT FOR GRAM-POSITIVE BACTERIA - A novel antibacterial agent for Gram-positive bacteria which disregards the drug-resistant mechanisms of bacteria is disclosed. The antibacterial agent contains as an effective ingredient particles having a particle diameter of not more than 5 μm, which particles are adhesive to cell wall of Gram-positive bacteria and not adhesive to mammalian cell membrane and substantially do not contain an active antibacterial ingredient effective against Gram-positive bacteria. By the antibacterial agent according to the present invention, the growth of the multidrug-resistant Gram-positive bacteria such as MRSA and VRE can be inhibited, as well as the occurrence of novel multidrug-resistant bacteria, which is a big problem in use of antibiotics, can be avoided. | 11-11-2010 |
20100291218 | IMMUNOMODULATORY COMPOSITIONS, FORMULATIONS, AND METHODS FOR USE THEREOF - The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMO/MC) complexes comprising 3-6mer immunomodulatory oligonucleotides. The IMO/MC complexes may be covalently or non-covalently bound. Also provided are immunomodulatory compositions comprising a 3-6mer IMO encapsulated in an MC. | 11-18-2010 |
20100291219 | METHODS AND COMPOSITIONS RELATING TO PROGENITOR CELLS - The invention provides compositions and methods for harvesting and enriching cells such as connective tissue progenitors cells using stirred bioreactors, and in some embodiments fibrin microcarriers. | 11-18-2010 |
20100291220 | ANTIBIOTIC FORMULATION AND METHOD OF TREATMENT - A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time. | 11-18-2010 |
20100291221 | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation - Disclosed are methods, and related compositions, that include administering a dose-sparing amount of a formulation that includes inhalation particles to a subject by inhalation; wherein the inhalation particles comprise formoterol fumarate and budesonide, the formoterol fumarate and budesonide being in a distributed encapsulated morphology with respect to one another within said inhalation particles and the formoterol fumarate being in a predetermined mass ratio with regard to the budesonide within said inhalation particles. | 11-18-2010 |
20100291222 | ANTIOXIDANT NANOSPHERE COMPRISING [1,2]-DITHIOLANE MOIETIES - The present invention is directed to multiple a-lipoic acid-containing hydrophobic compounds (mALAs) capable of acting as scavengers of free radicals, metals and reactive oxygen species (ROS). Methods of synthesizing novel antioxidant mALAs, spontaneous emulsification or nanoprecipitaion thereof to produce antioxidant nanospheres and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are also described. Another aspect of this invention is the use of these antioxidant nanospheres for the preparation of antioxidant particulate delivery system of therapeutic agents. | 11-18-2010 |
20100291223 | TREATMENT FOR DERMATOLOGICAL CONDITIONS - A composition and method of using a composition containing kunzea oil for treating dermatological conditions in humans and animals, particularly greasy heel occurring in horses, in which the kunzea oil is formulated into a composition for topical application at ambient temperatures to the skin of the animal or human to cover the area of the affected lesions. Improvement in certain dermatological conditions such as pastern dermatitis in horses was noted almost immediately with total resolution of the condition in about 7 days. The composition can be used to treat humans suffering from psoriasis and similar dermatological conditions. This invention offers persons and animals suffering from dermatological conditions a low cost effective treatment based on a natural product which shows significant improvement of the condition within days of applying an effective amount of the composition to the affected area as part of the treatment. | 11-18-2010 |
20100297240 | 1- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT - 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT | 11-25-2010 |
20100297241 | Amorphous Fesoterodine Fumarate - The present invention provides a novel amorphous form of fesoterodine fumarate, process for preparation, pharmaceutical compositions, and method of treating thereof. | 11-25-2010 |
20100297242 | LDL-LIKE CATIONIC NANOPARTICLES FOR DELIVERYING NUCLEIC ACID GENE, METHOD FOR PREPARING THEREOF AND METHOD FOR DELIVERYING NUCLEIC ACID GENE USING THE SAME - Disclosed are a LDL-like cationic nanoparticle for delivering a nucleic acid gene with improved transfection efficiency and stability, which is surface modified and re-constructed by mimicking lipid components of a natural LDL, a method for preparation of the same, and a method for delivering nucleic acid genes using the same. The cationic nanoparticle of the present invention could effectively be applied in treatment of cancer that overexpress LDL receptors. | 11-25-2010 |
20100297243 | PRION FREE NANOPARTICLE COMPOSITIONS AND METHODS OF MAKING THEREOF - The present invention provides prion-free compositions comprising nanoparticles comprising albumin and substantially water insoluble drugs. Also provided are methods of making prion-free compositions and methods of removing prion proteins from the nanoparticle compositions. Methods of using the compositions, as well as kits useful for carrying out the methods are also provided. | 11-25-2010 |
20100297244 | NANODISPERSION - The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivative, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts. | 11-25-2010 |
20100297245 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEIN AND PEPTIDE THERAPEUTIC AGENTS - The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide. | 11-25-2010 |
20100303915 | THERAPEUTIC OPTHALMIC EMULSIONS - Disclosed herein are non-irritating ophthalmic emulsion compositions useful for treating ocular disorders including dry eye and related methods. More specifically, the ophthalmic compositions disclosed herein combine a high HLB surfactant and a low HLB surfactant together with a plant-derived triglyceride having non-polar aliphatic side chains to form a therapeutic non-irritating eye drop. | 12-02-2010 |
20100303916 | ENHANCED DRUG DELIVERY WITH ORIENTABLE PARTICLES - Small airway deposition of orientable drug particles in the lung due to interception is increased through alignment of these particles with an externally applied force such as a magnetic field. Drug particles in one embodiment are made magnetically responsive by loading them with magnetic nanoparticles. Elongated particles have a natural tendency to align parallel to the direction of flow through an airway, and therefore also parallel to airway walls; accordingly, alignment with a magnetic field to any other orientation increases interception, with a maximum increase for alignment perpendicular to airway walls. By positioning a magnetic field across a specific site within the lung, for example in the area of a tumor, the increase in deposition by interception allows localized targeting of inhaled drug particles to that area. | 12-02-2010 |
20100303917 | COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS - Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating cystic fibrosis or a symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered fluids optionally in combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). Particular embodiments comprise use and/or synergy with tobramycin for treating bacterial infection, and use and/or synergy with a bronchiodilator. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (like, membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions). | 12-02-2010 |
20100303918 | COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS - Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential and/or conductance, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination therapies comprising administration of the electrokinetically generated fluids with at least one additional therapeutic agent. | 12-02-2010 |
20100310660 | DRY POWDER MICROPARTICLES FOR PULMONARY DELIVERY - The invention provides a dry powder microparticle for pulmonary delivery, which comprises at least one nanoparticle in the form of liposome or micelle wherein the nanopaparticle encapsulates one or more therapeutic agent therein, and a diluent layer surrounding the nanaparticles. | 12-09-2010 |
20100310661 | ORAL FORMULATIONS FOR PICOPLATIN - The invention provides formulations for the organoplatinum anticancer drug picoplatin. Self emulsifying compositions, stabilized nanoparticulate compositions, solid dispersions, and nanoparticulate suspensions in oils are provided, along with methods for preparation of the formulations. The formulations can provide improved oral availability of picoplatin relative a to a simple solution of picoplatin such as in water or normal saline solution and can be used in combination therapy. | 12-09-2010 |
20100310662 | Oral Drug Delivery System for Azole, Moxifloxacin and Rifampicin - An oral drug delivery system for treatment of tuberculosis is described. The oral drug delivery system includes (e.g., a mixture or combination of): poly DL-lactide-co-glycolide nano particles having encapsulated an azole therein; poly DL-lactide-co-glycolide nano particles having moxifloxacin encapsulated therein; and poly DL-lactide-co-glycolide nano particles having RIF encapsulated therein | 12-09-2010 |
20100310663 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and a poorly aqueous soluble polymer, and a resuspending material selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethylcellulose, and pharmaceutically acceptable salt forms thereof. | 12-09-2010 |
20100310664 | COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE AND DIABETES MELLITUS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 12-09-2010 |
20100310665 | BACTERIOSTATIC OR BACTERIOCIDAL COMPOSITIONS AND METHODS - Particular aspects provide compositions and methods for treating bacterial infection or at least one symptom related to bacterial infection in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically-altered fluid (including gas-enriched electrokinetically altered fluids) which comprise an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. The electrokinetically-altered ionic fluid compositions are sufficient to provide for modulation of intracellular signal transduction, wherein treating bacterial infection or at least one symptom related to bacterial infection is thereby afforded. In particular embodiments, the fluids are gas-enriched fluids or therapeutic compositions and methods, and include oxygen-enriched ionic aqueous solutions optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the gas-enriched therapeutic compositions. | 12-09-2010 |
20100316723 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION - Provided are electrokinetically-altered fluids (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating inflammation or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-generated fluids (electrokinetically-generated gas-enriched fluids and solutions) and therapeutic compositions. | 12-16-2010 |
20100316724 | COMPOSITION - The invention provides microparticles comprising an immunosuppressant, such as tacrolimus, sirolimus, pimecrolimus, ciclosporin, everolimus or a derivative thereof, and optionally a pharmaceutically acceptable excipient or carrier, such as a saccharide, amino acid, a sugar alcohol or a mixture thereof, and having a median geometric diameter of less than, or equal to, about 10 μm and which have a tap density of less than or equal to about 0.3 g/cm | 12-16-2010 |
20100316725 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS - This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm. | 12-16-2010 |
20100316726 | TOOTH SEALANT - The invention provides a method of treating sensitive teeth comprising attaching a sealant composition comprising a basic amino acid to a person's tooth and allowing the basic amino acid to be slowly released over time in order to reduce chrome and/or acute tooth sensitivity together with compositions and methods of use. | 12-16-2010 |
20100323017 | Escitalopram and Solid Pharmaceutical Composition Comprising the Same - The present invention relates to Escitalopram having a small median particle size and a solid pharmaceutical composition comprising the same. | 12-23-2010 |
20100323018 | Branched DNA/RNA monomers and uses thereof - The invention provides compositions and methods relating to delivery of agents in vivo or in vitro. More specifically, the invention provides nanoparticles synthesized from crosslinked nucleic acids, optionally having a lipid shell or coating, and may further comprise for example small molecule or high molecular weight compounds as therapeutic or diagnostic agents. | 12-23-2010 |
20100323019 | Microparticles for the treatment of disease - Microparticle-bioactive agent based treatments for local treatment of diseased tissues/organs are disclosed. | 12-23-2010 |
20100323020 | STABLE NANOPARTICULATE DRUG SUSPENSION - A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bc1-2 family protein inhibitory compound such as ABT-263, having a D | 12-23-2010 |
20100323021 | ANTITUMORAL TREATMENTS - The present invention relates to colloidal metal nanoparticles conjugated with Kahalalide F, or an analogue thereof, and their use in the treatment of cancer. The invention also relates to a method for increasing the antitumoral activity of Kahalalide F, or an analogue thereof, which comprises conjugating the Kahalalide F, on an analogue thereof, with a colloidal metal nanoparticle. | 12-23-2010 |
20100323022 | CALCIUM PHOSPHATE COMPOSITION AND PROCESS FOR PRODUCTION THEREOF - A calcium phosphate composition comprising calcium phosphate particles (A) and a sulfonic acid salt (B), wherein the calcium phosphate composition contains 0.5 to 20 parts by weight of the sulfonic acid salt (B) based on 100 parts by weight of the calcium phosphate particles (A). This provides a calcium phosphate composition that has a time between the addition of a liquid agent to the calcium phosphate composition and the completion of setting in the use at a clinical site and the like, i.e., a setting time which is within an appropriate range and that is high in mechanical strength and good in marginal sealing ability. | 12-23-2010 |
20100330185 | ACTIVE INGREDIENT FORMULATIONS CONTAINING 2-THIAZOLE-4YL-1H-BENZOIMIDAZOL (THIABEN-DAZOLE OR TBZ) FOR THE PRODUCTION OF WPC - Use of a biocidal mixture containing IPBC and TBZ for protecting wood-plastic composites (WPC), containing thermoplastic polymer and wood particles, from attack and/or destruction by microorganisms. | 12-30-2010 |
20100330186 | MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC - A pharmaceutical composition comprising a compound of formula 1 | 12-30-2010 |
20110003000 | Transvaginal Delivery of Drugs - Drug delivery compositions which are suitable for transvaginal administration for the treatment of diseases and disorders of the urogenital tract are described. The drug delivery compositions are administered directly to the vagina using a convenient transvaginal application that deposits a very small volume of drug at the desired site for delivery. This method of administration reduces the systemic levels of the drugs and decreases the side effects which are associated with systemic administration. In the preferred embodiment, the compositions are in the form of a gel. The formulation is administered in volumes of less than or equal to 1 milliliter. In the preferred embodiment, the composition contains an antimuscarinc drug, such as oxybutynin. | 01-06-2011 |
20110003001 | BISMUTH-THIOLS AS ANTISEPTICS FOR EPITHELIAL TISSUES, ACUTE AND CHRONIC WOUNDS, BACTERIAL BIOFILMS AND OTHER INDICATIONS - Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections. | 01-06-2011 |
20110008445 | SUSPENSION OF ASCORBIC ACID IN GLYCERIN AND PROCESS FOR PRODUCTION THEREOF - A suspension of ascorbic acid in glycerol or in glycerol comprising diglycerol, in which the content of ascorbic acid is 13% by mass or greater, and further in which 8 to 12% by mass of the ascorbic acid is dissolved in glycerol or in glycerol comprising diglycerol, and the rest of ascorbic acid is precipitated in the form of microcrystals having a particle diameter of 25 μm or smaller and is uniformly dispersed in the suspension. The suspension of ascorbic acid in glycerol is useful as a base material for cosmetics containing ascorbic acid which exhibits excellent feel in the use (spreadability and smooth feel on application to the skin). | 01-13-2011 |
20110008446 | Method of Drug Delivery - A drug delivery method for effective drug application is disclosed in this invention. In this method, a micro-carrier delivers an encapsulated, desired drug directly to targeted sites without significant interactions with other components in the biological system in the pathway. In one embodiment, a micro-carrier containing encapsulated drug is first delivered to the general area for treatment. It then scans the area and selectively attaches itself the cell site or organ location to be treated. Finally, the desired drug contained in the micro-carrier is released to the attached cell or organ. In another embodiment, a micro-device is first used to process the general area to be treated to enhance differentiation in properties (such as surface charge) between healthy cells and unhealthy cells (such as cancer cells). Drug encapsulated in the micro-carrier is next applied to preferentially attach onto the targeted sites (such as cancer cell sites) to be treated. Finally, drug is released from the micro-carrier onto the sites to be treated. Such micro-carrier preferably contains multiple functions comprised of at least two functions from the group of sensing, analyzing, logic processing, surface treatment, position detection, motion, injecting, delivering, cutting functions, removing functions, biodegradation and disintegration. | 01-13-2011 |
20110008447 | CARRIER COMPRISING NANODIAMOND - The present invention provides a carrier including a nanodiamond (ND) particle and a linker covalently bound to the ND particle, in which the linker is presented by the formula: —R | 01-13-2011 |
20110008448 | Diketopiperazine Salts for Drug Delivery and Related Methods - Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization. | 01-13-2011 |
20110014291 | Novel Polymorphs of Bosentan - Disclosed herein are novel polymorphic forms of bosentan, processes for preparation, pharmaceutical compositions, and method of treating thereof. | 01-20-2011 |
20110014292 | METHOD OF PROPHYLAXIS AND AGENTS FOR USE THEREIN - The present invention relates generally to a method of prophylactically or therapeutically treating antigen-induced airway tissue inflammation and agents for use therein. More particularly, the present invention provides a method of prophylactically or therapeutically treating allergic airway inflammation and agents for use therein via the administration of the method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by antigen-induced airway tissue inflammation. | 01-20-2011 |
20110014293 | CLEAVAGE KIT, AND GENE THERAPY BY USING THE SAME AND NUCLEIC ACID CLEAVAGE DETECTION APPARATUS - A nucleic acid cleavage kit is used to cleave a target nucleic acid. The nucleic acid cleavage kit includes a carrier, an oligonucleotide, and a nucleic acid cleavage agent. The oligonucleotide recognizes at least partial sequence of the target nucleic acid. Then, the nucleic acid cleavage agent cleaves the target nucleic acid. A nucleic acid cleavage detection apparatus including the nucleic acid cleaving kit and a gene therapy by administering the nucleic acid cleavage kit are also disclosed. | 01-20-2011 |
20110014294 | STIMULATION OF OCULAR RETROBULBAR BLOOD FLOW USING OCULAR IRRITANTS - Disclosed are uses of an ocular irritant such as saponin in stimulating the retrobulbar blood flow of an eye. Disclosed are also methods of treatment including administration of a pharmaceutical composition including an ocular irritant to an eye, for example as a mist, in order to stimulate the retrobulbar blood flow. In some embodiments, the stimulation of the retrobulbar blood flow has a beneficial effect. | 01-20-2011 |
20110020453 | Topical Formulations Comprising Ion Channel Modulators - Disclosed herein are pharmaceutical formulations comprising particles of formula 1: | 01-27-2011 |
20110020454 | NOVEL DOSAGE AND FORMULATION - The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide. | 01-27-2011 |
20110020455 | SOLID DISPERSION AND PHARMACEUTICAL COMPOSITION OF THE SAME, AND PRODUCTION PROCESSES THEREOF - A powdery porous carrier comprising a porous silicon-containing carrier is impregnated with a solution containing an organic solvent and an active ingredient hardly soluble in water, and the organic solvent is removed to give a solid dispersion having the active ingredient supported to the porous carrier without a treatment with a supercritical fluid. The porous silicon-containing carrier has a heating loss of not more than 4% by weight at a temperature of 950° C. for 2 hours (e.g., a spherical silicon-containing carrier such as a spherical porous silica). The porous silicon-containing carrier may be a spherical silica having a mean pore size of 10 to 40 nm and an oil absorption of 175 to 500 ml/100 g. A pharmaceutical composition (e.g., tablets, granules, or capsules) may be prepared from the solid dispersion and a pharmaceutically acceptable carrier. This invention provides a solid dispersion and a pharmaceutical composition (or a pharmaceutical preparation) which allows improvement in a solubility and a bioavailability of an active ingredient hardly soluble in water (e.g., a fibrate compound). | 01-27-2011 |
20110020456 | LANTHANUM COMPOSITION - The present invention discloses stable, solid oral pharmaceutical composition comprising Lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and pharmaceutically acceptable carriers or diluents, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s, such that the composition has comparable in-vitro dissolution profile similar to that of FOSRENOL®. | 01-27-2011 |
20110027371 | Nanoparticulate statin formulations and novel statin combinations - The present invention is directed to nanoparticulate compositions comprising statin such as lovastatin or simvastatin. The statin particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of statins and other cholesterol lowering agents are described and methods of using same are taught. | 02-03-2011 |
20110027372 | MULTIPARTICULATES COMPRISING LOW-SOLUBILITY DRUGS AND CARRIERS THAT RESULT IN RAPID DRUG RELEASE - Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed. | 02-03-2011 |
20110033544 | INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH IMPROVED PHARMACOKINETCS - Methods are provided for the engineering of inhalable dry powder pharmaceutical formulations with desired pharmacokinetic profiles and parameters. Compositions with improved pharmacokinetics are disclosed. | 02-10-2011 |
20110033545 | TOPICAL PHARMACEUTICAL PREPARATIONS HAVING BOTH A NANOPARTICLE SOLUTION AND A NANOPARTICLE SUSPENSION AND METHODS FOR THE TREATMENT OF ACUTE AND CHRONIC PAIN THEREWITH - This invention relates to topical pharmaceutical preparations and methods for the treatment of acute and chronic pain and inflammation therewith. The preparations have a saturated solution of an active pharmaceutical ingredient in a solvent therefor in intimate combination and contact with a suspension of nanoparticles of the active pharmaceutical ingredient in the solvent, and a pharmaceutically acceptable carrier therefor, and are administered topically. | 02-10-2011 |
20110038937 | Methods for delivering siRNA via Ionthophoresis - Disclosed herein are formulations of siRNA suitable for delivery by ocular iontophoresis, devices for iontophoretic delivery of siRNA and methods of use thereof. | 02-17-2011 |
20110038938 | Compositions for tissue augmentation - The embodiments set forth herein provide biocompatible self-setting compositions suitable for use in tissue augmentation applications. The biocompatible self-setting compositions described herein exhibit advantageous theological properties and may be applied to a site in the body of a patient by injecting the composition through a 20-30 gauge needle. Once applied to a site in the body, the composition sets to a slow resorbing or substantially non-resorbing matrix. Advantageously, exposure of the composition material to body heat at its site of use enhances setting of the composition. Composition materials prepared in accordance with the present disclosure may find use in applications involving, for example, soft tissue augmentation such as for dermal fold augmentation, prevention of adhesions, soft tissue void filling, soft tissue bleb creation, urethral sphincter augmentation for treatment of urinary incontinence, treatment of unilateral vocal fold paralysis, and lower esophageal sphincter augmentation for treatment of gastroesophageal reflux disease. In some embodiments, the presently described biocompatible compositions may serve as bone void fillers. | 02-17-2011 |
20110045079 | DRY POWDERS OF CELLULAR MATERIAL - Methods and compositions of spray drying cellular material are provided that allow preservation of the cellular material. In one aspect, the cellular material is spray dried with a quantity of excipient. In another aspect, the cellular material is spray dried using a cryoprotectant. | 02-24-2011 |
20110045080 | Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto - The present invention includes single-walled carbon nanotube compositions for the delivery of siRNA and methods of making such single-walled carbon nanotube compositions. A single-walled carbon nanotube composition for delivery of siRNA includes a nonfunctionalized single-walled carbon nanotube; and siRNA noncovalently complexed with the nonfunctionalized single-walled carbon nanotube, wherein the siRNA solubilizes such nonfunctionalized single-walled carbon nanotube. | 02-24-2011 |
20110045081 | MAGNETIC, PARAMAGNETIC AND/OR SUPERPARAMAGNETIC NANOPARTICLES - The present invention relates to nanoparticles having a mean diameter of <500 nm and comprising, at their surface, a selected material. The nanoparticles are taken up by cells under physiological conditions and can be used to isolate interaction partners of the selected material within the cells. The present invention provides important advantages in that it opens up new ways of identifying cellular components and of delivering a substance of interest specifically to a selected cell compartment. The nanoparticles are also useful as a tool of diagnosis and for the constitution of chemical libraries. | 02-24-2011 |
20110045082 | AGGLOMERATES BY CRYSTALLISATION - The present invention describes novel agglomerates in crystalline form of β-lactum compounds, Furthermore, a process for the preparation of said agglomerates, wherein a solution or suspension of at least one β-lactum compound in a solvent is mixed with one or more anti-solvents has been described. | 02-24-2011 |
20110045083 | USE LARCH WOOD FOR TREATING INFLAMMATION - The application of raw wood material from a tree of the genus | 02-24-2011 |
20110045084 | LIGHT-CURABLE BONE GROWTH MATERIAL FOR TREATING DENTAL BONE DEFECTS - Improved compositions comprising a mixture of particulate bone growth material and polymeric carrier are provided. The particulate is preferably porous, resorbable, anorganic bone material. The polymeric carrier can be light-cured to form a cross-linked, biodegradable hydrogel. In one version, the bone growth material is a synthetic peptide bound to anorganic bone matrix particles and the carrier is methacrylated sodium hyaluronate (MHy) or methacrylated hydroxyethylcellulose (MHEC). The composition is particularly suitable for repairing defective dental and orthopedic bone tissue. The particulate and hydrogel carrier are biodegradable so the composition can be replaced by new bone formation over time. | 02-24-2011 |
20110045085 | PROCESS FOR OBTAINING POWDER COMPOSITIONS OF ORLISTAT - The invention relates to a novel process for the manufacture of stable, meeting relevant quality requirements pharmaceutical compositions in the form of encapsulated powder comprising Orlistat and pharmaceutically acceptable additives. The invention further relates to pharmaceutical compositions of Orlistat in the form of encapsulated powder obtained in accordance with the process of the present invention. | 02-24-2011 |
20110045086 | Steroid Nebuliser Formulation - A nebulizer formulation comprises particles of size 0.5-3 microns obtained by crystallization of beclomethasone diproprionate monohydrate in the presence of ultrasound. | 02-24-2011 |
20110052701 | PARTICULATES OF A CRTH2 ANTAGONIST - Provided herein are particulates of {4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl} acetic acid in amorphous or crystalline forms, processes for their preparation, pharmaceutical compositions comprising them, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a CRTH2-mediated disorder or disease. | 03-03-2011 |
20110052702 | Method and Apparatus for Producing Organic Nanotubes - An object of the present invention is to provide a method and apparatus capable of continuously producing organic nanotubes, wherein an organic nanotube material dispersion solution consisting of an organic nanotube material and an organic solvent is pressurized and caused to pass through a very narrow orifice. | 03-03-2011 |
20110052703 | BETA-CASEIN ASSEMBLIES FOR MUCOSAL DELIVERY OF THERAPEUTIC BIOACTIVE AGENTS - Nanoparticulate assemblies of isolated beta-casein, are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. These nano-sized beta-casein assemblies are preferably formed at pH values which are at least one or more pH units below or above the pI of the protein. Pharmaceutical compositions comprising the beta-casein micelles may be used to administer the agents to the GI tract for treatment of local or systemic conditions. These carriers are stable over a wide temperature range (optionally at least from about 1° C. to at least about 45° C.). | 03-03-2011 |
20110052704 | TOCOTRIENOL COMPOSITIONS - Compositions containing tocotrienol, non-tocotrienol lipids and surface active agents; compositions containing particles having a statin and a tocotrienol wherein the particle size is less than 1000 nm; and microemulsions containing a statin and a tocotrienol are disclosed. Methods relating to the creation of such compositions and the use of such compositions are further disclosed. | 03-03-2011 |
20110052705 | CARTILAGE COMPOSITION AND PROCESS FOR PRODUCING THE CARTILAGE COMPOSITION - Disclosed is a method for regenerating articular cartilage in an animal comprising administering a therapeutically effective amount of a non-demineralized particulate articular cartilage having a distribution of particle sizes within the range of from about 60 microns to about 500 microns. | 03-03-2011 |
20110059177 | Cardioplegia Solution for Cardiac Surgery - The invention relates to improved cardioplegia solutions. The invention provides cardioplegia solutions and compositions that produce a readily reversible, rapid electrochemical arrest with minimal tissue ischaemia. The cardioplegia solutions and compositions are used for arresting, protecting and/or preserving organs, in particular the heart during open-heart surgery, transplanting, cardiovascular diagnosis or therapeutic intervention. | 03-10-2011 |
20110059178 | Tissue Engineered Meniscus Repair Composition - A meniscus repair composition for application to a meniscus defect site to promote growth of new tissue at the meniscus defect site is provided. The composition comprises: from about 10 to about 50 percent by weight of allograft meniscus particles having an average particle size of from about 10 μm to about 500 μm; a carrier selected from the group consisting of sodium hyaluronate, gelatin, collagen, polyethylene glycol, glycerin, carboxymethylcellulose, dextrose, blood derivatives, aqueous solutions thereof, and mixtures thereof; and a curing agent. The curing agent may be the carrier where the carrier is cross-linkable. When introduced to a defect site in a meniscus and cured, the composition will not flow away from the defect site, and the composition is non-adhering to the defect site after it is cured. | 03-10-2011 |
20110064811 | Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 03-17-2011 |
20110064812 | Oral Solid Dosage Form Containing Nanoparticles and Process of Formulating the Same Using Fish Gelatin - An oral solid dosage form containing nanoparticles is made by (a) reducing the particle size of at least one pharmaceutically active ingredient dispersed in a solution containing fish gelatin to form a nanosuspension and (b) freeze-drying the nanosuspension of step (a) to form the oral solid dosage form. | 03-17-2011 |
20110064813 | USE OF SALSALATE WITH OR WITHOUT CAFFEINE AND WITH OR WITHOUT OMEGA 3, AND OTHER PHARMACEUTICAL COMPOUNDS IN A DISTINCTIVELY UNIQUE NANO-PARTICULATE CAPSULE AND TABLET - The invention relates to a compound and administration of the compound to mammals containing salsalate in a nanofied form to reduce inflammation. This compound and administration may be combined with caffeine, omega 3 fatty acids, sodium bicarbonate, and/or simvastatin to further benefit that administration. | 03-17-2011 |
20110064814 | STABLE PHARMACEUTICAL PRODUCTS - Provided herein is a stable pharmaceutical product comprising a dry powder inhalation device, and a pharmaceutical composition that comprises R,R-Formoterol L-tartrate salt, in particular crystalline R,R-formoterol L-tartrate; and ciclesonide. | 03-17-2011 |
20110064815 | SILICIA FOR THE INHINITION OF A PROTEASE - There is provided a silica for use to inhibit a protease. In particular there is provided a silica for treatment or prevention of a disease or condition associated with adverse protease activity or adverse proteolytic degradation within the gastrointestinal tract. | 03-17-2011 |
20110064816 | ATORVASTATIN COMPOSITIONS - Compositions containing atorvastatin, including its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs and their mixtures, and processes for preparing the same. Further aspects relate to pharmaceutical formulations comprising compositions containing atorvastatin, or a salt thereof, processes for preparing the same, and their methods of use, treatment and administration. | 03-17-2011 |
20110070308 | BED BUG INSECTICIDE - The insecticide comprises an insecticide particularly for killing bed bugs comprising nanospheres and primary ingredients of Organic Andirobia, Orange, Citronella, Organic Neem and Australian Myrtle oils. The insecticide can further comprise Isopropyl Alcohol as a carrier, Phenoxyethanol, Lavandox and Leucojum Aestivum Bulb Extrac. | 03-24-2011 |
20110070309 | PHARMACEUTICAL FORMULATION COMPRISING A WATER-INSOLUBLE ACTIVE AGENT - A method of preparing a pharmaceutical formulation comprises providing a solution comprising a first solvent, a second solvent, an active agent, and an excipient. The second solvent is less polar than the first solvent and the excipient is more soluble in water than the active agent. The first and second solvents are removed from the solution to produce particles comprising the active agent and the excipient. In one version, the excipient comprises an amino acid and/or a phospholipid. A pharmaceutical formulation made by a version of the invention comprises particles comprising an active agent and an excipient which at least partially encapsulates the active agent, wherein the excipient is more soluble in water than the active agent. | 03-24-2011 |
20110070310 | TOPICAL OPHTHALMIC PHARMACEUTICAL FORMULATION OF (2S,3S,4R)-N''-CYANO-N-(6-AMINO-3,4-DIHYDRO-3-HYDROXY-2-METHYL-2-DIMETHOX- YMETHYL-2H-BENZOPYRAN-4-YL)-N'-BENZYLGUANIDINE - A topical ophthalmic pharmaceutical formulation may include particles of the compound (2S,3S,4R)—N″-cyano-N-(6-amino-3,4-dihydro-3-hydroxy-2-methyl-2-dimethoxymethyl-2H-benzopyran-4-yl)-N′-benzylguanidine suspended in a solution comprising monobasic sodium phosphate monohydrate, disodium phosphate heptahydrate, edetate disodium, benzalkonium chloride, sodium chloride, polysorbate 80, and water. A method of treating glaucoma may include topically applying to the eye of a patient in need thereof a therapeutically effective amount of this formulation. | 03-24-2011 |
20110076333 | METHOD AND COMPOSITIONS FOR SELECTIVELY TREATING SKIN - This invention relates to compositions, methods and kits for selectively depositing a benefit agent on skin without depositing the benefit agent on the hair. The method relates to exposing the skin to a composition containing anionic proteins, anionic polymers, anionic dyes, anionic pigments, or mixtures thereof which have an isoelectric point of less than about 4.5, the compositions having a pH of about 3.5 to about 5.5. In accordance with the methods of this invention, the benefit agent becomes deposited on the skin; however, any hair that is also contacted by the benefit compositions remains substantially untreated. | 03-31-2011 |
20110076334 | METHODS AND COMPOSITIONS FOR TREATMENT OF RAYNAUD'S PHENOMENON - Administration of a calcium channel blocker such as clevidipine or nicardipine in aerosol dry powder form directly to a patient's lungs for treating Raynaud's Phenomenon. | 03-31-2011 |
20110086103 | NOVEL MANDELATE SALT OF FESOTERODINE - Provided herein is a novel raantlelate sail of fesoterodine, process for the preparation, pharmaceutics!! compositions, and method of treating thereof. Provided also herein are solid state forms of fesoterodine mandelate, process for the preparation, pharmaceutical compositions, and method of treating thereof. The raandelate salt of fesoterodine is useful for preparing fesoterodine free base or a pharmaceutically acceptable salt thereof; particularly fesoterodine fumaraie, in high purity. | 04-14-2011 |
20110091556 | Antimicrobial compositions and methods of use - The present invention relates to compositions and methods for decreasing the infectivity, morbidity, and rate of mortality associated with a variety of pathogenic organisms and viruses. The present invention also relates to methods and compositions for decontaminating areas colonized or otherwise infected by pathogenic organisms and viruses. Moreover, the present invention relates to methods and compositions for decreasing the infectivity of pathogenic organisms in foodstuffs. In particular, decreased pathogenic organism infectivity, morbidity, and mortality is accomplished by contacting the pathogenic organism with an oil-in-water nanoemulsion comprising an oil, an organic solvent, and a surfactant dispersed in an aqueous phase. | 04-21-2011 |
20110091557 | COMPOSITE MATERIAL - The invention relates to a composite material, a precursor for forming the composite material and a method of forming the composite material from the precursor. The invention also relates to the use of said composite material and in particular to its use as an antibacterial or antimicrobial agent. | 04-21-2011 |
20110091558 | Pharmaceutical Compositions of Entacapone, Levodopa and Carbidopa with Improved Bioavailability - The present invention relates to single oral dose pharmaceutical compositions comprising a combination of entacapon, levodopa and carbidopa, or salts thereof along with one or more sugar alcohols, wherein the entacapone is co-micronized with one or more sugar alcohols. The composition of the invention exhibits bioequivalence to commercially available entacapone, levodopa and carbidopa combination formulation marketed under the trade name Stalcvo200®. The invention also relates to processes for making such compositions. | 04-21-2011 |
20110091559 | COMPOSITIONS COMPRISING ADJUVANT, MACROLIDE AND PROTEINACEOUS ANTIGEN AND METHODS OF USE THEREOF - The invention is directed to compositions comprising an oil adjuvant, a macrocyclic lactone effective for the prevention or control of parasitic infection in a warm-blooded animal and an immunizing amount of at least one immunogenic polypeptide and methods of use thereof. | 04-21-2011 |
20110091560 | COMPOSITIONS OF NANOPARTICLES AND METHODS OF MAKING THE SAME - Disclosed herein are compositions of nanoparticles. In some embodiments, the nanoparticles are Janus particles, where each particle includes a first component and second component that are exposed to the surface of the particle. Also, disclosed are methods and systems for making a composition of nanoparticles. Finally, a method of treating a mammal by administering a composition of nanoparticles is disclosed. | 04-21-2011 |
20110091561 | PERFLUORCARBON NANOEMULSIONS WITH ENDOCYTOSIS ENHANCING SURFACE FOR GENE-TRANSFER - The present invention provides stable perfluorcarbon nanoemulsions with endocytosis enhancing surfaces that are suitable for gene-transfer, its production and use. | 04-21-2011 |
20110097409 | PARTICLES COMPRISING A SALT OF 8-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-Q- UINOLINONE HAVING IMPROVED ADHESION PROPERTIES FOR POWDER FORMULATIONS FOR INHALATION - Powder particles comprising a pharmaceutically acceptable salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone (carmoterol) having a specific properties exhibit improved adhesion properties for dry powder formulations for inhalation. Such particles are useful for formulations in the form of powders for inhalation and the treatment of certain conditions and diseases. | 04-28-2011 |
20110097410 | FORMULATIONS OF PX COMPOUNDS - Nanoparticles of PX compounds in the size range of 10 to 1000 nanometers are incorporated into formulations that are safe for intravenous administration and used to treat disease conditions caused by phospholipase A | 04-28-2011 |
20110097411 | CARRIER PELLETS, METHOD FOR PRODUCTION THEREOF AND USE THEREOF - The invention relates to a method for the production of carrier pellets for pharmaceutical active substances. Likewise, the invention relates to such carrier pellets and also to pharmaceutical formulations containing these. The carrier pellets according to the invention are used for transporting and releasing pharmaceutical active substances, in particular in the human body. | 04-28-2011 |
20110097412 | METHODS OF TREATMENT OF ENDOBRONCHIAL INFECTIONS - The present invention provides methods for the treatment of an endobronchial infection in a patient by administering to the endobronchial system of the patient a dry powder aerosol composition comprising from 90 to 130 mg of an aminoglycoside antibiotic one to three times a day for a first treatment period of 20 to 36 days. | 04-28-2011 |
20110097413 | SOLID STATE FORMS OF DEFERASIROX SALTS AND PROCESS FOR THE PREPARATION THEREOF - Provided herein are novel solid state forms of deferasirox salts, process for the preparation, pharmaceutical compositions, and method of treating thereof. The solid state forms of deferasirox salts are useful for preparing deferasirox (I) in high purity. | 04-28-2011 |
20110104285 | PROCESS FOR THE MANUFACTURE OF A PHARMACEUTICAL PRODUCT - A process for the preparation of a pharmaceutical composition comprising a homogeneous or substantially homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulphate and, optionally, saccharin sodium and/or orange flavour; products, intermediate products, and uses thereof. | 05-05-2011 |
20110104286 | PHARMACEUTICAL COMPOSITIONS CONTAINING THE ENZYME CYPROSIN, AN ASPARTIC PEPTIDASE FROM CYNARA CARDUNCULUS AND ITS INCLUSION IN ANTITUMOUR FORMULATIONS - An aspect of the present invention is the use of a preparation containing a phytepsin, more specifically a cyprosin, containing the heterodimer, its N-terminal pro-peptide, the mature N-terminal peptide, and mature C-terminal peptide, as well as other precursor species, processing products, and aggregate species, either isolated or in any combinations of the former, native, extracted and partially purified from flowers of | 05-05-2011 |
20110104287 | FENOLDOPAM FORMULATIONS AND PRO-DRUG DERIVATIVES - Formulations of fenoldopam are disclosed for repeated administration or continued slow release administration, over prolonged periods of time or targeted slow and regulated delivery. The formulations include those formulations that increase the bioavailability of fenoldopam after oral intake, particularly lipid based nano dispersions and pronanodispersions and surfactant rich formulations. This may be accomplished by entrapment in nanoparticles or liposomal formulations or conjugation to a polymer or small molecule via a soft bond. | 05-05-2011 |
20110104288 | Microcrystalline Cellulose and Calcium Phosphate Compositions Useful as Pharmaceutical Excipients - Coprocessed compositions containing calcium phosphate and microcrystalline cellulose are useful as excipients in the preparation of solid dosage forms containing active pharmaceutical ingredients, particularly those prepared by processes involving multiple compaction steps. Such compositions may be obtained by preparing aqueous slurries of microcrystalline cellulose and calcium phosphate and drying such slurries to produce particulate products. The coprocessed products exhibit improved compactibility, as compared to dry physical blends of the same components. | 05-05-2011 |
20110104289 | METHOD AND PHARMACEUTICAL COMPOSITION FOR OBTAINING THE PLASMATIC PROGESTERONE LEVELS REQUIRED FOR DIFFERENT THERAPEUTIC INDICATIONS - The invention relates to the development of a method and pharmaceutical compositions for obtaining plasmatic progesterone levels in humans and for maintaining a plasmatic progesterone concentration between 42 and 3.5 ng/mL for eight days as well as maximum plasmatic concentrations (Cmax) between 12 and 42 ng/mL, sufficient for use in different therapeutic options that require said progesterone concentrations. | 05-05-2011 |
20110104290 | COMPOSITIONS FOR REDUCING BLOOD GLUCOSE LEVEL AND USES THEREOF - A composition, its preparation and use for reducing the blood glucose level in a subject, comprising Radix Ginseng, Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Ginger, and one or more components selected from the group consisting of Tartarian Buckwheat, Rhizoma Phragmitis ( | 05-05-2011 |
20110111036 | INTRACELLULAR ANTIBODY DELIVERY - The present invention concerns a composition comprising vesicles and encapsulated within the vesicles, an antibody, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. | 05-12-2011 |
20110111037 | ORODISPERSIBLE MANNITOL - Coagglomerates of mannitol, whose laser volume-average diameter D4,3 is between 1 and 200 μm, and of granular starch, are characterized in that they have a disintegration behaviour determined according to a test A such that the relaxation time measured is between 30 and 100 seconds and the swelling force is between 0.8 and 3.0 N. | 05-12-2011 |
20110111038 | PROCESS FOR PRODUCING A STABLE CONCENTRATED DIETARY SUPPLEMENT AND SUPPLEMENT PRODUCED THEREBY - A stable concentrated dietary supplement containing fucoxanthin as the main active component. The dietary supplement is made by a process including grinding crude freeze-dried flakes of wakame seaweed ( | 05-12-2011 |
20110117199 | FOAMY BIOMATERIAL FOR BIOLOGICAL TISSUE REPAIR - A kit for producing a foamed biocompatible material includes a container configured to sustain a high pressure, and a tissue-repair composition placed in the container. The composition contains a biocompatible material, a liquid carrier, and a gas. The container has an internal pressure of greater than 1 atm and less than 250 atm, and includes a valve and a nuzzle for releasing from the nuzzle a foam formed of the composition upon opening the valve. Methods of producing and applying the biocompatible material are also disclosed. | 05-19-2011 |
20110117200 | RASAGILINE MESYLATE PARTICLES AND PROCESS FOR THE PREPARATION THEREOF - Provided herein is rasagiline mesylate having a 90 volume-percent of the particles (D | 05-19-2011 |
20110117201 | COMPOSITION FOR TREATMENT OF WATER - The invention relates to a composition for treatment of water comprising rice husk ash and at least one bactericidal agent bonded to the rice husk ash. The bactericidal agent bonded to the rice husk ash is preferably silver and more particularly the bactericidal agent is nano silver. The invention also relates to a method of water purification using a composition comprising rice husk ash and at least one bactericidal agent bonded to the rice husk ash. | 05-19-2011 |
20110123622 | OPHTHALMIC FORMULATION AND METHOD OF MANUFACTURE THEREOF - Provided herein is an ophthalmic formulation that comprises a fine particle of an A | 05-26-2011 |
20110123623 | RHAMNOLIPID MECHANISM - A topical composition for treating a patient having rhamnolipid as an active ingredient. The rhamnolipid is absorbed by the skin of a human or animal, absorbed by the blood stream, and distributed through the human or animal body. | 05-26-2011 |
20110123624 | FORMULATIONS COMPRISING AMINOSTEROLS - This invention relates to stable aminosterol phosphate compositions. The aminosterol phosphate compositions permit administration without associated tissue damage and achieve a sustained release effect. | 05-26-2011 |
20110123625 | Compositions of Less Immunogenic and Long-Circulating Protein-Lipid Complexes - Provided are lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith therapeutic agents such as peptides, polypeptides or proteins. In these compositions, the therapeutic agents have reduced immunogenicity and/or longer circulating time. These compositions can be used for therapeutic administration of the peptides, polypeptides and/or proteins. | 05-26-2011 |
20110123626 | PULMONARY DELIVERY OF A FLUOROQUINOLONE - A composition for pulmonary administration comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an excipient. In one version, the particles have a mass median aerodynamic diameter from about 1 μm to about 5 μm, and the fluoroquinolone has a half life in the lungs of at least 1.5 hours. The composition is useful in treating an endobronchial infection, such as | 05-26-2011 |
20110123627 | HIGH DENSITY COMPOSITIONS CONTAINING POSACONAZOLE AND FORMULATIONS COMPRISING THE SAME - The present application provides novel compositions comprising posaconazole and a polymer wherein the composition has a glass transition temperature (Tg) of less than about 1100 C. The application also describes compositions comprising posaconazole and a polymer having a bulk density of greater than about 0.4 mg/mL. The application also describes compositions comprising posaconazole and a polymer which provide an exposure (AUCtf) of at least about 10,000 ng·hr/mL when administered to a patient in a fasted state. The application also describes a novel process for preparing these compositions. The preff erred polymer is HPMCAS. Preferably the composition is an extruded material. | 05-26-2011 |
20110123628 | RARE EARTH METAL COMPOUNDS, METHODS OF MAKING, AND METHODS OF USING THE SAME - Rare earth metal compounds, particularly lanthanum, cerium, and yttrium, are formed as porous particles and are effective in binding metals, metal ions, and phosphate. A method of making the particles and a method of using the particles is disclosed. The particles may be used in the gastrointestinal tract or the bloodstream to remove phosphate or to treat hyperphosphatemia in mammals. The particles may also be used to remove metals from fluids such as water. | 05-26-2011 |
20110135734 | Method For the Preparation of Nanoparticles From Nanoemulsions - The invention relates to a method for the production of nanoparticles from oil-in-water nanoemulsions, in which the nanoemulsion is prepared by phase inversion techniques. The phase inversion may be achieved by using a constant temperature, where the inversion occurs by continuous addition of water or by varying the temperature involving heating and rapid cooling. | 06-09-2011 |
20110135735 | PROCESS FOR PRODUCTION OF A COMPOSITE MATERIAL HAVING ANTIMICROBIAL ACTIVITY - The invention relates to a process for production of a composite material having antimicrobial activity, having the following steps: provision of a metal powder produced from a metal having antimicrobial activity, wherein the metal powder is formed from discrete agglomerates having a porosity of 30 to 98%, wherein the agglomerates have a spongy structure formed by solid material bridges; melting a thermoplastic and setting a predetermined viscosity; mixing the metal powder with the molten thermoplastic in a predetermined quantitative ratio; and cooling the mixture, wherein the metal powder is firmly bound to a matrix formed by the plastic. | 06-09-2011 |
20110135736 | Compositions and Methods for Producing Vascular Occlusion using a Solid-phase Platelet Binding Agent - The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion. | 06-09-2011 |
20110135737 | COMPOSITIONS FOR RESPIRATORY DELIVERY OF ACTIVE AGENTS AND ASSOCIATED METHODS AND SYSTEMS - Compositions, methods and systems are provided for pulmonary or nasal delivery of active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium. | 06-09-2011 |
20110135738 | SINGLE DOSAGE PHARMACEUTICAL FORMULATION COMPRISING EPROSARTAN MESYLATE - A dry formulation or granulation of eprosartan mesylate is described which comprises eprosartan mesylate in particulate form with a particle size, wherein at least 65 v/v % eprosartan mesylate particles fall in a particle size range of from 2 to 27 μm. In another aspect, a dry formulation or granulation of eprosartan mesylate comprises eprosartan mesylate combined with an excipient which at least comprises a PEG having molecular weight in the range of 400 to 20000 and mannitol. Further described is a single dosage pharmaceutical formulation such as tablet obtained from such a dry formulation or granulation of eprosartan mesylate by direct compression or dry granulation. A dry formulation or granulation of eprosartan mesylate, or a process for the preparation thereof is also described, which comprising eprosartan mesylate in particulate form mixed with one or more excipients or additives in a way that a limited water activity is obtained. The dry formulation or granulation of eprosartan mesylate can be directly compressed or processed by dry granulation, while maintaining the eprosartan mesylate in only one stable form. Suitable prophylactic and/or therapeutic uses are also described. | 06-09-2011 |
20110135739 | Oral Formulations of a Hedgehog Pathway Inhibitor - Oral formulations of the drug product IPI-926 are described. Pharmaceutical formulations (e.g., solid dosage forms) that are useful for the oral administration of a compound of formula (I), or a pharmaceutically acceptable salt thereof (e.g., IPI-926), to a human or animal subject are disclosed. | 06-09-2011 |
20110135740 | TISSUE SUBSTITUTES COMPRISING STEM CELLS AND REDUCED CERIA - A biocompatible composite includes a solid biocompatible material and a plurality of living human progenitor or living stem cells attached thereto. The composition resulting in accelerated repair to damaged bones and tissues. | 06-09-2011 |
20110142940 | Analgesic Apatitic Calcium-Phosphate Cement - The present invention concerns a composition useful as bone substitute comprising one or more calcium-phosphate compounds in association with an analgesic. It also refers to a preparation process of said composition, a preparation process of a drug-combined device comprising said composition, the drug combined device thus obtained, a kit comprising said composition and the use of said composition for the preparation of a drug-combined device useful for filling a bony defect caused in the iliac crest by collection of auto-graft bone, as a scaffold for tissue engineering and to produce a dental or bony implant. | 06-16-2011 |
20110142941 | Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed. | 06-16-2011 |
20110142942 | USE OF pH SENSITIVE COMPOUNDS IN TASTE MASKING OF DRUG SUBSTANCES WITHIN ORAL THIN FILM STRIPS - The present invention relates to an edible film dosage form that includes a film-forming polymer and a coated active composition capable of taste-masking an active contained therein. An edible film that includes an edible, water-soluble film forming polymer and an active with at least two coating layers is also disclosed. | 06-16-2011 |
20110142943 | TAMPER-RESISTANT PHARMACEUTICAL COMPOSITIONS OF OPIODS AND OTHER DRUGS - Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract. | 06-16-2011 |
20110142944 | ANDROGRAPHIS EXTRACT FORMULATIONS - A pharmaceutical formulation containing 50-90% by weight a powdered extract of Andrographis paniculata and 5-50% by weight a powdered blocking agent. The formulation may further contain a pore-forming agent, a filler, a lubricant, or a glidant. Also described are a method for preparing this pharmaceutical formulation and a method for treating inflammatory disease, immunological disease, or respiratory disease with it. | 06-16-2011 |
20110142945 | Hydrophobic Active Agent Compositions and Related Methods - Compositions and methods for providing hydrophobic active agents in a bioavailable form are disclosed and described. In one aspect of the invention, pharmaceutical composition containing a testosterone ester is provided. The composition includes a testosterone ester in both dissolved form and as undissolved particles and the dissolved form comprises at least 35 wt % of the testosterone ester present in the composition. The composition further includes a solubilizer and a stabilizer. | 06-16-2011 |
20110142946 | DRUG SUSTAINED-RELEASE AGENT, ADSORBENT, FUNCTIONAL FOOD, MASK AND ADSORPTION SHEET - Provided is a drug sustained-release agent including a carbon material (porous carbon material) which has an inverse opal structure. The drug sustained-release agent includes a porous carbon material which has spherical pores having an average diameter of 1×10 | 06-16-2011 |
20110151007 | CARBIDE-DERIVED-CARBON-BASED OXYGEN CARRIERS - An oxygen delivery system is disclosed. The basis of the oxygen deliver system is a carbide-derived carbon (CDC). The CDC can be tuned to carry O | 06-23-2011 |
20110151008 | Pulmonary Delivery for Levodopa - In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung. | 06-23-2011 |
20110151009 | USE OF FREE RADICAL SCAVENGERS FOR PROTECTING AND TREATING SKIN AND HAIR DAMAGES CAUSED BY CHEMOTHERAPY - The present invention relates to the use of one or more free radical scavengers as prophylactically or therapeutically effective substances and microparticles having an average particle size ranging from 5 to 200 μm for the preparation of a topical pharmaceutical composition for the protection or treatment of skin or hair damages caused by chemotherapeutic treatment. | 06-23-2011 |
20110151010 | ANTI-SNORING TREATMENT COMPRISING POSITIVELY CHARGED MULTILAMELLAR MICROPARTICLES - A composition for nasal or buccal application comprising a distribution of multilayer microparticles in an inactive base, at least one ingredient having activity on the mucosa of the nose/throat, being adsorbed within the layers of the microparticles so as to be progressively released over time in use. | 06-23-2011 |
20110159102 | Apparatus and Method for Continuous Production of Spherical Powder Agglomerates - The disclosure relates to a process for continuously producing spherical powder agglomerates, in which morphologically irregular starting agglomerates of micronized pulverulent particles are rounded off continuously by application to a surface induced to vibrate. | 06-30-2011 |
20110165250 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEOPLASTIC DISEASE - The present invention is concerned with immunostimulant compositions, in particular compositions comprising microparticulate form of murmyl dipeptide, and their use in the treatment of neoplastic disease. | 07-07-2011 |
20110165251 | LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS - The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent. | 07-07-2011 |
20110165252 | MEMANTINE FORMULATIONS - The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to methods of treating conditions, including childhood behavioral disorders (e.g., autism) and Alzheimer's disease by administering the same. | 07-07-2011 |
20110165253 | NICOTINE-CONTAINING GRANULATE - A dust-reduced nicotine-containing granulate comprising a homogenous mixture of nicotine or a pharmaceutically acceptable nicotine derivative and an excipient, the granulate having a particle size of at least 150 μm. Method for the preparation of a dust-reduced nicotine-containing granulate, and use of the nicotine-containing granulate for the preparation of pharmaceutical products. | 07-07-2011 |
20110171312 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE - Modified therapeutic peptide compositions comprising conjugates of therapeutic peptides covalently coupled to one or more hydrophilic polymers. Optionally, the therapeutic peptide is also covalently coupled to one or more moieties having one to ten carbon atoms. Methods of making and use are also provided. The conjugates, when administered by any of a number of administration routes, exhibit characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer and/or one or moiety having one to ten carbon atoms. | 07-14-2011 |
20110171313 | COMPOSITION CONTAINING ULTRA-MICRONIZED PALMITOYL-ETHANOLAMIDE - The present invention relates to a composition for pharmaceutical or veterinary use, comprising palmitoylethanolamide. In particular, the present invention relates to a pharmaceutical composition for human or veterinary use, containing a therapeutically efficient amount of palmitoylethanolamide in the ultra-micronized form, wherein more than 90% by weight of palmitoylethanolamide has particle sizes lower than 6 microns, together with pharmaceutically acceptable excipients. | 07-14-2011 |
20110182992 | PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES ASSOCIATED WITH EYE DISEASE - This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response, hi certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection. | 07-28-2011 |
20110182993 | FILM-FORM PREPARATION - An object of the present invention is to provide a film-form preparation to be used in desensitization therapy and a method for producing the same. This film-form preparation enables the patient to self-administer an allergen and adjust the dose, has excellent portability, has no residual sensation, provides excellent protection against accidental swallowing, is easy for a caregiver to administer, and can greatly improve the QOL of both patients and caregivers. Additionally, this film-form preparation enables arbitrary control of the dissolution time in the mouth, particularly sublingually and has very little gummy sensation in the mouth and better feeling when touched by the fingers. A film-form preparation including: an allergen; an edible polymer that is soluble in both water and a polar organic solvent; and one or two or more types of particles selected from the group consisting of monosaccharide to hexasaccharide sugars and sugar alcohols thereof that have an average particle size of 0.1 to 100 μm. | 07-28-2011 |
20110182994 | METHODS AND SYSTEMS FOR PRODUCTION OF NANOPARTICLES - Methods and systems for preparing nanoparticles. A source of a carrier fluid is connected to an inlet of a flow conduit, such as an intravenous solution administration tube with injection ports, such that the carrier fluid flows through the conduit. A substance (e.g., a drug solution or other substance solution) is introduced into the conduit at a first location causing substance nanoparticles to form within and continue to flow thought he conduit. A stabilizer is introduced into the conduit at a second location to cause a stabilizing effect on the nanoparticles. In some embodiments, the stabilizer may limit or deter agglomeration or growth of the nanoparticles, thereby limiting the size of the nanaparticles produced. | 07-28-2011 |
20110182995 | MEDICAL AND DENTAL BIOMATERIAL AND METHOD OF USE FOR THE SAME - The embodiments herein provide a dental and medical biomaterial and its use for sealing and/or filling the tooth and bone cavities. In the embodiments herein, the calcium salt, calcium oxide, calcium silicate, and calcium phosphate compounds are mixed with a water-base solution, and a bioactive phosphate and calcium enriched mixture is prepared. The mixture comprises high concentration of water-soluble calcium and phosphate, and consequently forms hydroxyapatite during and after setting. The dental/medical biomaterial is biocompatible, antibacterial and capable of forming an effective seal against reentrance of microorganisms into the filled cavity. The biomaterial is compatible to handle and set in an aqueous environment and to stimulate soft/hard tissue healing/generation/regeneration. | 07-28-2011 |
20110189293 | THERAPEUTIC REGIMENS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS - A method for treating an immunoinflammatory disorder in a subject in need thereof, said method comprising administering to said subject a unit dosage form comprising dipyridamole coated onto acid beads and formulated for controlled release. The method further including administering a corticosteriod concurrently with administration of the dipyridamole. | 08-04-2011 |
20110189294 | PESTICIDAL COMPOSITIONS - A formulated composition suitable for controlling or preventing pathogenic damage in a plant comprising (A) at least one solid active ingredient having a water solubility of at most 100 μg/litre at 25° C. at neutral pH, in an amount of at least 1 weight %, based on the total weight of the formulated composition, (B) at least one non-ionic surface active compound having a hydrophile-lipophile balance (HLB) of between 10 and 18, one or more customary formulation auxiliaries, and water; wherein active ingredient (A) is suspended or dispersed in the water, the weight ratio of surface active compound (B) to active ingredient (A) is in the range of from 1.5 to 15.0, provided the minimum amount of surface active compound (B) is at least 6 weight %, based on the total weight of the formulated composition. Also a method of improving pesticide residue levels in agriculture. | 08-04-2011 |
20110189295 | TELMISARTAN TABLETS - A composition containing the active substance telmisartan, which consists of granules of a telmisartan mixture, in which there is the active substance in the form of alkali salts, further contained is an organic or inorganic base selected from meglumine, sodium or potassium hydroxide, or a mixture of said bases, a binder, most preferably polyvinylpyrrolidone, sorbitol, and optionally other auxiliary substances; the composition further containing, outside the granules, particles of sorbitol, and optionally of other auxiliary substance, the size of 99% by\ weight of all particles of the telmisartan mixture being smaller than 1.0 mm and the size of 95% by weight of all particles of sorbitol contained in the composition inside as well as outside the granules of the telmisartan mixture being within the range of 0 to 0.250 mm. | 08-04-2011 |
20110189296 | BONE SUBSTITUTE CONTAINING POROUS BIO-GLASS AND CALCIUM SULPHATE - The invention relates to a composition for a bone substitute that includes powdery or populated porous bio-glass and powdery alpha hemihydrate calcium sulphate. The invention also relates to an injectable composition for forming a bone substitute that includes said composition of powdery or granulated porous bio-glass and powdery alpha hemihydrate calcium sulphate, with 10 to 50 wt % of added water. | 08-04-2011 |
20110189297 | STABLE SOLID ORAL DOSAGE CO-FORMULATIONS - Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics of drugs that undergo in vivo degradation by cytochrome P450 enzymes. Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Specifically, methods of inhibiting metabolic degradation of atazanavir sulphate for administering to a patient suffering from HIV infection are disclosed. | 08-04-2011 |
20110189298 | DOUBLE EMULSION AND METHOD TO PRODUCE SUCH - The invention is directed to a method to produce a water-in-oil-in-water (w/o/w) emulsion, comprising: a. preparing a water-in-oil (w/o) emulsion; b. atomizing said w/o emulsion in the presence of a carrier material comprising at least a water soluble matrix material and at least one emulsifier, to form agglomerates; c. dispersing said agglomerates in an aqueous liquid, such as water or an aqueous solution. Also provided is a new instant powder (obtained after step b) that can be used to prepare the w/o/w emulsion. The emulsion of the invention is advantageously suited for the encapsulation of active components. | 08-04-2011 |
20110195125 | Nanoparticles For Drug Delivery To The Central Nervous System - The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt of the formula: | 08-11-2011 |
20110200677 | PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES FOR THERAPY OF PROSTATE CANCER - The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor. | 08-18-2011 |
20110200678 | MANUFACTURING METHOD AND APPARATUS OF ULTRAFINE PARTICLES HAVING UNIFORM PARTICLE SIZE DISTRIBUTION - The present invention relates to a novel technology for forming fine particles with a size of 0.02˜3 microns from a solid that can be dissolved in a liquid solvent and is not decomposed by heat. The particle preparation technology according to the present invention may be applicable to the fields of food, cosmetics, biopolymer, polymer compositions, and pharmaceuticals. | 08-18-2011 |
20110200679 | METHOD FOR MANUFACTURING SUSTAINED RELEASE MICROSPHERE BY SOLVENT FLOW EVAPORATION METHOD - The present invention relates to a method for preparing a sustained-release microsphere which can control the long-term release of a drug. More particularly, as the preparation of a microsphere in which a drug is loaded in a carrier comprising a biodegradable polymer, the present invention relates to a method for preparing a sustained-release microsphere wherein a solvent intra-exchange evaporation method by means of co-solvent is used for suppressing the initial burst release of physiologically active substance, to release the physiologically active substance in the body continuously and uniformly. | 08-18-2011 |
20110200680 | WATER INSOLUBLE POLYMER: STARCH-BASED FILM COATINGS FOR COLON TARGETING - A controlled release delivery dosage form for controlled release of an active ingredient, includes an active ingredient coated in a polymeric mixture of: at least a water insoluble polymer and a starch composition including at least one component selected from the group consisting of a starch having an amylose content of between 20 and 45%, a modified starch having an amylose content of between 50 and 80% and a legume starch. The present invention also relates to the use and method for making the same. | 08-18-2011 |
20110206770 | ATOVAQUONE WITH A PARTICLE SIZE DIAMETER RANGE (D90) OF GREATER THAN 3 MICRONS TO ABOUT 10 MICRONS - Atovaquone or a pharmaceutically acceptable salt thereof having a particle size diameter range with a D | 08-25-2011 |
20110212179 | MICRO-SPHERICAL POROUS BIOCOMPATIBLE SCAFFOLDS AND METHODS AND APPARATUS FOR FABRICATING SAME - Provided herein are bimodal porous polymer microspheres comprising macropores and micropores. Also provided herein are methods and apparatus for fabrication such microspheres. Further provided herein are methods of using bimodal porous polymer microspheres. | 09-01-2011 |
20110217380 | PROTEINS THAT STIMULATE THE SECRETION OF SATIETY HORMONES - The invention is in the field of weight management, in particular in the field of weight management by influencing the mechanisms of body-weight regulation. Intact pea protein and intact wheat protein were found to be effective in reducing appetite or inducing or increasing satiety when brought into contact with their receptors in the duodenum. Since it is known that intact proteins hydrolyse in the gastrointestinal tract, intact pea protein and intact wheat protein will not exhibit their satiating effect when ingested in a conventional oral preparation. Therefore, special care should be taken to deliver the intact proteins to the duodenum in order for them to arrive there intact. One object of the invention may therefore be achieved by incorporating the intact protein in an enteric delivery vehicle. | 09-08-2011 |
20110217381 | PHARMACEUTICAL COMPOSITIONS - The present invention provides a substantially solvent-free nano-dispersion of an active in a carrier, wherein the carrier comprises an enteric carrier soluble at intestinal pH, but insoluble at stomach pH, and wherein the enteric carrier comprises at least 50% by weight of the nano-dispersion; and processes for the preparation of a substantially solvent-free nano-dispersion of an active in a carrier. | 09-08-2011 |
20110217382 | Methods and Compositions for Treating Pain Comprising a Statin - Methods and compositions are provided for reducing, treating or preventing pain and/or inflammation in a patient in need of such treatment, the methods and compositions comprising administering a therapeutically effective amount of a statin or pharmaceutically acceptable salt thereof to a target tissue site beneath the skin. | 09-08-2011 |
20110223255 | IMPLANTABLE PRODUCTS COMPRISING NANOPARTICLES - The present disclosure relates to nanoparticle-containing implantable and preferably biodegradable medical products and their use for the thermotherapeutic after-treatment after surgical removal of tumors and cancerous ulcers. | 09-15-2011 |
20110229575 | DEEP IMMERSION FLOTATION THERAPY FOR BURN VICTIMS - This invention provides compositions for and methods of treating burn wounds in a subject. | 09-22-2011 |
20110236487 | SOLID GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF - In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. | 09-29-2011 |
20110236488 | HERBAL FORMULATION FOR PREVENTION AND TREATMENT OF DIABETES AND ASSOCIATED COMPLICATIONS - An herbal formulation for prevention and treatment of Diabetes and associated complications comprising extracts from selected Indian medicinal herbs | 09-29-2011 |
20110236489 | VACCINE ADJUVANT COMBINATIONS - An immunological adjuvant comprises an oil-in-water emulsion, an immunostimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex. The adjuvant can be combined with immunogens for preparing vaccines. | 09-29-2011 |
20110236490 | TREATMENT OR PREVENTION OF VIRAL INFECTION BY CHLORINATION - The invention provides methods and systems for treating or preventing viral infection. In one embodiment, the invention provides a method of treating or preventing viral infection in an individual, the method comprising: administering to the individual, via at least one nasal cavity, nebulized ECAW containing a quantity of hypochlorous acid (HOCI) and a quantity of hypochlorite ion (OCI). | 09-29-2011 |
20110244046 | Charge Reversible Polymers - Described are charge reversible polymers, peptides and their resulting colloidal particles, comprising polymers and peptides having primary and secondary amines that are protected as easily hydrolysable amides. The amides are charge-reversible such that at neutral pH they are negatively charged but become positively charged at pH less than 6 and thus are relatively stable at neutral pH but quickly hydrolyze at pH below 6. Incorporating a drug in a micelle or a polymer comprised of the charge-reversible polymers or peptides provides a drug carrier for delivering the drug preferentially to the solid tumor or other targeted cells. | 10-06-2011 |
20110244047 | FILM-FORM PREPARATION AND METHOD FOR PRODUCING THE SAME - The present invention provides a film-form preparation having a rapid dissolution profile in the mouth and sufficient film strength, and also having excellent appearance and feel. More specifically, the present invention provides a film-form preparation including: a water-soluble edible polymer; and water-insoluble drug particles, wherein an average particle size of the drug particles is 0.1 to 60 μm. | 10-06-2011 |
20110250275 | PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS - Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of inflammatory disease or fibrous adhesions using low sulphate fucans and, if desired, one or more other anti-inflammatory disease or anti-fibrous adhesion agent. | 10-13-2011 |
20110250276 | Cosmetic Composition Containing Acetylated Oligoglucuronans - The present invention relates to the field of cosmetic and dermopharmaceutical compositions. It concerns oligomer compounds of D-glucuronic acid or D-glucuronate with a β (1-4) sequence (or oligoglucuronans) containing a degree of acetylation specifically between 8.7±0.5 and 9.2±0.5% by weight of O—CO—CH | 10-13-2011 |
20110250277 | Modified release compositions comprising tacrolimus - A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents. | 10-13-2011 |
20110256224 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY - The disclosure provides compounds and compositions, and methods of using these compounds and compositions, for the targeted delivery of therapeutic agents. In one embodiment, these compositions are used for the tumor-targeted delivery of chemotherapeutic agents useful for treating cancer. | 10-20-2011 |
20110256225 | BIODEGRADABLE NANOPARTICLES AS NOVEL HEMOGLOBIN-BASED OXYGEN CARRIERS AND METHODS OF USING THE SAME - Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(γ-methyl ε-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties. | 10-20-2011 |
20110262543 | PROCESS FOR PROVIDING PARTICLES WITH REDUCED ELECTROSTATIC CHARGES - Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared. | 10-27-2011 |
20110262544 | OPHTHALMIC ADMINISTRATION OF A COMPOSITION INCLUDING BRIMONIDINE AS A MIST - Disclosed are methods of treatment including administration of a pharmaceutical composition including brimonidine to an eye as a mist, the composition devoid of a penetration enhancer. | 10-27-2011 |
20110268802 | DELIVERY PARTICLE - The present application relates to encapsulated benefit agents, compositions comprising such encapsulated benefit agents and processes for making and using compositions comprising such encapsulated benefit agents. Such encapsulated benefit agents eliminate or minimize one or more of the drawbacks of current encapsulated benefit agents and thus provide formulators with additional perfume delivery opportunities. | 11-03-2011 |
20110268803 | LUNG TARGETING DUAL DRUG DELIVERY SYSTEM - The American Cancer Society estimated that in 2009, 1,479,350 new cancer cases would be diagnosed in the United States of which 219,440 would be lung and bronchus related. The standard treatments for NSCLC include surgery, chemotherapy, radiation, laser and photodynamic therapy, all with various success rates depending on the stage of the cancer. National Cancer Institute assesses, however, that results of standard treatment are generally poor with only a 15 percent 5-year survival rate for combined cancer stages. Challenges facing the current chemotherapy drugs include excessive toxicity to healthy tissues and limited ability to prevent metastases. A dual drug delivery system described herein selectively targets the lung to deliver anti-cancer drugs and inhibit the formation of metastases. | 11-03-2011 |
20110268804 | TARGETING OF ANTIGEN PRESENTING CELLS WITH IMMUNONANOTHERAPEUTICS - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. | 11-03-2011 |
20110268805 | ADJUVANT INCORPORATION IN IMMUNONANOTHERAPEUTICS - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 11-03-2011 |
20110274757 | NUCLEIC ACID DELIVERY VEHICLE AND USES THEREOF - A nucleic acid-delivery vehicle for delivering nucleic acids to target cells is provided. The nucleic acid-delivery vehicle comprises a plurality of nanoparticles; and a plurality of nucleic acids. The nanoparticles and the nucleic acids are agglomerated to form a nucleic acid-granulation particle having a dimension of at least 5 nm. Methods of making the nucleic acid-delivery vehicle and kits comprising nucleic acid-delivery vehicle are also provided. | 11-10-2011 |
20110274758 | MICROSPHERE-BASED COMPOSITION FOR PREVENTING AND/OR REVERSING NEW-ONSET AUTOIMMUNE DIABETES - AS-oligonucleotides are delivered in microsphere form in order to induce dendritic cell tolerance, particularly in the non-obese-diabetic (NOD) mouse model. The microspheres incorporate antisense (AS) oligonucleotides. A process includes using an antisense approach to reverse an autoimmune diabetes condition in NOD mice in vivo. The oligonucleotides are targeted to bind to primary transcripts CD40, CD80, CD86 and their combinations. | 11-10-2011 |
20110274759 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic)acid-poly(ethylene)glycol. | 11-10-2011 |
20110274760 | USE OF SYNTHETIC INORGANIC NANOPARTICLES AS CARRIERS FOR OPHTHALMIC AND OTIC DRUGS - The use of nanoparticles of inorganic materials (e.g., synthetic smectite clays) in ophthalmic and otic pharmaceutical compositions is described. The nanoparticles are utilized as biologically inert carriers or depots for ophthalmic and otic drugs. The nanoparticles may also be utilized to modify the rheological properties of the compositions, so as to enhance the viscosity or flow characteristics of the compositions and/or increase the retention time of the compositions in the eye or ear. | 11-10-2011 |
20110280943 | Sunscreen Compositions Comprising Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same - Aspects of the invention include sunscreen formulations that include uniform, rigid, spherical nanoporous calcium phosphate particles. Also provided are methods of making the sunscreen formulations. The sunscreen formulations find use in sunblocking applications. | 11-17-2011 |
20110293723 | SYNTHETIC NANOCARRIER COMBINATION VACCINES - Disclosed are dosage forms and related methods, that include a first population of synthetic nanocarriers that have one or more first antigens coupled to them, one or more second antigens that are not coupled to the synthetic nanocarriers, and a pharmaceutically acceptable excipient. | 12-01-2011 |
20110300218 | NOVEL SOLID STATE FORMS OF RANOLAZINE SALTS - Provided herein are solid state forms of ranolazine salts. Also provided is a stable amorphous form of ranolazine hydrochloride having a water content of less than about 0.5% by weight. Further provided are amorphous co-precipitates of ranolazine or a pharmaceutically acceptable salt thereof with povidone. Processes for the preparation of ranolazine forms, pharmaceutical compositions, and methods of treating thereof are also included. The solid state forms of ranolazine salts are useful for preparing ranolazine in high purity. | 12-08-2011 |
20110300219 | NANOSTRUCTURES FOR DRUG DELIVERY - The present invention provides compositions, preparations, formulations, kits, and methods useful for treating subjects having cancer or at risk of developing cancer. Some embodiments of the invention may comprise a composition comprising a plurality of particles comprising a platinum(IV) therapeutically active precursor. | 12-08-2011 |
20110300220 | SOLID CALCIUM LACTATE IN SUBSTANTIALLY SPHERICAL FORM - Solid calcium lactate in the form of substantially spherical particles, characterised in that the spherical particles have a particle size distribution such that most of the particles are between 280 and 550 microns in size and the calcium lactate can be rapidly dissolved in water. | 12-08-2011 |
20110305761 | POLYMERSOMES, COLLOIDOSOMES, LIPOSOMES, AND OTHER SPECIES ASSOCIATED WITH FLUIDIC DROPLETS - The present invention relates generally to vesicles such as liposomes, colloidosomes, and polymersomes, as well as techniques for making and using such vesicles. In some cases, the vesicles may be at least partially biocompatible and/or biodegradable. The vesicles may be formed, according to one aspect, by forming a multiple emulsion comprising a first droplet surrounded by a second droplet, which in turn is surrounded by a third fluid, where the second droplet comprises lipids and/or polymers, and removing fluid from the second droplet, e.g., through evaporation or diffusion, until a vesicle is formed. In certain aspects, the size of the vesicle may be controlled, e.g., through osmolarity, and in certain embodiments, the vesicle may be ruptured through a change in osmolarity. In some cases, the vesicle may contain other species, such as fluorescent molecules, microparticles, pharmaceutical agents, etc., which may be released upon rupture. Yet other aspects of the invention are generally directed to methods of making such vesicles, kits involving such vesicles, or the like. | 12-15-2011 |
20110305762 | PHARMACEUTICAL COMPOSITION COMPRISING N-[3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL]-6-[5[[[2-(METHYLSULFONYL)E- THYL]AMINO]METHYL]-2-FURYL]-4- QUINAZOLINAMINE - The present invention relates to a pharmaceutical composition comprising N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine as active pharmaceutical ingredient and a process of preparing such composition. | 12-15-2011 |
20110305763 | LANTIBIOTICS AND USES THEREOF - The present invention provides isolated lantibiotics that inhibit. Gram negative and Gram positive microbes. The antibiotic includes an amino acid sequence, wherein the amino acid sequence of the compound and the amino acid sequence of SEQ ID NO:21 or SEQ ID NO:22 have at least 80% identity. The lantibiotics have the characteristic of inhibiting growth of a Gram negative microbe in conditions that do not damage the outer membrane of the Gram negative microbe. The present invention also provides methods for making and using the lantibiotics. | 12-15-2011 |
20110311633 | Combination of a Silicon Containing Component and a Hormone - The invention relates to the use of a silicon-containing material to reduce the amount of hormone required in a method of hormone treatment to achieve a desired response, particularly in hormone replacement therapy (HRT) and especially in the maintenance of post-menopausal bone health and the management or treatment of osteoporosis, and to pharmaceutical compositions for use in such a method. | 12-22-2011 |
20110318417 | HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - Provided herein are impurities of cinacalcet, (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-(5,6,7,8-tetrahydronaphthalene)methaneamine (tetrahydro cinacalcet impurity), (R)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethaneamine-N-oxide (cinacalcet N-oxide impurity) and (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]methyl]-1-naphthalenemethaneamine (benzylamine impurity); and processes for preparation and isolation thereof. Provided further herein is a highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure cinacalcet or a pharmaceutically acceptable salt thereof substantially free of impurities. | 12-29-2011 |
20110318418 | COMPOSITIONS OF 5-ETHYL-2--PYRIMIDINE - This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations. | 12-29-2011 |
20110318419 | GRAFT MATERIALS CONTAINING BIOACTIVE SUBSTANCES, AND METHODS FOR THEIR MANUFACTURE - Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use. | 12-29-2011 |
20110318420 | FULVESTRANT NANOSPHERE/MICROSPHERE AND PREPARATIVE METHOD AND USE THEREOF - Fulvestrant nanosphere/microsphere and preparation method and use thereof are provided in the present invention. The carrier material of the fulvestrant nanosphere/microsphere is methoxy ended polyethylene glycol-polylactic acid block copolymer. The nanosphere/microsphere is prepared by solvent-nonsolvent method, in-liquid drying method and/or spray drying method, and has the features of high drug loading and high encapsulation efficiency, controllable release of medicine and no irritant to application site or blood vessel. The fulvestrant nanosphere/microsphere can be used to treat metastatic advanced breast cancer in post-menopausal woman. | 12-29-2011 |
20120003317 | STABLE PROBIOTIC GRANULATE, AND METHOD FOR PREPARING SAME - The invention pertains to the field of probiotic compositions useful for human and/or animal food and health. The invention particularly relates to compositions containing stable probiotic microorganisms during the production of tablets or granules for final use. The works of the applicant of the present invention show that the mortality of probiotic microorganisms during granulation is closely linked with granulation operating conditions and with the characteristics of the selected microorganisms. Said works have led to the establishment of a mathematical expression for defining both the characteristics of the yeast as well as the parameters of the method so that the microorganism losses after granulation are lower than 1 log CFU/g of granulated food. | 01-05-2012 |
20120003318 | UNIT DOSES, AEROSOLS, KITS, AND METHODS FOR TREATING HEART CONDITIONS BY PULMONARY ADMINISTRATION - Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated. | 01-05-2012 |
20120009264 | DRUG CARRIER FOR TREATING OF GASTROINTESTINAL ULCER - A drug carrier for treating of gastrointestinal ulcer comprises a microspheroid having a substrate and a plurality of particles distributed over and covered by the substrate, wherein the substrate is alginate and the plurality of particles is a drug for treating of gastrointestinal ulcer; and a coat covering up the surface of the microspheroid, which contains chitosan. | 01-12-2012 |
20120009265 | DRUG CARRIER - A drug carrier comprises a substance, a paramagnetic particle, a rod-shaped light-absorbing particle and a drug. The paramagnetic particle, the drug and the rod-shaped light-absorbing particle absorbing light and generating heat are provided in the substance. | 01-12-2012 |
20120015035 | Implantable Delivery Vehicle for Ocular Delivery of Muscarinic Antagonists - The present invention provides compositions and methods for treating ocular disorders such as myopia. | 01-19-2012 |
20120021055 | NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS - The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications. | 01-26-2012 |
20120027859 | Biodegradable Proline-Based Polymers - The invention provides sequential poly(ester amide)s derived from Proline and that are synthesized by a two-step method, involving a final thermal polyesterification reaction. Molecular weights of polymers prepared by this method are from 14,000 Da to about 77,000 Da.1 When invention proline-based PEAs were thermally characterized, their glass transition temperatures were lower than other alpha-amino acid based poly(ester amides) due to lack of internal hydrogen bonding. These Proline-based PEAs assemble as nano-particles in aqueous solutions and form complexes with various cations and biologies, including hydrophobic small molecule drugs and biologies. Therefore the invention Proline-based PEAs are useful for drug delivery applications requiring a polymer with a molecular weight in the range from 14,000 Da to about 77,000 Da and for fabrication of nanoparticles for delivery of hydrophobic drugs. | 02-02-2012 |
20120027860 | ENCAPSULATED ADIPOSE-DERIVED STEM CELLS, METHODS FOR PREPARATION AND THERAPUTIC USE - A therapeutic composition comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in a three-dimensional biocompatible gel matrix, and methods, and systems for preparing and using encapsulated adipose-derived mesenchymal stem cells. Hydrogel microbeads encapsulating stem cells maintain the viability and location of the stem cells for an extended period as compared to stem cells in suspension. The gel matrix allows the release of cellular factors from the encapsulated stem cells to surrounding tissues to achieve desired therapeutic results. | 02-02-2012 |
20120040003 | ANTI-DANDRUFF COMPOSITIONS WITH CITRUS FIBERS - A shampoo composition is described which includes from 1 to 25% by weight of mild surfactants, from 0.001 to 5% by weight of citrus fibers, from 0.01 to 5% by weight of anti-dandruff zinc salts, and a cosmetically acceptable carrier. The citrus fibers help structure the composition to maintain phase stability, provide appropriate viscosity and achieve deposition of the anti-dandruff zinc salts. | 02-16-2012 |
20120040004 | TREATMENT OF RADIATION-INDUCED FIBROSIS - The present invention relates to treatment or prevention of radiation induced fibrosis using TNF-alpha antagonism. Preferably, TNF-alpha is antagonized by direct binding or by inhibition of synthesis. In a preferred embodiment, the invention comprises intraperitoneal administration of a chitosan-siRNA nanoparticle, wherein the siRNA is targeted to the mRNA encoding TNF-alpha. | 02-16-2012 |
20120045514 | ANTI-CANCER MICROPARTICLE - The present invention relates to a microparticle and its use. The microparticle has a width of at least about 1 micron. The microparticle includes a biocompatible polymer, a nanoparticle, and an anti-cancer agent. | 02-23-2012 |
20120045515 | HOLLOW SILICA PARTICLE WITH A POLYMER THEREON - The present invention provides a hollow silica micro- or nanoparticle with a polymer immobilized thereon. The polymer is covalently linked to the silica particle via urethane groups. Provided is also a method of covalently coupling a polymer to a silica surface. The method comprises contacting a silica surface that carries amino functional groups with a polymer with a carbonate group of the general Formula (2). R | 02-23-2012 |
20120058188 | LIPID ENCAPSULATED INTERFERING RNA - The present invention provides compositions and methods for silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell. | 03-08-2012 |
20120064165 | TREATMENT OF TISSUE ADHESION - Dry powder compositions are useful in the treatment or prevention of tissue adhesions during or after surgery or during wound therapy. The dry powder compositions may contain trehalose. The dry powder compositions may be fibrin sealant compositions comprising fibrinogen and/or thrombin. | 03-15-2012 |
20120070498 | Submicron Particles of Antineoplastic Agents - The present invention is concerned with the formation of submicron particles of an antineoplastic agent, particularly paclitaxel, by precipitating the antineoplastic agent in an aqueous medium to form a pre-suspension followed by homogenization. Surfactants with phospholipids conjugated with a water soluble or hydrophilic polymer such as PEG are used as coating for the particles. The particles produced generally have an average particle size of less than about 1000 nm and are not rapidly soluble. | 03-22-2012 |
20120076859 | Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases - A method of treatment of cystic fibrosis and other pulmonary diseases identified by nitric oxide deficiency, comprising administration of a nebulized solution of citrulline and/or another nitric oxide precursor as an inhalable aerosol or an inhalable dry powder for targeted delivery into conducting and central airways. Citrulline or another nitric oxide precursor is formulated as a composition having predetermined limited volume, salinity, pH and osmolality. The composition is nebulized into an aerosol having a mass median aerodynamic diameter (MMAD) between 2 μm and 6 μm. | 03-29-2012 |
20120076860 | COMPOSITIONS, METHODS, AND SYSTEMS RELATING TO CONTROLLED CRYSTALLIZATION AND/OR NUCLEATION OF MOLECULAR SPECIES - The present invention generally relates to compositions, methods, and systems relating to controlled crystallization and/or nucleation of a molecular species. In some embodiments, the crystallization and/or nucleation of the molecular species may be controlled by tuning the surface chemistry and/or the morphology of a crystallization substrate. In some embodiments, the molecular species is a small organic molecule (e.g., pharmaceutically active agent). | 03-29-2012 |
20120082725 | Composition Comprising Immunogenic Microparticles - The invention provides an immunogenic composition comprising at least one antigen in association with microparticles, wherein the microparticles are in the same size range as viruses. In addition the invention also provides vaccine compositions and methods of eliciting immune responses in a subject. | 04-05-2012 |
20120082726 | SURFACE-TREATED MODAFINIL PARTICLES - The present invention is directed to solid oral dosage forms comprising surface-treated particles comprising modafinil particles and a hydrophilic treating agent, methods of making the same, and uses thereof. | 04-05-2012 |
20120087983 | ORTHOPEDIC APPLICATION OF ENCAPSULATED STEM CELLS - Described herein are orthopedic applications of mesenchymal stem cell encapsulated and delivered for treatment of cartilage damage in joints. A therapeutic composition is prepared comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in microbeads of a three-dimensional biocompatible gel matrix. The hydrogel microbeads encapsulating stem cells maintain the viability and location of the stem cells for an extended period as compared to stem cells in suspension. The microbeads are implanted adjacent a target orthopedic treatment site where the microbeads allow the release of cellular factors from the encapsulated stem cells to surrounding orthopedic tissues to achieve desired therapeutic results such as healing of cartilage damage in joints. | 04-12-2012 |
20120093931 | Inhibition of Neovascularization by Cerium Oxide Nanoparticles - The present invention provides methods for reducing, reversing or inhibiting neovascularization in a tissue of a mammalian subject having a pathological condition involving neovascularization by administration in vivo of nanoceria particles (cerium oxide nanoparticles) to the subject. The method of the invention is useful, for example, for reducing, treating, reversing or inhibiting neovascularization in ocular tissue such as the retina, macula or cornea; in skin; in synovial tissue; in intestinal tissue; or in bone. In addition, the method of the invention is useful for reducing or inhibiting neovascularization in a neoplasm (tumors), which can be benign or malignant and, where malignant, can be a metastatic neoplasm. As such, the invention provides compositions, which contain nanoceria particles and are useful for reducing, treating, reversing or inhibiting angiogenesis in a mammalian subject. | 04-19-2012 |
20120093932 | TARGETED SUSTAINED-RELEASE MICROSPHERE OF VASCULAR OCCLUSIVE AGENT CONTAINING SODIUM ALGINATE AND SORAFENIB, PRODUCTION METHOD AND USE THEREOF - A targeted sustained-release microsphere vascular embolizing agent, the production method and the use thereof are disclosed. The microsphere comprises sodium alginate as the carrier and sorafenib as the targeted anti-tumor medicine and sorafenib is encapsulated by sodium alginate. The weight ratio of sorafenib to sodium alginate is 1:1˜1:30. The microspheres are used for manufacturing medicament for the treatment of solid tumors with advantages including high medicine concentration in the target regions with reduced systemic dosage and toxic and side effects. | 04-19-2012 |
20120093933 | DENATURED LACTOGLOBULIN AND POLYPHENOL COASSEMBLIES - The present invention is directed to co-assembled nanoparticle composition comprising denatured β-lactoglobulin and at least one nutraceutical compound, specifically polyphenols, such as EGCG, compositions comprising same and methods of preparing thereof. | 04-19-2012 |
20120100218 | Intralymphatic Chemotherapy Drug Carriers - A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not toxic. The composition can include a pharmaceutically acceptable carrier, and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous administration. The nanoconjugate can include a nanocarrier configured for preferential intralymphatic accumulation after subcutaneous or interstitial administration, and a plurality of chemotherapeutic agents coupled to the nanocarrier. The nanoconjugate can have a dimension of about 10 nm to about 5 nm. Also, the nanoconjugate can be loaded with the chemotherapeutic agents from about 10% to about 50% w/w. The nanocarrier can be a hyaluronan polymer of about 3 kDa to about 50 kDa. Alternatively, the nanocarrier can be a dendrimer. | 04-26-2012 |
20120100219 | COMPOSITION FOR THE PRODUCTION OF TABLETS, AND METHOD FOR THE PRODUCTION OF SAID COMPOSITION - The present invention relates to a process for the preparation of a composition for the production of tablets and to a composition obtained thereby. This composition is a directly compressible composition which results both in improved tabletting properties and in improved tablet properties. | 04-26-2012 |
20120114757 | PARTICLES COMPRISING DROSPIRENONE ENCAPSULATED IN A POLYMER - The present invention relates to particles comprising Drospirenone encapsulated in a polymer selected from the group consisting of glycolic acid polymer, lactic acid polymer, poly caprolactones, poly anhydrides and any copolymer of these, e.g., poly(lactic acid-co-glycolic acid) polymer and any combination of these. Furthermore, the present invention also relates to compositions comprising such particles. The present invention also relates to the use of such particles or compositions as contraceptives and for treatment of diseases, disorders and symptoms associated with deficient endogenous levels of estrogen in women. | 05-10-2012 |
20120121707 | Tolbutamide Particle And Preparing Method Thereof And Method Of Reducing A Blood Glucose - A method for preparing a tolbutamide particle is provided. The method comprises steps of mixing a bulk drug of tolbutamide with a supercritical fluid to form a supercritical mixture; and expanding the supercritical mixture to obtain the tolbutamide particle. | 05-17-2012 |
20120121708 | Acetazolamide Microparticle And Its Preparation Method And Use - A method for preparing an acetazolamide microparticle having a mean particle size ranged between 0.36 μm and 18 μm is provided. The method includes steps of dissolving an acetazolamide in a solvent to form an acetazolamide solution; and mixing the acetazolamide solution with a supercritical fluid at a temperature and a pressure above a critical point of the supercritical fluid for forming the acetazolamide microparticle, wherein the solvent is miscible with the supercritical fluid. | 05-17-2012 |
20120121709 | PHASE TRANSITION BIOPOLYMERS AND METHODS OF USE - The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive. | 05-17-2012 |
20120121710 | Mucosal Immunization - Methods and compositions for eliciting an immune response to an antigen are disclosed. In certain aspects, these methods concern eliciting an immune response in a subject by administering to the mucosa of the subject a composition comprising a virus-like particle (“VLP”) and Murabutide. | 05-17-2012 |
20120121711 | MICROSPHERE DRUG CARRIER, PREPARATION METHOD, COMPOSITION AND USE THEREOF - A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH | 05-17-2012 |
20120128775 | BIOCARRIER AND METHOD OF USING THE SAME - The present invention discloses a biocarrier for delivery of a bioactive substance near/into a target cell, comprising a bioactive substance-loaded core with a first electricity, and one or more block copolymer, each block copolymer comprising a zwitterionic block and an anchoring block with an initial electricity opposite to the first electricity, wherein the anchoring block binds to the core by electrostatic attraction, and the zwitterionic block extends outwardly to increase the biocarrier stability in mammalian blood. Additionally, the present invention also discloses a method of using the biocarrier. | 05-24-2012 |
20120128776 | METHOD FOR THE PREPARATION OF MICROPARTICLES WITH EFFICIENT BIOACTIVE MOLECULE INCORPORATION - The present invention relates to relates to a method for the preparation of drug filled polymer microparticles comprising a gas core and shell, which particles are suitable as part of a therapeutic composition, especially for drug delivery. By using this method, polymeric microparticles are obtained that combine high incorporation efficiency for hydrophilic and/or hydrophobic drugs with a large, preferably hollow, core. | 05-24-2012 |
20120141588 | DENTIFRICE COMPOSITIONS CONTAINING CALCIUM SILICATE AND A BASIC AMINO ACID - An oral care composition includes an effective amount of a basic amino acid in free or salt form; and an effective amount of calcium silicate particles. The calcium silicate particles have an average diameter of less than about 5 microns, such that they can occlude dentinal tubules of the teeth. An oral care method includes applying the composition to an oral cavity of a subject to reduce or inhibit hypersensitivity of the teeth and to achieve other benefits. | 06-07-2012 |
20120141589 | PARTICLES FOR DRUG DELIVERY AND OTHER APPLICATIONS - The present invention generally relates to particles for drug delivery and other applications. In one aspect, the present invention relates to a technique for reacting precursor compounds in the presence of a pharmaceutically-active agent to form product (e.g., in the form of particles) in which the agent is substantially contained within the product, and the product is soluble within typical gastric fluid of a mammal. In another aspect, the present invention is generally directed to particles comprising an inorganic pharmaceutically acceptable carrier, such as CaCO | 06-07-2012 |
20120148675 | TESTOSTERONE UNDECANOATE COMPOSITIONS - The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier. | 06-14-2012 |
20120148676 | ARTIFICIAL CELL CONSTRUCTS FOR CELLULAR MANIPULATION - The present invention contemplates induction of immunological tolerance thereby providing permanent allogcaft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (T | 06-14-2012 |
20120156300 | MICROBUBBLES AND METHODS FOR OXYGEN DELIVERY - Compositions containing a carrier and microbubbles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 mL oxygen/dL suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and/or one or more tissues or organs. | 06-21-2012 |
20120164226 | Compositions and Methods for Improving Prognosis of a Human with Subarachnoid Hemorrhage - The described invention provides a pharmaceutical composition, delivery system and a method for treating a delayed complication associated with a brain injury in a mammal and improving its prognosis in a mammal by implanting a therapeutically effective amount of the pharmaceutical composition containing a voltage-gated calcium channel blocker and a pharmaceutically acceptable carrier into a predetermined location in the brain, which reduces signs or symptoms of at least one delayed complication associated with brain injury. | 06-28-2012 |
20120164227 | NEW GRANULATING PROCESS AND THUS PREPARED GRANULATE - The present invention relates to a process for manufacturing microcrystalline ezetimibe containing granulate, wherein a) ezetimibe is dissolved; b) the dissolved ezetimibe is precipitated with water, which if necessary contains pharmaceutical excipients, preferably lauryl-sulfate derivatives, and c) granulates are formed from the obtained suspension by spraying the suspension onto pharmaceutical excipients. A further aspect of the present invention is the granulate obtained by the present process and the pharmaceutical composition containing such granulate. | 06-28-2012 |
20120164228 | NOVEL PHARMACEUTICAL FORMULATIONS TO PREVENT THE MISUSE OF MEDICINAL DRUGS - Granules having a solid core on which an active ingredient is supported, the core being chosen preferably from among insoluble supports, the granules also having, supported on said the core, the following compounds: one or more colouring agents, one or more metallic pigments, one or more gas-releasing compounds, and optionally one or more embittering agents. | 06-28-2012 |
20120164229 | DEPOT SYSTEMS COMPRISING GLATIRAMER OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF - The present invention provides long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection. | 06-28-2012 |
20120171290 | HPV PARTICLES AND USES THEREOF - The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors. | 07-05-2012 |
20120177740 | DRUG DELIVERY FORMULATION FOR CONTROLLING OF INITIAL BURST AND MANUFACTURING METHOD THEREOF - Provided is a drug delivery system for control of initial burst of a drug. More particularly, there are provided a drug delivery formulation including: a granule containing a biodegradable polymer and a drug; and a temperature-sensitive hydrogel, and a method for preparing the same. The presently disclosed drug delivery formulation can be prepared via a relatively simple process and allows a drug to be released slowly at a constant rate without initial burst and thus maintains a constant blood level of the drug for a long period of time. Consequently, it is capable of preventing the initial burst of the existing injection-type drug delivery formulations and slow-release granules and providing a desired release profile, including sustained release with time. | 07-12-2012 |
20120177741 | POSITIVELY-CHARGED POLY (D,L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES AND FABRICATION METHODS OF THE SAME - The present technology provides compositions with positively-charged poly(d,l-lactide-co-glycolide) nanoparticles capable of releasing a bioactive substance in a body tissue for extended periods of time, as well as methods for manufacture of the same and methods for prophylactic and therapeutic treatment of a subject in need thereof. | 07-12-2012 |
20120189700 | Nanoparticle Based Immunological Stimulation - A nanoparticle-based delivery system and methods for its use are disclosed. In one aspect, a nanoparticle-based delivery system comprising at least one molecule such as proteins, DNA/RNA or fragments thereof, carbohydrates, enzymes, chemicals, virus cells, bacteria, parts of a virus, parts of a bacteria, parts of a cell, part of a tissue, or a combination of one or more of these, which shall be referred to as immunogens, are chemically or physically combined with water soluble nanoparticles which, when administered to a living system, is capable of eliciting a desired immunological response. More particularly, the invention relates to nanoparticle-based delivery systems that are specifically engineered to enhance humoral or cellular immune response without the use of adjuvants. | 07-26-2012 |
20120207838 | Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps - Psoriasis is treated by oral administration of a pharmaceutical composition containing a nitrone spin trap such as α-phenyl t-butyl nitrone (PBN) and derivatives thereof. Preferred compositions and method of treatments further comprise at least one adjunct ingredient including fatty acid esters of ascorbic acid such as ascorbyl palmitate and ascorbyl stearate. The pharmaceutical composition can be prepared as an immediate release formulation or controlled released formulations. | 08-16-2012 |
20120207839 | Mineralized Collagen/Bioceramic Composite and Manufacturing Method Thereof - The present invention discloses a mineralized collagen/bioceramic composite useful as a hard tissue replacement material or substitute material, comprising about 10% to 95% by weight of mineralized collagen and about 5% to 90% by weight of bioceramics, and a method of manufacturing the same. Wherein, the mineralized collagen is used as a binder for the bioceramics, such as calcium phosphate ceramics, calcium sulfate ceramics, calcium carbonate ceramics, and other biocompatible ceramics. The bioceramic used in the mineralized collagen/bioceramic composite can be either in powder form or in granular form. | 08-16-2012 |
20120207840 | Virion Derived Protein Nanoparticles For Delivering Diagnostic Or Therapeutic Agents For The Treatment Of Non-Melanoma Skin Cancer - This invention relates to a transdermal delivery system for treating skin related diseases employing protein nanoparticles to deliver drugs to the keratinocytes and basal membrane cells for the treatment of non-melanoma skin cancer. The current invention presents an effective method for delivering small molecule nucleic acids to the epidermal cells. | 08-16-2012 |
20120213854 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS - Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates. | 08-23-2012 |
20120225125 | Nanoparticles for Extravascular Administration - Disclosed are drug delivery systems and methods for extravascular administration of drug, vaccine, and/or diagnostic agents, for use in research and medical applications. | 09-06-2012 |
20120276205 | SILVER OXIDE FORMULATIONS - A formulation including at least one silver oxide including a silver(II) oxide, the silver(II) oxide having an irregular macrocrystal structure, the silver oxide having an average particle size (D | 11-01-2012 |
20120282341 | Lipid Formulated Compositions And Methods For Inhibiting Expression Of Eg5 And VEGF Genes - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a SNALP formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as cancer. | 11-08-2012 |
20120294945 | DRUG DELIVERY SYSTEM USING HYALURONIC ACID-PEPTIDE CONJUGATE MICELLE - The present invention relates to a drug delivery composition comprising a hyaluronic acid-peptide conjugate micelle and a production method thereof. According to the drug delivery composition and the production method of the drug-loaded, hyaluronic acid-peptide conjugate micelle of the present invention, the reaction for encapsulating can proceed in a mixed solvent of an aqueous solvent and an organic solvent. Therefore, the present invention can be applied to various types of water-insoluble active components and the biocompatible and biodegradable derivative can encapsulate a drug to provide a drug-loaded micelle, which is safe to be applied for human bodies. Moreover, the micelle has a therapeutic effect from the peptide contained therein, which can act in combination with the drug as packing therein. Therefore, the drug delivery composition and its production method can be utilized in the field of producing a sustained release formulation with an extended duration of the medicinal effect. | 11-22-2012 |
20120321714 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 6-OXO-6,7,8,9,10,11-HEXAHYDROCYCLOHEPTA (C)CHROMEN-3-YL SULFAMATE AND POLYMORPHS THEREOF - The present invention relates to a solid pharmaceutical composition including the active principle 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. The present invention also relates to polymorphs of the 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate compound. | 12-20-2012 |
20120321715 | MICELLES FOR THE SOLUBILIZATION OF GOSSYPOL - The invention provides biocompatible micelles loaded with one or more active agents. The micelles can encapsulate anticancer drugs such as gossypol, and combinations of drugs, such as gossypol and paclitaxel, gossypol and 17-AAG, gossypol and cyclopamine, gossypol, paclitaxel, and 17-AAG, and gossypol, paclitaxel, and cyclopamine. The micelle compositions provide effective solubilization of difficult to solubilize drug combinations without the need for additional surfactants that can be toxic to patients. Thus, the invention provides stable and biocompatible drug formulations that improve bioavailability without causing toxicity. | 12-20-2012 |
20130011480 | CYTOTOXIC THERAPY BY PROTON FLUX MODULATION - Compositions and methods for treating cancer are described. Some of the methods include administering to a cancer patient in need thereof a substance, such as a carbonic anhydrase inhibitor, that at a therapeutic dose produces a metabolic acidosis in humans; and administering to the patient at least one of: (a) a monocarboxylate transport inhibitor; (b) a sodium-hydrogen exchange inhibitor; (c) a chloride-bicarbonate exchange inhibitor; or (d) a proton pump inhibitor; wherein the at least one of (a) through (d) is in an amount effective to induce selective cytotoxicity in cancer cells relative to noncancerous cells in humans. | 01-10-2013 |
20130034608 | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents - The present disclosure is directed in part to a biocompatible nanoparticle composition comprising a plurality of non-colloidal long circulating nanoparticles, each comprising a α-hydroxy polyester-co-polyether and a therapeutic agent, wherein such disclosed compositions provide a therapeutic effect for at least 12 hours. | 02-07-2013 |
20130034609 | SMART POLYMERS FUNCTIONALIZED HOLLOW SILICA VESICLES - The present invention provides a porous hollow silica micro- or nanoparticle with a polymer grafted thereon, wherein the polymer is selected from poly(methacrylic acid) and copolymers thereof. The polymer may be covalently linked to the silica particle via a bridging group. Provided is also a method of covalently coupling a poly(methacrylic acid) to a silica surface of a hollow silica particle. The method comprises contacting a silica surface of a hollow silica particle that carries amino functional or halogen functional groups with a poly(methacrylic acid) or a copolymer or a respective monomer thereof. The method further comprises allowing the carboxyl group of the monomer or the poly(methacrylic acid) and an amino functional group or a halogen functional group on the silica surface to undergo a coupling reaction, thereby covalently coupling the polymer to the silica surface. | 02-07-2013 |
20130039986 | Silk-Based Ionomeric Compositions - Disclosed herein are pH-dependent silk fibroin-based ionomeric compositions and colloids, and methods of making the same. The state of the silk fibroin ionomeric compositions is reversible and can transform from a gel-like colloid to a more fluid-like solution, or vice versa, upon an environmental stimulus, e.g., pH. Thus, the silk-based ionomeric compositions and colloids can be applied in various industries, ranging from electronic applications to biomedical applications, such as sensors, gel diodes, absorbent materials, drug delivery systems, tissue implants and contrast agents. | 02-14-2013 |
20130059008 | DRYING METHODS FOR TUNING MICROPARTICLE PROPERTIES - Described herein are drying methods for tuning one or more properties of a microparticle. In one aspect, the release profile of a microparticle comprising a bioactive agent therein can be affected by the disclosed drying methods. | 03-07-2013 |
20130064894 | NOVEL CATIONIC LIPIDS AND METHODS OF USE THEREOF - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 03-14-2013 |
20130089614 | Magnetic Nanoparticles and Uses Thereof - Magnetic nanoparticles are provided that have a superparamagnetic core and a nanoporous silica shell surrounding the core. The shell is functionalized with amine or S-nitrosothiol groups both inside and outside the nanopores. A process to provide such nanoparticles involves hydrolyzing tetraethoxysilane (TEOS) in a microemulsion of a superparamagnetic nanoparticle to form a superparamagnetic nanoparticle encapsulated by an incompletely hydrolyzed nanoporous silica shell, and hydrolyzing an amine-containing compound or a thiol-containing compound in situ in the presence of the incompletely hydrolyzed nanoporous silica shell before hydrolysis and densification of the silica shell is complete to functionalize the nanoporous silica shell with amine or thiol groups both inside and outside the nanopores and to maintain nanoporosity of the shell. Such magnetic nanoparticles are useful as carriers for chemical or biological species, particularly for magnetic resonance imaging, optical imaging, targeted drug delivery, cell delivery and magnetic separation applications. | 04-11-2013 |
20130122097 | ANTIFUNGAL THERAPY - Described here are various compositions for the delivery active agents, e.g., antifungal agents. The compositions may be beneficial due to the particular release kinetics associated with them. Various locations and methods for placement of the compositions into the tissues of the nail unit, as well as tissues surrounding the nail unit are also described. | 05-16-2013 |
20130149381 | ABSORPTION METHOD FOR ENTRAPMENT OF DRUGS IN POLYMERIC NANOPARTICLES - A method for preparing polymeric nanoparticles having entrapped active ingredients or drugs, the method includes the step of preparing a reaction by mixturing water, a surfactant, and a water-soluble radical initiator; polymerizing a polymerizable monomer in the reaction to obtain a dispersion of polymeric nanoparticles having a controlled size with average diameters smaller than 50 nm; dissolving one or more active ingredients in a suitable solvent; adding the solution of active ingredients to the dispersion of polymeric nanoparticles and allowing that the active ingredients to become entrapped within polymeric nanoparticles; and evaporating the dispersion of polymeric nanoparticles having entrapped active ingredients to evaporate the residual monomer and the solvent used as a vehicle for loading the active ingredient. | 06-13-2013 |
20130156856 | ANTICOAGULANT-CONJUGATED CARBON NANOCAPSULE, ANTITHROMBOTIC AGENT CONTAINING THEREOF - The embodiments provide a carbon nanocapsule conjugated with at least one of the anticoagulants on the surface and an antithrombotic drug containing the anticoagulant-conjugated carbon nanocapsule as an active ingredient. The anticoagulant-conjugated carbon nanocapsule has less cytotoxicity and good biocompatibility. A method for preparing the anticoagulant-conjugated carbon nanocapsule is also provided. | 06-20-2013 |
20130171258 | Pharmaceutical composition for elevating radio-sensitivity of cancer cells, pharmaceutical composition for detecting cancer cells with radio-sensitivity, and detection method thereof - The present invention relates to a pharmaceutical composition for elevating radiation-sensitivity of cancer cells, which comprises: a nanoparticle containing with a first element, which is iron, copper, or the combination thereof; and a pharmaceutically acceptable carrier, wherein the nanoparticle is a metal nanoparticle, an alloy nanoparticle, or a metal nanoparticle with core-shell structure, and the size of the nanoparticle is under a controllable range of 3 nm to 150 nm. In addition, the present invention provides a detection method to detect radiation-sensitivity of the cancer cells through different modalities such as CT or MRI due to its native high CT number and magnetic property. Furthermore, the present invention provides a pharmaceutical composition for elevating radiation-sensitivity of the cancer cells through preferential uptake of the nanoparticle, in order to enhance the radiation-sensitivity of the cancer cells and improve the efficiency of radiation therapy to the cancer cells. | 07-04-2013 |
20130202706 | NANOSTRUCTURED ATORVASTATIN, ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS OF THEM, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention is directed to nanostructured Atorvastatin, its pharmaceutically acceptable salts and compositions of them, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Atorvastain, its pharmaceutically acceptable salts and compositions of them according to the invention have an average particle size of less than about 600 nm. The stable amorphous nanostructured particles of the present invention are characterized by increased solubility and bioequivalent biological performance compared to the marketed crystalline drug. Atorvastatin is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. | 08-08-2013 |
20130202707 | Controlled Delivery of TLR Agonists in Structural Polymeric Devices - The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents. | 08-08-2013 |
20130209563 | COMBINATION IMMEDIATE/DELAYED RELEASE DELIVERY SYSTEM FOR SHORT HALF-LIFE PHARMACEUTICALS INCLUDING REMOGLIFLOZIN - A combination immediate/delayed release delivery system for compounds which have short half-life's, such as the antidiabetic remogliflozin etabonate, is provided which provides a dosage form that has two distinct phases of release, a formulation that promotes immediate release of the compound upon ingestion and another formulation which delays the release of the compound so that a dosing regimen of remogliflozin etabonate, once daily, may be achieved while providing effective control of plasma glucose and minimizing the nighttime exposure of this compound. The delivery system includes, but is not limited to, a combination of enteric coating of an immediate release formulation such that a delay in release is provided. Methods for forming the so-described immediate/delayed release delivery system and using such delivery system for treating diabetes are also provided. | 08-15-2013 |
20130216621 | BIFUNCTIONAL CONJUGATE COMPOSITIONS AND ASSOCIATED METHODS - Bifunctional conjugate compositions are provided comprising a Signal-1 moiety bound to a first polymer carrier, wherein the combined size of the Signal-1 moiety and the first polymer carrier is about 1 nanometer to about 500 nanometers; and a Signal-2 moiety bound to a second polymer carrier, wherein the combined size of the Signal-2 moiety and the second polymer carrier is about 1 nanometer to about 500 nanometers. In some embodiments, the Signal-1 moiety and the Signal-2 moiety are bound to the same polymer carrier. Associated methods are also provided. | 08-22-2013 |
20130224301 | SOLID PHARMACEUTICAL DISPERSIONS WITH ENHANCED BIOAVAILABILITY - Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment. | 08-29-2013 |
20130224302 | POROUS PHOTONIC CRYSTALS FOR DRUG DELIVERY TO THE EYE - A minimally invasive controlled drug delivery system for delivering a particular drug or drugs to a particular location of the eye, the system including a porous film template having pores configured and dimensioned to at least partially receive at least one drug therein, and wherein the template is dimensioned to be delivered into or onto the eye. | 08-29-2013 |
20130230593 | Orally Dosed Pharmaceutical Compositions Comprising a Delivery Agent in Micronized Form - Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin. | 09-05-2013 |
20130230594 | COMPOSITIONS WITH ANTIBACTERIAL AND WOUND HEALING ACTIVITY - The present invention relates to compositions based on silver and hyaluronic acid and their use in the management of cutaneous lesions of various origin (acute and chronic wounds, ulcerations, burns, etc.) mainly when characterized by the presence of exudate and hence at high risk of infection. | 09-05-2013 |
20130236548 | Method for treating cancer by using Fe-based particles - A method for treating a cancer is disclosed, which comprises: administering an effective amount of Fe-based particles to a subject in need, wherein the Fe-based particles have core-shell structures. Herein, each Fe-based particle of the present invention comprises: an Fe elemental core with zero valent irons; and a covering layer formed on partial or whole surface of the Fe elemental core, wherein a material of the covering layer is a metal, a metal doped with dopants, a metal alloy, a polymer, carbon, a metal oxide or a nonmetal oxide, and the shape of the Fe-based particles is a rod, a sphere, a cubic or a dumbbell, with the proviso that the metal is not Au. | 09-12-2013 |
20130236549 | TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT - An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. | 09-12-2013 |
20130236550 | PHARMACEUTICAL MICROPARTICLES - Microparticles consisting of (a) a matrix with a mixture of (a | 09-12-2013 |
20130243862 | PHOTOCHEMICAL ACTIVATION OF SURFACES FOR ATTACHING BIOMATERIAL - A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell. | 09-19-2013 |
20130243863 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 09-19-2013 |
20130251805 | LOW VISCOSITY LIQUID DOSAGE FORMS - The present invention relates to liquid dosage forms of nanoparticulate active agents having very low viscosities. | 09-26-2013 |
20130251806 | NATURAL BIOCOMPOSITE POWDER PREPARED FROM PICHIA PASTORIS BIOMASS, METHOD OF PREPARATION AND ITS USE AS EXCIPIENT - The present invention concerns a natural biocomposite powder prepared from the biomass of yeast | 09-26-2013 |
20130251807 | MICRONIZED TANAPROGET, COMPOSITIONS, AND METHODS OF PREPARING THE SAME - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 09-26-2013 |
20130251808 | PHARMACEUTICAL COMPOSITION, METHOD OF PREPARATION AND METHODS OF TREATING ACHES/PAINS - Provided are methods and compositions useful for treating/aches and/or pains. The composition includes ibuprofen and arginine in a clear stable aqueous ethanol vehicle that is stable at room temperature for at least 6 months without separation or precipitation. The composition is effective for delivering ibuprofen directly through the mucosal or buccal tissue without passing through the GI tract. | 09-26-2013 |
20130259942 | PARTICULATE SUBSTANCES COMPRISING CERAMIC PARTICLES FOR DELIVERY OF BIOMOLECULES - A particulate substance comprising particles of a ceramic matrix bearing a functional group, the functional group being capable of promoting penetration of the particles into cells, and a biomolecule disposed within pores of the particles, the biomolecule being releasable from the particles by dissolution of the ceramic matrix. | 10-03-2013 |
20130259943 | AEROSOL COMPOSITION WITH ENHANCED DISPERSION EFFECTS - A stable, high VOC, single phase, non-aqueous liquid aerosol composition having enhanced dispersion based on reduced particle size and increased evaporation rate to result in improved active ingredient dispersion, slower settling in air and less residue on surfaces. The composition includes at least one hydrocarbon propellant, at least one active ingredient and a solvent blend. The solvent blend includes at least one low volatility solvent and at least one high volatility solvent wherein each has a defined vapor pressure and Hansen solubility parameter. The composition upon dispersion as a spray has an aerosol particle size of less than 30 microns. | 10-03-2013 |
20130266652 | LIQUID PHARMACEUTICAL COMPOSITION FOR THE DELIVERY OF ACTIVE INGREDIENTS - The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions. | 10-10-2013 |
20130266653 | MONOVALENT METAL CATION DRY POWDERS FOR INHALATION - The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible. | 10-10-2013 |
20130266654 | METHOD FOR TREATMENT OF ACNE USING PHARMACEUTICAL COMPOSITIONS OF CLINDAMYCIN - The present invention relates to a method for treating, reducing or preventing acne. In particular, the present invention relates to methods for reducing the total number, incidence and severity of acne lesions on the skin which includes both inflammatory and non-inflammatory lesions. Further, the invention relates to reducing the incidence and severity of adverse events resulting from topical application of anti-acne agents resulting in improvement of skin tone. The method includes administering a novel and stable topical anti-acne pharmaceutical composition. | 10-10-2013 |
20130273163 | DRUG-DELIVERY SYSTEMS - The invention relates to novel particulate drug-delivery systems based on a polymer support containing at least one linear, branched or cross-linked polymer in a fraction of over 50 percent by weight in relation to the total weight of the support. The system is characterised in that at least one signal substance for transport through a biological barrier and at least one active ingredient are stored, the support, signal substance and active ingredient having no covalent links and no active-ingredient specific and signal substance specific coordinative links between one another. | 10-17-2013 |
20130273164 | NANOTECHNOLOGY APPROACH FOR INHALATION THERAPIES - This invention relates to lipid nanoparticle compositions and methods for the localized delivery of active agents via inhalation therapy. | 10-17-2013 |
20130273165 | CARNITINE GRANULATE AND METHODS FOR ITS PRODUCTION - Subject of the invention is a method for the production of a carnitine granulate, which includes the steps of | 10-17-2013 |
20130273166 | BREAST ENHANCEMENT ACCELERATOR - A method for enlarging a breast includes the step of administering to a subject in need thereof a composition that includes a fine particle of calcium phosphate. The fine particle of calcium phosphate may be a fine particle of hydroxyapatite. An average particle size of the fine particle of calcium phosphate is 10 to 1,000 nm. The fine particle of calcium phosphate may be a sintered body. The sintered body may be manufactured by a method including: a mixing step in which a primary particle containing calcium phosphate is mixed with a fusion inhibitor, and a sintering step in which the mixed particle obtained by the mixing step defined above is exposed to a sintering temperature. | 10-17-2013 |
20130273167 | SUSTAINED-RELEASE POLYMERIC MICROPARTICLES CONTAINING POORLY WATER-SOLUBLE DRUG AND METHOD FOR PREPARING THE SAME - Disclosed are sustained-release polymeric microparticles containing a poorly water-soluble drug and a method for preparing the same. | 10-17-2013 |
20130280330 | MICROSPHERE DRUG CARRIER, PREPARATION METHOD, COMPOSITION AND USE THEREOF - A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH | 10-24-2013 |
20130280331 | Depot Compositions with multiple drug release rate controls and uses thereof - Injectable depot compositions with dual mechanisms of release rate control are provided for sustained beneficial agent delivery in a patient. The composition includes bioerodible particles and an injectable depot vehicle containing a bioerodible polymer in an organic solvent, for forming a bioerodible depot implant after administration to the patient. The bioerodible particles are dispersed in the depot vehicle and contain a beneficial agent and a release rate controlling agent retarding the release of the beneficial agent from the bioerodible particles and from the depot implant. | 10-24-2013 |
20130280332 | Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients - A method of reducing or treating parainfluenza or influenza virus infection in an immunocompromised patient by administering to the respiratory tract of the patient a composition comprising a therapeutically effective amount of protein having sialidase activity. | 10-24-2013 |
20130280333 | COMPOSITIONS CONTAINING ULTRA-MICRONIZED PALMITOYL-ETHANOLAMIDE - The present invention relates to a composition for pharmaceutical or veterinary use, comprising palmitoylethanolamide. In particular, the present invention relates to a pharmaceutical composition for human or veterinary use, containing a therapeutically efficient amount of palmitoylethanolamide in the ultra-micronized form, wherein more than 90% by weight of palmitoylethanolamide has particle sizes lower than 6 microns, together with pharmaceutically acceptable excipients. | 10-24-2013 |
20130287851 | LIQUID GANAXOLONE FORMULATIONS AND METHODS FOR THE MAKING AND USE THEREOF - In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm. | 10-31-2013 |
20130287852 | COMPOSITIONS FOR NASAL ADMINISTRATION OF PHARMACEUTICALS - Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals. | 10-31-2013 |
20130287853 | COMPOSITIONS AND METHODS FOR NANOPOLYMER-BASED NUCLEIC ACID DELIVERY - Provided herein are p-GlcNAc nanoparticle/nucleic acid compositions. In one aspect, the p-GlcNAc nanoparticle/nucleic acid compositions comprise deacetylated poly-N-acetylglucosamine lactate derivative nanoparticles less than 500 nm and a nucleic acid. Also, provided herein are methods for administering a nucleic acid to a subject, the method comprising administering to the subject a p-GlcNAc nanoparticle/nucleic acid composition. In certain embodiments, the p-GlcNAc nanoparticle/nucleic acid composition is administered subcutaneously to the subject. | 10-31-2013 |
20130287854 | COMPOSITIONS AND USES - According to the invention there is provided a method of treating and/or preventing the symptoms of Parkinson's disease comprising delivering apomorphine, optionally in combination with levodopa and/or a dopamine agonist that is not apomorphine, wherein apomorphine is administered by inhalation. | 10-31-2013 |
20130287855 | COMPOSITIONS BASED ON CLAY AND BEE POLLEN, METHOD FOR PREPARING SAME, AND NUTRITIONAL AND THERAPEUTIC USES THEREOF - The present invention relates to complexes of beepollen and clay, as well as to their preparation methods and to their therapeutic uses or as a food supplement, a functional food, in human and animal healthcare. | 10-31-2013 |
20130295180 | SALT PRODUCT - A method of preparing a salt product comprises the steps of: (i) providing a mixture which comprises salt dissolved in a solvent, said mixture further containing an organic material that is solid under ambient temperature conditions; and (ii) atomising said mixture and evaporating said solvent to produce a salt product comprised of particles of salt incorporating said organic material. The organic material may be a polymer such as a carbohydrate (e.g. maltodextrin or Gum Arabic). Novel salt products are disclosed which comprise hollow particles having a shell formed for individual crystallites of salt. The salt product is useful as a seasoning for food and may be used in lower amounts than conventional salt to provide the same taste. Particular advantages are obtained in the baking of bread. | 11-07-2013 |
20130295181 | COMPOSITIONS BASED ON PROPOLIS NANOCAPSULES WHICH CAN BE USED AS CARRIERS FOR SUBSTANCES OF INTEREST, METHODS FOR PRODUCING SAME AND USE THEREOF - A process for obtaining compositions constituted by propolis nanoparticles is disclosed. The nanoparticles are optionally associated to a substance of interest such as active ingredients, and, optionally, substances of secondary effect such as synergists and adjuvants. The process includes preparing a fraction A, which consists of propolis extract dissolved in an organic solvent, to which stabilizer and/or emulsifier may be added, and, optionally, substances of interest and/or of secondary effect; ii) preparing a fraction B, aqueous phase, constituted by: (ii.1) water; or (ii.2) an aqueous solution or dispersion, to which stabilizer and/or emulsifier may be added; (iii) dropping the fraction A onto the fraction B or vice versa; iv) homogenizing the mixture by stifling and spontaneous formation of nanoparticles with average size from 1 to 1000 nm in a dispersion; and v) optionally (v-1) removing organic solvent and/or (v-2) drying the nanodispersion. | 11-07-2013 |
20130295182 | LIQUID CRYSTALLINE PHYTOSTEROL-GLYCERINE COMPLEX FOR ENHANCED BIOAVAILABILITY AND WATER DISPERSAL - Edible phytosterol-containing compositions include molecular complexes of non-esterified phytosterols (P) and glycerine (G) in the form of liquid crystalline microparticles. Addition of an emulsifier (M) such as a monoglyceride or a modified lecithin, and optionally an ionic surfactant, to the complex facilitates its dispersal in an aqueous medium. A composition containing either the binary PG or ternary PGM molecular complexes can be formulated as a beverage, food product, or nutritional supplement. When administered to a human subject, the complexes sequester cholesterol in the gastrointestinal tract and reduce LDL cholesterol and total plasma cholesterol levels. | 11-07-2013 |
20130295183 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 11-07-2013 |
20130295184 | MEDICAL DEVICES WITH GALVANIC PARTICULATES - Implantable medical devices having galvanic particulates are disclosed. The particulate may be coated onto at least part of a surface of the medical device. In addition, the galvanic particulates may be contained in the material used to manufacture the antimicrobial medical devices, or may be embedded into the surface of the medical devices. The present invention also provides novel coating methods and processing methods. The present invention further provides a combination of galvanic particulates with an aqueous gel, a method of making this combination, and a method of treatment using this combination. The devices and compositions may have advantageous characteristics and effects including anti-microbial, anti-inflammatory, tissue regeneration promoting, and pain reduction or elimination. | 11-07-2013 |
20130295185 | COMPOUNDS AND METHODS FOR INDUCING APOPTOSIS IN CANCER CELLS USING A BH3 ALPHA-HELICAL MIMETIC - A novel BH3 α-helical mimetic, BH3-M6, which binds to Bcl-X | 11-07-2013 |
20130302421 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE CONDITIONS - The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and/or ameliorate autoimmune diseases. | 11-14-2013 |
20130302422 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES - Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof. | 11-14-2013 |
20130302423 | Aerosol Formulation of Aminoglycoside and Fosfomycin Combination for Treatment of Ventilator Associated Pneumonia (VAP) and Ventilator Associated Tracheal (VAT) Bronchitis - The present invention is antibiotic compositions, ventilator-based systems and methods relating to ventilator-associated pneumonia (VAP) and ventilator-associated tracheal (VAT) bronchitis. Antibiotic combinations of fosfomycin and an aminoglycoside, preferably amikacin, are administered via an inline nebulizer within the airway of the ventilator. Humidified conditions create an improved aerosol mist to treat VAP and VAT. | 11-14-2013 |
20130302424 | COMPOSITION FOR PREVENTING AND TREATING MASTITIS - The purpose of the present invention is to reduce the amounts of nitrate nitrogen and ammonia, which can be absorbed through the digestive tract and are factors for causing mastitis in livestock animals, thereby reducing the incidence rate of mastitis. A composition for preventing and treating mastitis for livestock animals comprises a rock powder containing silicic acid and aluminum oxide as active ingredients. When the composition is mixed with feed and the feed is given to livestock animals, nitrogen compounds including ammonia nitrogen and nitrate nitrogen generated in the body of the livestock animals can be chemically adsorbed by aluminum oxide and silicic acid, whereby the over-absorption of the nitrogen compounds through the digestive tract can be suppressed. At the same time, minor elements contained in the rock powder act to fully elicit the activity of a nutritional component capable of suppressing mastitis, e.g., vitamin A, vitamin E, copper, zinc and manganese obtained from the feed. In this manner, the onset of mastitis can be suppressed in a nutritional manner, and a therapeutic effect can be achieved on mastitis that has already been developed. | 11-14-2013 |
20130302425 | HIGHLY DISPERSIBLE POWDERS, COMPOSITIONS AND METHODS FOR PREPARATION - A method for the selection of pharmaceutically acceptable excipients that allow for the production of highly dispersible powders produced by spray drying. | 11-14-2013 |
20130309304 | COMPOUNDS AND METHODS - The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment, methods of treatment administering the same and methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted. In one aspect, the pharmaceutical formulation comprises a hydrogel and one or more growth factors. In one aspect, the hydrogel is ureido-pyrimidinone (UPy). In one aspect, the growth factor is insulin-like growth factor-1 (IGF-1) and hepatocyte growth factor (HGF). | 11-21-2013 |
20130309305 | Sunscreen Compositions Comprising Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same - Aspects of the invention include sunscreen formulations that include uniform, rigid, spherical nanoporous calcium phosphate particles. Also provided are methods of making the sunscreen formulations. The sunscreen formulations find use in sunblocking applications. | 11-21-2013 |
20130309306 | INTRAPULMONARY BENZODIAZEPINE FOR THE TREATMENT AND PREVENTION OF SEIZURES - This invention provides methods for the amelioration, termination and/or abortion of a seizure by the intrapulmonary administration of a benzodiazepine, for example, midazolam. | 11-21-2013 |
20130309307 | Bilayer Pharmaceutical Tablet Comprising Telmisartan and a Diuretic and Preparation Thereof - The present invention relates to a bilayer pharmaceutical tablet comprising a first layer formulated for immediate release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix which contains telmisartan in substantially amorphous form, and a second layer formulated for immediate release of a diuretic like hydrochlorothiazide from a fast disintegrating tablet matrix. A method of producing the bilayer tablet is also disclosed. | 11-21-2013 |
20130309308 | METHOD OF CONVERTING LIMESTONE INTO TRI-CALCIUM PHOSPHATE AND TETRA-CALCIUM PHOSPHATE POWDER SIMULTANEOUSLY - The present invention relates to a method of converting limestone into tri-calcium phosphate (TCP) and tetra-calcium phosphate (TTCP) powder simultaneously. In particular, the method provides for a method of converting limestone into TCP and CTTCP powder simultaneously having specific particle size and with specific crystallographic structure. | 11-21-2013 |
20130315997 | Parenteral Composition Comprising Microspheres With a Diameter Between 10 And 20 Microns - The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment, methods of treatment administering the same and methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted. | 11-28-2013 |
20130315998 | Topical Foam Composition - A topical foam pharmaceutical composition for rectal administration comprising rifaximin is described. Also described is a method of making the composition and the use of the composition as a medicament. | 11-28-2013 |
20130323305 | COMPOSITIONS AND METHODS COMPRISING ENERGY ABSORBING MATERIALS FOR FOLLICULAR DELIVERY - The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets. | 12-05-2013 |
20130323306 | INJECTABLE BIODEGRADABLE PARTICLES FOR CONTROLLED THERAPEUTIC AGENT RELEASE - In accordance with one aspect, embolic particles are provided that comprise a biodegradable polymer and a therapeutic agent, wherein the particles are configured such that, upon administration to a body lumen of a subject, the therapeutic agent is released from the time of administration up until a first point in time that ranges anywhere from about 1 week after administration to about 4 weeks after administration, at which point in time the therapeutic agent release ceases. The particles are also configured such that particles remain present in the body lumen from the first point in time at which therapeutic agent release ceases up to a second point in time that ranges anywhere from about 2 weeks to about 12 months after the first point in time, at which point the particles are completely degraded. Other aspects pertain to methods of making such particles. Still other aspects pertain to injectable compositions that comprise such particles and to methods of treatment that employ such injectable compositions. | 12-05-2013 |
20130323307 | SILDENAFIL-FREE BASE-CONTAINING FILM PREPARATION AND METHOD FOR PRODUCING SAME - The present invention provides a method for preparing a film comprising a high amount of a sildenafil free base uniformly dispersed therein and having a suitable thickness and size, as well as flexibility providing good handling stability and being not prone to breaking. The present invention also provides a sildenafil free base-containing film prepared from the method. | 12-05-2013 |
20130330409 | Dosage Form - The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising; non-stretched melt extruded particulates comprising a drug selected from an opioid agonist, a tranquilizer, a CNS depressant, a CNS stimulant or a sedative hypnotic; and a matrix; wherein said melt extruded particulates are present as a discontinuous phase in said matrix. | 12-12-2013 |
20130337066 | Membrane Encapsulated Nanoparticles and Method of Use - Provided are nanoparticles and methods of using and making thereof. The inventive nanoparticle comprises a) an inner core comprising a non-cellular material; and b) an outer surface comprising a cellular membrane derived from a cell or a membrane derived from a virus. Medicament delivery systems or pharmaceutical compositions comprising the inventive nanoparticles are also provided. Further provided are immunogenic compositions comprising the inventive nanoparticles, and methods of using the inventive immunogenic compositions for eliciting an immune response, and for treating or preventing diseases or condition, such as neoplasm or cancer, or disease or conditions associated with cell membrane inserting toxin. Vaccines comprising the immunogenic composition comprising the nanoparticles are also provided. | 12-19-2013 |
20130337067 | NON-VIRAL NANOPARTICLE-BASED DELIVERY SYSTEM - The present invention concerns a polymeric material for the production of a non-viral nanoparticle. The polymeric material comprises (i) a hydrophilic linear polymer having a first end and a second end, (iii) a cross-linkable cationic polymer covalently bonded to the first end of the hydrophilic linear polymer, and (iii) at least one targeting/penetrating peptide covalently associated to the second end of the hydrophilic linear polymer. Also disclosed herein are nanoparticles produced with these polymeric material, processes for making the polymeric material and the nanoparticles as well as use of the nanoparticles. | 12-19-2013 |
20130337068 | CAROTENOID PARTICLES AND USES THEREOF - This invention relates to the incorporation of bioactive cargo molecules into particles with carotenoids, such as lycopene. The incorporation of a cargo molecule into a carotenoid particle may for example increase the bioavailability of the cargo molecule in the bloodstream compared to other delivery systems. Carotenoid particles as described herein may be useful in the formulation of therapeutic and nutritional compounds for oral administration to individuals. | 12-19-2013 |
20130344152 | PEROXIDE DISPERSIONS - The viscosity of aqueous dispersions of normally solid organic peroxides may be advantageously lowered through the use of surfactants which are polyglyceryl esters of C6-C12 fatty acids. The reduction in viscosity facilitates milling the peroxides to reduce particle size and also provides dispersions of small particle size peroxides which may be readily poured or pumped. The aqueous dispersions are useful as components of pharmaceutical, personal care, and cleaning products and the like and are effective decolorizing agents for food products, industrial products and the like. | 12-26-2013 |
20130344153 | METHOD FOR REDUCING INCIDENCE OR RATE OF DEVELOPMENT OF SKIN CANCERS AND RELATED CONDITIONS - A method for treatment to reduce the incidence or rate of development of skin cancers and related conditions caused by or exacerbated by or associated with UVR-induced skin damage in an immuno-compromised subject, such as an organ transplant patient, comprises the step of administering to said subject an amount of an alpha-MSH analogue effective to protect the skin of the subject from UVR-induced skin damage. | 12-26-2013 |
20140004192 | PHARMACEUTICAL FORMULATIONS OF INDIBULIN AND USES THEREOF | 01-02-2014 |
20140004193 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME | 01-02-2014 |
20140004194 | HIGHLY STABLE COLLOID FROM AQUEOUS SOLUTIONS OF SMALL ORGANIC MOLECULES | 01-02-2014 |
20140004195 | MEDICATED PARTICUALTE ANIMAL FEED SUPPLEMENTS AND METHODS OF PREPARATION | 01-02-2014 |
20140004196 | POLYAMIDE-AMINE DENDRIMER OR DERIVATIVE THEREOF-MATH1 GENE NANO PARTICLE AND USE THEREOF IN TREATMENT OF HEARING LOSS | 01-02-2014 |
20140004197 | O/W-EMULSIONS COMPRISING SEMIFLUORINATED ALKANES | 01-02-2014 |
20140004198 | GLP-1 PARTICLES AND COMPOSITIONS | 01-02-2014 |
20140004199 | DRUG CARRIER FOR TUMOR-TARGETED THERAPY, ITS PREPARATION METHOD AND ITS USE | 01-02-2014 |
20140004200 | POLYMER COMPOSITIONS WITH BIOACTIVE AGENT, MEDICAL ARTICLES, AND METHODS | 01-02-2014 |
20140010880 | Tricalcium Phosphate Coarse Particle Compositions and Methods for Making the Same - Methods for preparing a tricalcium phosphate coarse particle composition are provided. Aspects of the methods include converting an initial tricalcium phosphate particulate composition to hydroxyapatite, sintering the resultant hydroxyapatite to produce a second tricalcium phosphate composition and then mechanically manipulating the second tricalcium phosphate composition to produce a tricalcium phosphate coarse particle composition. The subject methods and compositions produced thereby find use in a variety of applications. | 01-09-2014 |
20140010881 | LOW SURFACTANT IODINE TOPICAL DISINFECTANT - Iodine-containing germicidal compositions are disclosed that remain physically stable for extended storage periods with little to no iodine complexing agent being present. The compositions employ a mixture of emollients, such as glycerin and ethoxylanolin, to create a composition that in certain embodiments presents a cloudy or emulsion-like appearance. | 01-09-2014 |
20140017314 | METHOD FOR MAKING HOMOGENEOUS SPRAY-DRIED SOLID AMORPHOUS DRUG DISPERSIONS UTILIZING MODIFIED SPRAY-DRYING APPARATUS - Conventional spray-drying methods are improved by incorporation of a pressure nozzle and a diffuser plate to improve the flow of drying gas and a drying chamber extension to increase drying time, such improvements leading to the formation of homogeneous solid dispersions of drugs in concentration-enhancing polymers. | 01-16-2014 |
20140017315 | METHODS AND COMPOSITIONS FOR TREEATING PROLIFERATIVE DISEASES - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 01-16-2014 |
20140017316 | METHODS AND COMPOSITIONS FOR TREATING RECURRENT CANCER - The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein. | 01-16-2014 |
20140017317 | METHODS OF TREATMENT OF SOLID TUMORS USING COENZYME Q10 - The invention provides methods and compositions for treatment of a subject with a solid tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject has failed at least one prior chemotherapeutic regimen. | 01-16-2014 |
20140017318 | METHOD TO PRODUCE A MEDICINAL PRODUCT COMPRISING A BIOLOGICALLY ACTIVE PROTEIN AND THE RESULTING PRODUCT - The present invention pertains to a method for producing a medicinal product comprising a biologically active protein comprising the steps of providing an aqueous composition comprising a solvent, the biologically active protein and between 20% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, thereby forming at least one frozen body comprising the solvent in frozen form, putting the frozen body in a drying apparatus while being carried by a support, the support comprising one or more restraining elements that define one or more boundaries of the support, wherein at most 30% of the surface of the body is contiguous with the one or more restraining elements, reducing the pressure in the drying apparatus below atmospheric pressure, providing heat to the body in order to sublimate the frozen solvent of the body and obtain a dried body. The invention also pertains to a product obtainable by this method. | 01-16-2014 |
20140017319 | PROCESS FOR PRODUCING CELLULOSE DERIVATIVES OF HIGH BULK DENSITY AND GOOD FLOWABILITY - A particulate cellulose derivative is obtained in a process of grinding and drying a moist cellulose derivative which comprises the steps of A) providing a cellulose derivative having a moisture content of from 60 to 95 percent, based on the total weight of the moist cellulose derivative, B) grinding and partially drying the moist cellulose derivative in a gas-swept impact mill; and C) contacting the ground and partially dried cellulose derivative with an additional amount of a drying gas outside the gas-swept impact mill. The obtained particulate cellulose derivative has a high untapped bulk density and a good flowability. | 01-16-2014 |
20140017320 | WOUND CARE COMPOSITIONS - A method for treating a wound, and a dressing for wound care management comprising a three-dimensional body of glass-based fibers comprising one or more glass-formers selected from the group consisting of P | 01-16-2014 |
20140023712 | Aqueous Transparent Oil-In-Water Emulsion Comprising an Emulsified Carotenoid - The invention relates to an aqueous transparent oil-in-water emulsion comprising a carotenoid and a process for producing said emulsion. | 01-23-2014 |
20140023713 | CLATHRATE COMPLEX OF CYCLODEXTRIN OR ARABINOGALACTAN WITH 9-PHENYL-SYM-OCTA-HYDROSELENOXANTENE - The invention relates to novel clathrate complexes of cyclodextrin or arabinogalactan with 9-phenyl-sym-octahydroselenoxanthene, possibly in α-crystalline form, The clathrate complex may be in crystalline form, possibly in the form of nano-particles. In the clathrate complex, cyclodextrin is selected from α-, β-, γ- or hydroxypropyl-β-cyclodextrin, primarily β-cyclodextrin. The proposed clathrate complexes make it possible to increase the water-solubility of the active compound, to improve the bioavailability, to reduce the dosage of the drug and, consequently, to reduce the toxic effect of 9-phenyl-sym-octahydroselenoxanthene. The complexes exhibit cytoradioprotective activity. The invention also relates to a liquid-phase and solid-phase methods for producing clathrate complexes, as well as to pharmaceutical compositions and drugs thereof. | 01-23-2014 |
20140023714 | HEMOSTATIC COMPOSITIONS - The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device. | 01-23-2014 |
20140030335 | CERIUM OXIDE NANOPARTICLES FOR THE TREATMENT AND PREVENTION OF STROKE AND CARDIOVASCULAR DISEASE - A method of treating or preventing neurological injury in a subject who has suffered a stroke is described. The method includes administering a therapeutically effective amount of cerium oxide nanoparticles to the subject. Methods for prophylaxis against neurological injury from stroke, and methods for treating or preventing cardiovascular disease by administration of a therapeutically effective amount of cerium oxide nanoparticles are also described. | 01-30-2014 |
20140030336 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE DISORDERS - A pharmaceutical composition for the treatment or acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders. | 01-30-2014 |
20140030337 | COMPOSITION FOR A TOPICAL OPHTHALMIC CLEAR COLLOIDAL LIQUID WHICH UNDERGOES A LIQUID-GEL PHASE TRANSITION IN THE EYE - The present invention is directed to a topical ophthalmic composition for a liquid comprised of clear colloidal polar nanolipids delivered in submicron sized particles, aqueous colloidal lubricants, aqueous polymers, emulsifies, and a unique stabilizing buffer system, which undergoes a liquid-gel phase transition in the eye. Said composition is designed to deliver advanced eye lubricants, protect the three (3) layers of corneal film from dryness, and provide a unique system of Dry Eye treatment that addresses and treats all three layers of corneal tear film. Said composition is further designed to provide a superior delivery system of various Active Pharmaceutical Ingredients (APIs), and/or anti-infective/antibiotic/anti-fungal agents, accepted as safe and efficacious for ophthalmic use. | 01-30-2014 |
20140030338 | PRODUCT - A synthetic bone substitute, includes a mixture of osteoconductive particles of first and second average particle sizes, suspended in a water-soluble reverse-phase hydrogel carrier in which the first average particle size is less than about 100 μm, and the second average particle size is about 100-500 μm. A method of producing the same is also described. | 01-30-2014 |
20140030339 | GRAFTED PARTICLES FOR USE IN SKIN CARE APPLICATIONS - A skin care formulation includes a dispersion or emulsion including at least one particle-polymer hybrid and a cosmetically acceptable additive. The polymer-particle hybrid includes at least one particle grafted with at least one polymer. The skin care formulation provides improved water-resistance with limited impact on the sensory feel of the formulation (such as tackiness). | 01-30-2014 |
20140030340 | PREPARATION OF DRUG PARTICLES USING EVAPORATION PRECIPITATION INTO AQUEOUS SOLUTIONS - A method for preparing poorly water soluble drug particles is disclosed. The method comprises dissolving a drug in at least one organic solvent to form a drug/organic mixture, spraying the drug/organic mixture into an aqueous solution and concurrently evaporating the organic solvent in the presence of the aqueous solution to form an aqueous dispersion of the drug particles. The resulting drug particles are in the nanometer to micrometer size range and show enhanced dissolution rates and reduced crystallinity when compared to the unprocessed drug. The present invention additionally contemplates products and processes for new drug formulations of insoluble drug particles having high dissolution rates and extremely high drug-to-excipient ratios. | 01-30-2014 |
20140030341 | POLYMERS AND METHODS FOR THE TREATMENT OF PAIN - Polymers, microspheres, and associated methods are presented for the treatment of chronic and acute pain. An anhydride polymer comprising a biodegradable backbone that comprises one or more pendant residues of a non-steroidal anti-inflammatory (NSAID). NSAIDs may be incorporated in to the polymers as pendant groups that are not part of the polymer backbone. The polymer comprises repeating units that form the biodegradable backbone, wherein in each repeating unit comprises a pendant residue of the NSAID. | 01-30-2014 |
20140030342 | PROCESS FOR PRODUCING AN IMMUNOGENIC COMPOSITION CONTAINING TETANUS TOXOID - The present invention relates to the field of vaccines for protecting against tetanus, and in particular processes for the production of vaccines comprising tetanus toxoid adsorbed onto aluminium salts. Processes are provided whereby tetanus toxoid is absorbed onto aluminium salt adjuvant having defined characteristics for optimal results. | 01-30-2014 |
20140037732 | METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT - This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF. | 02-06-2014 |
20140037733 | FOOD SUPPLEMENT AND INJECTABLE MATERIAL FOR PROPHYLAXIS AND THERAPY OF OSTEOPOROSIS AND OTHER BONE DISEASES - The invention relates to the application of inorganic polyphosphates (polyP) and complexes of polyP and calcium [polyP (Ca | 02-06-2014 |
20140037734 | UNIFORM FILMS FOR RAPID DISSOLVE DOSAGE FORM INCORPORATING TASTE-MASKING COMPOSITIONS - The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method. | 02-06-2014 |
20140037735 | INHALABLE AZTREONAM FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS - A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by | 02-06-2014 |
20140037736 | Targeting of Antigen Presenting Cells With Immunonanotherapeutics - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface. The nanocarriers are capable of targeting antigen presenting cells when administered to a subject. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 02-06-2014 |
20140037737 | PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION - The invention provides a method of making a composition for inhalation which includes the step of mixing particles of additive material having a diameter of not more than 2 μm with active particles, wherein the additive material is suitable for promoting the dispersal of active particles upon aerolisation of a dry powder in a dry powder inhaler. | 02-06-2014 |
20140044785 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 02-13-2014 |
20140044786 | ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE - An orally deliverable pharmaceutical composition provides controlled release of aripiprazole. The composition includes a therapeutically effective amount of aripiprazole and at least one pharmaceutically acceptable excipient. The compositions of the invention may exhibit one or more of the release profiles defined in the specification. | 02-13-2014 |
20140044787 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS - The present application discloses a sustained release composition in pellet form, wherein the core of the pellet comprises:
| 02-13-2014 |
20140044788 | Solid Oral Formulations of a Pyridopyrimidinone - A solid oral dosage pharmaceutical formulation of (R)-2-Amino-7-[4-fluoro-2-(6-methoxy-pyridin-2-yl)-phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one or its salt; and a surfactant or an acid. | 02-13-2014 |
20140044789 | MELANIN NANOSHELLS FOR PROTECTION AGAINST RADIATION AND ELECTRONIC PULSES - This invention provides melanin nanoshells and their use for protection against radiation, particularly ionizing radiation, and electronic pulses, and methods of making materials comprising melanin nanoshells. | 02-13-2014 |
20140044790 | APPARATUS AND METHOD FOR CRYOGRANULATING A PHARMACEUTICAL COMPOSITION - Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing. | 02-13-2014 |
20140050788 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions composed of micronized placental components, extracts of micronized placental components, and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions and the extracts thereof are also described herein. | 02-20-2014 |
20140050789 | MITIGATION OF EPILEPTIC SEIZURES BY COMBINATION THERAPY USING BENZODIAZEPINES AND NEUROSTEROIDS - Provided are compositions comprising a benzodiazepine and a neurosteroid, containing one or both of the benzodiazepine and the neurosteroid in a subtherapeutic dose, and administration of such compositions for mitigation of an epileptic seizure. Further provided are compositions comprising a benzodiazepine, a neurosteroid, and an NMDA blocker, and administration of such compositions for mitigation of an epileptic seizure. | 02-20-2014 |
20140050790 | TRITERPENE-CONTAINING OLEOGEL-FORMING AGENT, TRITERPENE-CONTAINING OLEOGEL AND METHOD FOR PRODUCING A TRITERPENE-CONTAINING OLEOGEL - The invention relates to an oleogel-forming agent which comprises at least one highly dispersed triterpene. The invention also relates to an oleogel which comprises a nonpolar liquid in an amount ranging from 80% by weight to 99% by weight based on the total weight of the oleogel and an oleogel-forming agent comprising a highly dispersed triterpene in an amount ranging from 1% by weight to 20% by weight based on the total weight of the oleogel. The invention also relates to a method for producing an oleogel. | 02-20-2014 |
20140050791 | Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size - The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The inventions further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention. | 02-20-2014 |
20140050792 | TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT - An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. | 02-20-2014 |
20140056981 | METHOD FOR PRODUCING DRUG-LOADED POLYMERIC NANOPARTICLES BY POLYMERIZATION IN PRESENCE OF DRUGS - A method for producing drug-loaded polymeric nanoparticles, which includes the steps of: (a) preparing a first solution by dissolving a drug in a polymerizable monomer; (b) preparing a micellar solution by dissolving a surfactant and a water-soluble radical initiator in water; (c) adding said first solution to said micellar solution for polymerizing said polymerizable monomer, obtaining a dispersion of drug-loaded polymeric nanoparticles, the drug-loaded polymeric nanoparticles have a controlled size with average diameter smaller than 50 nm; and (d) evaporating residual polymerizable monomer from the dispersion of drug-loaded polymeric nanoparticles. | 02-27-2014 |
20140056982 | Enhanced Carriers For The Delivery of Microparticles To Bodily Tissues And Fluids - Improved compositions for tissue augmentation are provided. These compositions comprise an amount of crosslinked material sufficient to provide a melt temperature (T | 02-27-2014 |
20140065219 | Inhalable Pharmaceutical Compositions - Methods for making inhalable composite particles comprising a pharmaceutically-active agent, the method comprising: a) providing composite particles comprising a millable grinding matrix and a solid pharmaceutically-active agent, wherein the pharmaceutically-active agent has an median particle size on a volume average basis between 50 nm and 3 μm; and b) milling the composite particles in a mill without milling bodies for a time period sufficient to produce inhalable composite particles having a mass median aerodynamic diameter between 1 μm and 20 μm are described. | 03-06-2014 |
20140065220 | BINDER FOR FORMING TABLETS - The present invention relates to a novel binder having high bondability and fluidity. The binder of the present invention has a BET specific surface area of 80 to 400 m | 03-06-2014 |
20140065221 | COMPOSITIONS COMPRISING A FILLER PRODUCT AND AT LEAST ONE BIORESORBABLE AND BIODEGRADABLE SILICA-BASED MATERIAL - A combination product including at least one filler product and at least at least one bioresorbable and biodegradable silica-based material, for treating incontinence or treating aging of the skin and scars. Also, a composition including, in a physiologically acceptable medium, at least one filler product and at least at least one bioresorbable and biodegradable silica-based material. | 03-06-2014 |
20140065222 | NOVEL PREPARATION TECHNIQUE FOR HIGHER-ORDER STRUCTURE THAT EXHIBITS ANTICELLULAR EFFECT - Disclosed is a novel means by which cyanoacrylate polymer particles still more useful as an antibacterial agent, an anticancer agent, etc., than conventional particles. The method for production of cyanoacrylate polymer particles according to the present invention comprises anionically polymerizing a cyanoacrylate monomer(s) in the presence of at least one selected from the group consisting of amino acids, amino acid derivatives, and oligomers and polymers thereof, and substantially in the absence of a saccharide and substantially in the absence of a polysorbate. Cyanoacrylate nanoparticles containing an amino-based molecule(s) exhibit their cell-damaging activity via specific adhesion to cells, and effectively inhibit the growth of cancer cells and bacteria. Their cell-damaging activity can be further increased by producing the nanoparticles by the above-mentioned novel production method. | 03-06-2014 |
20140065223 | PERFLUORINATED COMPOUNDS FOR THE NON-VIRAL TRANSFER OF NUCLEIC ACIDS - The invention relates to a compound of general formula (I): A-B-C(F, G′)-D-E-F-G-A′ or a structure of general formula (II): A-B-C-(F′, G′)-D-B-E-F-G-A′ (II), wherein -A is at least one molecule selected from the group of the perfluorocarbons (PFCs), perfluorinated silicon compounds, and/or further perfluorinated compounds, -B is at least one predetermined breaking point in the form of a physically, chemically, or enzymatically severable bond, -C is absent or at least one linker molecule, -D is absent or at least one spacer molecule, -E is at least one molecule selected from the group containing nucleobases, nucleosides, nucleotides, oligonucleotides, nucleic, acids, modified nucleobases, modified nucleosides, modified nucleotides, modified oligonucleotides, modified nucleic acids, monomers of peptide nucleic acids, oligomers or peptide nucleic acids and peptide nucleic acids or other nucleic acid analogs, -F, F′ is absent or at least one ligand, -G, G′ is absent or at least one marker molecule, -A′ is absent or has the meaning of A, and wherein the compounds i), ii), iii), iv), v), vi) are excluded. The invention farther relates to the use of said compound for the non-viral transfer of molecule E into a cell, to a pharmaceutical composition containing said compound, and to the use of said pharmaceutical composition. | 03-06-2014 |
20140065224 | CRYSTALLINE N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINY- L)PHENYL]ACETAMIDE MONO MESYLATE MONOHYDRATE HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION RANGE AND A SPECIFIC SURFACE AREA RANGE FOR USE IN PHARMACEUTICAL FORMULATIONS - The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range. Moreover, the present invention relates to the pharmacokinetic and pharmacodynamic in vivo profiles of the resultant free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide after administration of the afore-mentioned crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide mono mesylate monohydrate salt to a subject in need thereof. | 03-06-2014 |
20140065225 | Modified release compositions comprising tacrolimus - A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents. | 03-06-2014 |
20140072630 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS - The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a hedgehog inhibitor that inhibits a hedgehog signaling pathway. | 03-13-2014 |
20140072631 | COMBINATIONS AND MODES OF ADMINISTRATION OF THERAPEUTIC AGENTS AND COMBINATION THERAPY - The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that inhibits a pro survival and/or inflammatory signal. | 03-13-2014 |
20140072632 | METHODS FOR FABRICATING ISOLATED MICRO- OR NANO-STRUCTURES USING SOFT OR IMPRINT LITHOGRAPHY - The presently disclosed subject matter describes the use of fluorinated elastomer-based materials, in particular perfluoropolyether (PFPE)-based materials, in high-resolution soft or imprint lithographic applications, such as micro- and nanoscale replica molding, and the first nano-contact molding of organic materials to generate high fidelity features using an elastomeric mold. Accordingly, the presently disclosed subject matter describes a method for producing free-standing, isolated nanostructures of any shape using soft or imprint lithography technique. | 03-13-2014 |
20140072633 | POLYMER-EPOTHILONE CONJUGATES, PARTICLES, COMPOSITIONS AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer or neurological deficits. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 03-13-2014 |
20140072634 | CONTINUOUS SILICA PRODUCTION PROCESS AND SILICA PRODUCT PREPARED FROM SAME - Disclosed herein is a continuous process for preparing a silica product, comprising: (a) continuously feeding an acidulating agent and an alkali metal silicate into a loop reaction zone comprising a stream of liquid medium; wherein at least a portion of the acidulating agent and the alkali metal silicate react to form a silica product in the liquid medium of the loop reaction zone; (b) continuously recirculating the liquid medium through the loop reaction zone; and (c) continuously discharging from the loop reaction zone a portion of the liquid medium comprising the silica product. Silica products and dentifrice compositions comprising the silica products are also disclosed. A continuous loop reactor is also disclosed. | 03-13-2014 |
20140072635 | THYROID HORMONE ANALOGS AND METHODS OF USE - Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed. | 03-13-2014 |
20140072636 | BULKING AGENTS - The invention relates to bulking agents and apparatus and methods for using the disclosed bulking agents. The bulking agents can be used to treat such conditions as urinary and fecal incontinence, gastro-esophageal reflux, ancurismal blockages, and cosmetic deformities. The invention also relates to an injection method that reduces the injection pressure required to place the bulking agents. | 03-13-2014 |
20140079782 | PARTICULATE MATERIALS - The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process. | 03-20-2014 |
20140079783 | Pharmaceutical Compositions Comprising Rifaximin and Amino acids, Preparation Methods and Use Thereof - The present invention relates to rifaximin compositions comprising amino acids, characterized in that they increase rifaximin solubility in aqueous solutions and are useful in the treatment of disease wherein amino acids and rifaximin are efficacious. The present invention also relates to pharmaceutical compositions comprising rifaximin or one of the pharmaceutically acceptable salts thereof and one or more amino acid(s), wherein the molar ratio between the amino acid(s) and rifaximin is from 1:1 to 10:1, together with pharmaceutically acceptable excipients. The present invention further relates to rifaximin crystals obtained by dissolving rifaximin and amino acids in solutions formed by ethanol/water and evaporating the solution. | 03-20-2014 |
20140079784 | AEROSOLIZED LFA-1 ANTAGONISTS FOR USE IN LOCALIZED TREATMENT OF IMMUNE RELATED DISORDERS - This invention provides specifically formulated LFA-1 antagonists or pharmaceutically acceptable salts thereof that are suitable for aerosolized delivery. In particular, the LFA-1 antagonists are particularly well suited for localized treatment by having a rapid systemic clearance rate. The invention also encompasses methods of treatment and prevention of immune related disorders using the LFA-1 aerosolized formulations of the present invention. | 03-20-2014 |
20140079785 | COMPOSITION COMPRISING LIPID NANOPARTICLES AND A CORTICOSTEROID OR VITAMIN D DERIVATIVE - A pharmaceutical composition comprises, as a therapeutically active ingredient, a corticosteroid and/or vitamin D derivative incorporated as a solid solution or dispersion in lipid nanoparticles, said lipid nanoparticles being solid at ambient temperature and comprising a first lipid with a melting point above body temperature, the first lipid being a wax selected from the group consisting of esters of C | 03-20-2014 |
20140086990 | SUSTAINED RELEASE SMALL MOLECULE DRUG FORMULATION - An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having C | 03-27-2014 |
20140086991 | Controlled Agglomeration - A process for the preparation of a particu 1265 late material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5 DEG C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material. | 03-27-2014 |
20140086992 | Storage-Stable Dust-Free Homogeneous Particulate Formulation - Described is a storage-stable dust-free homogeneous particulate formulation. The formulation consists of (a) at least one water-soluble Vitamin E-derivative, (b) at least one hydrophilic polymer, (c) optionally additional surface-active substances, and (d) optionally additional pharmaceutical additives. The sum of (a), (b), (c) and (d) equals 100% by weight of the formulation. The fines fraction with particle diameters of less than 100 μm is less than 10% by weight. Describe also is a process for manufacturing the formulation, and use of the formulation as a solubilizing composition in pharmaceutical formulations. | 03-27-2014 |
20140086993 | Storage-Stable Dust-Free Homogeneous Particulate Formulation Comprising At Least One Water-Soluble Vitamin E-Derivative And At Least One Hydrophilic Polymer - A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble Vitamin E-derivative and at least one hydrophilic polymer. In one embodiment the storage-stable dust-free homogeneous particle formulation, consists of
| 03-27-2014 |
20140086994 | Synthesis of Small Particles - The invention provides an apparatus for forming fine particles of a substance in a precipitation chamber, in which the apparatus has means to convey the fine particles from the precipitation chamber to at least one particle collection chamber, downstream of the precipitation chamber, the particle collection chamber having an inlet and an outlet separate from the inlet. The invention also provides a method of forming fine particles of a substance, the method comprising contacting a non-gaseous fluid containing the substance with a dense fluid to expand the non-gaseous fluid in a precipitation chamber, conveying a resulting mixture of fluid and the fine particles from the precipitation chamber to a collection chamber, the collection chamber having an inlet and an outlet separate from the inlet. | 03-27-2014 |
20140086995 | POLYMER MICROSPHERE COMPOSITIONS FOR LOCALIZED DELIVERY OF THERAPEUTIC AGENTS - Compositions and methods for localized delivery of a therapeutic agent to a biological tissue over time. The composition includes a temperature-responsive polymer and one or more microspheres, each having degradation rate different from the other, and each comprising a therapeutic agent. In the method, the composition is applied to a biological tissue and forms a gel that adheres to the tissue. | 03-27-2014 |
20140093570 | Solid Oral Formulations and Crystalline Forms of an Inhibitor of Apoptosis Protein - The present disclosure relates to crystalline form of (S)—N—((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluorobenzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, salts and hydrates thereof. This disclosure also relates to solid oral formulation of (S)—N—((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluoro-benzoyl)-thiazol-2-yl]-pyrrolidin-1-yl}-2-oxo-ethyl)-2-methylamino-propionamide, pharmaceutically acceptable salts, solvates (including hydrates) thereof, as well as methods of treatment using the same. | 04-03-2014 |
20140093571 | KNEADABLE AND PLIABLE BONE REPLACEMENT MATERIAL - A kneadable and moldable bone-replacement material includes a mixture of calcium-containing ceramic particles and a hydrogel or a substance which can be swelled into a hydrogel. The ceramic particles are of fully synthetic origin and the individual ceramic particles have a structure which is at least partially cohesive and porous. In addition, the majority of the ceramic particles have a non-spheric shape. | 04-03-2014 |
20140093572 | ACTIVE MATERIALS FOR PREVENTION AND TREATMENT OF FOULED SURFACES - A method, composition and structure to treat fouling. In one embodiment, the method of treating fouling includes providing a structure including a first component of a base material and a second component of an energetically activated nanostructure, and applying a stimuli to the structure that effectuates an increase or decrease in the temperature of the energetically activated nanostructure. The increase or decrease in the temperature of the energetically activated nanostructure modifies the chemical and/or mechanical properties of the base material. The modifications to the chemical and/or mechanical properties of the base material obstruct fouling of the structure. | 04-03-2014 |
20140099371 | MEDICINAL CARRIERS, AND PREPARATION METHOD AND USES THEREOF - A medicinal carrier is provided. The medicinal carrier comprises a first component, which is a biocompatible polymer with an amino group (—NH | 04-10-2014 |
20140099372 | CRYSTALLINE MICROSPHERES AND THE PROCESS OF MANUFACTURING THE SAME - The present invention relates to microspheres comprising a core material, wherein the microsphere is perfectly spherical and has a moisture content less than 1%, and the method of manufacturing the same. The present invention is useful in the manufacture of sustained and modified release active pharmaceutical ingredient (API) microspheres, as a free flowing excipient for mini-tablets and in the manufacture of API dispersions. | 04-10-2014 |
20140099373 | CLAY PRODUCT AND USES THEREOF - The present invention relates to a combination of an anti-toxin, The present invention relates to a combination of an anti-toxin, an immunomodulator and a component that provides energy to mucosal cells, which may be useful for decreasing effects of | 04-10-2014 |
20140099374 | BIORESORBABLE EMBOLIZATION MICROSPHERES - The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin. | 04-10-2014 |
20140099375 | METHODS OF THERAPEUTIC TREATMENT OF EYES - Provided are electrokinetically-altered aqueous fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating an irritation, infection or inflammatory eye condition, comprising administering to, by contacting the eye of a subject in need thereof a therapeutically effective amount of an electrokinetically-altered aqueous fluid. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids) and therapeutic compositions for use in treating eye conditions. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids to treat a cosmetic and/or therapeutic symptom related to eye conditions and/or diseases. | 04-10-2014 |
20140105980 | METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS AND RELATED DISORDERS - This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen. | 04-17-2014 |
20140105981 | PREVENTATIVE SOLUTION AND METHOD OF USE - A preventative solution includes an aqueous base, 1 wt % to 6 wt % titanium dioxide having an average particle size of not greater than 100 nm, 0.5 wt % to 20 wt % alcohol having 2 to 4 carbons, and 3 wt % to 15 wt % of a binding agent. The preventative solution can be dispersed using a fogger, for example, sequentially with an odor neutralizing solution or a disinfectant solution. | 04-17-2014 |
20140105982 | SILVER NANOPLATE COMPOSITIONS AND METHODS - Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoplates, such as silver nanoplates or silver platelet nanoparticles, and to nanoparticles, solutions and substrates prepared by said methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates. The process can also include increasing the concentration of silver nanoplates within the solution, and thus increasing the solution optical density. | 04-17-2014 |
20140105983 | Pulmonary Delivery for Levodopa - In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung. | 04-17-2014 |
20140105984 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS - This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions. Also encompassed by the invention are compositions comprising a nanoparticulate active agent, at least one surface stabilizer and a flake-like aggregation reducing agent, such as a buffer and a sugar. The nanoparticulate active agent compositions comprise particles of the active agent having an effective average particle size of less than about 2000 nm. | 04-17-2014 |
20140105985 | TOPICAL USE OF LEVOFLOXACIN FOR REDUCING LUNG INFLAMMATION - The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided. | 04-17-2014 |
20140105986 | TOPICAL COMPOSITIONS - Provided herein are anhydrous compositions that include at least one viscosity increasing agent, at least one organic solvent and at least one humectant. Such compositions may also include at least one active pharmaceutical ingredient (API) and/or at least one water repellant. Related compositions, methods and kits are also provided. | 04-17-2014 |
20140112991 | TOPICAL STEROID COMPOSITION AND METHOD - Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include a halobetasol material comprising halobetasol or its pharmaceutically acceptable salts, esters, and solvates; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. Storage stable, topical lotion compositions for treating corticosteroid-responsive dermatoses are provided by the present invention which include 0.05% halobetasol propionate; and a pharmaceutically acceptable carrier which includes: (a) one or more fatty alcohols and/or one or more alkoxylated fatty alcohols, (b) one or more polyol humectants, and (c) diisopropyl adipate. | 04-24-2014 |
20140112992 | PROCESS FOR FEBUXOSTAT - The present invention provides a process for the preparation of 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester. The present invention also provides a process for the preparation of 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester. The present invention further provides novel crystalline Forms of febuxostat, processes for their preparation and pharmaceutical compositions comprising them. The present invention further provides febuxostat crystalline particles having a mean particle size of less than about 25 μm, the methods for the manufacture of said crystalline particles, and pharmaceutical compositions comprising said crystalline particles. | 04-24-2014 |
20140112993 | FREEZE-DRIED ARIPIPRAZOLE FORMULATION - An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water. The present invention provides a freeze-dried aripiprazole formulation obtained by a process comprising the steps of spraying for freezing an aripiprazole suspension containing (I) aripiprazole, (II) a vehicle for the aripiprazole, and (III) water for injection, and drying | 04-24-2014 |
20140120165 | CORTICOSTEROID PARTICLES AND METHOD OF PRODUCTION - A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area. | 05-01-2014 |
20140120166 | COMPOSITION OF ENTACOPONE - A composition of entacapone comprising entacapone or pharmaceutically acceptable salts, PVPK30 and SDS is disclosed in the present invention, wherein the mass ratio of entacapone: PVPK30: SDS is 1:0.05-0.6:0.06-0.1. The present invention also discloses preparative method and use of the composition of entacapone. | 05-01-2014 |
20140127301 | Adjuvant Incorporation in Immunonanotherapeutics - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof. | 05-08-2014 |
20140127302 | Analgesic Pharmaceutical Composition For Oral Administration - The disclosed analgesic pharmaceutical composition for oral administration is characterised in that it contains an opioid and a pharmaceutically admissible magnesium (II) compound, possibly along with one or more pharmaceutically admissible ancillary substances. | 05-08-2014 |
20140127303 | SUSTAINED-RELEASE COMPOSITION CONTAINING PEPTIDES AS ACTIVE INGREDIENT - The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium. | 05-08-2014 |
20140134251 | PHARMACEUTICAL FORMULATIONS AND METHODS FOR TREATING RESPIRATORY TRACT INFECTIONS - The present invention relates to pharmaceutical formulations for treating a respiratory tract infection or a pulmonary disease in an individual, comprising a calcium salt and a sodium salt, wherein the ratio of Ca | 05-15-2014 |
20140134252 | TOPICAL PHARMACEUTICAL FORMULATIONS CONTAINING A LOW CONCENTRATION OF BENZOYL PEROXIDE IN SUSPENSION IN WATER AND A WATER-MISCIBLE ORGANIC SOLVENT - An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. | 05-15-2014 |
20140134253 | DRY POWDER FOSFOMYCIN/TOBRAMYCIN FORMULATION FOR INHALATION - The present invention provides an inhaled dry powder formulation containing a combination of fosfomycin salt and tobramycin-leucine compound particles. The use of such formulation for the treatment of patients who have Chronic Obstructive Pulmonary Disease (COPD) and who are experiencing or at risk of experiencing acute exacerbation, as well as patients who have other bacterial infections of the respiratory tract, particularly the lower respiratory tract, and methods for treating the same are also provided. | 05-15-2014 |
20140134254 | METHOD FOR PRODUCING POWDERS FOR INHALATION - A method for producing powders for inhalation includes a first mixing step of stirring a first active ingredient and a carrier in the presence of a milling medium, and mixing the first active ingredient and the carrier while crumbling the agglomerates of the first active ingredient to obtain a mixture of the carrier and the first active ingredient; and a second mixing step of adding fine powders to the mixture obtained in the first mixing step, and stirring and mixing the mixture and the fine powders in the presence of a milling medium. | 05-15-2014 |
20140134255 | Oil-In-Water-Type Emulsion Cosmetic - The present invention is to provide an oil-in-water emulsion cosmetic having excellent in emulsion stability, temporal emulsion stability, and feeling in use such as the free of stickiness. An oil-in-water emulsion cosmetic is characterized by comprising the following components (a) to (d):
| 05-15-2014 |
20140141083 | NANOPARTICULATE MELOXICAM FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm. | 05-22-2014 |
20140141084 | HYPOXIA-RESPONSIVE NANOPARTICLE FOR THERAPY AND IMAGING OF HYPOXIA-INVOLVING DISEASES - The present invention relates to an amphiphilic polymer whose property and structure can change under hypoxic conditions, and to nanoparticles formed by self-assembly of the amphiphilic polymer. The hypoxia-responsive nanoparticles according to the present invention release a drug selectively under hypoxic conditions. Thus, the nanoparticles can be used for the selective diagnosis and treatment for diseases that are accompanied by hypoxia. Particularly, the nanoparticles can release a drug only to a targeted tumor in cancer therapy, and thus have minimized side effects and maximized therapeutic effects. | 05-22-2014 |
20140141085 | TRACER PARTICLES, AND METHODS FOR MAKING SAME - The invention relates generally to tracer particles for product identification and/or authentication. When incorporated into a manufactured item, that item can be subsequently authenticated by either detecting, or failing to detect, the tracer particle. The tracer particles of the invention are magnetically attractable, with micromarkings, and in some embodiments, are manufactured with food grade materials and of a particle size suitable for ingestion by humans. The particles can be analyzed qualitatively or quantitatively. In other aspects, the invention provides methods for the manufacture of the tracer particles, and in other aspects, provides methods for using the particles. Examples of products that can be tagged using the tracer particles of the invention include pharmaceuticals, animal feeds or feed supplements, and baby formula. Other applications include forensics, such as in explosive materials. | 05-22-2014 |
20140141086 | Injectable Depot Compositions and Uses Thereof - Injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having a miscibility in water of less than or equal to 7 wt. % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith, a thixotropic agent, and a beneficial agent. The solvent comprises an aromatic alcohol, an ester of an aromatic acid, an aromatic ketone, or mixtures thereof. The compositions have substantially improved the shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patients body surface by injection. | 05-22-2014 |
20140141087 | Oral Composition Comprising An Antacid, an Anaesthetic and an Inorganic Matrix Comprising Silicon Dioxide and Titanium Dioxide - The invention provides an oral composition comprising a pharmaceutically acceptable carrier, at least one antacid, an inorganic matrix comprising at least silicon dioxide and titanium dioxide, and an anaesthetic, wherein the composition is substantially evenly dispersed in the carrier and is palatable. | 05-22-2014 |
20140147503 | Pharmaceutical Composition Comprising Deferasirox - The present invention relates to a pharmaceutical composition comprising deferasirox, a process for preparing such pharmaceutical composition, and its use in the treatment of chronic iron overload. The pharmaceutical composition comprises nanosized deferasirox having improved surface area and solubility. It also relates to a method for treatment of chronic iron overload which comprises administering a pharmaceutical composition comprising nanosized deferasirox. | 05-29-2014 |
20140147504 | TETRACYCLINE TOPICAL FORMULATIONS, PREPARATION AND USES THEREOF - The invention relates to a topical suspension formulation that includes a tetracycline, a liquid medium and a polymeric gelling agent. The tetracycline may be in the form of its pharmaceutically acceptable salts, hydrates, or polymorphs and is in a suspended form within the formulation. The liquid medium is selected such that it does not dissolve or substantially minimally dissolves the tetracycline. The gelling agent is a polymeric hydrocarbon gelling agent. Preferably, the tetracycline has a particle size of less than or equal to about 20 microns. | 05-29-2014 |
20140147505 | SOLID PHARMACEUTICAL DOSAGE FORM OF TICAGRELOR - The present invention relates to a solid pharmaceutical dosage form comprising ticagrelor as pharmaceutically active ingredient, to certain particles of ticagrelor and to processes of preparing the same. | 05-29-2014 |
20140147506 | Delivery of Submicrometer and Nanometer Aerosols to the Lungs using Hygroscopic Excipients or Dual Stream Nasal Delivery - Pharmaceutically engineered aerosols (e.g. submicrometer and nano-particles and droplets) containing a hygroscopic growth excipient or agent are employed to improve the delivery of respiratory aerosols to the lung. Inclusion of the hygroscopic agent results in near zero depositional loss in the nose-mouth-throat regions and near 100% deposition of the aerosol in the lung. Targeting of the aerosol to specific lung depths is also possible. In addition, methods and apparatuses for delivering aerosols to the lung are provided. The aerosol is delivered to one nostril of a patient while a relatively high humidity gaseous carrier is delivered to the other nostril, resulting in post-nasopharyngeal growth of the aerosol to a size that promotes deposition in the lung. | 05-29-2014 |
20140154322 | FOR INJECTABLE FORMULATIONS CONTAINING ASENAPINE AND METHOD OF TREATMENT USING SAME - The present invention provides a formulation comprising asenapine hemipamoate suspended particles, which formulation can be administered via a Depot provided by an IM injection of the formulation, and which depot does not display a particle-size dependent release rate. The present invention provides also methods of treatment using the same. | 06-05-2014 |
20140154323 | METHOD FOR TREATING BRONCHIAL DISEASES - Administration of a loop diuretic in nebulized dry powder form directly to a patient's lungs for treating bronchial disease. | 06-05-2014 |
20140161881 | REDUCED DOSE PHARMACEUTICAL COMPOSITIONS OF FENOFIBRATE - The present invention provides a reduced dose oral pharmaceutical composition comprising mixture of nanoparticulate fenofibrate and micronized fenofibrate and one or more pharmaceutically acceptable excipients. | 06-12-2014 |
20140161882 | METHODS OF THERAPEUTIC TREATMENT OF EYES AND OTHER HUMAN TISSUES USING AN OXYGEN-ENRICHED SOLUTION - Particular embodiments disclosed herein relate to electrokinetically altered gas-enriched fluids, methods of making the same, systems for making the same and/or methods of treatment utilizing the gas-enriched fluids for eye related conditions and/or diseases. In certain embodiments, the electrokinetically altered gas-enriched fluid is oxygen-enriched water. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids to treat a cosmetic and/or therapeutic symptom related to eye conditions and/or diseases. | 06-12-2014 |
20140161883 | Cosmetic Compositions With Near Infra-Red (NIR) Light - Emitting Material And Methods Therefor - Cosmetic or dermatological compositions and substrates, containing a NIR light-emitting material, and methods for stimulating healing and/or regenerative properties in the skin, hair and/or scalp are provided. | 06-12-2014 |
20140161884 | Multistage Nanoparticle Drug Delivery System for the Treatment of Solid Tumors - Nanoparticles for a selective, two stage delivery to tumors have been developed. The nanoparticles are initially sized so that they preferentially accumulate in the tumor tissue as a result of leakage through the defective vascular in the solid tumors. Once in the tumor tissue, the nanoparticles are cleaved hydrolytically and/or by enzymatic cleavage over time to release smaller nanoparticles carrying therapeutic, prophylactic or diagnostic agents into the necrotic interior of the tumors. This provides a simple, elegant and highly effective means of delivery drug selectively not just to tumors generally, but, more importantly, into the poorly vascularized necrotic interiors which drugs are normally unable to penetrate. The nanoparticles have a number of advantages: less toxicity due to selective accumulation only in the tumors; access into the poorly vascularized necrotic interiors of the tumor; and sustained release over a period of time within the tumor. | 06-12-2014 |
20140161885 | LANTHANUM CARBONATE HYDROXIDE, LANTHANUM OXYCARBONATE AND METHODS OF THEIR MANUFACTURE AND USE - The present invention is a method of producing a lanthanum carbonate hydroxide or lanthanum oxycarbonate which has improved properties. The method involves the use of a water soluble lanthanum and a water soluble non-alkali metal carbonate or bicarbonate. The resulting material can be used as a phosphate binder individually or for treating patients with hyperphosphatemia. | 06-12-2014 |
20140170220 | MULTIMODAL PARTICULATE FORMULATIONS - Multimodal particulate formulations of medicaments and methods for their use, e.g. by nasal or pulmonary administration for the treatment of various medical conditions, are provided. | 06-19-2014 |
20140170221 | METHODS AND COMPOSITIONS FOR LOCALIZED DELIVERY OF AGENTS TO VIRALLY INFECTED CELLS AND TISSUES - The invention provides compositions and methods for delivering an agent to virally infected tissues and/or cells of a subject by conjugating agent-loaded nanoparticles to virus-specific T cells, such as cytotoxic T lymphocytes. The agent may be a latency-reversing drug (LRD), an antiviral agent and/or an agent that enhances cytotoxic efficacy of T lymphocytes. | 06-19-2014 |
20140170222 | XANTHOPHYLL COMPOSITIONS AND METHODS OF USE - The present invention encompasses a carotenoid composition, a process for producing a carotenoid composition, and methods of use thereof. | 06-19-2014 |
20140170223 | POST OXIDATIVE HAIR TREATMENT AGENT WITH SILICONE - A method for oxidative lightening and/or coloring of keratinic fibers include:
| 06-19-2014 |
20140178475 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles. | 06-26-2014 |
20140178476 | Highly Efficient Delivery of a Large Therapeutic Mass Aerosol - A method for delivering an agent to the pulmonary system, in a single, breath-activated step or a single breath, comprises administering from a receptacle enclosing a mass of particles, to a subject's respiratory tract, particles which have a tap density of less than 0.4 g/cm | 06-26-2014 |
20140178477 | SOLID PREPARATION - The present invention provides a solid preparation formulation containing a poorly water-soluble agent having a low melting point, a saccharide, and a cellulose selected from a crystalline cellulose and a low-substituted hydroxypropylcellulose, in which the saccharide/cellulose weight ratio exceeds 2 and the cellulose content is not less than 5 wt %. This formulation provides a composition that can be produced with direct granulation, yet which delivers stability during production and storage. | 06-26-2014 |
20140178478 | Immuno-Adjuvant Emulsion - The invention relates to an oil-in-water adjuvant emulsion which comprises at least:
| 06-26-2014 |
20140178479 | Concentrated Felbamate Formulations for Parenteral Administration - Formulations of a neuroprotective agent for parenteral administration are described herein. The formulation is in the form of a concentrated (supersaturated) solution or a concentrated suspension of microparticles. The suspension medium or the solution solvent carrier may also contain dissolved neuroprotective agent. For the supersaturated solutions, the agent is dissolved at high concentrations of at least about 1% by weight, 5% by weight, 10% by weight, 15% by weight, or 20% by weight in a solvent suitable for parenteral administration. For the concentrated suspension, the microparticles have an effective particle size from about 100 nm to about 5 microns, preferably from about 50 nm to about 3 microns, more preferably from about 10 nm to about 2 microns. The formulations described herein can be used to treat a variety of neurological diseases/disorders and/or neurological injury or trauma. | 06-26-2014 |
20140186442 | Topical Minocycline Compositions and Methods of Using the Same - Topical minocycline compositions with reduced fluorescence are provided. In some instances, the compositions include an amount of a minocycline active agent associated with porous calcium particles. Also provided are methods of using the compositions, e.g., in the treatment of acne. | 07-03-2014 |
20140186443 | CYCLODEXTRIN NANOTECHNOLOGY FOR OPHTHALMIC DRUG DELIVERY - The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and/or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided. | 07-03-2014 |
20140186444 | DRUG FORMULATIONS HAVING IMPROVED PHARMACOKINETIC PROPERTIES - The present application relates to novel drug formulations of vardenafil which dissolve rapidly in the mouth and lead to increased bioavailability and to a plateau-like plasma concentration profile, and to processes for their preparation. | 07-03-2014 |
20140186445 | METHOD FOR MAKING CUSTOMISED NANOPARTICLES, NANOPARTICLES AND USES THEREOF - A method for the production of biodegradable nanoparticles with an average particle size of less than 400 nm. In a first step, a macromonomer is prepared in a ring opening polymerization process between a hydrophilic acrylate compound (A) as an initiator and hydrophobic cyclic monomers (B), wherein the macromonomer comprises at least two repetitive units based on the cyclic monomer. In a second step, this macromonomer or a mixture of macromonomers and/or commercial biocompatible monomers is polymerized, e.g. in a starved, miniemulsion or emulsion radical polymerization in water in the presence of a surfactant to the nanoparticle without necessitating additional subsequent steps for the actual production of the nanoparticles. The correspondingly made nanoparticles and uses thereof also are disclosed. | 07-03-2014 |
20140186446 | Delivery of Biologic Therapeutics - Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 μm. | 07-03-2014 |
20140193499 | BIOACTIVE GLASS COMPOSITION, ITS APPLICATIONS AND RESPECTIVE PREPARATION METHODS - The present invention relates to development of bioactive glass/glass-ceramic composition that are able to promote a fast deposition layer of carbonated hydroxyapatite upon immersion in simulated body fluid (SBF) for time periods as short as one hour. Such composition might include fluorides, and a variety of oxides (or their precursor compounds), such as Na | 07-10-2014 |
20140193500 | DRY SHAMPOO COMPRISING UREA-FORMALDEHYDE - A method of treating hair and/or skin of a human or animal, the method comprising applying to the hair and/or skin a composition comprising particles of a urea formaldehyde polymer wherein the particles have an average size of less then 300 microns; an oil absorption value of greater than 40 g/100 g; and a bulk density of greater than 0.2 gcm | 07-10-2014 |
20140193501 | Pulmonary Delivery in Treating Disorders of the Central Nervous System - A method for treating a disorder of the central nervous system includes administering to the respiratory tract of a patient a drug which is delivered to the pulmonary system, for instance to the alveoli or the deep lung. The drug is administered at a dose which is at least about two-fold less than the dose required by oral administration. Particles that include the drug can be employed. Preferred particles have a tap density of less than about 0.4 g/cm | 07-10-2014 |
20140193502 | Foam Prepared From Nanoemulsions And Uses - The present invention provides a foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum, and methods of using such a composition to treat, alleviate, or prevent a disorder of the skin, body cavity, or mucosal surface. The foamable oil in water nano emulsion composition includes: (a) a nano oil globule system, comprising substantially of sub-micron oil globules; (b) about 0.1% to about 5% by weight of at least one stabilizing agent selected from (i) a non-ionic surfactant, (ii) an ionic surfactant, or (iii) a polymeric agent; and (c) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition, water and optional ingredients. Upon release from an aerosol container, the foamable composition forms and expanded foam suitable for topical administration. | 07-10-2014 |
20140193503 | AQUEOUS SUSPENSION CONCENTRATE COMPRISING AN ACID SALT OF DODECYLGUANIDINE - The invention concerns a suspension concentrate comprising, expressed by weight based on the total weight of the composition: a) 40 to 80% particles of dodecylguanidine or an acid salt of dodecylguanidine of the structure (1), wherein X represents an acid residue of a monocarboxylic, dicarboxylic or a mineral acid, b) 0 to 10% of an anti-freeze compound, c) 1 to 10% of a wetting agent and/or d) a dispersing agent, e) 0 to 5% of an antifoaming agent, f) remainder water characterized in that, the median diameter of the particles (d | 07-10-2014 |
20140199395 | NOVEL FORMULATION OF MELOXICAM - The present invention relates to methods for producing particles of meloxicam using dry milling processes as well as compositions comprising meloxicam, medicaments produced using meloxicam in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of meloxicam administered by way of said medicaments. | 07-17-2014 |
20140199396 | PROCESS FOR THE MANUFACTURE OF A POWDER CONTAINING LUTEIN - Process for the manufacture of a powder containing lutein, powder obtainable by said process and food composition containing said powder. | 07-17-2014 |
20140199397 | Benzoyl Peroxide Microparticle Process - The present invention relates to the manufacture of microparticle benzoyl peroxide. The process of the invention provides for an aqueous slurry of USP benzoyl peroxide, optionally containing additives, being processed via microfluidization technology. The process comprises forcing a slurry of benzoyl peroxide at high pressure through a narrow channel designed to produce high shear, thereby achieving primary particle size reduction in addition to de-agglomeration. | 07-17-2014 |
20140199398 | HIGH CAPACITY DIEKTOPIPERAZINE MICROPARTICLES AND METHODS - Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation. | 07-17-2014 |
20140199399 | USE OF TGF-BETA ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA - The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-β antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-β antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother. | 07-17-2014 |
20140205665 | BIORESORBABLE MICROPARTICLES - Polyurethane microparticles are derived from structural units comprising poly(alkylene oxide) moieties, caprolactone moieties and urethane moieties. The microparticles may include an active agent and have a particle size from 0.1 to 100 microns. Microparticles for injection have a particle size of 15 to 80 microns; for use as a aerosol 1 to 3 microns; and for intraocular use 0.02 to 2 microns. Dispersivity is in the range 1 to 3. | 07-24-2014 |
20140205666 | IMINOSUGAR IN CRYSTALLINE FORM - Iminosugar, which possesses known activity as a glycosyltransferase inhibitor, and is used, for example, in the treatment of Gaucher's disease, in crystalline form, a process for its preparation and a pharmaceutical composition thereof. | 07-24-2014 |
20140205667 | Method - There is provided a method of producing a mixed metal compound comprising at least Mg | 07-24-2014 |
20140205668 | SURFACE MODIFIED PROTEINACEOUS SPHERICAL PARTICLES AND USES THEREOF - An aspect of embodiments of the invention relates to surface modified proteinaceous spherical particles (SMOP). SMOPs according to an embodiment of the invention may comprise a protein layer and an amyloid-binding moiety bound to the protein. In an embodiment, the protein layer is spherical in shape and comprises proteins linked to each other by disulfide bonds. It is suggested that SMOPs are effective in preventing formation of amyloid and aggregation of Aβ when administered to a patient in need thereof. | 07-24-2014 |
20140212494 | Methods of Improving Digestive Health - A method of treating constipation is disclosed. The method includes administering starch-entrapped microbeads. | 07-31-2014 |
20140212495 | NANOPARTICULATE COMPOSITIONS OF TUBULIN INHIBITOR COMPOUNDS - The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as “Indibulin,” and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases. | 07-31-2014 |
20140212497 | COATED NANOPARTICLES - The present invention relates to a method for preparing a composition comprising nanoparticles of a noble metal functionalised with at least one type of metal complex and surfactant. The method comprises providing a first solution comprising nanoparticles and surfactant, and a second solution comprising a first type of metal complex, and adding the second solution to the first solution. Each nanoparticle has a loading of at least 500 and the method permits independent control of particle size and loading and enables large particles with high loading to be reproduced without agglomeration. | 07-31-2014 |
20140212498 | OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS - This invention generally relates to cationic oil-in-water emulsions that can be used to deliver nucleic acid molecules, such as an RNA molecule. The emulsion particles comprise an oil core and a cationic lipid. The emulsion particles have an average diameter of about 80 nm to about 180 nm, and the emulsion have an N/P ratio of at least 1.1:1. | 07-31-2014 |
20140212499 | COMPOSITIONS AND METHODS FOR REPAIRING BONE - Bone repair compositions comprising bone particles and periosteum tissue. The bone particles may be demineralized, and may comprise powder or fibers from cortical bone or from cancellous bone. The periosteal tissue can be micronized periosteal tissue, and may comprise periosteal powder, particulates, pieces, or combinations thereof. The bone repair composition can further comprise bone chips, mineralized cancellous bone, or additional materials. The present technology also provides methods of repairing a bone defect, comprising administering a bone repair composition to the site of the bone defect. | 07-31-2014 |
20140212500 | COMPOSITIONS CONTAINING DIVERSE NATURAL ANTIGENS AND USES THEREOF IN BALANCING IMMUNE RESPONSES - Compositions containing sterilized antigens with a high diversity, which can be collected from primitive jungle areas, and uses thereof for balancing immune responses and treating immunological diseases in a subject. | 07-31-2014 |
20140212501 | COMPOSITIONS OF LOPINAVIR - The present invention relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug lopinavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). | 07-31-2014 |
20140220131 | Personal Care Compositions Containing Volumizing, Fixative, And Conditioning Particles For Fine Hair - The present invention is directed to a personal care composition comprising: a personal care composition comprising a particle complex consisting of a hydrolyzed corn starch, a starch/cellulose polymer, a hydrogenated phospholipid, and gum arabic; and an aqueous carrier. The personal care composition is suitable for delivery as a sprayable composition which provides volumizing, hair fixing, and conditioning as a leave-on treatment. The present invention is also directed to a method for forming a particle complex wherein the complex provides volumizing, hair fixing, and conditioning benefits when applied to hair. | 08-07-2014 |
20140220132 | Pharmaceutical Formulation Comprising Compounds of the Jasmonate Family - The current invention pertains to pharmaceutical formulation including at least one jasmonate compound of the jasmonate family of compounds combined with a carrier, such as inclusion compounds, particularly those able to form nano or micro encapsulation systems. The invention generally refers to inclusion complexes which includes jasmonate compounds. | 08-07-2014 |
20140220133 | Nanotechnology Based Medicine for Biodefense - A composition and methods to bind and remove toxic agents from a subject exposed to the toxic agents are described herein. The composition comprises a stealth agent and scavenging agent bound to a nanoparticle platform. The stealth agent prevents the nanomedicine from detection and elimination by the immune system allowing the scavenging agent to bind the target toxic agent. The stealth agent comprises an exposing group that once removed from the stealth agent allows the nanomedicine and bound toxic agent to be detected and eliminated from the subject's body. | 08-07-2014 |
20140220134 | METHOD FOR TREATING DIABETES WITH EXTENDED RELEASE FORMULATION OF GLP-1 RECEPTOR AGONISTS - The disclosure provides methods for treating diabetes, treating overweight, treating obesity, reducing body weight, treating cardiovascular diseases, treating fatty liver diseases, treating gastrointestinal diseases, and treating neurodegenerative diseases through the once monthly administration of pharmaceutical formulations containing a non-aqueous carrier and GLP-1 receptor agonists that provides therapeutically effective plasma concentration levels of the GLP-1 receptor agonists over the course of a month. | 08-07-2014 |
20140220135 | PERMEATION ENHANCED ACTIVE-CARRYING NANOPARTICLES - Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein an active agent and a permeation enhancer are bound to or associated with the nanoparticles. | 08-07-2014 |
20140220136 | SYSTEM AND METHOD FOR DELIVERING PROTEASE INHIBITORS - The disclosed invention provides a system and method of artificially retarding fibrin-based blood clot degradation via the sustained release of a protease inhibitor, such as, for example, aprotinin or tranexamic acid (“TA”). The sustained release of the protease inhibitor is accomplished through incorporation within a biodegradable polymer microsphere to produce a protease inhibitor formulation. Next, the formulation along with fibrinogen and thrombin is applied to a wound site where an outer surface of the polymer microsphere degrades in a proteolytic environment to expose and release the incorporated protease inhibitor to the surrounding hydrogel or sealant or clot matrix at the wound site. | 08-07-2014 |
20140220137 | HIGH ACTIVITY ANTIPARASITIC COMPOSITION AGAINST RHYNCHOPHORUS FERRUGINEUS - Synergistic composition able to rapidly and efficiently terminate | 08-07-2014 |
20140220138 | ENHANCED NITRIC OXIDE DELIVERY AND USES THEREOF - Methods and compositions are disclosed that enhance delivery of nitric oxide (NO) by combining nitric oxide releasing nanoparticles (NO-np) with exogenous glutathione (GSH), as well as therapeutic uses of the methods and compositions. | 08-07-2014 |
20140220139 | SKIN COMPOSITION FOR EXTERNAL USE CONTAINING CERAMIDES - The present invention provides a ceramide lamella structure comprising a glucoside surfactant, a preparation method thereof, and a skin composition for external use containing the same. According to the skin preparation composition for external use of the present invention, phase stability is very excellent and a greater amount of ceramides can be stably formed according to the stability of ceramides using multilayered lamellar liquid crystals, thereby showing excellent skin moisturizing and skin barrier function repairing effects when applied to the skin. | 08-07-2014 |
20140220140 | COMPOSITIONS OF EFAVIRENZ - The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drug efavirenz. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). | 08-07-2014 |
20140220141 | COMPOSITIONS OF LOPINAVIR AND RITONAVIR - The present inventions relates to a solid composition and an aqueous dispersion comprising nanoparticles of the anti-retroviral drugs lopinavir and ritonavir. The solid composition and aqueous dispersion additionally comprise a mixture of a hydrophilic polymer and a surfactant. The surfactant is selected from vitamin-E-polyethylene glycol-succinate (Vit-E-PEG-succinate), a polyoxyethylene sorbitan fatty acid ester, N-alkyldimethylbenzylammonium chloride, sodium deoxycholate, dioctyl sodium sulfosuccinate, polyethyleneglycol-12-hydroxystearate, polyvinyl alcohol (PVA), and a block copolymer of polyoxyethylene and polyoxypropylene, or a combination thereof. The hydrophilic polymer is suitably selected from polyvinyl alcohol (PVA), a polyvinyl alcohol-polyethylene glycol graft copolymer, a block copolymer of polyoxyethylene and polyoxypropylene, polyethylene glycol, hydroxypropyl methyl cellulose (HPMC), and polyvinylpyrrolidone, or a combination thereof. The present invention also relates to processes for preparing both the solid composition and the aqueous dispersion, as well as to their use in therapy for the treatment and/or prevention of retroviral infections such as human immunodeficiency virus (HIV). | 08-07-2014 |
20140220142 | COMPOSITION FOR BONE REGENERATION - The present invention provides a composition for bone regeneration comprising: particulate demineralized bone matrix; fibrous demineralized bone matrix; and a hydrate. In addition, it is preferable that the present invention comprises a demineralized solution-derived isolated product obtained by neutralizing a demineralized solution, separated from a demineralization process, and separating the precipitate generated. | 08-07-2014 |
20140234420 | Method of Treating Skin Disorders using Nanoscale Delivery Devices and Transdermal Enhancing Compositions - The present invention describes methods and compositions for treating diverse dermatological conditions, including acne and psoriasis, using zein containing nanocarrier devices for topical delivery of methotrexate, retinoic acid and benzoyl peroxide to select targets in the skin. | 08-21-2014 |
20140234421 | DENTAL ANESTHETIC COMPRISING TETRACAINE AND A VASOCONSTRICTOR FOR INTRANASAL ADMINISTRATION - The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations. | 08-21-2014 |
20140234422 | Vaccine Composition With Aluminium Hydroxide Nanoparticles - A vaccine composition comprising at least one antigen and one adjuvant, characterized in that the adjuvant comprises sterile-filterable nanoparticles comprising pseudo-boehmite and polyacrylate. | 08-21-2014 |
20140234423 | PROGRAMMING OF CELLS FOR TOLEROGENIC THERAPIES - Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease. | 08-21-2014 |
20140234424 | PRAME PURIFICATION - Methods and processes for the purification of PRAME are provided. In particular, methods for reducing the aggregation of PRAME during a diluent exchange from diluent A to diluent B comprising: (i) adding a polyanionic compound to diluent A prior to or contemporaneously with the exchange; and (ii) exchanging protein from diluent A to diluent B are provided. Compositions produced by the method are also provided. | 08-21-2014 |
20140234425 | AQUEOUS FUNGICIDAL COMPOSITION AND USE THEREOF FOR COMBATING HARMFUL MICROORGANISMS - The invention relates to aqueous fungicidal active substance compositions and to their use in the control of harmful microorganisms and in particular in the protection of cellulose-comprising materials, particularly wood, from infection by microorganisms, in particular those harmful fungi which can damage wood or cellulose. | 08-21-2014 |
20140234426 | COSMETIC - A cosmetic, includes: a composite powder containing titanium oxide and 4-tert-butyl-4-methoxybenzoylmethane and having an average particle diameter of less than 1 μm; and sorbitan fatty acid ester represented by the following Formula (I): wherein, in Formula (I), R | 08-21-2014 |
20140234427 | USE OF SYNTHETIC JANUS PARTICLES FOR PREVENTING OR REDUCING CRYSTAL GROWTH - The invention provides a method of preventing or reducing the growth of crystals in a substance which is susceptible to crystal growth in which colloidal particles having an amphiphilic structure, e.g. Janus particles, are contacted with the substance. Colloidal particles suitable for use in the invention include cross-linked, colloidal materials formed from hydrophobic monomers such as acrylates or methacrylates and hydrophilic monomers such as those derived from acrylic and/or methacrylic acid. The colloidal particles find particular use in methods of cryopreservation of biological samples (e.g. cells, tissues or organs), as a texture modifier in frozen food products, in the inhibition of gas hydrate formation, and as scale inhibitors. | 08-21-2014 |
20140242171 | OIL-IN-WATER EMULSION OF MOMETASONE AND PROPYLENE GLYCOL - Novel pharmaceutical compositions of mometasone or a pharmaceutically acceptable derivate thereof in the form of an oil-in-water emulsion, notably a cream. The composition has excellent stability and therapeutic effect. The compositions contain mometasone in micronised form, propylene glycol and water and the weight ratio between the propylene glycol and water contained in the oil-in-water emulsion is from 1:1 to about 1:3. | 08-28-2014 |
20140242172 | Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide - The present invention relates to solid state forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1), pharmaceutical compositions thereof and methods therewith. | 08-28-2014 |
20140242173 | TARGETED SYNTHETIC NANOCARRIERS WITH PH SENSITIVE RELEASE OF IMMUNOMODULATORY AGENTS - This invention relates to compositions, and related methods, of synthetic nanocarriers that target sites of action in cells, such as antigen presenting cells (APCs), and comprise immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. Also disclosed are compositions and methods relating to synthetic nanocarriers that encapsulate labile immunomodulatory agents that dissociate from the synthetic nanocarriers in a pH sensitive manner. | 08-28-2014 |
20140242174 | TREATING COUGH AND TUSSIVE ATTACKS - The invention is directed towards carcainium in the form of a salt having an anion An | 08-28-2014 |
20140248354 | CONTROLLED RELEASE VACCINES AND METHODS FOR TREATING BRUCELLA DISEASES AND DISORDERS - Methods and compositions for the treatment of | 09-04-2014 |
20140248355 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment - 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT | 09-04-2014 |
20140248356 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment - 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT | 09-04-2014 |
20140248357 | Respiratory Disease Treatment - A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles. | 09-04-2014 |
20140248358 | Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same - The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles. | 09-04-2014 |
20140248359 | NOVEL FORMULATION OF DICLOFENAC - The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments. | 09-04-2014 |
20140248360 | NANOPARTICLE TUMOUR VACCINES - The present invention provides a vaccine for the prophylactic or therapeutic treatment of a tumour in a mammalian subject, as well as methods of using the vaccine, including in treatment of tumours and in generating a CTL response. The vaccine comprises a plurality of nanoparticles and a pharmaceutically acceptable carrier, salt or diluents. The nanoparticles comprise a core comprising a metal and/or a semiconductor atom; and a corona comprising a plurality of ligands covalently linked to the core, wherein at least a first ligand of said plurality comprises a carbohydrate moiety that is covalently linked to the core via a first linker, and wherein at least a second ligand of said plurality comprises an epitopic peptide that is covalently linked to the core via a second linker, said second linker comprising a peptide portion and a non-peptide portion, wherein said peptide portion comprises the sequence X | 09-04-2014 |
20140248361 | HERBAL EXTRACT COMPOSITION AND A PROCESS THEREOF - A composition is provided that includes extracts of green tea and rosemary extract optionally along with adjuvant and/or excipient. In addition, provided is a process for the preparation of said composition. Also provided is a composition including extract of green tea, rosemary extract and synthetic antioxidant optionally along with adjuvant and/or excipient. | 09-04-2014 |
20140248362 | SUSTAINED-RELEASE PREPARATION - Provided is a sustained-release preparation containing pioglitazone or a salt thereof as an active ingredient and showing superior sustainability. A sustained-release preparation containing pioglitazone or a salt thereof, which shows a dissolution ratio of pioglitazone of average 25-58% at the 2-hour time point, and average 60-100% at the 4-hour time point, in a dissolution test according to the 50 rpm USP Paddle Method and using pH 2.0 KCl/HCl buffer at 37° C. as a test solution. | 09-04-2014 |
20140255488 | LONG ACTING SUSTAINED-RELEASE FORMULATION CONTAINING DOPAMINE RECEPTOR AGONIST AND THE PREPARATION METHOD THEREOF - The present invention relates to a long-acting sustained-release dosage form for treatment of Parkinson Disease, comprising a dopamine receptor agonist and a pharmaceutically acceptable biodegradable polymer accessories, wherein the content of the dopamine receptor agonist in the sustained-release dosage form is 5-50% by weight, and the content of the pharmaceutically acceptable polymer accessories is 50-95% by weight. | 09-11-2014 |
20140255489 | CONSISTENT CALCIUM CONTENT BONE ALLOGRAFT SYSTEMS AND METHODS - Embodiments of the present invention provides bone graft compositions, and methods for their use and manufacture. A bone graft composition may include a first amount of non-demineralized cancellous bone. The composition may further include a second amount of demineralized cancellous bone. The composition may also include a third amount of demineralized cortical bone. The non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone may be obtained from the same cadaveric donor. | 09-11-2014 |
20140255490 | PARTICULARLY STORAGE-STABLE AND THIXOTROPICALLY STABLE PROPHYLAXIS PASTE FOR PROFESSIONAL DENTAL USE - The invention relates to a particularly storage-stable and thixotropically stable dental prophylaxis paste for professional tooth cleaning which is very easy to use and thoroughly cleans and polishes the teeth of the patient and causes little abrasion of natural tooth substance. Such a dental prophylaxis paste may comprise:
| 09-11-2014 |
20140255491 | Method and System For the Treatment of Chronic Obstructive Pulmonary Disease With Nebulized Anticholinergic Administrations - Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as COPD, are provided. | 09-11-2014 |
20140255492 | FINE DRY PARTICULATE ADENOSINE COMPOSITIONS AND TOPICAL FORMULATIONS INCLUDING THE SAME - Fine dry particulate adenosine compositions suitable for use in topical formulations, as well as methods of making the same, are provided. In the dry particulate adenosine composition, the adenosine active agent is associated with the particles, e.g., via entrapment in the pores of the particles and/or ionic binding and/or non-covalent binding to the surface of the particles and/or loosely associated with the particles. Also provided are topical formulations which include the dry particulate adenosine compositions of the invention, and methods of using the same. | 09-11-2014 |
20140255493 | EXTRUDATE AND METHODS OF USING SAID EXTRUDATE - The invention relates to a method for the preparation of a silicic acid comprising extrudate, comprising the steps of: i) forming of stabilised silicic acid, by hydrolysing a silicon compound into orthosilicic acid and/or oligomers thereof in the presence of a stabilizing agent, which is a quaternary ammonium compound, or an amino-acid, or an amino acid source or combinations thereof; ii) mixing of the stabilised silicic acid with a carrier in an amount up to the loading capacity of the carrier for silicic acid; and iii) extruding the resulting mixture thereby forming the extrudate, to extrudates obtainable with the method, to an extrudate for use in the production of animal feed, feed supplement, human food and/or food supplement and of a pharmaceutical or cosmetic preparation, and for the treatment of infections, nails, hair, skin, teeth, collagen, connective tissue, bones, osteopenia, cell generation and degenerative (ageing) processes, and to a pharmaceutical composition comprising an extrudate. | 09-11-2014 |
20140255494 | Novel Formulation of Indomethacin - The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments. | 09-11-2014 |
20140255495 | COLON LAVAGE SYSTEM - The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion. | 09-11-2014 |
20140255496 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions composed of micronized placental components, extracts of micronized placental components, and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the micronized compositions and the extracts thereof are also described herein. | 09-11-2014 |
20140255497 | Organic Compounds - A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol. | 09-11-2014 |
20140255498 | PHARMACEUTICAL NANOSUSPENSION - The present invention in general relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one active ingredient and at least one dicarboxylic acid. It in particular relates to a pharmaceutical suspension comprising nano-sized cocrystals of at least one anthelmintic drug and at least one dicarboxylic acid. The invention further relates to uses, methods for use and methods for manufacturing the pharmaceutical suspension according to this invention. | 09-11-2014 |
20140255499 | Method of Forming Fine Particles of a Drug Substance - A method of forming fine particles of a drug substance using a piston-gap high pressure homogeniser. | 09-11-2014 |
20140271869 | HIGH DRUG LOAD BUPRENORPHINE MICROSPHERES AND METHOD OF PRODUCING SAME - A sustained release microsphere formulation with a high drug load may be formed by a continuous oil-in-water emulsion process by combining an organic dispersed phase with an aqueous continuous phase. The dispersed phase may include an encapsulating polymer, a primary solvent, such as dichloromethane, a pharmaceutically effective amount of an active agent having a solubility relative to the dispersed phase, and a co-solvent, such as benzyl alcohol, which is capable of increasing the solubility of the active agent relative to the dispersed phase. The continuous phase may include an aqueous solution of polyvinyl alcohol and water. | 09-18-2014 |
20140271870 | TREATMENT OF PAIN USING PROTEIN SOLUTIONS - Methods for treating pain using a protein solution comprising two or more of IL1-ra, sTNF-R1, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-β1, and sIL-1RII, Compositions may also contain white blood cells and platelets. | 09-18-2014 |
20140271871 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION - The present invention features methods for treating, stabilizing, preventing, and/or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and/or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and/or nanoparticles that comprise a carrier protein and a taxane (e.g., paclitaxel) or a derivative4 thereof. | 09-18-2014 |
20140271872 | DRUG DELIVERY SYSTEM - Disclosed herein are novel methods of treating diseases, novel dosage forms, and novel methods of modulating the pharmacokinetics of active ingredients. | 09-18-2014 |
20140271873 | APPLICATION OF ENCAPSULATED CAPSAICIN AND ANALOGUES THEREOF FOR CONTROLLING CALORIE INTAKE - A zero-calorie to near-zero-calorie snacking product that, when consumed, provides a feeling of fullness prior to absorption of energy-providing food, i.e., pre-absorptive satiation is disclosed. The snacking product is based on the stimulation of vagal nerve endings in the gastro-intestinal tract by encapsulated capsaicin. The encapsulation of capsaicin avoids the burning sensation in the mouth which may be objectionable to some consumers. | 09-18-2014 |
20140271874 | STABLE CRYSTALLINE MONOHYDRATE OF EPIRUBICIN HYDROCHLORIDE AND METHOD OF PRODUCTION - The present invention relates to a stable crystalline monohydrate of epirubicin hydrochloride having water content in the range between 2.7% and 3.5% (w/w) and being devoid of residual solvents as well as to a corresponding method for its production. The method comprises: (a) adding at least a first solvent and at least a second solvent to epirubicin hydrochloride, wherein the first solvent is a linear or branched C | 09-18-2014 |
20140271875 | COMPOSITIONS INCLUDING ENCAPSULATED ISOTRETINOIN AND METHODS FOR USE THEREOF - The present invention provides topical dermal compositions including microsphere encapsulated isotretinoin. Pharmaceutically acceptable salts, esters, or amides of isotretinoin are also contemplated for use in the practice of the invention. The compositions of the invention are useful for treating a variety of conditions associated with excess sebum production, such as, for example, acne. | 09-18-2014 |
20140271876 | OPHTHALMIC FORMULATIONS - The present invention relates to an ophthalmic formulation which comprises a fine particle of Compound A in an aqueous suspension and a manufacturing process thereof. More specifically, the present invention relates to a topically applied ophthalmic aqueous suspension which is obtainable by suspending fine particles of Compound A in an aqueous vehicle containing a surfactant and boric acid. The invention also provides processes for making the ophthalmic formulations and to methods of use thereof. | 09-18-2014 |
20140271877 | SUBSTANTIALLY SURFACTANT-FREE, SUBMICRON DISPERSIONS OF HYDROPHOBIC AGENTS CONTAINING HIGH LEVELS OF WATER MISCIBLE SOLVENT - A composition is provided to apply to the skin, hair, or external mucosa of a human or animal, and a method for using the composition. The composition includes for example a composition for application to skin, hair or external mucosa comprising: a) dispersed submicron particles of hydrophobic agent(s) having average particle size from 100 nm to 999 nm; b) an aqueous-solvent fluid; and c) rheological modifying agent(s); wherein the aqueous-solvent fluid is 10% to 95% wt. of one or more water miscible solvent(s), 4.99% to 89.99% wt. water, and 0.01% to 10% wt. of the rheological modifying agent(s); and wherein the hydrophobic agents comprise 0.01 to 70% wt. of the skin, hair or mucosal composition; and wherein the composition is substantially surfactant-free. | 09-18-2014 |
20140271878 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF - The subject invention provides a mixture of crystalline laquinimod sodium particles, wherein (i) 90% or more of the total amount by volume of the laquinimod sodium particles have a size of 40 microns or less or (ii) 50% or more of the total amount by volume of the laquinimod sodium particles have a size of 15 microns or less, and wherein:
| 09-18-2014 |
20140271879 | FINE DRY PARTICULATE RETINOID ACTIVE AGENT COMPOSITIONS AND TOPICAL FORMULATIONS INCLUDING THE SAME - Fine dry particulate retinoid compositions suitable for use in topical formulations, as well as methods of making the same, are provided. In the dry particulate retinoid compositions, the retinoid active agent is associated with the particles, e.g., via entrapment in the pores of the particles and/or ionic binding and/or non-covalent binding to the surface of the particles and/or loosely associated with the particles. Also provided are topical formulations which include the dry particulate retinoid compositions of the invention, and methods of using the same. | 09-18-2014 |
20140271880 | FINE DRY PARTICULATE RESVERATROL ACTIVE AGENT COMPOSITIONS AND TOPICAL FORMULATIONS INCLUDING THE SAME - Fine dry particulate resveratrol compositions suitable for use in topical formulations, as well as methods of making the same, are provided. In the dry particulate resveratrol composition, the resveratrol active agent is associated with the particles, e.g., via entrapment in the pores of the particles and/or ionic binding and/or non-covalent binding to the surface of the particles and/or loosely associated with the particles. Also provided are topical formulations which include the dry particulate resveratrol compositions of the invention, and methods of using the same. | 09-18-2014 |
20140271881 | ANTISEPTIC COMPOSITION - The invention relates to an antiseptic composition. The composition comprises an association of at least silver metal, preferably in a micronised form, and hyaluronic acid or one of the salts thereof having a molecular weight of between 50 kDa and 2000 kDa. The invention can be especially applied to the field of veterinary medicine, for the treatment of skin wounds and the healing thereof. | 09-18-2014 |
20140271882 | 17-HYDROXYPROGESTERONE ESTER CONTAINING ORAL COMPOSITIONS AND RELATED METHODS - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 09-18-2014 |
20140271883 | CURCUMINOIDS AND METABOLITES THEREOF FOR TREATING ALLERGIC NASAL CONDITIONS - A pharmaceutical composition for nasal administration comprising: a nanoemulsified curcumin component; a liquid medium for the curcumin component; and a pharmaceutically acceptable excipient. The curcumin component is a natural curcuminoid, a synthetic curcuminoid, a metabolite of a natural or synthetic curcuminoid, or a mixture thereof. The excipient is effective in increasing the bioavailability of the curcumin component. | 09-18-2014 |
20140271884 | HIGH-LOADING NANOPARTICLE-BASED FORMULATION FOR WATER-INSOLUBLE STEROIDS - Compositions comprising water-insoluble steroids encapsulated into nanoparticle forms are provided. Methods of preparing water-insoluble steroids encapsulated in a nanoparticle form are provided. Methods of treating disease by delivering a water-insoluble steroid encapsulated into nanoparticle form to a patient in need thereof are provided. | 09-18-2014 |
20140287043 | COMPOSITIONS AND METHODS FOR STABILIZATION OF ACTIVE AGENTS - Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein. | 09-25-2014 |
20140287044 | FIBRIN SEALANT (FIBRINGLURAAS) CONSISTING OF A KIT OF LYOPHILIZED OR FROZEN HIGH CONCENTRATE FRIBINOGEN - The application is directed to a fibrin sealant (FIBRINGLURAAS®) consisting of a kit of lyophilized or frozen high concentrate fribinogen in which 5% a1at will be added into the final bulk and or 5% a1at as a diluent for high concentrate fibrinogen and new found proteins kh30, kh31, kh32, kh44, kh46, kh47, and kh52 in which the kh good healthy cells are present, either non-heated or heating to at least 1° C. and above, preferably at least 101° C., and lyophilized or frozen thrombin used to compound glue membrane, the diameter of which is less than 10 micrometers the actual size of the glue membrane of the fibrin sealant (FIBRINGLURAAS®) is from 0.6 μm, to 101° C. heating 0.005 micrometers and its topical applications for all solid tumor cancer | 09-25-2014 |
20140287045 | METHOD OF PREPARING MICROSPHERES BY USING POLYMER HAVING SOL-GEL TRANSITION PROPERTY AND MICROSPHERES PREPARED THEREBY - The present invention relates to a method of preparing microspheres by using a polymer having a sol-gel transition property and microspheres prepared thereby, and more particularly, to a method of preparing microspheres by using a polymer having a sol-gel transition property and microspheres prepared thereby capable of preventing a solvent in a polymer solution for a carrier from being rapidly diffused to the aqueous medium before formation of the microspheres to reduce porosity of the microspheres and reduce surface roughness of the microspheres in order to obtain microspheres having a sphere shape, and increasing an encapsulation ratio of a bioactive substance, by using a polymer having a sol-gel transition property as a surfactant included in an aqueous medium into which a primary emulsion is injected and gelating a secondary emulsion formed after injecting the primary emulsion using the sol-gel transition property of the polymer used as the surfactant. | 09-25-2014 |
20140287046 | NON-FLUORIDE CONTAINING DIETARY SUPPLEMENT TOOTHPASTE AND METHODS OF USING THE SAME - A non-fluoride containing toothpaste enriched with at least one dietary supplement. The non-fluoride containing toothpaste comprising a dentally acceptable oral vehicle containing a sufficient amount of thickening agent to impart a pasty consistency; and at least one dietary supplement wherein a serving size portion of the non-fluoride containing toothpaste contains more than about 2 percent of the reference daily intake (RDI) of the dietary supplement. | 09-25-2014 |
20140287047 | NANOEMULSION THERAPEUTIC COMPOSITIONS AND METHODS OF USING THE SAME - The present invention relates to methods and compositions for treating pulmonary infection. In particular, the present invention provides nanoemulsion compositions and methods of using the same to treat bacteria associated with biofilms (e.g., found in pulmonary infections). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications. | 09-25-2014 |
20140287048 | PASTE COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUG - An oral paste comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) at least one viscosity modifying agent; and (iii) a liquid vehicle. | 09-25-2014 |
20140287049 | NANOPARTICLE-BASED DRUG DELIVERY - Embodiments provide systems, methods, and compositions for nanoparticle-based drug delivery to target cells or tissues. A drug delivery system may include a nanoparticle with a targeting component and a therapeutic component. The nanoparticle may have a predetermined number or valence of targeting molecules for multivalent interaction with a target cell or tissue. Binding of the targeting molecules to the target cell may result in receptor-mediated uptake of the nanoparticle by the target cell. The therapeutic component may be subsequently released within an endocytic vesicle of the target cell. Nanoparticle-based drug delivery systems as described herein may provide improved efficacy and/or reduced toxicity. | 09-25-2014 |
20140294961 | HEPATIC PROTECTION AGENT CONTAINING EGGSHELL MEMBRANE AND PHARMACEUTICAL COMPOSITION, FOOD ADDITIVE AND FOOD USING THE SAME - The hepatoprotective agent contains eggshell membrane-containing fine powder, wherein the eggshell membrane-containing fine powder is eggshell membrane-containing fine powder having a volume mean particle diameter of 6 μm or less and/or eggshell membrane-containing fine powder having a volume maximum particle diameter of 20 μm or less. When fed with feed including eggshell membrane-containing fine powder with these values (sample C), the liver injury group (CCl | 10-02-2014 |
20140294962 | METHOD OF PREPARING POLYMORPHIC PURE FORM A OF BAZEDOXIFENE ACETATE - The present invention provides a reliable process for the preparation of polymorphic pure form A of Bazedoxifene x acetate. In addition, the present invention relates to a process of wet granulation of polymorphic pure form A of Bazedoxifene x acetate. The present invention also relates to pharmaceutical compositions comprising polymorphic pure form A of Bazedoxifene x acetate as well as to the use of cyclic ethers for the preparation of such pharmaceutical composition. | 10-02-2014 |
20140294963 | Novel Gold-Platinum Based Bi-Metallic Nanocrystal Suspensions, Electrochemical Manufacturing Processes Therefor and Uses for the Same - The present invention relates to novel gold-platinum based bi-metallic nanocrystal suspensions that have nanocrystal surfaces that are substantially free from organic or other impurities or films associated with typical chemical reductants/stabilizers and/or raw materials used in nanoparticle formation processes. Specifically, the surfaces are “clean” relative to the surfaces of metal-based nanoparticles made using chemical reduction (and other) processes that require organic (or other) reductants and/or surfactants to grow (and/or suspend) metal nanoparticles from metal ions in a solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the bi-metallic nanocrystal suspensions. The techniques do not require the use or presence of chlorine ions/atoms and/or chlorides or chlorine-based materials for the manufacturing process/final suspension. The invention further includes pharmaceutical compositions thereof and the use of the bi-metallic nanocrystals or suspensions or colloids thereof for the treatment or prevention of diseases or conditions for which metal-based therapy is already known, including, for example, for cancerous diseases or conditions. | 10-02-2014 |
20140294964 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH DACARBAZINE NANOEMULSIONS - A uniform microfluidized nanoemulsion is disclosed containing an anti-cancer agent, such as dacarbazine. The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of anticancer agents. As a nanoemulsion, dacarbazine has a greater anti-cancer efficacy than when applied as a free solution. | 10-02-2014 |
20140294965 | COMPOSITIONS AND METHODS FOR EXFOLIATING PARTICLES - Various embodiments provide compositions for exfoliating particles and methods for their manufacture. In one exemplary embodiment, the exfoliating particles may comprise a derivative of a botanically-sourced emollient, stearyl stearate, and at least one of: candelilla wax, is bran wax, sunflower wax, jojoba esters, carnauba wax, bees wax, corn wax, a saturated wax-ester, castor wax, ouricury wax, hydrogenated lanolin, and a hydrogenated triglyceride wax, Exemplary methods for producing the exfoliating particles may comprise melting, combining, and/or homogenizing the components of the exfoliating particles and cooling the resultant mixture in a process to form particles of a desired shape and/or size. The exfoliating particles may be for topical use and may be stable in personal care compositions. | 10-02-2014 |
20140294966 | STABLE NANOCOMPOSITION COMPRISING DOCETAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both or to the surface of the nanoparticle; (ii) an active compound selected from the group of docetaxel and its pharmaceutically acceptable salts and derivatives especially its hydrates, especially docetaxel trihydrate and docetaxel trihydrate monohydrochloride; and optionally (iii) at least one complexing agent, a metal ion and a stabilizer/formulating agent, or a PEGylating agent. The present invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 10-02-2014 |
20140294967 | STABLE NANOCOMPOSITION COMPRISING PACLITAXEL, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both or to the surface of the nanoparticle; (ii) paclitaxel as active compound; and optionally (iii) at least one complexing agent, a metal ion and a stabilizer/formulating agent or a PEGylating agent. The invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 10-02-2014 |
20140294968 | POLYACRYLATE-BASED ACTIVE COMPOUND-COMPRISING PARTICLES - The invention relates to novel polyacrylate-based active compound-comprising particles which bind to hair, and to the use of these particles for preparing medicaments, in particular for veterinary medicine. The particles comprise uncharged and cationic polyacrylate and are at most 10 um big. | 10-02-2014 |
20140294969 | Method and formulation for inhalation - This invention relates to drug delivery and in particular to the delivery of biologically active agents in the form of dry powders for inhalation. The invention also relates to methods for preparing such dry powder formulations and methods for their use. | 10-02-2014 |
20140294970 | STABILIZED PHARMACEUTICAL SUB-MICRON SUSPENSIONS AND METHODS OF FORMING SAME - The present invention is directed to a pharmaceutical submicron suspension and a method of forming the submicron suspension. The submicron suspension is useful for delivery of relatively hydrophobic and/or low solubility therapeutic agent. The submicron suspension and method of forming the submicron suspension typically employ a polymeric material that aids in preventing aggregation of the therapeutic agent. | 10-02-2014 |
20140294971 | CANCER CELL-INHIBITING CERAMIC, PROCESS FOR PRODUCING CANCER CELL-INHIBITING CERAMIC, METHOD FOR TREATING BONE TUMOR, AND USE OF BETA-TRICALCIUM PHOSPHATE POROUS GRANULES WITH PARTICLE SIZE OF 1 TO 10 MICROMETER - Proliferation of cancer cells is effectively inhibited. Provided is a cancer cell-inhibiting ceramic containing a β-tricalcium phosphate porous granule with a particle size of 1 to 10 μm. The β-tricalcium phosphate porous granule is taken up into cancer cells at an affected area and have an effect of inhibiting proliferation of a cancer tissue. The β-tricalcium phosphate porous granule with a particle size of 1 to 10 μm can be used to more effectively inhibit the proliferation of the cancer cells. | 10-02-2014 |
20140294972 | Oral Suspension - A liquid pharmaceutical composition for use in the treatment of acute lymphoblastic leukaemia (ALL) comprising 6-mercaptopurine or a salt, hydrate or solvate thereof and a pharmaceutically-acceptable excipient, wherein the composition is a suspension for oral administration, a kit of parts for the accurate dosing and administration of the liquid pharmaceutical composition, and a method for the treatment of ALL in a human patient comprising administration of a therapeutically effective amount of the liquid pharmaceutical composition. | 10-02-2014 |
20140294973 | PHARMACEUTICAL COMPOSITIONS OF HYDROPHOBIC CAMPTOTHECIN DERIVATIVES - The present invention provides a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or a pharmaceutically acceptable salt of said derivative and a polyethylene glycol (PEG) conjugated phospholipid. Also provided is a method to inhibit cancer cells in a subject in need thereof by administering the pharmaceutical composition of the present invention. | 10-02-2014 |
20140294974 | COSMETIC COMPOSITION - The invention relates to a cosmetic composition comprising an emulsion comprising hydrophobically modified particles, amino functionalized silicone and water; the cosmetic composition further comprising a moisturizing agent and at least one component selected from the group consisting of vitamin, anti-dandruff agent and surfactant, wherein the composition comprises at least a vitamin or anti-dandruff agent. The invention further relates to a method of treating a skin condition comprising the step of topically applying to the skin the cosmetic composition of the invention. | 10-02-2014 |
20140294975 | SOLID ANTI-SUN COMPOSITION BASED ON LIPOPHILIC ORGANIC UV SCREENING AGENT AND AEROGEL PARTICLES OF HYDROPHOBIC SILICA - The present invention thus relates to a solid composition, in particular in the form of a loose or compact powder, comprising, in a cosmetically acceptable medium: a) at least one pulverulent phase; b) at least one lipophilic organic UV screening agent characterized in that the pulverulent phase comprises at least aerogel particles of hydrophobic silica exhibiting a specific surface per unit of weight (S | 10-02-2014 |
20140294976 | COSMETIC PREPARATION COMPRISING PULVERIZED HYDROPHILIC SUBSTANCES - A substance, which is in principle insoluble in a cosmetic or dermatological anhydrous preparation is converted into a powdery product by absorption onto a carrier, the powdery product being soluble in the preparation. The anhydrous preparations comprise one or more hydrophilic substances or substance mixtures which are liquid, pasty at room temperature and/or meltable up to a temperature of 150° C. and which are absorbed on one or more particulate carriers. The hydrophilic substance or substance mixture in itself is insoluble or sparingly soluble in the preparation and the carriers are characterized by a particle size ranging from 5 nm to 2 mm, a tamped density of between 50 kg/m | 10-02-2014 |
20140294977 | Radiation-Sterilized Biodegradable Drug Delivery Composition - The present disclosure is directed to a method of making a composition by combining a vehicle, e.g., a single phase vehicle, and an insoluble component comprising a beneficial agent, and sterilizing the composition using ionizing radiation prior to use, wherein the beneficial agent is stable following exposure to a sterilizing dose of ionizing radiation. Related compositions and methods are provided. | 10-02-2014 |
20140302145 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER USING CARBONATE APATITE NANOPARTICLES - A principal object of the present invention is to provide a pharmaceutical composition that can produce a high antitumor effect by efficiently delivering a drug with antitumor activity to tumor tissues with the aid of carbonate apatite nanoparticles. The present invention provides a pharmaceutical composition including carbonate apatite nanoparticles with an average particle size of at most 50 nm containing a drug with antitumor activity and a pharmacologically acceptable solvent in which the carbonate apatite nanoparticles containing the drug are dispersed. | 10-09-2014 |
20140302146 | Ophthalmic Aqueous Composition - The present invention provides an ophthalmic aqueous composition having an oil-in-water emulsion including a vegetable oil, a non-ionic surfactant, and a terpenoid, wherein an average particle diameter of emulsion particles is within the range of 30 nm to 300 nm. | 10-09-2014 |
20140302147 | RESPIRABLE AGGLOMERATES OF POROUS CARRIER PARTICLES AND MICRONIZED DRUG - Embodiments of the present invention provide a dry powder composition comprising porous carrier particles associated with one, two, three or more micronized drugs or APIs wherein an ordered mixture between the micronized drug or drugs and the carrier particle results, such that the micronized drug or drugs adhere strongly to the carrier particles forming a stable ordered mixture of respirable agglomerates. Embodiments of the present invention further comprise a spray-drying process to create the respirable agglomerates. Embodiments of the present invention further relate to the use of the dry powder formulation comprising respirable agglomerates for the treatment of a patient having a disease or condition which is treatable thereby. | 10-09-2014 |
20140302148 | CANNABINOID FORMULATIONS - The present invention provides stable, fast-acting liposomal and micelle formulations of cannabinoids that are suitable for pharmaceutical and nutraceutical applications. | 10-09-2014 |
20140302149 | Selective Chemokine Modulation - A method of treating or preventing a disease characterized by adverse expression and/or release of 10 kDa interferon-γ inducible protein, IP-10, comprises administering granules or particles made of a metal or an oxide of a metal to a subject suffering from the disease. A method of reducing IP-10 in a subject suffering from a disease characterized by adverse expression and/or release of IP-10 comprises administering granules or particles made of a metal or an oxide of a metal to the subject. The metal is a metal of group 4 or 5 of the periodic table of the elements and selected from the group consisting of titanium, zirconium, hafnium, niobium and tantalum. | 10-09-2014 |
20140302150 | DPP-IV INHIBITOR FORMULATIONS - The present invention relates to a pharmaceutical formulation, characterized by comprising a DPP-IV inhibitor and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. | 10-09-2014 |
20140302151 | METHODS AND COMPOSITIONS FOR TREATING PAIN - Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy. | 10-09-2014 |
20140308351 | Method of Forming Non-Immunogenic Hydrophobic Protein Nanoparticles, and Uses Therefor - Methods are described for producing non-immunogenic nanoparticles from protein sources by controlling the pH in a nanoprecipitation process. The nanoparticles that are produced by the disclosed methods range in diameter size from about 100 ran to about 400 nm, with a preferred diameter size of from approximately 100 nm to approximately 300 nm, thereby rendering them non-immunogenic. The invention further discloses methods for producing nanoconjugates that are suitable for a variety of therapeutic, diagnostic and other uses. | 10-16-2014 |
20140308352 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT, AND HIGH VISCOSITY LIQUID CARRIER MATERIAL - Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. | 10-16-2014 |
20140308353 | DELIVERY OF AN ACTIVE MATERIAL - A composition for use as a topical delivery system for an active material is provided, the composition comprising a plurality of skin cell removal particles and a plurality of active material molecules, at least some of the skin cell removal particles each carrying at least one active material molecule, wherein carrying of an active material molecule by a skin cell removal particle maintains activity of the active material molecule. A topical delivery system for an active material, and a method of topical delivery of an active material are also provided. | 10-16-2014 |
20140308354 | SUSTAINED RELEASE BIMATOPROST, BIMATOPROST ANALOGS, PROSTAMIDES AND PROSTAGLANDINS FOR FAT REDUCTION - The present invention is directed to compositions and methods for injection into fat deposits for sustained release of compounds which result in localized fat reduction. | 10-16-2014 |
20140308355 | Oral Compositions Containing Polyorganosilsesquioxane Particles - Oral compositions containing a polyorganosilsesquioxane particle, preferably polymethylsilsesquioxane particles and an orally-acceptable carrier containing a gel network. Method of using such compositions for the cleaning and polishing of dental enamel, such methods including the step of applying such oral care compositions to the teeth of a user. | 10-16-2014 |
20140308356 | GRANULAR MATERIAL FOR DOSAGE FORMS - A granular material which has
| 10-16-2014 |
20140308357 | MELATONIN-BASED SOLUTIONS AND POWDERS FOR THEIR PREPARATION - The present invention relates to a powder for reconstitution before use for preparations for injection containing melatonin, at least one soluble excipient and at least one surfactant for the treatment of neonatal cerebral infarction. The present invention also relates to a preparation for injection in the form of a solution obtained by dissolving a powder to be reconstituted comprising melatonin, at least one soluble excipient and at least one surfactant, in a mixture of water and polyalkylene glycol, in which the melatonin is present in quantities of from 3 to 30 mg/ml and the polyalkylene glycol is present in quantities from 5 to 40% of the total volume of the liquid used. | 10-16-2014 |
20140314850 | FUNCTIONALIZED NANODIAMONDS AS DELIVERY PLATFORMS FOR NUCLEIC ACIDS - The present application relates to functionalized nanodiamonds, to complexes comprising a functionalized nanodiamond reversibly bound to a nucleic acid and to compositions comprising such functionalized nanodiamonds and complexes. In particular, the functionalized nanodiamonds comprise at least one naturally occurring basic amino acid, or analogs or derivatives thereof, covalently linked to a nanodiamond. The present application also includes methods and uses of the complexes and compositions, for example for delivering a nucleic acid to a cell. | 10-23-2014 |
20140314851 | DAIRY PRODUCT AND PROCESS - The invention relates to liquid nutritional compositions, particularly shelf stable liquid nutritional compositions including compositions comprising non-hydrolysed whey protein, and methods of producing and using these compositions. | 10-23-2014 |
20140314852 | NANOPARTICULATE SYSTEMS PREPARED FROM SORBITAN ESTERS - The invention relates to systems comprising homogenous nanoparticles having an average size of less than 1 micrometer and containing at least a sorbitan ester, a macrogol ester, a macrogol ether or a derivative of same and, optionally, at least one component derived from oxyethylene and/or at least one component having an electric charge (positive or negative). According to the invention, the components are incorporated in a single step consisting in mixing two solutions. The invention also relates to the use of said systems as medicines or medical devices, in tissue engineering or regenerative medicine, for cosmetic, hygienic or nutritional uses, and in surface coatings. The invention further relates to methods for preparing same. | 10-23-2014 |
20140314853 | MICROSPHERES FOR CONTROLLED- OR SUSTAINED-RELEASE DELIVERY OF THERAPEUTICS - A new microsphere formulation (composition) for controlled- or sustained-release delivery of therapeutic ingredient(s), mainly peptides and proteins not over 10K in molecular weight, comprises at least a therapeutic ingredient, a helping agent (such as PH sensitive agent whose solubility is a function of pH) and a biodegradable polymer. The therapeutic ingredient(s) and the helping agent are in the form of fine particles, less than 1O um in diameter, encapsulated in the polymer which forms the microsphere matrix. A method for preparing the composition comprises a step of in-situ precipitating the therapeutic ingredient(s) and the helping agent to the fine particles and successive steps for forming the microspheres. Such a microsphere formulation offers a well-controlled release profile for prolonged period and encapsulation efficiency over 95%. | 10-23-2014 |
20140322328 | DRY POWDER FORMULATIONS AND METHODS OF USE - The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin. | 10-30-2014 |
20140322329 | MULTIPURPOSE GEL FOR VAGINAL DRYNESS WITH DIRECT AND DELAYED EFFECT - The present invention relates to topical vaginal compositions in gel form containing immune mediators, growth factors, chemotactic factors and antibacterial/antiviral factors extracted from bovine colostrum, and optionally other ingredients with complementary activity. | 10-30-2014 |
20140322330 | METHODS FOR FORMING MINIEMULSIONS AND USE THEREOF FOR DELIVERING BIOACTIVE AGENTS - The present invention relates to methods of forming miniemulsions and use of the miniemulsions as a delivery system for bioactive agents. In particular, the present invention relates to methods for forming a miniemulsion comprising providing a first phase comprising a hydrophilic surfactant, lipophillic surfactant and water and a second phase comprising a lipid, wherein said miniemulsion comprises emulsified particles having a mean diameter of 1 μm or less. | 10-30-2014 |
20140322331 | CALCIPOTRIOL MONOHYDRATE NANOCRYSTALS - Calcipotriol monohydrate nanocrystals prepared by the process disclosed herein may be incorporated in a pharmaceutical composition for use in the prevention or treatment of dermal diseases and conditions. | 10-30-2014 |
20140322332 | ANTAGONISTS OF MUC1 - The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics. | 10-30-2014 |
20140322333 | CHELATED NANOCERIA FOR THE TREATMENT OF OXIDATIVE STRESS - A process for making cerium-containing nanoparticles with biocompatible stabilizers is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid, a stabilizer (chelator) selected from the group consisting of nitrilotriacetic acid, ethylene glycol tetraacetic acid and diethylenetriaminepentaacetic acid, and an oxidant, is provided, followed by a heating step to effectively form the nanoparticles. These biocompatible nanoparticles can be used to treat oxidative stress related diseases and events, such as ischemic stroke. | 10-30-2014 |
20140322334 | ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE - [Object] An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high dissolubility even in persons having low stomach acid, and that can also ensure dissolubility after being allowed to stand for a certain period of time. Another object is to provide a simple method for producing the oral solid preparation. | 10-30-2014 |
20140322335 | SUSPENSIONS OF CYCLOSPORIN A FORM 2 - Disclosed herein are methods of formulating cyclosporin A Form 2. | 10-30-2014 |
20140322336 | SUSTAINED-RELEASE MICROSPHERES AND METHODS OF MAKING AND USING SAME - Provided, among other things, are compositions and methods for making sustained-release microspheres, as well as a microsphere delivery system for the sustained release of an active agent. The microsphere delivery system comprises a homogenous mixture of biodegradable polymer, active agent, and a so-called release-modifying agent (including a pH-stabilizing agent), and provides protected and sustained release of active agents from the microsphere delivery system. According to the invention, the microspheres preferably are produced by an oil-in-water emulsion method that involves the production of a homogeneous oil phase prepared by mixing active agent and a release-modifying agent, such as arginine, with biodegradable polymer, each dissolved in organic solvent. The homogeneous oil phase desirably is then dispersed in an aqueous phase containing an emulsifying agent, followed by solvent removal, to produce the microspheres in which the active agent and release-modifying agent are distributed homogeneously throughout the biodegradable polymer matrix. | 10-30-2014 |
20140322337 | HEAT GENERATING NANOMATERIALS - The present invention relates to a heat-generating composition, comprising a hetero-structure nanomaterial which comprises (a) a first material comprising at least one component selected from the group consisting of a metal, a metal chalcogen, a metal pnicogen, an alloy and a multi-component hybrid structure thereof; and (b) a second material comprising at least one component selected from the group consisting of metal, metal chalcogen, metal pnicogen, alloy and the multi-component hybrid structure thereof; wherein the first material is enclosed in the second material; wherein at least one of the first material and the second material comprise a magnetic material. The specific loss power of the present nanomaterial is much higher than that of conventional nanomaterials (e.g., 40-fold higher than commercially accessible Feridex) and may be controlled by changing compositions or ratios of the first material and/or the second material. The heat-generating nanomaterial of the present invention may be used in a variety of application fields, for example cancer hyperthermia. | 10-30-2014 |
20140322338 | FLURBIPROFEN FORMULATIONS - This invention relates to a pharmaceutical formulation, characterized by comprising flurbiprofen and polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. | 10-30-2014 |
20140328917 | ORGANIC COMPOUND NANO-POWDER, METHOD FOR PRODUCING THE SAME AND SUSPENSION - An organic compound nano-powder comprising a granular organic compound with an average particle diameter of 500 nm or less and a 90%-diameter of less than 1500 nm and a carbohydrate compound comprising at least any one of a sugar and a sugar alcohol and with amount of 0.3 times or more by mass relative to amount of the organic compound, a method for producing the same, and a suspension having the organic compound dispersed in a liquid dispersion medium in which the organic compound is insoluble or poorly soluble. | 11-06-2014 |
20140328918 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS - Described herein are methods for treating a subject with combinations of polymer-agent particles and cyclodextrin polymer agent conjugates. The methods herein may be used to treat subjects identified with cancer, cardiovascular disorders, autoimmune disorders, or inflammatory disorders. Also described herein are compositions, dosage forms, and kits comprising polymer-agent particles and cyclodextrin polymer agent conjugates. | 11-06-2014 |
20140328919 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE - Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles. | 11-06-2014 |
20140328920 | SYSTEM FOR THE DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS INTO AN ORGANISM AND METHOD FOR THE PREPARATION OF SAID SYSTEM - The invention relates to the field of pharmaceutics, pharmaceutical nano-technology and pharmacology and concerns a system for delivering biologically active agents into an organism, the system comprising a nano-diamond with a particle size of 2-10 nm, the surface of said particles being modified by chlorine with a chlorine content of up to 14%, and to a method for producing said system. | 11-06-2014 |
20140328921 | TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE OR PREVENT ANAPHYLAXIS IN RESPONSE TO A NON-ALLERGENIC ANTIGEN - This invention relates to methods for reducing or preventing anaphylaxis to non-allergenic antigens with compositions comprising immunosuppressants, and related compositions. | 11-06-2014 |
20140328922 | LOCAL, CONCOMITANT ADMINISTRATION OF TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE TYPE I AND TYPE IV HYPERSENSITIVITY - Disclosed are methods and related compositions for concomitantly, locally administering immunosuppressants and doses of therapeutic macromolecules for reducing Type I and Type IV hypersensitivity. | 11-06-2014 |
20140328923 | DOSING COMBINATIONS FOR REDUCING UNDESIRED HUMORAL IMMUNE RESPONSES - Disclosed are dosings of therapeutic macromolecules and immunosuppressants, in some embodiments attached to synthetic nanocarriers, in combination with dosings of therapeutic macromolecules without synthetic nanocarriers, and related methods that provide reduced humoral immune responses. | 11-06-2014 |
20140328924 | DELIVERY OF IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE-LIFE AND ANTIGEN FOR THE INDUCTION OF IMMUNE TOLERANCE - This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule. | 11-06-2014 |
20140328925 | MICRONIZED TANAPROGET, COMPOSITIONS, AND METHODS OF PREPARING THE SAME - The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 11-06-2014 |
20140328926 | MODIFIED HYALURONIC ACID POLYMER COMPOSITIONS AND RELATED METHODS - The present application provides compositions comprising hyaluronic acid having low levels of functional group modification, mixtures formed by controlled reaction of such lightly modified hyaluronic acid with suitable difunctional or multi-functional crosslinkers, and hydrogel precursor compositions and the resulting hydrogels. The compositions are lightly cross-linked and possess low pro-inflammatory properties when injected in vivo, and can be used as, for example, medical devices, biomedical adhesives and sealants, and for localized delivery of bioactive agents, among other uses. | 11-06-2014 |
20140328927 | ANTI-CANCER NANOPARTICLE COMPOSITIONS AND METHODS OF USE - The present invention encompasses a composition capable of delivering and expressing a nucleic acid encoding UDP-Glucuronosyltransferases, p53 or a combination thereof into a cell, and methods for treating tumors. | 11-06-2014 |
20140328928 | Stable Aqueous Suspension - An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension. | 11-06-2014 |
20140328929 | Method of Preventing Acute Graft-Versus-Host Disease using Oral Beclomethasone Dipropionate - Results from two randomized trials have shown that oral beclomethasone dipropionate (BDP) is effective for treatment of acute gastrointestinal graft-versus-host disease (GVHD). Here, we report results of a double-blind, randomized placebo-controlled phase II study designed to test the hypothesis that acute GVHD could be prevented by administration of oral BDP, beginning before hematopoietic cell transplantation (HCT) and continuing until day 75 after HCT. Study drug (BDP or placebo) was administered as 1 mg immediate-release formulation plus 1 mg delayed-release formulation orally four times daily. According to the primary endpoint, systemic glucocorticoid treatment for GVHD was given to 60 of the 92 participants (65%) in the BDP arm, versus 31 of 46 participants (67%) in the placebo arm. The secondary efficacy endpoints showed no statistically significant differences between the two arms. The proportion of participants who took at least 90% of the prescribed study drug during the first 4 weeks after HCT was 54% overall. Lower severity of mucositis strongly correlated with higher adherence to the schedule of study drug administration. Inconsistent adherence related to mucositis during recovery after myeloablative conditioning may have obscured a beneficial therapeutic effect in the current study. | 11-06-2014 |
20140335184 | NANOPARTICLE ASSEMBLY, PREPARATION THEREOF, AND ACTIVE MATERIAL DELIVERING COMPOSITE COMPRISING THE SAME - Provided are a nanoparticle assembly including a DNA hydrogel and gold nanoparticles, methods of preparing thereof, and an active material delivering composite including the same. The nanoparticle assembly has an excellent biocompatibility, an ability to prevent an accumulation of the nanoparticle assembly in a body, and is capable of being used to provide physical and chemical treatment. | 11-13-2014 |
20140335185 | NOVEL MICROCARRIER BEADS - The invention relates to a novel microcarrier bead; a method for producing same; a therapeutic comprising said microcarrier bead and attached thereto or grown thereon at least one selected cell or tissue type; a method for making said therapeutic; and a method of treatment involving the use of said microcarrier bead or said therapeutic. | 11-13-2014 |
20140335186 | METHODS AND COMPOSITIONS FOR ENHANCING CD4+ REGULATORY T CELLS - Disclosed are methods and related compositions for administering immunosuppressants and therapeutic macromolecules for enhancing CD4+ regulatory T cells. | 11-13-2014 |
20140335187 | COMPOSITIONS AND METHODS FOR DECREASING THE EFFECTS OF ALCOHOL - The present invention relates probiotic compositions useful in accelerating alcohol catabolism in a subject. | 11-13-2014 |
20140335188 | COSMETIC PREPARATION COMPRISING PULVERIZED HYDROPHOBIC SUBSTANCES - A substance, which is in principle insoluble in a cosmetic or dermatological preparation, is converted into a powdery product by absorption onto a carrier, wherein said powdery product can be distributed better in the preparation. The preparations comprise water and one or more hydrophobic substances or substance mixtures which are liquid and pasty at room temperature and/or meltable up to a temperature of 150° C. and which are absorbed on one or more particulate carriers. The hydrophobic substance or substance mixture in itself is insoluble or sparingly soluble in the preparation and the carriers are characterized by a particle size ranging from 5 nm to 2 mm, a tamped density of between 50 kg/m | 11-13-2014 |
20140335189 | INTESTINAL PEPTIDE TARGETING LIGANDS - Peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed. | 11-13-2014 |
20140341995 | Conjugate With Target-Finding Ligand and Use Thereof - Described is a conjugate of agent complex and at least one target-finding ligand, where the agent complex comprises an agent encapsulated by an encapsulation material and where the target-finding ligand is a prostacyclin analog, and the use of the conjugate. | 11-20-2014 |
20140341996 | Nanoengineering of Functionalized Polymers and Its Manufacturing and Formulation Methods for Personalized Cancer Therapies - Nanoengineering of inert polymers to develop functionalized sulfonated polymers to harness the power of Alternate complement system to stimulate and amplify cytotoxic potentials of classical and lectin based complement system Manufacturing functionalized sulfonated polymer to better penetrate tumor microenvironment, actively target various cancer antigens in conjunction with monoclonal antibodies in a safe way to inhibit host inflammatory reactions while maximizing cytotoxic potentials. The methods provide nanopolymers to safely maximize the cytotoxic potential of existing and evolving cancer therapies. Combining nanopolymers with existing and evolving cancer drugs to provide personalized cancer therapies. | 11-20-2014 |
20140341997 | CONTINUOUS PROCESS FOR PREPARING MICROSPHERES AND MICROSPHERES PREPARED THEREBY - The present invention relates to a continuous process for preparing microspheres and microspheres prepared thereby, and in particular, a process for preparing microspheres comprising steps of injecting a first emulsion and a second emulsion at the same time to form microspheres instantaneously, applying high pressure to the microspheres formed, and injecting the microspheres into an agitator, wherein the steps can be carried out continuously, and microspheres prepared thereby. | 11-20-2014 |
20140341998 | PHARMACEUTICAL COMPOSITION FOR INHALATION - The present invention relates to a powder formulation which reduces side effect risk of a medicine having a side effect of drug-induced photodermatosis and increases therapeutic effect, and relates to the method for producing the same. | 11-20-2014 |
20140341999 | ANTITUBERCULAR COMPOSITION AND METHOD FOR PRODUCING SAME - The invention relates to the field of pharmaceutics and medicine and concerns a medicinal composition of antitubercular preparations with a phospholipid transport system, the composition consisting of a fatty acid salt, phosphatidylcholine of vegetative origin (73-97%), maltose and an antitubercular agent selected from rifamycin, protionamide, rifabutin and rifapentine, and a method for producing the composition. | 11-20-2014 |
20140342000 | POROUS SCAFFOLD WITH CARBON-BASED NANOPARTICLES - A biocompatible porous scaffolds, especially bone regeneration scaffolds, comprising carbon-based nanoparticles, especially diamond nanoparticles, methods for the production of such biocompatible porous scaffolds, the use of such biocompatible porous scaffolds and methods for treating bone defects by inserting such biocompatible porous scaffolds comprising carbon-based nanoparticles into the bone defect. | 11-20-2014 |
20140342001 | MEDICAMENTS - There is described a bimodal pharmaceutical composition comprising effective amounts of a first active ingredient which substantially comprises a coarse fraction and a second active ingredient which substantially comprise a fine fraction characterized in that the coarse fraction possesses a greater mass median aerodynamic diameter than the fine fraction. There is also described a method of delivering a therapeutically effective amount of a substantially fine active ingredient to the lung of a patient by co-administration with a substantially coarse active ingredient. | 11-20-2014 |
20140342002 | PARTICULATE MATERIALS - Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μm suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof. In some examples, the alkaloid ergotamine contains dihydroergotamine, such as dihydroergotamine mesylate and the hydrofluorocarbon fluid vehicle contains HFA 134a, HFA 227ea, or mixtures thereof. | 11-20-2014 |
20140348921 | NOVEL HEMOSTATIC COMPOSITION - The present invention relates to a novel hemostatic composition notably useful to ensure good hemostasis and maintain the sulcular opening after a gingival eviction procedure. | 11-27-2014 |
20140348922 | PROCESS FOR PRODUCING A PARTICULATE COMPOSITION COMPRISING AN HYDROUS CRYSTALLINE 2-O-ALPHA-D-GLUCOSYL-L-ASCORBIC ACID - The invention provides a process for enabling the production of a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside that does not significantly cake even when the production yield of ascorbic acid 2-glucoside does not reach 35% by weight. The process for producing a particulate composition containing anhydrous crystalline ascorbic acid 2-glucoside, which comprises allowing a CGTase to act on a solution containing either liquefied starch or dextrin and L-ascorbic acid and then allowing a glucoamylase to act on the resulting solution to obtain a solution with an ascorbic acid 2-glucoside production yield of at least 27%, purifying the obtained solution to increase the ascorbic acid 2-glucoside content to a level of over 86% by weight, precipitating anhydrous crystalline ascorbic acid 2-glucoside by a controlled cooling method or pseudo-controlled cooling method, collecting the precipitated anhydrous crystalline ascorbic acid 2-glucoside, and ageing and drying the collected anhydrous crystalline ascorbic acid 2-glucoside. | 11-27-2014 |
20140348923 | Polymeric Drug-Delivery Material, Method For Manufacturing Thereof And Method For Delivery Of A Drug-Delivery Composition - A method for manufacturing a drug-delivery composition includes providing at least one pharmaceutically active compound, a dry powder comprising at least a polymer, and an aqueous solution. The dry powder, the pharmaceutically active compound and the aqueous solution are mixed to form a paste-like or semi-solid drug-delivery composition, wherein the aqueous solution is added in an amount of less than or equal to twice the total dry mass of the dry powder. | 11-27-2014 |
20140348924 | PARTICLES COMPRISING SINGLE STRANDED RNA AND DOUBLE STRANDED RNA FOR IMMUNOMODULATION - The present invention relates to chimeric particles comprising single stranded RNA (ssRNA), double stranded RNA (dsRNA) and at least one cationic agent, a pharmaceutical composition containing said particles and to a method of producing the same. The particles of the present invention are particularly useful as an immunostimulating medicament with a superlative pattern of immunostimulation. | 11-27-2014 |
20140348925 | Antioxidant Ingredient With Low Calorie Content, Method for Obtaining Same and Use Thereof - The present invention relates to an antioxidant ingredient with low calorie content obtainable by a process that comprises the following steps: (a) selecting as raw material at least one fruit and/or plant material with high antioxidant content, greater than 6 g/100 g dry matter; (b) obtaining juice and pulp by means of grinding, squeezing and/or pressing the raw material; (c) extracting sugars from the pulp obtained in the preceding step in order to produce a pulp with low calorie content; (d) dehydrating the pulp by means of a method selected from air drying, low-temperature drying with application of vacuum and/or freeze-drying; and (e) milling the pulp in order to produce the antioxidant ingredient with low calorie content. Likewise, the invention relates to the process for obtaining said ingredient and to the use thereof for the production of functional foods. | 11-27-2014 |
20140348926 | FORMULATION AND METHOD FOR INCREASING ORAL BIOAVAILABILITY OF DRUGS - The application discloses a formulation and method for increasing bioavailability of an orally administered drug. | 11-27-2014 |
20140348927 | CONDITIONING HAIR-CLEANING AGENT - Cosmetic cleaning agents include in a cosmetically acceptable carrier a) at least one anionic surfactant, b) at least one cationic guar polymer, c) at least one silicone emulsion, in which the silicone particles have an average diameter of a maximum of 600 nm, and d) at least one wax. The cosmetic cleaning agents are suitable in particular for use as a shampoo. After application they impart improved properties to the hair treated therewith, in particular improved wet and dry combability. | 11-27-2014 |
20140348928 | SUBSTITUTED N-ARYL PYRIDINONES - Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 11-27-2014 |
20140348929 | Omega-3 Fatty Acid Ester Compositions - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 11-27-2014 |
20140348930 | Omega-3 Fatty Acid Ester Compositions - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 11-27-2014 |
20140356433 | Pharmaceutical Carrier and Drug Structure Using the Same - The present invention provides a pharmaceutical carrier and a drug structure using the carrier. The drug of the present invention comprises particular contents of chitosan, a negatively charged polymer, sodium tripolyphosphate, and an active ingredient, which combine with each other via electrostatic attraction. The drug structure has better release property and longer retention time; therefore overcomes the current drawbacks of the conventional treatment. | 12-04-2014 |
20140356434 | PHARMACEUTICAL FORMULATION - Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises an insoluble corticosteroid; a soluble corticosteroid; and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, intra-lesional injection, or an intra-ocular injection. | 12-04-2014 |
20140356435 | Hydrophobic Drug-Delivery Material, Method For Manufacturing Thereof And Methods For Delivery Of A Drug-Delivery Composition - A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition. | 12-04-2014 |
20140356436 | DERMOCOSMETIC COMPOSITIONS BASED ON A SYNERGISTIC COMBINATION OF COLLOIDAL SILVER AND DEOXYRIBONUCLEIC ACID - The present invention relates to dermocosmetic compositions containing, as active ingredients, a synergistic combination of colloidal silver and deoxyribonucleic acid, characterized in that the colloidal silver is more particularly an aqueous solution of electro colloidal silver. | 12-04-2014 |
20140356437 | Corticosteroids for the Treatment of Joint Pain - Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production. | 12-04-2014 |
20140356438 | PERIPHERALLY ADMINISTERED VISCOUS FORMULATIONS - Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25° C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time. | 12-04-2014 |
20140363508 | PHARMACEUTICAL FORMULATIONS OF FLURBIPROFEN AND GLUCOSAMIN - The present invention relates to pharmaceutical formulations of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly, the present invention relates to a stable formulation of this combination having desired levels of dissolution rate and solubility which comprises at least one polymer having a low glass transition temperature. | 12-11-2014 |
20140363509 | COMPOSITIONS FOR THE TREATMENT OF MUCOUS MEMBRANE DISEASES - Composition comprising at least one active principle, at least one vehicle for said active principle and particles of porous silica, in which the active principle is contained in at least one pore of at least a first portion of such silica particles and in that vehicle, for use in the treatment of a disease of a mucous membrane. | 12-11-2014 |
20140363510 | PHARMACEUTICAL COMPOSITION INCLUDING PIMOBENDAN - A solid formulation includes pimobendan or a pharmaceutically acceptable salt thereof, which is homogenously dispersed with a polyvalent acid and a flavor suitable to animals. | 12-11-2014 |
20140363511 | METHOD OF TREATING MIDDLE EAR INFECTIONS - Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane. | 12-11-2014 |
20140370095 | Weight Loss Compositions and Methods for Appetite Suppression - A beverage composition for weight loss is provided which includes cayenne pepper; a palate enhancing agent selected from the group consisting of fruits, herbs, vegetables and mixtures thereof, the agent including pulp of the fruits, the herbs, the vegetables or the mixtures thereof; a least two spices selected from the group consisting of black or white pepper, ginger, cinnamon, mustard seed and mixtures thereof; and water in an amount from 80 to 99% by weight of the composition; and wherein the composition has a total calorie content from 0 to 100 based on 100 gram of the composition. | 12-18-2014 |
20140370096 | GAS TRANSPORTING RHEOLOGICAL MEDIUM, END USES AND RELATED APPARATUS-METHOD - A two-phase mixture is provided having a dissolved gas and a suspension of bubbles in a liquid. Methods for making, maintaining, and using the two-phase mixture are also provided. The gas molecules may be introduced into the liquid at a high velocity under elevated pressure to form a supersaturated solution that retains the dissolved gas concentration in solution when the solution is exposed to ambient conditions. The mixture may be used in a number of applications where high concentrations of gas must be retained in solution during prolonged exposure to ambient conditions. An example is the treatment of wounds to non-surgically remove dead, devitalized, contaminated and foreign matter from tissue cells. | 12-18-2014 |
20140370097 | STERILE PHARMACEUTICAL COMPOSITIONS - The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects. | 12-18-2014 |
20140370098 | TINTED EMULSION - The present invention relates to a cosmetic composition for caring for and/or making up keratin materials which is in the form of an oil-in-water emulsion which undergoes phase inversion when it is applied to said keratin materials, comprising: (i) at least one pigment having a particle size greater than 100 nanometers, and (ii) a combination of at least one hydrophilic surfactant and at least one lipophilic surfactant. It also relates to the associated cosmetic process. | 12-18-2014 |
20140370099 | ARTIFICIAL ANTIGEN PRESENTING CELLS HAVING A DEFINED AND DYNAMIC SHAPE - Compositions and methods comprising asymmetrical artificial antigen presenting cells (aAPCs) are disclosed. The non-spherical aAPCs more closely mimic endogenous cell-cell interactions and can be used for antigen-specific immunotherapy. | 12-18-2014 |
20140370100 | BONE FILLER COMPOSITION - A bone filler composition comprises a mixture of a curable calcium phosphate based bone filler which is formed from a liquid component and a calcium phosphate based powder component, and a formulation which comprises a bisphosphonate in particulate form. The particles of the bisphosphonate being embedded in particles of a polymeric material which resorbs when the formulation is implanted. | 12-18-2014 |
20140370101 | 2,2',6,6'-TETRAISOPROPYL-4,4'-BIPHENOL LIPID MICROSPHERE PREPARATIONS AND PREPARATION METHODS THEREFOR - This invention relates to a 2,2′,6,6′-tetraisopropyl-4,4′-biphenol lipid microsphere preparation having 2,2′,6,6′-tetraisopropyl-4,4′-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water. | 12-18-2014 |
20140370102 | METHOD AND COMPOSITION FOR PHARMACEUTICAL PRODUCT - This invention is directed to a composition comprising dry granulated tenofovir DF and emtricitabine, and a method for making same. Dry granulation was unexpectedly found to be important in preparing a tenofovir DF containing composition suitable for inclusion in a combination dosage form containing emtricitabine, efavirenz and tenofovir DF. | 12-18-2014 |
20140370103 | NON-IMMUNOGENIC DELIVERY VEHICLE FOR BETTA-, GAMMA-, AND DELTA-TOCOPHEROLS AND METHODS OF USING AND MAKING SAME - This disclosure provides microparticles for the delivery of non-immunogenic compositions providing delivery of β-, γ- and/or δ-tocopherols. | 12-18-2014 |
20140377355 | Levofloxacin Inhalation Composition - An antibiotic inhalation composition for the treatment of bacteria related diseases in the respiratory tract is provided. The antibiotic inhalation composition may include a mixture of levofloxacin and a micronized poloxamer composition (excipient/solubilizer). Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. The manufacturing method for micronized poloxamer composition may include any suitable process, such as non-contact mixing technology. This technology may include an apparatus for applying low-frequency acoustic field, in order to facilitate the mixing process. Antibiotic inhalation composition may be delivered to the respiratory tract employing any suitable inhalation devices, such as metered-dose inhalers (MDIs), dry powder inhalers, aerosols, syringe, pipette, forceps, measured spoon, eyedropper, nebulizers, or any suitable medically approved delivery apparatus. Furthermore, the synergistic effect of micronized poloxamer composition may provide improved solubility, dispersibility, and bioavailability of any suitable API within the antibiotic inhalation composition; thus, decreasing side effects and time of treatment. | 12-25-2014 |
20140377356 | Inhalation Composition for Treating Respiratory Tract Infections - An inhalation composition for the treatment of bacteria related diseases in the respiratory tract is provided. The inhalation composition may include a mixture of levofloxacin, betamethasone, and a micronized poloxamer composition (excipient/solubilizer). Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. The manufacturing method for micronized poloxamer composition may include any suitable process, such as non-contact mixing technology. This technology may include an apparatus for applying low-frequency acoustic field, in order to facilitate the mixing process. Inhalation composition may be delivered to the respiratory tract employing suitable inhalation devices, such as metered-dose inhalers (MDIs), dry powder inhalers, aerosols, syringe, pipette, forceps, measured spoon, eyedropper, nebulizers, or any suitable medically approved delivery apparatus. Furthermore, the synergistic effect of micronized poloxamer composition may provide improved solubility, dispersibility, and bioavailability of any suitable API within the inhalation composition; thus decreasing side effects and time of treatment. | 12-25-2014 |
20140377357 | Poloxamer Based Inhalation Composition - An inhalation composition for the treatment of bacteria related diseases is provided. The disclosed composition may include a mixture of three or more API(s) and a micronized poloxamer composition. Micronized poloxamer composition may include poloxamer 188 and poloxamer 407. According to an embodiment, an inhalation composition including one or more APIs may be delivered to the respiratory tract by employing inhalation devices, such as inhalers and nebulizers. Antibiotic inhalation composition may provide improved solubility and bioavailability for three or more API(s), such as levofloxacin, betamethasone, and clindamycin. Furthermore, the synergistic effect of micronized poloxamer composition may provide improved solubility and bioavailability of any suitable API. | 12-25-2014 |
20140377358 | NANOPARTICULATE FORMULATION COMPRISING A TRPA1 ANTAGONIST - The present invention relates to a nanoparticulate formulation comprising a transient receptor potential ankyrin-1 receptor (“TRPA1”) antagonist. Particularly, the present invention relates to a nanoparticulate formulation comprising a thienopyrimidinedione derivative as a TRPA1 antagonist and a surface stabilizer; a process for preparing such formulation; and its use in treating a respiratory disorder or pain in a subject. | 12-25-2014 |
20140377359 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 12-25-2014 |
20140377360 | COMPOSITION FOR CONTROLLED RELEASE OF PHYSIOLOGICALLY ACTIVE SUBSTANCE - A composition for controlled release of a physiologically active substance can release a physiologically active substance in vivo at the desired timing. The composition includes an inner layer that is formed of a biodegradable substance that supports a physiologically active substance, and an outer layer that is formed of a biodegradable substance that differs from that of the inner layer. | 12-25-2014 |
20140377361 | STABLE METAL ION-LIPID POWDERED PHARMACEUTICAL COMPOSITIONS FOR DRUG DELIVERY - A microparticle for drug delivery comprises an active agent and an excipient, the excipient comprising a metal ion-lipid complex. The metal ion is chosen from the group consisting of lanthanide metals, actinide metals, group IIa and IIIb metals, transition metals or mixtures thereof. The lipid comprises a phospholipid. The complex results in a glass transition temperature increase of the microparticle. | 12-25-2014 |
20140377362 | HEMOSTATIC COMPOSITIONS, DEVICES, AND METHODS - Compositions that include a clay such as kaolin dispersed in a liquid such as water may be useful for promoting the clotting of blood. The compositions may be in a liquid, gel, paste, foam, or another form. Uses may include treating a traumatic injury such as in injury caused by a bullet, an explosive, a blade etc., or an injury caused during a medical procedure such as surgery. | 12-25-2014 |
20140377363 | 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-HT3 And 5-HT1a Activity For The Treatment Of Cognitive Impairment - This disclosure relates to a method of treating a disease selected from the group consisting of affective disorders, depression, major depressive disorder, anxiety, general anxiety disorder, social anxiety disorder, obsessive compulsive disorder, panic disorder, and panic attacks. The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to a patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine. | 12-25-2014 |
20150010631 | IMMUNE-MODIFYING NANOPARTICLES FOR THE TREATMENT OF INFLAMMATORY DISEASES - The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles. | 01-08-2015 |
20150010632 | NOVEL AEROSOL FORMULATIONS OF GRANISETRON AND USES THEREOF - Aerosol formulations of granisetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations. | 01-08-2015 |
20150010633 | NOVEL AEROSOL FORMULATIONS OF ONDANSETRON AND USES THEREOF - Aerosol formulations of ondansetron useful for pulmonary delivery are provided. The formulations are useful in the reduction, elimination or prevention of nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Also provided are novel methods to treat chemotherapy-induced nausea and vomiting (CINV), radiation-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) using the inhalation formulations. | 01-08-2015 |
20150010634 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS - The present invention relates to pharmaceutical compositions comprising hydrogel-linked prodrug for use in the treatment, prevention and/or diagnosis a condition of the eye and ophthalmic devices comprising said pharmaceutical compositions. | 01-08-2015 |
20150010635 | CONTROLLED RELEASE PARTICLES, WOOD TREATMENT AGENT, AND PRODUCING METHOD THEREOF - Controlled release particles are obtained by dissolving a hydrophobic antibiotic compound with a hydrophobic polymerizable vinyl monomer to prepare a hydrophobic solution, blending water with an emulsifier to prepare an aqueous emulsifier solution, emulsifying the hydrophobic solution in the aqueous emulsifier solution, and polymerizing the polymerizable vinyl monomer by mini-emulsion polymerization in the presence of a polymerization initiator, thereby producing a polymer containing an antibiotic compound and having an average particle size of below 1 μm. | 01-08-2015 |
20150010636 | Apparatus and Method for Reducing the Occurrence of Post-Surgical Adhesions - A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range up to seven days. Tests conducted on laboratory rats established that the method reduced the incidence of adhesions from 100 percent (100%) in a test model to near zero in the majority of treated animals. In an alternative embodiment, andrographalide was delivered via a pump with similar results. In still another embodiment, an effective amount of 50% phosphatidylchorene and propylene glycol was delivered, via a pump, into the abdominal cavity, again with similar results. | 01-08-2015 |
20150010637 | Aqueous Suspensions of TMC278 - This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection. | 01-08-2015 |
20150017244 | DRY POWDER FORMULATION OF AZOLE DERIVATIVE FOR INHALATION - A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate. | 01-15-2015 |
20150017245 | METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES - The present disclosure relates in part to methods of treating cholangiocarcinoma or tonsillar cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein nanoparticle composition comprises nanoparticles. | 01-15-2015 |
20150024050 | DRY POWDER FORMULATIONS OF DNASE I - DNase I formulations for pulmonary administration and, more particularly, but not exclusively, a dry powder formulation comprising, as an active ingredient, human DNase I, methods, dry powder inhalation devices and systems for the therapeutic use thereof are provided. | 01-22-2015 |
20150024051 | INJECTABLE HYDROGEL SYSTEM TO MODULATE HOST RESPONSE AT BONE IMPLANT INTERFACE - A bone implant primer is provided. A biodegradable hydrogel component is provided. A plurality of biomolecule release depots are dispersed within the biodegradable hydrogel component wherein the plurality of biomolecule release depots comprise biomolecules for aiding implant osseointegration or biomolecules for mitigation of foreign body response. Different biomolecules may be released by the microspheres at different times. | 01-22-2015 |
20150024052 | Nitric Oxide Releasing Pharmaceutical Compositions - The present invention generally relates to nitric oxide releasing pharmaceutical compositions and methods of using the same. | 01-22-2015 |
20150024053 | TOPICAL WOUND TREATMENT METHOD AND COMPOSITION - A topical wound treatment composition comprises a hydrogen peroxide generator; alkaline powder; not more than 5 percent by weight of water; additional topical active agent if desired, and emollient (preferably hygroscopic emollient) to balance. When topically applied to a wound and water from the surrounding environment diffuses into the composition, the hydrogen peroxide generator and/or the alkaline compound diffuse into one another, causing a chemical reaction that generates treatment-effective amounts of oxygen to occur. The oxygen can then diffuse out of the composition and aid in wound treatment or healing. | 01-22-2015 |
20150024054 | SOLID PHARMACEUTICAL DISPERSIONS WITH ENHANCED BIOAVAILABILITY - Spray dried solid dispersions comprising a sparingly soluble drug and hydroxypropylmethylcellulose acetate succinate (HPMCAS) provide increased aqueous solubility and/or bioavailability in a use environment. | 01-22-2015 |
20150024055 | ENHANCED IMMEDIATE RELEASE FORMULATIONS OF TOPIRAMATE - The present invention provides enhanced immediate release formulations of topiramate, in which 80% of the active ingredient is released in the period of time of not more than 30 min. These formulations may be advantageously used for the treatment of acute neurological conditions, such as migraine. | 01-22-2015 |
20150024056 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD - A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle thereof, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided. | 01-22-2015 |
20150030678 | Methods and Compositions for Treating Wounds and Reducing the Risk of Incisional Hernias - Provided are methods and compositions for treating a wound in a subject. The methods include applying a pharmaceutical composition that includes a first precursor material agent including fibrinogen, a second precursor material agent including thrombin, and silver particles to an abdominal incision site in an amount effective to treat the abdominal incision site. Also provided are pharmaceutical compositions and devices for use in the subject methods. | 01-29-2015 |
20150037418 | COSMETIC COMPOSITION - A cosmetic composition, comprising the following components (A), (B), (C), and (D): | 02-05-2015 |
20150037419 | Functional PLA-PEG Copolymers, the Nanoparticles Thereof, Their Preparation and Use for Targeted Drug Delivery and Imaging - Functional PLA-PEG copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging The present invention concerns novel functional PEG-PLA containing copolymers, the nanoparticles containing the same, their process of preparation and their use for site specific targeted drug delivery and imaging. | 02-05-2015 |
20150044288 | AEROSOL TYROSINE KINASE INHIBITOR COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of imatinib or a phenylaminopyrimidine derivative compound for aerosolization and use of such formulations for inhaled aerosol administration of imatinib or a phenylaminopyrimidine derivative compound for the prevention or treatment of various fibrotic, carcinogenic, vascular and viral infectious diseases, including diseases associated with the lung, heart, kidney, liver, eye, central nervous system and surgical sites. In some embodiments, formulations and delivery options described herein allow for efficacious local delivery of imatinib or a phenylaminopyrimidine derivative compound or salt thereof. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described. Also included are methods for identifying compounds and indications that may benefit by reformulation and inhalation administration. | 02-12-2015 |
20150044289 | HYPROMELLOSE ACETATE SUCCINATE FOR USE AS HOT-MELT EXTRUSION CARRIER, HOT-MELT EXTRUSION COMPOSITION, AND METHOD FOR PRODUCING HOT-MELT EXTRUDATE - Provided are hypromellose acetate succinates (HPMCAS) for use as a hot-melt extrusion carrier having a volume average particle size (D | 02-12-2015 |
20150044290 | TREATMENT METHOD USING LIQUID FOOD COMPOSITION - Provided is a liquid food composition capable of semi-solidifying in the stomach, which is a one-pack type product containing a water-soluble dietary fiber preliminarily added thereto and in the form of a liquid that can be easily taken, and stably sustains the liquid nature thereof during distribution and storage. The liquid food composition, which is capable of semi-solidifying in an acidic region, comprises a water-soluble dietary fiber (a), a specific metal compound (b), a protein (c) and an emulsifier (d), and the particle size distribution of particles contained in said liquid food composition shows two or more peaks in a neutral region. | 02-12-2015 |
20150044291 | METHODS FOR THE TREATMENT OF ENDOMETRIOSIS - Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided. | 02-12-2015 |
20150050342 | COMPOSITIONS FOR TREATMENT OF SKIN DISORDERS - Compositions are provided comprising: (i) chlorhexidine or a pharmaceutically acceptable salt thereof; (ii) niacinamide or niacin; and (iii) salicylic acid or a pharmaceutically acceptable salt or derivative thereof. The compositions are suitable for use in treating and preventing disorders of the skin. The compositions are also provided in the form of cosmetic products. | 02-19-2015 |
20150050343 | METHODS OF WOUND CARE AND TREATMENT - Provided are electrokinetically-altered fluids (e.g., gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating a wound to a surface tissue or a symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 02-19-2015 |
20150050344 | COMPOSITIONS AND METHODS FOR UPREGULATING HIPPOCAMPAL PLASTICITY AND HIPPOCAMPUS-DEPENDENT LEARNING AND MEMORY - Provided are methods for enhancing hippocampal plasticity and hippocampal-mediated learning and memory, and/or enhancing the synaptic maturation of neurons, and/or optimizing or enhancing neuronal synaptic transmission, and/or enhancing intracellular oxygen delivery or utilization, and/or enhancing ATP synthesis, comprising administration, to a subject in need thereof of a sufficient amount over a sufficient time, of an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures (e.g., nanobubbles) having an average diameter of less than 100 nm (e.g., in at least one subject group selected from but not limited to normal subjects, subjects recovering from neurological trauma (e.g., accidents or injury to the brain, stroke, oxygen deprivation, drowning, and asphyxia), and subjects with learning disorders (e.g., dyslexia, dyscalculia, dysgraphia, dyspraxia (sensory integration disorder), dysphasia/aphasia, auditory processing disorder, non-verbal learning disorder, visual processing disorder, and attention deficit disorder (ADD)). | 02-19-2015 |
20150050345 | METHODS FOR FINE PARTICLE MANUFACTURE - Processes for preparing micronized particles comprising a poorly water soluble bioactive agent are provided. The processes utilize a superheated aqueous phase which can serve as the continuous phase of an emulsion. The superheated aqueous phase can be used to melt poorly water soluble bioactive agents and/or matrix materials which them form molten droplets dispersed within the superheated aqueous phase. The size and size distribution of the molten droplets can be controlled using a variety of suitable methods. The molten droplets can then be cooled to form micronized particles comprising the poorly water soluble bioactive agent. If desired, the cooling rate can be selected to control the crystalline morphology of the resulting micronized particles. | 02-19-2015 |
20150050346 | COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE AND DIABETES MELLITUS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 02-19-2015 |
20150050347 | REVERSE MICELLE SYSTEM COMPRISING NUCLEIC ACIDS AND USE THEREOF - The present invention relates to reverse micelle system based on sterols, acylglycerols, phospholipids or sphingolipids and nucleic acids. The reverse micelle system of the invention is able to cross mucosa and cellular membranes. It thus allows vectorization of nucleic acids to target sites. It is advantageously useful in the pharmaceutical and dietetic fields. | 02-19-2015 |
20150056282 | Electrophoretically Deposited Strontium Fluoride Nanoparticle/Polymer Coatings For Medical Implants - The present disclosure provides for co-electrophoretic deposition (co-EPD) of organo-functionalized strontium fluoride nanoparticles (SrF | 02-26-2015 |
20150056283 | METHODS OF USING CERIUM OXIDE NANOPARTICLES TO MITIGATE OR PROTECT AGAINST RADIATION INJURY - Methods of mitigating the effects of radiation exposure or providing a radioprotective effect in a subject are provided herein. The methods include administering a therapeutically effective amount of cerium oxide nanoparticles to the subject to mitigate the effects of radiation exposure or to offer a radioprotective effect to the subject. The cerium oxide nanoparticles are suitably less than 20 nm in diameter and have over 50% of the cerium in the 3+ oxidation state. | 02-26-2015 |
20150056284 | PHARMACEUTICAL COMPOSITION - A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1′R,2′S,3′R,4′S)-2,3-bicyclo[2,2,1]-heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied. | 02-26-2015 |
20150056285 | SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS - The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance. | 02-26-2015 |
20150056286 | NANOPARTICULATE MEGESTROL FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm. | 02-26-2015 |
20150056287 | NANOPARTICULATE MEGESTROL FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm. | 02-26-2015 |
20150064254 | METHOD FOR TREATMENT OF PAIN AND INFLAMMATION - The present invention relates to a method for the treatment of pain and inflammation. In particular, the present invention relates to a method for the treatment of musculo-skeletal and connective tissue pain/inflammations. Further, the invention relates to reducing the incidence and seventy of adverse events resulting from administration of diclofenac. The method comprises administration of a topical pharmaceutical composition of diclofenac or its salts. | 03-05-2015 |
20150064255 | NANOSTRUCTURES FOR TREATING CANCERS AND OTHER CONDITIONS - Nanostructures, compositions and methods for treating cancers and other conditions are provided. In some cases, the nanostructures and/or compositions may be used to treat cancers or other diseases or conditions at least in part by controlling cholesterol metabolism in cells. The nanostructures and compositions may be used, for example, to control cholesterol influx and/or efflux in cells. In some cases, the nanostructures or compositions may be used to kill the cells. Examples of cancer cells that may be affected by the nanostructures and compositions described herein include those having scavenger receptor type B-I (SR-B1), B-cell lymphoma cells, non-Hodgkin's lymphoma cells, melanoma cells and/or others. In some embodiments, the nanostructures may be mimics of natural high-density lipoprotein (HDL). | 03-05-2015 |
20150064256 | POROUS CARBON PARTICLES FOR USE IN THE TREATMENT OR PREVENTION OF LIVER DISEASE - The invention provides porous carbon particles for use in the treatment or prevention of liver disease, wherein at least 20% of the total pore volume is made up of pores having a mean diameter of from 2 to 200 nm and/or wherein the particles comprise micropores of diameter 2 nm or less and small macropores of diameter 50 nm to 500 nm, but substantially no mesopores of diameter greater than 2 nm and less than 50 nm, and substantially no large macropores of diameter greater than 500 nm. | 03-05-2015 |
20150064257 | METALAXYL AND PROTHIOCONAZOLE COCRYSTALS AND METHODS OF MAKING AND USING - The invention relates to co-crystals of metalaxyl and prothioconazole, to methods of making them, to compositions containing them and to the methods of using said co-crystals and said compositions to treat crops and plants. | 03-05-2015 |
20150064258 | DICLOFENAC FORMULATIONS AND METHODS OF USE - Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting. | 03-05-2015 |
20150064259 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS RELATED TO LACK OF BLOOD SUPPLY, SHOCK AND NEURONAL INJURIES - A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure and correct hypovolemia. | 03-05-2015 |
20150064260 | COLLAGEN PRODUCTION ENHANCER - A collagen production enhancer for increasing the amount of collagen contained in the skin tissues, comprising calcium phosphate fine particles as effective ingredients. | 03-05-2015 |
20150072009 | Mesoporous Silica Compositions for Modulating Immune Responses - A composition comprising mesoporous silica rods comprising an immune cell recruitment compound and an immune cell activation compound, and optionally comprising an antigen such as a tumor lysate. The composition is used to elicit an immune response to a vaccine antigen. | 03-12-2015 |
20150072010 | Combination of Azelastine and Mometasone for Nasal Administration - A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration. | 03-12-2015 |
20150072011 | CARBOXYLVINYL POLYMER-CONTAINING NANOPARTICLE SUSPENSIONS - The present invention generally relates to suspension compositions having a carboxyvinyl polymer such as a carbomer, a galactomannan such as guar, and a borate compound. A sparingly soluble particulate compound such as nepafenac is also included in the compositions. The sparingly soluble particulate compound has a small particle size to enhance bioavailability of the compound. | 03-12-2015 |
20150072012 | NOVEL HIGHLY BIOAVAILABLE, WATER SOLUBLE AND SUSTAINED RELEASE NANOFORMULATIONS HYDROPHOBIC PLANT DERIVED COMPOUNDS AND EXTRACTS - A highly bioavailable, water soluble, sustained release nanoformulation comprising a hydrophobic plant derived compound(s) in an emulsifier phase, and aqueous phase. The formulation provides sustained release of the hydrophobic plant derived compound(s) over a 24 hr time period. A process for preparation of the water soluble nanoformulation is described. | 03-12-2015 |
20150072013 | INTRA-ARTICULARLY SUPPLEMENTATION METHOD FOR TREATING JOINT DISEASES AND INJURIES - A hydrogel bead for intra-articular supplement made by: | 03-12-2015 |
20150079173 | FORMULATIONS DECREASING PARTICLE EXHALATION - Formulations have been developed for pulmonary delivery to treat or reduce the infectivity of diseases such as viral infections, especially tuberculosis, SARS, influenza and respiratory synticial virus in humans and hoof and mouth disease in animals, or to reduce the symptoms of allergy or other pulmonary disease. Formulations for pulmonary administration include a material that significantly alters physical properties such as surface tension and surface elasticity of lung mucus lining fluid, which may be isotonic saline and, optionally, a carrier. The formulation may be administered as a liquid solution, suspension, aerosol, or powder where the particles consist basically of an osmotically active solute. Drugs, especially antivirals or antibiotics, may optionally be included with the formulation. These may be administered with or incorporated into the formulation. | 03-19-2015 |
20150079174 | ANTIMICROBIAL COMPLEXES - The invention relates to an antimicrobial surfactant complexed with a nanomaterial. The surfactant can be a quaternary ammonium cationic surfactant which is coated on the surface of a nanomaterial such as a silica nanoparticle or a carbon nanotube. | 03-19-2015 |
20150079175 | Topical Pharmaceutical Composition, Method for Producing the Topical Pharmaceutical Composition, Use of the Topical Pharmaceutical Composition and Method for the Topical Treatment of Psoriasis, Atopic Dermatitis or Chronic Eczema - This invention relates to a topical pharmaceutical composition comprising a combination of methotrexate, alpha bisabolol and allantoin; a process for producing the same and the use of the composition in the treatment of plaque psoriasis (psoriasis vulgaris), atopic dermatitis and chronic eczema. The composition of this invention can be used alone or in combination with other topical or systemic therapies. The present invention further discloses a process for producing the pharmaceutical composition. | 03-19-2015 |
20150079176 | ANTI-OXIDANT SYNERGY FORMULATION NANOEMULSIONS TO TREAT CANCER - A uniform microfluidized nanoemulsion is disclosed containing a synergistic combination of two antioxidants and a cell membrane stabilizer phospholipid (i.e., an anti-oxidant synergy formulation; ASF). The microfluidized nanoemulsion improves the combination's cell membrane permeability by at least four-fold over conventional nanoemulsion compositions, which significantly increases the intracellular concentration of typically cell-impermeant antixoidants (i.e., for example, tocopherol) and/or systemic bioavailability. As a nanoemulsion, synergistic combination has greater anticancer efficacy than the same combination applied as a free solution. | 03-19-2015 |
20150079177 | METHODS AND COMPOSITIONS FOR TREATING PROLIFERATIVE DISEASES - The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. | 03-19-2015 |
20150079178 | STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE - The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject. | 03-19-2015 |
20150079179 | SUSTAINED RELEASE FORMULATIONS OF PEPTIDOMIMETIC DRUGS AND USES THEREOF - The invention provides sustained release formulations comprising a C5a receptor antagonist. In certain embodiments the sustained-release formulations include microparticles that comprise a complement C5aR antagonist and a biodegradable polymeric matrix. Methods of treatment comprising the sustained release formulations of the invention are also provided. | 03-19-2015 |
20150079180 | NANOPARTICLE COMPOSITIONS OF DIMETHYL FUMARATE - Disclosed herein are compositions of dimethyl fumarate exhibiting reduced gastrointestinal irritation and related side effects. | 03-19-2015 |
20150079181 | METHODS AND COMPOSITIONS FOR TREATING RECURRENT CANCER - The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein. | 03-19-2015 |
20150079182 | PHARMACEUTICAL COMPOSITIONS COMPRISING SILICA MICROSPHERES - A topical composition which includes a silica microspheres and an active ingredient in the amount of 0.01 to 15.0% w/w wherein the active ingredient is selected from adapalene, an antibiotic, tazarotene, tretinoin, a retinoid, or any combination thereof. The topical composition may also include benzoyl peroxide as an active ingredient. The topical compositions provide sustained release of the active ingredient so as to reduce skin irritation. | 03-19-2015 |
20150086630 | Composition and Methods for Enhancing Surface Reflectance - Microspheres, typically sterile, inert, silica glass microspheres, are dispersed in a carrier suitable for use relative to the object to be imaged and analyzed. In the case of ophthalmic imaging, an ophthalmically-acceptable gel is used and the resulting composition is dispensed into a mammalian eye. The gel and microspheres dispersed therein coat and conform to the surface of the eye. The microspheres enhance reflectance from the eye which improves signal-to-noise ratio and improves imaging quality. | 03-26-2015 |
20150086631 | Multi-Functional Micro and Nanoparticles for Use in Root Canal Therapies - Chitosan nanoparticles are provided for use in the in vivo treatment of connective tissues in root canal therapies. The nanoparticles are optionally linked with one or more photoactivatable compounds for providing antibactenal/antibiofilm properties, neutralizing bacterial byproducts and/or chemical/photodynamic crosslinking to achieve enhanced mechanical properties, chemical stability in connective tissues and/or to improve surface/interfacial integrity between filling material and connective tissue. | 03-26-2015 |
20150086632 | Injectable Formulation - An object of the present invention is to provide a sustained-release injectable preparation which is in a medication administration form that can provide the effect of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for a prolonged period of time, the preparation releasing a therapeutically effective amount of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one for at least one week. The present invention provides an injectable preparation containing 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-3H-quinolin-2-one or a salt thereof as an active ingredient, which releases the active ingredient in such a manner that its blood concentration is maintained for at least one week. | 03-26-2015 |
20150086633 | SURFACE MODIFIED INORGANIC OXIDE FINE PARTICLES, AND SUNSCREEN COSMETIC MATERIAL CONTAINING SAME - Provided are surface-modified inorganic oxide fine particles that are added with water dispersibility while maintaining properties of inorganic oxide fine particles, such as transparency, ultraviolet blocking ability, weatherability, and photodiscoloration resistance; a method for producing the surface-modified inorganic oxide fine particles; and a sunscreen cosmetic containing the surface-modified inorganic oxide fine particles. | 03-26-2015 |
20150086634 | COSMETIC USES OF MOLDED PLACENTAL COMPOSITIONS - Described herein are methods of using molded dehydrated placental compositions, and cosmetic compositions thereof. The compositions have numerous cosmetic applications. | 03-26-2015 |
20150086635 | NANOPARTICULATE MEGESTROL FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm. | 03-26-2015 |
20150086636 | MYOSTATIN INHIBITION FOR ENHANCING MUSCLE AND/OR IMPROVING MUSCLE FUNCTION - The present invention relates to methods for inhibiting myostatin, a regulator of muscle mass, for muscle enhancement (including inducing hypertrophy and/or hyperplasia) as well as improving muscle function (including decreasing atrophy and/or increasing endurance, force and/or strength). Some of the methods involve delivering genes to cells using gene delivery or other delivery techniques known in the art in order to inhibit myostatin. Examples of genes to be delivered are genes encoding proteins such as Follistatin, Follistatin-related gene-1 (FLRG-1), growth differentiation factor associated protein-1 (GASP-1) and myostatin precursor propeptide. The genes can be delivered using, for example, a recombinant Adeno-associated virus (rAAV), lentivirus or equine-associated virus capable of infecting the cells. Following introduction, the genes are expressed in the cell body of the infected cell and the encoded proteins are secreted systemically. In other methods of the invention, expression of proteins such as activin IIb and myostatin is inhibited by oligonucleotide techniques to effect muscle enhancement. All the methods have applications in the treatment of musculoskeletal and neurodegenerative disorders among others, as well as enhancing muscle in livestock. | 03-26-2015 |
20150086637 | NOVEL COMPOSITION FOR TREATMENT OF ESSENTIAL THROMBOCYTHEMIA - The present invention relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable watersoluble acid and its use for the treatment of essential thrombocythemia. | 03-26-2015 |
20150086638 | AQUEOUS PARASITICIDAL SUSPENSION - Aqueous parasiticidal suspension typically comprising from 1 to 15% by weight of silica and from 30 to 45% by weight of sodium bicarbonate and method for controlling the development of parasites on animals raised in buildings, according to which the environment of the animal in the building is brought into contact with this aqueous suspension. | 03-26-2015 |
20150086639 | TUMOR VACCINE AND METHOD FOR PRODUCING THE SAME - The invention provides a tumor vaccine and method for producing the same. The tumor vaccine comprises cell vesicles derived from apoptotic tumor cells and an adjuvant. The invention further provides a preparation method of the tumor vaccine, comprising the steps of using the UV to irradiate the tumor cells to induce apoptosis, and collecting the cell vesicles released from the apoptotic tumor cells and then mixing the cell vesicles with the adjuvant to form the tumor vaccine. The tumor vaccine provided by the invention contains a broad and comprehensive tumor antigen spectrum, the defect that the existing tumor vaccine cannot have the killing capacity against the broad tumor cells can be overcome, and at the same time the tumor vaccine has good use safety and immune targeting property. | 03-26-2015 |
20150093440 | AGGREGATE NANOPARTICULATE MEDICAMENT FORMULATIONS, MANUFACTURE AND USE THEREOF - A method of making aggregate particles suitable for a powder aerosol composition that includes forming a dispersion of nanoparticulate drug and/or excipient in a non-aqueous liquid, and spray-drying the dispersion to generate aggregate particles having a mass median aerodynamic diameter of less than or equal to about 100 microns, and particles generated by such method, and compositions of said particles. | 04-02-2015 |
20150093441 | ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE AND METHOD FOR PRODUCING ORAL SOLID PREPARATION COMPRISING ARIPIPRAZOLE - An object of the present invention is to provide an oral solid preparation that can be produced in a simpler manner than conventional methods, that exhibits high bioavailability and high dissolubility even in persons having low stomach acid, and that can also ensure dissolubility after being allowed to stand for a certain period of time. Another object is to provide a simple method for producing the oral solid preparation. | 04-02-2015 |
20150093442 | INJECTABLE PREPARATION - An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s | 04-02-2015 |
20150093443 | MICROCOMPOSITES FOR TREATMENT OF BONE - Compositions having a drug-loaded microparticle and bone cement and methods of making such compositions are disclosed. Also disclosed are methods of employing such compositions for the treatment of injected joint spaces and bone disease. | 04-02-2015 |
20150098998 | CONTINUOUS MATRIX WITH OSTEOCONDUCTIVE PARTICLES DISPERSED THEREIN, METHOD OF FORMING THEREOF, AND METHOD OF REGENERATING BONE THEREWITH - The present disclosure provides compositions useful in regeneration of connective tissue, particularly bone. The compositions comprise a continuous matrix formed of a polypeptide crosslinked with a second polymer and further comprise particles of a porous, osteoconductive material dispersed in the continuous matrix. The composition can be provided in a dehydrated form. The disclosure further provides methods of preparing the composition in a clinically useful form, methods of using the composition in regenerating bone, and kits including the composition. | 04-09-2015 |
20150098999 | PHARMACEUTICAL PRODUCTS AND COMPOSITION COMPRISING SPECIFIC ANTIOCHOLINERGIC AGENTS, BETA-2 AGONISTS AND CORTICOSTEROIDS - This invention relates to pharmaceutical products and compositions for use in the treatment of asthma and related disorders, and especially but not exclusively for the treatment of chronic obstructive pulmonary disease (COPD). More particularly, the invention provides pharmaceutical products and compositions comprising specific anticholinergic agents, β-2 agonists and corticosteroids. | 04-09-2015 |
20150099000 | Polyamine Derivatives - Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules. | 04-09-2015 |
20150104515 | Particles for Inhalation Having Sustained Release Properties - The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion. | 04-16-2015 |
20150104516 | PROCESS FOR PREPARING PHARMACEUTICAL FORMULATIONS FOR INHALATION COMPRISING A HIGH-DOSAGE STRENGTH ACTIVE INGREDIENT - Cohesive high-dosage strength micronized active ingredients may be dispersed in dry powder formulations for inhalation comprising carrier particles, by use of the apparatus described herein. | 04-16-2015 |
20150104517 | AMINO-ACID-CONTAINING MEDICINAL GRANULAR PREPARATION HIGHLY EASY TO TAKE - The present invention aims to provide an amino acid-containing granule preparation improved in the ease of taking medication than conventional products, which disintegrates rapidly. The amino acid-containing granule preparation of the present invention containing granules having a maximum particle size of substantially not more than 1000 μm and a bulk density of not less than 0.57 g/mL markedly improves ease of taking medication without impairing disintegration property, as compared to conventional amino acid-containing granule preparations. | 04-16-2015 |
20150104518 | ENHANCED NITRIC OXIDE DELIVERY AND USES THEREOF - Methods and compositions are disclosed that enhance delivery of nitric oxide (NO) by combining nitric oxide releasing nanoparticles (NO-np) with exogenous glutathione (GSH), as well as therapeutic uses of the methods and compositions. | 04-16-2015 |
20150104519 | Pharmaceutical Compositions - Provided herein are formulations and methods for treating pain in human beings. Also provided are optimal ratios at which an opioid and an opioid antagonist may be combined for administration to humans such that the opioid activity is inhibited. These ratios may also be used to formulate compositions containing both an opioid and an opioid antagonist within a single pharmaceutical dosing unit. | 04-16-2015 |
20150110875 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF - Bolaamphiphilic compounds are provided according to formula I: | 04-23-2015 |
20150110876 | NOVEL COMPOSITION FOR GENE DELIVERY - Disclosed is a pharmaceutical composition for gene delivery, comprising: (i) a gene; (ii) a water-soluble chitosan; (iii) a thiamine pyrophosphate or a pharmaceutically acceptable salt thereof; (iv) a protamine or a pharmaceutically acceptable salt thereof; and (v) a neutral or anionic phospholipid. The composition can introduce a gene into cells safely and effectively. Composed of non-toxic and injectable components, the composition is safe for the body and can be advantageously commercialized. Notably, it can deliver a gene at high efficiency in vivo as well as in vitro, and is stable in the blood. | 04-23-2015 |
20150110877 | CANCER THERAPEUTICS - The invention relates to the treatment of cancer. In one embodiment, the present invention provides a composition comprising a micelle construct attached to a glut-1 antibody and a curcumin molecule. In another embodiment, the present invention provides a method of treating colon and/or breast cancer by administering a therapeutically effective amount of composition comprising a targeted construct attached to an inhibitor of NF-kB. | 04-23-2015 |
20150110878 | NANOPARTICLES OF INDIRUBIN, DERIVATIVES THEREOF AND METHODS OF MAKING AND USING SAME - The disclosure provides nanoparticles of indirubin and methods of making and using these particles for the treatment of cancer, neurodegenerative disorders and inflammatory diseases. The effective average particle size of the nanoparticles is less than 2000 nm. | 04-23-2015 |
20150118310 | ORGANIC-INORGANIC HYBRID COMPOSITE OF POLYMERIZED NITROXIDE COMPOUND AND INORGANIC PARTICLES - Provided is an organic-inorganic hybrid composite of a polymerized cyclic nitroxide radical compound and inorganic nanoparticles. Such a composite is capable, for example, of maintaining a stable nanoparticle shape in gastric fluid, and can be used by itself or as a carrier for delivery of another drug to the intestines. | 04-30-2015 |
20150118311 | Highly Penetrative Nanocarriers for Treatment of CNS Disease - Brain-penetrating polymeric nanoparticles that can be loaded with drugs and are optimized for intracranial convection-enhanced delivery (CED) have been developed. In the preferred embodiment, these are loaded with FDA-approved compounds, identified through library screening to target brain cancer stem cells (BSCSs). The particles are formed by emulsifying a polymer-drug solution, then removing solvent and centrifuging at a first force to remove the larger particles, then collecting the smaller particles using a second higher force to sediment the smaller particles having a diameter of less than 100 nm, more preferably less than 90 nanometers average diameter, able to penetrate brain interstitial spaces. | 04-30-2015 |
20150118312 | NOVEL DOSAGE AND FORMULATION - A pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a delivered dose of aclidinium equivalent to about 322 micrograms aclidinium free base. | 04-30-2015 |
20150118313 | ENHANCED FOLIC ACID FLUORESCENT MATERIAL, MULTIFLUORESCENT POROUS COMPOSITIONS OF MATTER AND POTENTIAL APPLICATIONS THEREOF - A method for the preparation of enhanced fluorescent folic acid mesoporous material, multifluorescent mesoporous materials, their novel properties and applications such as: a mesoporous fluorescent composition suitable for printing identification marks on metals, glass, plastic, ceramics, or paper which are visible only when excited by an external radiation; and applications in life science applications such as diagnostic, biodistribution markers, and targeted drug delivery applications. | 04-30-2015 |
20150118314 | COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF DERMATOLOGICAL/MUCOSAL DISEASES, AND USES THEREOF - A topical composition comprises a clay material with a negative surface charge; magnesium ions and calcium ions; water and/or a non-aqueous solvent; and a substantially non-cationic carrier. The mean particle size of the clay material is at least | 04-30-2015 |
20150125529 | Omega-3 Fatty Acid Ester Compositions - Described herein are compositions including at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 05-07-2015 |
20150125530 | Omega-3 Fatty Acid Ester Compositions - Described herein are compositions including at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 05-07-2015 |
20150125531 | ACTIVE SELF-HEALING BIOMATERIAL SYSTEM - Methods and compositions are provided that load and encapsulate an agent, such as a protein, in a porous self-healing polymer. A delivery system includes a porous self-healing polymer, an ionic affinity trap within the pores of the self-healing polymer, and an agent associated with the ionic affinity trap. Methods of encapsulating an agent in a polymer include providing a porous self-healing polymer comprising an ionic affinity trap within the pores. The polymer is incubated with an agent having an affinity for the ionic affinity trap. At least a portion of the pores in the polymer are then healed. Active encapsulation of macromolecules at low concentrations may be achieved due to affinity of the agent for the ionic affinity trap within the pores. | 05-07-2015 |
20150125532 | Etanercept Formulations Exhibiting Marked Reduction in Sub-Visible Particles - The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, with substantial reduction in sub-visible particles, and methods of manufacture of these compositions, methods of administration, and articles of manufacture. | 05-07-2015 |
20150132384 | POLYMERIC NANOPARTICLES USEFUL IN THERANOSTICS - Synthesis and characterization of starch based pH-responsive nanoparticles for controlled drug delivery are described. Polymethacrylic acid grafted starch (PMAA-g-St) nanoparticles with various molar ratio of starch to MAA were synthesized by a new one-pot method that enabled simultaneous grafting of PMAA and nanoparticle formation in an aqueous medium. NMR data showed that polysorbate 80 was polymerized into the graft polymer. Nanoparticles were relatively spherical with narrow size distribution and porous surface morphology and exhibited pH-dependent swelling in physiological pH range. The particle size and magnitude of volume phase transition were dependent on PMAA content and formulation parameters such as surfactant levels, cross-linker amount, and total monomer concentration. The results showed that the new pH-responsive nanoparticles possessed useful properties for controlled drug delivery. | 05-14-2015 |
20150132385 | NANOCRYSTALLINE SOLID DISPERSION COMPOSITIONS AND PROCESS OF PREPARATION THEREOF - The present invention relates to nanocrystalline solid dispersion compositions having discrete particles, wherein each discrete particle comprises crystals of at least one pharmaceutical active; veterinary active; nutraceutical active dispersed in the matrix of at least one crystallization inducer and/or coexisting with crystals of crystallization inducer, optionally along with pharmaceutically acceptable excipients. The present invention also encompasses a novel one-step process for generation of nanocrystalline solid dispersions. The present invention is particularly of use for improving the dissolution of pharmaceutical actives, veterinary actives; nutraceutical actives exhibiting dissolution-limited bioavailability. Dissolution enhancement is because of the decreased crystallite size of the pharmaceutical active. | 05-14-2015 |
20150132386 | DRY POWDER FORMULATION - A dry powder formulation comprising a combination of at least a first pharmaceutically active quinolone and a second pharmaceutically active quinolone. | 05-14-2015 |
20150132387 | TREATMENT OF INFLAMMATORY BOWEL DISEASE - The invention relates to the treatment of inflammatory bowel disease, also termed IBD, including ulcerative colitis and Crohn's disease. To this end, the invention proposes clinoptilolite having a particle size between 0.2 and 1 μm for use in the treatment of inflammatory bowel disease, also termed IBD, in mammals and humans. In the case of such use, the clinoptilolite is preferably freed of heavy metals. In one variant, it is administered orally, optionally with pharmaceutically harmless carrier materials and/or diluents. | 05-14-2015 |
20150132388 | COMPLEXES OF FULVESTRANT AND ITS DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to pharmaceutically acceptable complex formulae comprising complexes of Fulvestrant, or a salt, or derivatives thereof and complexation agents and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present invention have improved physicochemical properties which makes the compound orally available and makes oral administration of the compound possible in the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. | 05-14-2015 |
20150132389 | Omega-3 Fatty Acid Ester Compositions - Described herein are compositions including at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 05-14-2015 |
20150132390 | PATHOGENIC ATTENUATION VIA THE ADMINISTRATION OF AN EQUILIBIOTIC COMPOUND - A pharmaceutical preparation comprising as an active ingredient micron-sized sulphur particles [-(300 microns]. The pharmaceutical preparation further comprises an excipient, i.e. a sodium lignin sulphate or other suitable agents. The preparation is used for the prevention and treatment of pathogenic disorders in humans and animals, in a nutritional and/or supplemental regime, as well as, to improve feed and reproductive performance. A variety of conditions were treated including: pneumonia, arthritis, ulcers, diabetes mellitus, GI cancer, lupus, herpes, psoriasis and early menopause. | 05-14-2015 |
20150132391 | COMPOSITION COMPRISING NANOPARTICLES OF TI02 - The present invention is directed to a composition comprising nanoparticles of TiO | 05-14-2015 |
20150140096 | COMPOSITION AND METHOD OF PREPARATION OF BONE ALLOGRAFT FROM ENDOSTEAL PORTION OF BONE AND ISOLATED BONE PERIOSTEUM - Particulate bone and structural bone, more specifically decalcified bone from endosteum having osteoinductive capacity and methods for their isolation and production are provided, more specifically, decalcified bone preparations derived from endosteal layer of bone are provided. Compositions formulated with material from endosteal layer of bone are provided along with preparation and methods of using decalcified endosteal compositions are disclosed. Endosteum is avascular and areolar in distinction to bone marrow which fills the canal. Because of its structure and anatomic position, endosteum is difficult to isolate and recognize, and therefore not regarded as an important constituent of allograft materials. One embodiment of the present invention allows for recognition and isolation of endosteum. | 05-21-2015 |
20150140097 | CRYSTALLINE MICROSPHERES AND THE PROCESS FOR MANUFACTURING THE SAME - The present invention relates to microspheres and compositions comprising a plurality of microspheres, wherein the microspheres are perfectly spherical and have a moisture content less than 1%, and the method of manufacturing the same. The present invention is useful in the manufacture of sustained and modified release active pharmaceutical ingredient (API) microspheres, as a free flowing excipient for mini-tablets and in the manufacture of API dispersions. | 05-21-2015 |
20150140098 | ANIMAL FEED COMPRISING GRAIN AND AGARICUS BLAZEI EXTRACT AND USE OF THE FEED MATERIAL - The invention relates to the use of feed material comprising grain and | 05-21-2015 |
20150140099 | NOVEL DOSAGE FORM AND FORMULATION OF ABEDITEROL - A pharmaceutical composition for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a delivered dose of aclidinium equivalent to about 322 micrograms aclidinium free base. | 05-21-2015 |
20150140100 | MEDICAL DEVICE FOR TREATMENT OF WOUNDS - The present invention describes a medical device comprising a set of particles of titanium oxide, wherein at least a substantial amount of the particles are of micrometer—millimeter size, and wherein at least 10 wt % of the titanium oxide is in the amorphous form. | 05-21-2015 |
20150140101 | SOLID ORAL COMPOSITIONS OF SILODOSIN - The present disclosure relates to solid oral compositions of silodosin or its pharmaceutically acceptable salt thereof. More particularly capsule compositions of silodosin with one or more pharmaceutically acceptable excipients and process for their preparation. | 05-21-2015 |
20150140102 | METHOD TO PRODUCE A MEDICINAL PRODUCT COMPRISING A BIOLOGICALLY ACTIVE PROTEIN AND THE RESULTING PRODUCT - The present invention pertains to a method for producing a medicinal product comprising a biologically active protein comprising the steps of providing an aqueous composition comprising a solvent, the biologically active protein and between 20% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, thereby forming at least one frozen body comprising the solvent in frozen form, putting the frozen body in a drying apparatus while being carried by a support, the support comprising one or more restraining elements that define one or more boundaries of the support, wherein at most 30% of the surface of the body is contiguous with the one or more restraining elements, reducing the pressure in the drying apparatus below atmospheric pressure, providing heat to the body in order to sublimate the frozen solvent of the body and obtain a dried body. The invention also pertains to a product obtainable by this method. | 05-21-2015 |
20150140103 | VACCINE - The present invention relates to a nucleic acid for vaccine that has undergone codon optimization for expression in | 05-21-2015 |
20150140104 | THERAPEUTIC POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME - Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles. | 05-21-2015 |
20150140105 | FREE FLOWING, FROZEN COMPOSITIONS COMPRISING A THERAPEUTIC AGENT - Disclosed are frozen, free-flowing compositions that may contain one or more therapeutic agents and at least one flavoring agent, such compositions being useful for the delivery of an effective amount of a therapeutic agent to an individual in need thereof. Also disclosed are methods of making and using such compositions. | 05-21-2015 |
20150147396 | NANOPARTICLE DELIVERY VEHICLE FOR S-NITROSO-N-ACETYL CYSTEINE AND USES THEREOF - Nanoparticles are provided that comprise S-nitrosothiol (SNO) groups covalently bonded to the nanoparticles and/or S-nitrosothiol containing molecules encapsulated within the nanoparticles, as well as methods of making and using the nanoparticles. The invention also provides methods of preparing nanoparticles comprising Snitrosothiol (SNO) groups covalently bonded to the nanoparticles, where the methods comprise a) providing a buffer solution comprising chitosan, polyethylene glycol, nitrite, glucose, and hydrolyzed 3-mercaptopropyltrimethoxysilane (MPTS); b) adding hydrolyzed tetramethoxysilane (TMOS) to the buffer solution to produce a sol-gel; and c) lyophilizing and ball milling the sol-gel to produce nanoparticles of a desired size. | 05-28-2015 |
20150147397 | Biomatrix Hydrogels and Methods of Use Thereof - This invention is directed to aragonite and calcite hydrogel biomatrices, optionally seeded with precursor cells and uses thereof in tissue engineering, regeneration and repair, including in inducing or enhancing bone formation, cartilage formation or a combination thereof in a subject, and kits related thereto. | 05-28-2015 |
20150147398 | Paliperidone Implant Formulation - An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods. | 05-28-2015 |
20150147399 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEIN AND PEPTIDE THERAPEUTIC AGENTS - The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide. | 05-28-2015 |
20150290222 | PHARMACEUTICAL COMPOSITIONS COMPRISING ACTIVE DRUGS, CONTRACEPTIVE KITS COMPRISING ACTIVE DRUGS, AND METHODS OF ADMINISTERING THE SAME - A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m | 10-15-2015 |
20150290239 | PVAX COPOLYMER AND PVAX MICROPARTICLES COMPRISING THE SAME - The present invention includes a vanillyl alcohol-containing copolyoxalate copolymer (PVAX). The present invention also includes a PVAX microparticle comprising PVAX. In one aspect, the compositions of the invention can be used as a drug delivery system, an antioxidant or anti-inflammatory composition, a composition for preventing or treating ischemic disease, a composition for inhibiting the side effects of anticancer drugs, a contrast agent, and/or a composition for diagnosing ischemic disease. | 10-15-2015 |
20150290339 | NOVEL COMPOUND WITH EFFECTS OF THROMBOLYSIS, FREE RADICAL SCAVENGING AND THROMBUS-TARGETING AS WELL AS PREPARATION METHOD AND USE THEREOF - The present invention discloses a novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting, as well as a preparation method and use thereof. The compound is a ternary conjugate formed by conjugating a thrombolytic peptide, a free radical scavenger and a thrombus-targeting/antithrombotic peptide together via a linking arm. The present invention also discloses a pharmaceutical composition containing the compounds, wherein the compounds form a nanospherical structure. | 10-15-2015 |
20150290355 | POLYMETHYLMETHACRYLATE BONE CEMENT - Two-component bone cement comprising A) a paste as component A, comprising a1) methylmethacrylate; a2) at least one methylmethacrylate-soluble polymer having a number average molar mass of less than 500,000 Dalton; a3) at least one methylmethacrylate-insoluble particulate polymer having a particle size D50 of less than 50 μm; a4) at least one methylmethacrylate-soluble hydroperoxide; and a5) at least one methylmethacrylate-soluble tertiary amine; and B) a powder as component B, comprising b1) at least one particulate radiopaquer having a particle size D50 of less than 50 μm; b2) at least one methylmethacrylate-soluble heavy metal salt; and b3) at least one methylmethacrylate-soluble reducing agent. | 10-15-2015 |
20150297520 | MEDICAMENT-CONTAINING HOLLOW PARTICLE - The invention provides a particle composed of a shell and a hollow, wherein the shell contains a medicament and a polymer, and a volume ratio of the hollow relative to the whole particle is 1%-50%. The invention also provides a process for preparation of the hollow particle, which includes a step of granulating a powder mixture containing a medicament and a polymer, while spraying a solvent capable of dissolving the polymer. | 10-22-2015 |
20150297567 | TREATMENT FOR CHRONIC KIDNEY DISEASE - A method of treating chronic kidney disease by administering to a subject a composition that includes L-arginine, glycine, L-glutamine, L-histidine, L-aspartic acid L-glutamic acid, and L-carnosine. | 10-22-2015 |
20150297601 | PHOSPHODIESTERASE INHIBITOR TREATMENT - Methods and compositions are disclosed for the treatment of taste and smell disorders. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal administration. | 10-22-2015 |
20150297630 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON - The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof. | 10-22-2015 |
20150297737 | CHIMERIC IMMUNOMODULATORY COMPOUNDS AND METHODS OF USING THE SAME-IV - The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds. | 10-22-2015 |
20150299101 | SOLID STATE FORMS OF TAPENTADOL SALTS - Provided herein are novel solid state forms of tapentadol salts, process for their preparation, pharmaceutical compositions, and method of treating thereof. The tapentadol salts include an L-(−)-camphorsulfonate salt, a dibenzoyl-(L)-tartrate salt, a dibenzoyl-(D)-tartrate salt, a malate salt, a maleate salt, or a salicylate salt. | 10-22-2015 |
20150306039 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS - The present invention relates to lipid nanoparticles containing a biodegradable cationic lipid which provide improved delivery of active pharmaceutical ingredients, such as siRNA. | 10-29-2015 |
20150306062 | TREATMENT AND PREVENTION OF EPITHELIAL INFECTIONS - Provided herein are sprayable copper and zinc chelate formulations for the treatment and prevention of epithelial infections in sheep, goats, horses, and cattle. More particularly, the compositions comprise micronized copper and zinc chelates suspended in a liquid, wherein the total amount of copper and zinc chelate ranges from 5 to 50 percent by weight; and less than 5% (w/v) of the chelates are dissolved. | 10-29-2015 |
20150313935 | ENHANCED NITRIC OXIDE DELIVERY AND USES THEREOF - Methods and compositions are disclosed that enhance delivery of nitric oxide (NO) by combining nitric oxide releasing nanoparticles (NO-np) with exogenous glutathione (GSH), as well as therapeutic uses of the methods and compositions. | 11-05-2015 |
20150313938 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA WITHOUT CO-ADMINISTRATION OF LITHIUM - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. The present invention also relates to the use of the microporous zirconium silicate compositions in the treatment of diseases, where the subject is not concurrently receiving lithium based drugs. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 11-05-2015 |
20150313961 | Materials and Methods for Regulating Whole Body Glucose Homeostasis - Described herein are methods and materials for improving whole body glucose homeostasis in a subject. The methods and materials described herein are useful for preventing, delaying, and/or treating insulin-related diseases and conditions, including but not limited to type I and II diabetes, chronic pancreatitis, pancreatectomy, insulin resistance, prediabetes, and age-related insulin resistance, by increasing the efficiency of insulin secretion by β cells, and increasing the sensitivity of peripheral tissues, including skeletal muscle and adipose tissues. | 11-05-2015 |
20150313994 | SURFACE-MODIFIED IRON OXIDE PARTICLES FOR CANCER ABLATION - An object of the present invention is to provide surface-modified ferromagnetic iron oxide particles suitable for electromagnetic-induction cancer ablation, which have excellent heat generation properties and also have excellent dispersion stability in a medium for injection. The surface-modified iron oxide particles for cancer ablation of the present invention as a means for achieving the object are characterized in that a block copolymer of polyethylene glycol and polystyrene having a phosphorous acid group in the side chain is bound to the surface of ferromagnetic iron oxide particles having a plate-like shape with a length of 20 to 200 nm and a length-to-thickness ratio of 1.5 to 30 and having magnetic properties such that the coercivity is 30 to 300 Oe, the saturation magnetization is 20 to 80 emu/g, and the squareness ratio of the magnetic hysteresis loop is 0.20 to 0.50. | 11-05-2015 |
20150315574 | PRODUCTION OF STABLE NON-POLYADENYLATED RNAS - The invention relates in aspects to hybrid RNAs lacking a poly-A tail and nucleic acid vectors for expressing the RNA. The hybrid RNAs in some instances have a 3′ terminal stabilizing triple helical structure. Related methods for expressing said RNAs in vivo and in vitro are also disclosed. | 11-05-2015 |
20150320096 | Dietary Supplement - The present dietary supplement improves enzymatic function by supplying the increase demand of nutrients caused by diseases and toxins. The dietary supplement is scientifically designed to balance the Glucose/insulin system and provide energy. The continued use of the present dietary supplement stimulates a metabolic correction by means of providing the necessary cofactors that are lacking or are insufficient in our body, especially when continuously challenged by different stressors. | 11-12-2015 |
20150320684 | REHYDRATABLE PHARMACEUTICAL PRODUCT - A pharmaceutical product comprising lyophilised polymer matrix including a biologically active compound, of particular utility for embolisation, having improved rehydration properties is packaged in an airtight package under vacuum. | 11-12-2015 |
20150320736 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES - The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed. | 11-12-2015 |
20150320740 | ENHANCED DELIVERY OF DRUG COMPOSITIONS TO TREAT LIFE THREATENING INFECTIONS - Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (C | 11-12-2015 |
20150320768 | 17-Hydroxyprogesterone Ester-Containing Oral Compositions and Related Methods - The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier. | 11-12-2015 |
20150320809 | COMPOSITIONS AND METHODS FOR IMPROVING HUMAN HEALTH AND NUTRITION - The present invention provides compositions and methods of promoting human health and nutrition. | 11-12-2015 |
20150320833 | OSSIFICATION-INDUCING COMPOSITIONS AND METHODS OF USE THEREOF - Mesenchymal stem cells (MSCs) and uses thereof are provided. MSCs for inducing ossification and enhancing bone and/qr cartilage repair in a patient in need thereof are also provided. The method and compositions combine MSCs, at least one bone regeneration protein, such as bone morphogenetic protein (e.g. BMP-2), optionally in combination with additional cell growth factors including the components of a cell growth medium, further in combination with a biomaterial for delivery of the cells to the repair site in the patient are also provided. | 11-12-2015 |
20150320883 | FINITE FULLY ADDRESSABLE NUCLEIC ACID NANOSTRUCTURES AS NANOCARRIERS FOR DELIVERY OF PHARMACEUTICALS - The present invention provides nanostructures that are particularly well suited for delivery of bioactive agents to organs, tissues, and cells of interest in vivo, and for diagnostic purposes. In exemplary embodiments, the nanostructures are complexes of DNA strands having fully defined nucleotide sequences that hybridize to each other in such a way as to provide a pre-designed three dimensional structure with binding sites for targeting molecules and bioactive agents. The nanostructures are of a pre-designed finite length and have a pre-defined three dimensional structure. | 11-12-2015 |
20150320894 | Amorphous Carbon Supported Nanoparticles Comprising Oxides Of Lanthanides And Method For Preparing Them - The invention is directed to bodies comprising an amorphous carbon particle on which are supported nanoparticles of an oxide of lanthanide. These bodies find use as a pharmaceutical for use in a surgery or therapy and diagnostic methods. The bodies can be made by a process comprising impregnating a carbon source material by contacting it with a solution of a salt of said lanthanide; drying said impregnated carbon source material; and subjecting said dried impregnated material to pyrolysis under inert conditions. | 11-12-2015 |
20150327444 | PROCESS FOR THE OVERPRODUCTION OF SHIKIMIC ACID AND PHENOLIC ACIDS IN FRUIT AND VEGETABLE CROPS - The invention relates to a process for the overproduction of shikimic acid and phenolic compounds in fruit and vegetable crops, by means of the combined post-harvest application of abiotic stresses and glyphosate to fruit and vegetable crops in order to produce bioactive compounds of wide-ranging interest and commercial value. The carrot ( | 11-19-2015 |
20150328090 | COMPOSITION HAVING EARTH MATERIALS COMPRISING THE PIGMENT - A nail polish composition including a suspension base and a pigment, wherein at least 80% of the pigment is comprised of a noble metal, is provided. Furthermore, an associated method is also provided. | 11-19-2015 |
20150328157 | APPLICATION OF SILICON DIOXIDE AEROGEL AS NANO-DRUG CARRYING SYSTEM IN PHARMACY - The invention relates to an application of silicon dioxide aerogel as a nano-drug carrying system in pharmacy. The silicon dioxide aerogel has a nanosized drug carrying hole structure, and is a nanosized pharmaceutical excipient capable of realizing a physical drug carrying scale below 100 nm. | 11-19-2015 |
20150328159 | Composition - The invention provides microparticles comprising an immunosuppressant, such as tacrolimus, sirolimus, pimecrolimus, ciclosporin, everolimus or a derivative thereof, and optionally a pharmaceutically acceptable excipient or carrier, such as a saccharide, amino acid, a sugar alcohol or a mixture thereof, and having a median geometric diameter of less than, or equal to, about 10 μm and which have a tap density of less than or equal to about 0.3 g/cm | 11-19-2015 |
20150328169 | POLYMERIC PARTICLES-BASED TEMOZOLOMIDE DOSAGE FORM - The invention relates to pharmacology and medicine, and more specifically to slow-release antitumor drug composition based on biodegradable poly(lactic-co-glycolic acid) (PLGA). The composition comprises temozolomide (TMZ) as the active ingredient and comprises, in addition, surface-active material and a cryoprotectant as parts of nanoparticles. | 11-19-2015 |
20150328177 | STABLE MICELLES OF FATTY ACID ESTERS - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 11-19-2015 |
20150328178 | FUNCTIONAL FOODS AND KITS CONTAINING STABLE MICELLES OF FATTY ACID ESTERS - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 11-19-2015 |
20150328232 | PROSTACYLIN COMPOSITIONS AND METHODS FOR USING THE SAME - The present invention relates to pharmaceutical compositions comprising a prostacyclin, a cationic compound, and a surfactant. Particulate compositions, including liposomal, solid nanoparticulate prostacyclin compositions, including treprostinil formulations comprising cationic compound and the surfactant are also described. The present invention also relates to a system comprising the pharmaceutical composition and an inhalation device. Methods for treating pulmonary hypertension and portopulmonary hypertension with the compositions and systems described herein are also provided. | 11-19-2015 |
20150328264 | Placental Membrane Preparations and Methods of Making and Using Same for Regenerating Cartilage and Spinal Intervertebral Discs - A method for treating cartilage defects including providing a placental membrane preparation that includes ground or minced placental membranes and optionally, a ground or minced cartilage and/or biocompatible glue, and introducing the preparation to a cartilage defect within a skeletal joint. The cartilage defect may include a hyaline cartilage defect, such as a chondral defect, or meniscal defect. The treatment may be provided in combination with other treatments such as marrow stimulation treatments and surgical repair treatments using sutures or other fixation techniques. The preparation promotes the regeneration of cartilage within the skeletal joint. | 11-19-2015 |
20150328324 | STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 11-19-2015 |
20150328325 | STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASES - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 11-19-2015 |
20150328326 | STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF MACULAR DEGENERATION AND PRIMARY SCLEROSING CHOLANGITIS - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 11-19-2015 |
20150328327 | STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF DISEASE STATES - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 11-19-2015 |
20150328364 | A COMPOSITION FOR MAKING A CEMENT OR AN IMPLANT - A composition for making a cement or an implant, the composition comprising a silicate glass and at least one compound selected from the group consisting of a calcium phosphate salt, a strontium phosphate salt and a phosphate glass. | 11-19-2015 |
20150335573 | DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES - The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection. | 11-26-2015 |
20150335574 | COMPOSITIONS AND METHODS FOR MAKING AND USING NANOEMULSIONS - The present invention discloses an improved nanoemulsion comprising a uniform and discrete range of very small particle nano-sized diameters. This uniformity results in improved bioavailability of incorporated compounds (i.e., pharmaceuticals or nutraceuticals) as reflected in various pharmacokinetic parameters including, but not limited to, decreased Tmax, increased CmaX3 and increased AUC. The improved method of making these uniform nanoemulsions utilizes microfluidization which differs in both process and mechanics when compared to conventional milling and grinding techniques used to generate nanoparticulate compositions. Further, the improvement results, in part, from a novel step of mixing a substantially soluble compound into a heated dispersion medium. This is unlike current nanoparticulate composition methods that mix an insoluble compound with an unheated dispersion medium. Further, these nanoemulsions are observed to be bacterial-resistant and stable to extremes in both temperature and pH changes. Consequently, these nanoemulsions are expected to have a significantly prolonged shelf-life than currently available nanoemulsions. | 11-26-2015 |
20150335576 | METHODS OF USING POLYMERS - Provided herein are materials and methods of reducing contamination in a biological substance or treating contamination in a subject by one or more toxins comprising contacting the biological substance with an effective amount of a sorbent capable of sorbing the toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and sorbing the toxin. Also provided are kits to reduce contamination by one or more toxins in a biological substance comprising a sorbent capable of sorbing a toxin, wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm and a vessel to store said sorbent when not in use together with packaging for same. | 11-26-2015 |
20150335577 | MICROPARTICLES FOR ENCAPSULATING PROBIOTICS, PRODUCTION AND USES THEREOF - The invention relates to microparticles comprising a matrix formed by casein and chitosan, and probiotic bacteria; said matrix protects said probiotic bacteria during (i) processing, (ii) storage and (iii) transit through the gastrointestinal tract, prolonging their lifetime. The present invention also relates to the method for obtaining the microparticles and to the products and compositions incorporating them. | 11-26-2015 |
20150335595 | NOVEL VETERINARY PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to an oily composition of a non-steroidal anti-inflammatory agent (NSAIA) for parenteral administration with at least one micronised NSAIA, having an acid function and a biocompatible oily vehicle, such that said NSAIA is in the form of a free acid and said composition does not contain any added liquid agent that can solubilise said NSAIA. The invention also relates to the veterinary use thereof. | 11-26-2015 |
20150335620 | OIL SUSPENSION OF METRONIDAZOLE - The present invention relates to a palatable oral veterinary pharmaceutical composition consisting of an oil suspension of metronidazole and comprising metronidazole in an edible animal, vegetable or mineral oil and the use thereof for treating diarrhoea in animals, in particular giardiasis, or inflammatory diseases of the digestive tract. | 11-26-2015 |
20150335686 | MICRONIZED WHARTON'S JELLY - The present invention provides compositions and formulations of micronized Wharton's jelly having a controlled viscosity such that when delivered to the injured region of a subject, it remains substantially localized with little or no migration out of the injured region for the repair and/or regeneration thereof. Micronized Wharton's Jelly can be suspended in a pharmaceutically acceptable aqueous carrier, such as saline, sterile water, or any suitable buffer, to form a suspension or a gelatinous gel composition, or it can be in the form of a paste, suitable for delivery into the space adjacent the articular surface cartilage injured region of a subject. The micronized Wharton's jelly when employed at sufficient concentrations can be hydrated into a gel or paste and administered topically, or it can be injected into the body through the use of a needle and syringe. Accordingly, micronized Wharton's Jelly, compositions, or formulations thereof, can be delivered in a manner that is more convenient than Wharton's jelly that has not been micronized in accordance with the present invention. | 11-26-2015 |
20150337261 | EXTRACELLULAR MATRIX DERIVED FROM STEM CELLS AND METHODS FOR PRODUCTION - The subject invention pertains to acellular extracellular matrix (ECM) and methods for preparing it. In one embodiment, the ECM is prepared from 3-D aggregates of pluripotent stem cells or from embryoid bodies. In one embodiment, the ECM is in the form of acellular microspheres. The stem cells used in the present invention can be embryonic stem cells (ESC). In a specific embodiment, the stem cells or embryoid bodies are from human. The ECM of the invention can be mass produced using PSC aggregates or embryoid bodies in large scale bioreactors. The acellular ECM produced using the present invention can be used for injection into a person or animal to regenerate tissue and/or treat a disease or condition. A method of the invention comprises growing stem cells in suspension culture as aggregates, e.g., in a bioreactor. Acellular ECM is then prepared from the cell aggregates by decellularization. In a specific embodiment, a decellularization reagent comprising Triton X-100 is used, followed by treatment with a DNase. | 11-26-2015 |
20150342878 | Particles for Inhalation Having Sustained Release Properties - The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of a therapeutic, prophylactic or diagnostic agent comprising administering to the respiratory tract of a patient in need of treatment, prophylaxis or diagnosis an effective amount of particles comprising a therapeutic, prophylactic or diagnostic agent or any combination thereof in association with a charged lipid, wherein the charged lipid has an overall net charge which is opposite to that of the agent upon association with the agent. Release of the agent from the administered particles occurs in a sustained fashion. | 12-03-2015 |
20150342885 | Ultra Low Density Pulmonary Powders - The invention provides pharmaceutical compositions for pulmonary delivery comprising particles containing a pharmaceutical agent and having a geometric size of greater than about 5 μm and a tap density of less than about 0.075 g/cm | 12-03-2015 |
20150342897 | POLYPEPTIDE LOADED POCA NANOPARTICLES FOR ORAL ADMINISTRATION - Nanoparticles comprising biologically active peptides and poly(octylcyanoacrylate) as well as related subject matter is disclosed. | 12-03-2015 |
20150342910 | PHARMACEUTICAL COMPOSITIONS - The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula (I) (Formula (I)), wherein R | 12-03-2015 |
20150342936 | DRY POWDER FORMULATION COMPRISING A PHOSPHODIESTERASE INHIBITOR - Pharmaceutical formulations in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient are useful for the prevention and/or treatment of respiratory diseases, such as asthma and COPD. | 12-03-2015 |
20150342988 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 12-03-2015 |
20150342991 | ORALLY ADMINISTERED ADSORBENT, THERAPEUTIC AGENT FOR RENAL DISEASE, AND THERAPEUTIC AGENT FOR LIVER DISEASE - An object of the present invention is to provide spherical activated carbon exhibiting excellent adsorption ability for uremic substances in the body, and particularly for -aminoisobutyric acid. Accordingly, provided is an orally administered adsorbent comprising spherical activated carbon containing not less than 0.5 wt % of nitrogen atoms, having a specific surface area determined by the Brunauer-Emmett-Teller (BET) method of 700 m | 12-03-2015 |
20150343075 | PLACEBO FORMULATIONS AND USES THEREOF - The present technology relates to placebo compositions and their use in clinical trials for oral immunotherapy of peanut allergies. Therapy can be treatment or desensitization of peanut allergies. The placebo formulation is used as a control compared to an active ingredient formulation. Further, the present technology relates to methods for the preparation of the placebo compositions. | 12-03-2015 |
20150352041 | INJECTABLE DEPOT FORMULATION COMPRISING OPTICALLY ACTIVE TOLVAPTAN AND PROCESS OF PRODUCING THE SAME - This invention provides an injectable formulation to be administered intramuscularly or subcutaneously that is used for the prevention or treatment of polycystic kidney disease, and that can maintain a therapeutically effective blood concentration of tolvaptan for a long period of time; and a process for producing the same. More specifically, this invention relates to an injectable depot formulation comprising (1) a particle containing optically active tolvaptan as an active ingredient and (2) a pharmaceutically acceptable carrier for injection, and a process for producing the same. | 12-10-2015 |
20150352127 | INHALATION PARTICLES COMPRISING A COMBINATION OF AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC - Microparticles comprising a combination of an anticholinergic, a beta | 12-10-2015 |
20150352163 | EDIBLE PRODUCTS HAVING A HIGH COCOA POLYPHENOL CONTENT AND IMPROVED FLAVOR AND THE MILLED COCOA EXTRACTS USED THEREIN - Milling dry extracts containing cocoa polyphenols (CPs) to reduce the particle size improves the flavor of edible products (e.g., foods, medical foods, nutritional supplements, and pharmaceuticals) or additives containing the milled cocoa extracts. The products, e.g., chocolates, are less astringent and less bitter. The mean particle size after milling is less than about 15 microns, preferably less than about 10 microns, and most preferably less than about 5 microns. The total CP content of the milled extracts is at least about 300 milligrams and preferably about 300 to about 700 milligrams per gram of milled extract. The additives consist essentially of (i) the milled high CP cocoa extract and (ii) a fat (e.g., cocoa butter), an oil (e.g., vegetable oil), or a syrup (e.g., corn syrup). | 12-10-2015 |
20150352173 | INSTANT WATER SOLUBLE BIOACTIVE DIETARY PHYTONUTRIENTS COMPOSITION OF SPICE/HERB EXTRACTS AND A PROCESS FOR ITS PREPARATION - The present invention relates to a method for the preparation of the instant water soluble, stable, phytonutrient rich spice/herb extracts exhibiting significant antioxidant and other bioactivities, in a ready to use form and a composition for beverage and food applications to deliver physiologically relevant amounts of phytonutrients per serving without taste or aroma issue and in organic quality. The composition derived in the present invention include the bioactive phytonutrient molecules along with its natural counter parts comprising mainly proteins, carbohydrates and dietary fibre of the spice and/or herb. | 12-10-2015 |
20150352253 | INJECTABLE FIBRIN COMPOSITION FOR BONE AUGMENTATION - The present invention relates to a biodegradable injectable composition for bone augmentation comprising fibrin, a contrast agent and calcium salt-containing particles, as well as a method for bone augmentation in a patient suffering from a bone disorder comprising injecting said composition into a non-mineralized or hollow portion of said bone. | 12-10-2015 |
20150353821 | AN UPCONVERSION FLUORESCENT NANOPARTICLE - The present disclosure provides upconversion fluorescent nanoparticles comprising: a first nanocrystal layer, a second nanocrystal layer, and an energy absorbing layer disposed between the first nanocrystal layer and the second nanocrystal layer. There is also provided an article of manufacture comprising the upconversion fluorescent nanoparticles, as well as a bio-imaging and/or bio-detection apparatus comprising the upconversion fluorescent nanoparticles. The bio-imaging and/or bio-detection apparatus may further comprise a biomolecule and a source of excitation. | 12-10-2015 |
20150359735 | ORAL AND/OR BUCCAL COMPOSITION IN THE FORM OF A THIN FILM OF A WEAKLY SOLUBLE ACTIVE INGREDIENT, METHOD OF PREPARING SAME AND USE OF SAME - The present invention relates to an oral and/or buccal composition in the form of a thin film of a pharmaceutically active ingredient weakly soluble in water and gastro-intestinal tract fluids, comprising particles of said active ingredient dispersed in a film-forming polymer, at least 50% by weight of the total weight of the active ingredient having a particle size distribution such that at least 90% of said particles have a size below 1000 nm, preferably less than 800 nm, and even more preferably less than 600 nm, and to the method of preparing that composition and the use thereof. | 12-17-2015 |
20150359745 | Sodium bicarbonate particles manufactured by atomization - Method for producing sodium bicarbonate particles by spray-drying of an aqueous solution comprising 1 to 10% by weight of sodium bicarbonate and an additive selected from the group consisting of: magnesium salt, sodium alkylbenzene sulfonate and soybean lecithin. Sodium bicarbonate particles obtainable by such process and comprising at least 20 mg of the additive per kg of sodium bicarbonate particles. | 12-17-2015 |
20150359804 | EXTENDED-RELEASE DRUG DELIVERY COMPOSITIONS - An extended-release drug delivery composition and method of administering the same is provided. The composition comprises microspheres loaded with a biologically-active agent and suspended in a soluble polymer capable of forming a film upon injection onto a biological surface. | 12-17-2015 |
20150359821 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred composition has at least 95% ZS-9. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. These compositions are also useful in the treatment of chronic kidney disease, coronary vascular disease, diabetes mellitus, and transplant rejection. | 12-17-2015 |
20150359841 | METHODS AND COMPOSITIONS COMPRISING A C-TERMINAL BAX PEPTIDE - In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells. | 12-17-2015 |
20150359865 | TOLEROGENIC SYNTHETIC NANOCARRIERS FOR T-CELL-MEDIATED AUTOIMMUNE DISEASE - Disclosed are synthetic nanocarrier compositions, and related methods, comprising autoimmune antigens and immunosuppressants to reduce immune responses to autoimmune antigens. | 12-17-2015 |
20150359934 | Articles for Tissue Regeneration with Biodegradable Polymer - The invention is also directed to particulate articles comprising extracellular matrix components that are encased in a biodegradable polymer composition. Methods of for treating damaged tissue and regenerating new tissue at sites of the damaged tissue by placing a particulate article in mammals are claimed. | 12-17-2015 |
20150366805 | POROUS SILICA GEL AS A CARRIER FOR LIQUID TECHNOLOGIES - Compositions containing a biologically active ingredient and an inorganic oxide material are disclosed. Methods of making and using compositions containing a biologically active ingredient and an inorganic oxide material are also disclosed. The present invention relates to compositions comprising inorganic oxide porous material containing a biologically active ingredient in liquid form, methods of making such compositions, and methods of using them. | 12-24-2015 |
20150366818 | Nanoparticles containing a Taxane and their Use - Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclilaxei and its derivatives, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy. | 12-24-2015 |
20150366823 | PHARMACEUTICAL COMPOSITIONS INCORPORATING LOW-DOSE DRUGS - The present invention relates to novel pharmaceutical compositions in powder or granule form which comprise a low-dose drug attached to a water-soluble carrier, such as by adhesion or adsorption. The compositions further comprise an oily liquid which facilitates the attachment of the active ingredient to the carrier particles. Moreover, the invention provides methods for preparing such powders or granules, and compressed tablets incorporating them. | 12-24-2015 |
20150366849 | CRYSTALLINE N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINY- L)PHENYL]ACETAMIDE MONO MESYLATE MONOHYDRATE HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION RANGE AND A SPECIFIC SURFACE AREA RANGE FOR USE IN PHARMACEUTICAL FORMULATIONS - The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range. Moreover, the present invention relates to the pharmacokinetic and pharmacodynamic in vivo profiles of the resultant free base of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide after administration of the afore-mentioned crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide mono mesylate monohydrate salt to a subject in need thereof. | 12-24-2015 |
20150366875 | PRE-MIX COMPOSITION FOR CATTLE - The present invention concerns a premix composition for feeding cattle, comprising:
| 12-24-2015 |
20150366995 | MESOPOROUS OXIDE NANOPARTICLES AND METHODS OF MAKING AND USING SAME - Mesoporous oxide nanoparticles, compositions comprising such nanoparticle, and methods of making and using such nanoparticles. The nanoparticles (e.g., compositions comprising the nanoparticles) have an average size of less than 15 nm and a narrow size distribution. The nanoparticles can be used in imaging applications and delivery of molecular cargo (e.g., a drug) to an individual. | 12-24-2015 |
20150374629 | METHOD FOR FORMATION OF MICRO-PRILLED POLYMERS - A method for formation of micro-prilled poloxamer particles is disclosed. The particles find special use in pharmaceutical formulations. The process involves use of atomizing nozzles at higher than normal pressure atomizing gas, high atomizing gas temperature, use of high feed temperatures to reduce the viscosity of the poloxamer and optionally sieving after prill formation in prilling towers. The poloxamer particles are spherical and preferably have an average nominal diameter of less than or equal to 106 microns. The process is very cost effective and rapid. | 12-31-2015 |
20150374676 | HELICASE-PRIMASE INHIBITORS FOR USE IN A METHOD OF TREATING ALZHEIMER'S DISEASE - The present invention relates to the use of helicase-primase inhibitors in a method of treating Alzheimer's Disease (AD). Particularly, the present invention relates to the use of helicase-primase inhibitors in a method of treating AD in a subject that is having HSV-1 infection and is having AD or is having HSV-1 infection and is suspected of having AD. | 12-31-2015 |
20150374685 | PULMONARY DELIVERY OF A FLUOROQUINOLONE - A composition for pulmonary administration comprises a fluoroquinolone betaine, such as ciprofloxacin betaine, and an excipient. In one version, the particles have a mass median aerodynamic diameter from about 1 μm to about 5 μm, and the fluoroquinolone has a half life in the lungs of at least 1.5 hours. The composition is useful in treating an endobronchial infection, such as | 12-31-2015 |
20150374725 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING INTESTINAL INJURY AND DISEASES RELATED TO TIGHT JUNCTION DYSFUNCTION - Methods and compositions for treating and preventing intestinal injury are described. In particular, methods and delayed-release enteric coated compositions of glycerophosphate salts for treating and preventing an intestinal injury, such as exercise-induced intestinal injury, intestinal injury induced or aggravated by ingestion of a nonsteroidal anti-inflammatory drug (NSAID), or exercise-induced intestinal injury aggravated by an NSAID, are described. Orally or nasally administering a therapeutically effective amount of a glycerophosphate salt, particularly calcium glycerophosphate, to a subject engaging in exercise, particularly a subject engaging in exercise and ingesting a NSAID for the treatment or prevention of musculoskeletal pain resulting from exercise, reduces exercise-induced intestinal injury, particularly exercise-induced intestinal injury aggravated by the NSAID. A method of increasing tight junction integrity in a subject in need thereof is also described. The method involves administering to the subject a composition comprising an effective amount of glycerophosphate, such as calcium glycerophosphate. A method of treating or preventing a disease related to tight junction dysfunction, such as an inflammatory disease or a cancer, is also described. | 12-31-2015 |
20150374743 | ORALLY ADMINISTERED ADSORBENT, THERAPEUTIC AGENT FOR RENAL DISEASE, AND THERAPEUTIC AGENT FOR LIVER DISEASE - An object of the present invention is to provide an orally administered adsorbent capable of adsorbing large quantities of tryptophan or indoxyl sulfate in the presence of bile acid. The problem can be solved by an orally administered adsorbent comprising spherical active carbon having bulk density from 0.30 to 0.46 g/mL, specific surface area determined by the Brunauer-Emmett-Teller (BET) method of not less than 2000 m | 12-31-2015 |
20150374748 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred composition has at least 95% ZS-9. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. These compositions are also useful in the treatment of chronic kidney disease, coronary vascular disease, diabetes mellitus, and transplant rejection. | 12-31-2015 |
20150374761 | FREEZE DRIED FECAL MICROBIOTA FOR USE IN FECAL MICROBIAL TRANSPLANTATION - The present invention provides freeze-dried compositions that include an extract of human feces and a cryoprotectant, and methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon. | 12-31-2015 |
20150374835 | LIQUID TOPICAL PHARMACEUTICAL NANO-EMULSION FORMULATIONS - Aspects of the present invention are directed to compositions that are useful for delivery of an active ingredient to a subject. Some embodiments are formulated with an active ingredient, including, for example, a non-steroidal anti-inflammatory drug (NSAID), such as aspirin, ibuprofen, ketoprofen, or naproxen, acetaminophen, or a polypeptide or protein, such as insulin, wherein the active ingredient is stabilized and greater than 90% of the particles of the active ingredient have a particle size that is less than or equal to or any number in between 100, 90, 80, 70, 60, 50, 40, 30, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, or 4 nanometers, or smaller, as determined by Dynamic Light Scattering (DLS), using a volume-weighted particle size distribution calculation method. | 12-31-2015 |
20150374850 | COMPOSITION FOR GENE DELIVERY COMPRISING CHITOSAN AND LIQUID CRYSTAL FORMATION MATERIAL - Disclosed herein is a composition for gene delivery which forms into liquid crystals in an aqueous fluid including chitosan and a liquid crystal formation material. The composition of the present invention including chitosan and a liquid crystal formation material improves the relatively low binding strength between chitosan and a gene, and also considerably increases the stability of a chitosan nanocomposite in blood serum, thereby performing highly efficient gene delivery and providing excellent stability, thus being useful as a gene therapeutic agent. | 12-31-2015 |
20160000703 | ABUSE DETERRENT IMMEDIATE RELEASE FORMULATIONS COMPRISING NON-CELLULOSE POLYSACCHARIDES - The present disclosure provides pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. In particular, the pharmaceutical compositions comprise at least one pharmaceutically active ingredient, at least one non-cellulose polysaccharide, at least one hydrophilic gelling polymer, and an effervescent system. | 01-07-2016 |
20160000711 | Stabilized Granules Containing Glyceryl Trinitrate - Solid pharmaceutical preparation with the active substance glyceryl trinitrate for oromucosal or oral administration characterized in that it contains between 0.05 and 2 weight % glyceryl trinitrate, at least one carrier material, and at least one substance that reduces the volatility of the GTN, whereby this substance is a non-volatile ester stabilizer. | 01-07-2016 |
20160000713 | SOLVENT EXTRACTION FROM BIODEGRADABLE MICROPARTICLES - Embodiments may include a method for reducing a solvent concentration in a plurality of microparticles. The method may involve contacting a mixture including the plurality of microparticles and the solvent with water to form an aqueous suspension. A first portion of the solvent may dissolve into the water of the aqueous suspension to reduce the solvent concentration in the plurality of microparticles from a first solvent concentration in the mixture to a second solvent concentration in the aqueous suspension. The method may also include transferring the aqueous suspension to a concentration unit that may further reduce the solvent concentration from the second solvent concentration to a third solvent concentration. The method may further include transferring a microparticle concentrate with the third solvent concentration to a washing unit to form an amalgam of washed microparticles with a fourth solvent concentration. The method may also include drying the amalgam of washed microparticles. | 01-07-2016 |
20160000720 | Pharmaceutical compositions comprising Tadalafil - Pharmaceutical compositions comprising tadalafil or a pharmaceutically acceptable salt thereof are provided. The present invention also relates to a process for preparation of pharmaceutical compositions comprising tadalafil or a pharmaceutically acceptable salt thereof. The present invention also relates to method of administering the compositions comprising tadalafil in a subject in need thereof. | 01-07-2016 |
20160000825 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 01-07-2016 |
20160000827 | ORALLY ADMINISTERED ADSORBENT, THERAPEUTIC AGENT FOR RENAL DISEASE, AND THERAPEUTIC AGENT FOR LIVER DISEASE - An object of the present invention is to provide an orally administered adsorbent capable of adsorbing large quantities of tryptophan or indoxyl sulfate in the presence of bile acid. Accordingly, the above object can be solved by an orally administered adsorbent characterized by containing surface-modified spherical activated carbon having bulk density from 0.30 g/mL to 0.46 g/mL, a specific surface area determined by the Brunauer-Emmett-Teller (BET) method of not less than 1900 m | 01-07-2016 |
20160002313 | HER-1, HER-3 AND IGF-1R COMPOSITIONS AND USES THEREOF - Provided herein are HER-3, HER-1 and IGF-1R B cell epitopes, peptide mimics, chimeric peptides and multivalent peptides. In some embodiments, the chimeric peptides include one or more HER-3, HER-1 and/or IGF-1R B cell epitopes, a linker, and a T helper cell (Th cell) epitope. Pharmaceutical compositions are also provided that contain one or more HER-3, HER-1 and/or IGF-1R chimeric peptides, and optionally, one or more HER-2 chimeric peptides and/or VEGF peptides. Also included herein are methods of treating a cancer using the HER-3, HER-1 and IGF-1R B cell epitopes, chimeric peptides and multivalent peptides. | 01-07-2016 |
20160008281 | ANTIVIRAL COMPOSITIONS | 01-14-2016 |
20160008341 | CRYSTALLINE N-[5-(AMINOSULFONYL)-4-METHYL-1,3-THIAZOL-2-YL]-N-METHYL-2-[4-(2-PYRIDINY- L)PHENYL]ACETAMIDE MONO MESYLATE MONOHYDRATE HAVING A SPECIFIC PARTICLE SIZE DISTRIBUTION RANGE AND A SPECIFIC SURFACE AREA RANGE FOR USE IN PHARMACEUTICAL FORMULATIONS | 01-14-2016 |
20160008396 | RARE EARTH METAL COMPOUNDS, METHODS OF MAKING, AND METHODS OF USING THE SAME | 01-14-2016 |
20160008410 | MICRONIZED WHARTON'S JELLY | 01-14-2016 |
20160008507 | ADHESIVE BONE FILLING AGENT AND ADHESIVE BONE FILLING AGENT KIT | 01-14-2016 |
20160011213 | ASSAY METHOD | 01-14-2016 |
20160015632 | SUSPENSION COMPOSITIONS OF CYCLOSPORIN A FOR SUBCONJUNCTIVAL AND PERIOCULAR INJECTION - The present disclosure relates to suspension formulations and systems for the treatment of ocular conditions. The suspension formulations can include cyclosporin A and in some embodiments, Form 1 or Form 2 cyclosporin A. A delivery system can be provided that includes two parts, a first part containing particles of cyclosporin and a second part containing other components that can be combined with the first part to make a suspension formulation. The suspension can be injected into the subconjunctival or other periocular space to treat ocular conditions, such as dry eye disease. | 01-21-2016 |
20160015636 | NOVEL LOW DENSITY LIPOPROTEIN NANOCARRIERS FOR TARGETED DELIVERY OF OMEGA-3 POLYUNSATURATED FATTY ACIDS TO CANCER - The presently disclosed LDL nanocarrier is an effective and appropriate transporter for DHA in biological systems. The LDL-DHA nanoparticle was shown to be preferentially cytotoxic to malignant liver cells. LDL-DHA nanoparticles show great promise as an anti-cancer agent. | 01-21-2016 |
20160015640 | CRYSTALLINE MICROSPHERES AND THE PROCESS OF MANUFACTURING THE SAME - Microspheres comprising a core material, wherein the microspheres have a circularity greater than 0.95 and an aspect ratio greater than 0.95, and methods of manufacturing the same. The microspheres may be useful in the manufacture of sustained and modified release active pharmaceutical ingredient (API) microspheres, as a free flowing excipient for mini-tablets and in the manufacture of API dispersions. | 01-21-2016 |
20160015738 | COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE AND DIABETES MELLITUS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 01-21-2016 |
20160015742 | TRANSCRANIAL BURST ELECTROSTIMULATION APPARATUS AND ITS APPLICATIONS - The invention relates to a method of using metal nanoparticle or metallic particle to promote neurite outgrowth and treat and/or prevent neurological disorders. Particularly, the method of the invention uses gold nanoparticles or gold particles to promote neurite outgrowth and treat and/or prevent neurological disorders. | 01-21-2016 |
20160015753 | SPINAL DISK REGENERATIVE COMPOSITION AND METHOD OF MANUFACTURE AND USE - The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material ( | 01-21-2016 |
20160015754 | SPINAL DISK REGENERATIVE COMPOSITION AND METHOD OF MANUFACTURE AND USE - The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material ( | 01-21-2016 |
20160015774 | TOPICAL VANCOMYCIN FORMULATION AND METHODS OF USE - Disclosed herein are methods, compositions, and kits for treating a skin condition caused by a bacterial infection at a skin depth with a topical ointment comprising vancomycin hydrochloride. Also disclosed herein are methods, compositions, and kits for testing susceptibility of vancomycin for treating a bacterial infection at a skin depth, and of optimizing a topical ointment therapeutic regimen. | 01-21-2016 |
20160022582 | HIGHLY CONCENTRATED DRUG PARTICLES, FORMULATIONS, SUSPENSIONS AND USES THEREOF - Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present invention comprise, for example, macromolecules, such as proteins and/or small molecules (such as steroid hormones). The particle formulation typically further includes one or more additional component, for example, one or more stabilizer (e.g., carbohydrates, antioxidants, amino acids, and buffers). Such concentrated particle formulations can be combined with a suspension vehicle to form suspension formulations. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a highly concentrated drug particle formulation. Devices for delivering the suspension formulations and methods of use are also described. The present invention provides needed improvements in drug formulation and delivery to improve patient compliance and expand drug availability. | 01-28-2016 |
20160022583 | PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION, CONTAINING DONEPEZIL - The present invention relates to a composition for parenteral administration, containing donepezil as an active ingredient, and a preparation method therefor. Donepezil, which has been conventionally used for oral or transdermal administration, is prepared as microparticles comprising a biodegradable and biocompatible polymer and a release controller so as to be provided as a pharmaceutical composition for sustained release parenteral administration, thereby enabling in vivo sustained release continuously for 2-12 weeks or more. Therefore, it is possible to reduce the frequency of administration to a patient and maintain an effective concentration in the blood for a long time. | 01-28-2016 |
20160022584 | PHARMACEUTICAL COMPOSITIONS OF GOSERELIN SUSTAINED RELEASE MICROSPHERES - A composition of goserelin sustained release microspheres is provided. The microspheres comprise goserelin, at least one poly(lactide-co-glycolide) and poloxamer or PEG. The sustained release microspheres have comparatively high bioavailability, which promotes the drug taking its full effect and have entrapment efficiency over 90%. | 01-28-2016 |
20160022604 | DIRECTLY COMPRESSED OSPEMIFENE COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising ospemifene or a pharmaceutically acceptable salt thereof prepared by direct compression process. The compositions of the invention may be advantageously used for the treatment or prevention of atrophy-related diseases or disorders in women, especially in women during or after the menopause. | 01-28-2016 |
20160022719 | COMPOSITION FOR BUFFERED AMINOALKYL GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND ITS USE FOR ENHANCING AN IMMUNE RESPONSE - There is provided a composition comprising an aminoalkyl glucosaminide phosphate compound or a pharmaceutically salt thereof and a buffer for use as an immunomodulator. | 01-28-2016 |
20160022729 | Compounds to Modulate Intestinal Absorption of Nutrients - This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity. | 01-28-2016 |
20160022740 | Minced Cartilage Systems and Methods - Compositions comprising a plurality of cartilage particles from a human adult cadaveric donor, wherein the cartilage particles comprise viable chondrocytes, and a biocompatible carrier are provided. Methods of manufacturing cartilage compositions comprising a plurality of cartilage particles from a human adult cadaveric donor are also provided. | 01-28-2016 |
20160022835 | Targeted Polymeric Inflammation-Resolving Nanoparticles - Sub-100 micron multimodal nanoparticles have four main components: 1) a target element (peptides, lipids, antibodies, small molecules, etc.) that can selectively bind to cells, tissues, or organs of the body; 2) a diagnostic agent such as a fluorophore or NMR contrast agent that allows visualization of nanoparticles at the site of delivery and/or a therapeutic or prophylactic agent; 3) an outside “stealth” layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; and 4) a biodegradable polymeric material, forming an inner core which can carry therapeutics and release the payloads at a sustained rate after systemic, intraperitoneal, or mucosal administration. These particles possess excellent stability, high loading efficiency, multiple agent encapsulation, targeting and imaging. They are targeted to sites of, or associated with, inflammation caused by a disease, disorder; trauma, chemotherapy or radiation. | 01-28-2016 |
20160029640 | ADDITIVE FOR COATINGS CONTAINING METALLIC NANOPARTICLES - The additive of the present invention is intended for transferring, to a final coating, biocidal, UV protection, and flame retardant properties and in general the selected properties intrinsic to the metals and compounds of Ag, Au, Cu, Mg, Zn, Bi, Sb, said additive includes the use of solvents, surfactants, dispersants and resins that make it compatible with the final coating. Said coating treated with additive ensures perfect distribution and dispersion of the nanoparticles throughout it, without the need to be subjected to an inorganic substrate. | 02-04-2016 |
20160030346 | ENGINEERED AEROSOL PARTICLES, AND ASSOCIATED METHODS - An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated nanoparticle body member being non-spherical. The fabricated nanoparticle body member is configured to provide at least one of auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time of the fabricated nanoparticle body member. An associated method is also provided. | 02-04-2016 |
20160030351 | SUSTAINED RELEASE MICROSPHERES AND METHOD OF PRODUCING SAME - A method of making a sustained release microsphere formulation, wherein the release rate of a bioactive ingredient is manipulated by controlling the crystallinity of said bioactive ingredient, includes the steps of combining the active ingredient and an encapsulating polymer in at least one solvent, or mixtures thereof, to form a dispersed phase and processing the dispersed phase without filtering, filtering the combined dispersed phase with a hydrophobic or a hydrophilic filter, or filtering the active ingredient and encapsulating polymer individually with a hydrophobic or hydrophilic filter before combining them to form the dispersed phase. The dispersed phase is then combined with a continuous phase to form the microsphere formulation. | 02-04-2016 |
20160030434 | THEOBROMINE COMPOSITIONS USEFUL FOR INCREASING FETAL WEIGHT GAIN AND ENHANCING BONE PROPERTIES - Compositions and methods for culturing cells with theobromine are provided, as well as cells derived thereby. Theobromine compositions for enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, increasing fetal birth weight, preventing tooth decay, remineralizing a tooth surface, treating dentine hypersensitivity, and application to a bone site to promote new bone growth at the site are also provided. | 02-04-2016 |
20160030450 | TOPICAL CORTICOSTEROID COMPOSITIONS - Compositions for the topical administration of an active agent comprise a corticosteroid and a fatty alcohol as a skin penetration enhancer, in the form of topical sprays. Processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders, are described. | 02-04-2016 |
20160030467 | Modified Pectins, Compositions and Methods Related Thereto - The present invention provides compositions of modified pectin and methods for preparing and using them. | 02-04-2016 |
20160030475 | USE OF A CLAY PRODUCT OR A CLAY BLEND PRODUCT TO DECREASE THE EFFECTS OF BACTERIAL DISEASE IN SHRIMP - Applicants have examined two | 02-04-2016 |
20160030596 | GAS-FILLED STABILIZED PARTICLES AND METHODS OF USE - Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described. | 02-04-2016 |
20160030618 | PREVENTATIVE SOLUTION AND METHOD OF USE - A preventative solution includes an aqueous base, 1 wt % to 6 wt % titanium dioxide having an average particle size of not greater than 100 nm, 0.5 wt % to 20 wt % alcohol having 2 to 4 carbons, and 3 wt % to 15 wt % of a binding agent. The preventative solution can be dispersed using a fogger, for example, sequentially with an odor neutralizing solution or a disinfectant solution. | 02-04-2016 |
20160030626 | Rapid Setting High Strength Calcium Phosphate Cements Comprising Cyclodextrins - Rapid setting high strength calcium phosphate cements and methods of using the same are provided. Aspects of the cements include fine and coarse calcium phosphate particulate reactants and a cyclodextrin which, upon combination with a setting fluid, produce a flowable composition that rapidly sets into a high strength product. The flowable compositions find use in a variety of different applications, including the repair of hard tissue defects, e.g., bone defects such as fractures. | 02-04-2016 |
20160030627 | KIT FOR ADHERING BIOLOGICAL HARD TISSUES - A kit for bonding to biological hard tissues, containing a phosphorylated polysaccharide, a polyvalent metal salt other than phosphates, and a solvent. The adhesive composition for biological hard tissues provided by the kit for bonding to biological hard tissues is suitably used in for medical uses, such as cement for bones or dental cement. In addition, since the adhesive composition has excellent bio-absorbability, it is useful as fusion materials for artificial joint prosthesis, fusion materials for spine fracture, fusion materials for extremity fracture, filling materials for bone tumors in the region of orthopedics, filling materials and restorative materials at dental caries-defective sites, luting materials for prosthetic restorative materials such as inlay and crown, pulp-capping and lining materials, implant surface treatment materials, periodontal disease therapeutic materials, hyperesthesia preventive materials, dental pulp capping materials, substrates for DDS, substrates for systems engineering, and tissue bonding materials in the dental region. | 02-04-2016 |
20160031833 | MICROCRYSTALLINE DIKETOPIPERAZINE COMPOSITIONS AND METHODS - Disclosed herein are DKP microcrystals made by an improved method where they do not irreversibly self-assemble into microparticles. The microcrystals can be dispersed by atomization and re-formed by spray drying into particles having spherical shell morphology. Active agents and excipients can be incorporated into the particles by spray drying a solution containing the components to be incorporated into microcrystalline diketopiperazine particles. In particular, the microcrystalline particle compositions are suitable for pulmonary drug delivery of one or more peptides, proteins, nucleic acids and/or small organic molecules. | 02-04-2016 |
20160038419 | COMPOSITION AND METHODS FOR THE TREATMENT OF PERIPHERAL NERVE INJURY - Provided herein are methods of treating a peripheral nerve injury in a subject. The methods include administering to the subject at or near the site of the peripheral nerve injury an effective amount of a composition comprising an agent that promotes remyelination of the peripheral nerve. Also provided are methods of determining whether a peripheral nerve injury has a capacity for recovery. The methods include selecting a subject with a peripheral nerve injury, administering to the subject a first dose of a composition comprising and agent that promote remyelination and detecting after the first dose one or more characteristics of peripheral nerve recovery, the presence of one or more characteristics of peripheral nerve recovery indicating a peripheral nerve injury has a capacity for recovery and the absence of characteristics of peripheral nerve recovery indicating a peripheral nerve injury without a capacity for recovery. | 02-11-2016 |
20160038538 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred composition has at least 95% ZS-9. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. These compositions are also useful in the treatment of chronic kidney disease, coronary vascular disease, diabetes mellitus, and transplant rejection. | 02-11-2016 |
20160038569 | PARTICLES CONTAINING A GROWTH FACTOR, AND USES THEREOF - The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof. | 02-11-2016 |
20160038575 | COMPOSITIONS AND METHODS FOR IMMUNE TOLERANCE INDUCTION TO FACTOR VIII REPLACEMENT THERAPIES IN SUBJECTS WITH HEMOPHILIA A - This disclosure relates to tolerance inducing peptide (TIP) derived from the amino acid reference locus (AARL) within a FVIII replacement product (FVIIIrp) based on the differences between the expression product of a subject's F8 gene (sFVIII) and the FVIIIrp to provide tolerance induction before, during, and/or after a FVIII replacement therapy in a subject suffering from Hemophila A. Methods of deriving, making, and using the TIP are also disclosed. In some embodiments, the TIP is associated with a nanoparticle, e.g., PLGA or PLGA-PEMA nanoparticle. | 02-11-2016 |
20160038752 | Atherosclerosis therapy via delivery and localized heating of micro size particles - The present invention relates generally to the treatment of atherosclerosis and thrombosis. Specifically, the invention relates to a method for removing vascular deposits by locally heating plaque sites with micron size particles that are administered intravenously and are heated inductively. | 02-11-2016 |
20160045396 | Pulmonary Delivery of Progestogen - The present invention relates to a pharmaceutical formulation powder that contains 17α-hydroxyprogesterone caproate (17-OHPC) powder and the method of producing the formulation produces particles that are suitable as an inhalant. The formulations, methods and kits of powdered 17-OHPC as taught herein may be used to reduce cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and involve the inhibition of p38 mitogen activating protein kinase (MAPK) activity. The 17-OHPC powder formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) and/or fluticasone with 17-OPHC. | 02-18-2016 |
20160045435 | USE OF STEARATE IN AN INHALABLE FORMULATION - The present invention concerns a method for making an inhaled pharmaceutical composition with improved powder handling properties comprising a stearate, a method of preparing such a composition, and the use of such a stearate in a composition when dispensed into a receptacle for use in a dry powder inhaler receptacle. | 02-18-2016 |
20160045438 | GRANULATE FOR THE FORMULATION OF ORODISPERSIBLE TABLETS - This invention relates to a granulate comprising mannitol and sorbitol in a weight ratio of between 70:30 and 97:3. This invention also relates to the use of the said granulate in the preparation of orodispersible tablets, to the orodispersible tablets obtained with the said granulate and to a process of production for obtaining the said granulate. | 02-18-2016 |
20160045450 | PHARMACEUTICAL FORMULATION FOR USE IN THE TREATMENT AND/OR PREVENTION OF RESTENOSIS - The present invention relates generally to a pharmaceutical formulation for use in the treatment and/or prevention of restenosis in a subject in need thereof. Methods of treatment and/or prevention are also provided. | 02-18-2016 |
20160045495 | ARIPIPRAZOLE PRODRUG COMPOSITIONS - Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition. | 02-18-2016 |
20160045518 | VISCOUS BUDESONIDE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT - Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 02-18-2016 |
20160045529 | Pharmaceutical Compositions Containing Palmitoylethanolamide And Cytidine-Diphosphocholine And Methods Of Treatment Therewith - The described herein is a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide and Cytidinediphosphocholine for the treatment of pathologies of the Central Nervous System of a traumatic, vascular, degenerative nature associated with neurodegeneration. The pharmaceutical composition containing palmitoylethanolamide (PEA) and Cytidinediphosphocholine (CDP-Choline or Citicoline), possibly with the addition of an antioxidant compound such as for example a polyphenol, alpha-lipoic acid or L-acetylcysteine. | 02-18-2016 |
20160045553 | CELL DELIVERY - The invention provides a cell delivery medium comprising a liquid phase, wherein the liquid phase comprises (i) one or more cells suspended within the liquid phase and (ii) a plurality of polymer gel particulates. Methods of producing the cell delivery systems are also provided. | 02-18-2016 |
20160045595 | Nanoparticles, Composed of Sterol and Saponin From Quillaja Saponaria Molina Process for Preparation and Use Thereof as Carrier for Amphipatic of Hydrophobic Molecules in Fields of Medicine Including Cancer Treatment and Food Related Compounds - A nanoparticle comprising at least one sterol, e.g. cholesterol and a component from | 02-18-2016 |
20160045613 | PARTICLES HAVING PEG-YLATED SURFACES MODIFIED FOR LYMPHATIC TRAFFICKING - The subject matter disclosed herein is directed to modifying and utilizing properties of micro and/or nano-particles to traffic the particles to lymph nodes. As described herein, the properties include size, charge, and surface characteristics of the particles. | 02-18-2016 |
20160046582 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF - The subject invention provides a mixture of Crystalline Laquinimod sodium particles, wherein (i) ≧90% of the total amount by volume of the laquinimod sodium particles have a size of ≦40 μm or (ii) ≧50% of the total amount by volume of the laquinimod sodium particles have a size of ≦15 μm and wherein: a) the mixture has a bulk density of 0.2-0.4 g/mL; b) the mixture has a tapped density of 0.40-0.7 g/mL; c) an amount of heavy metal in the mixture is no more than 20 ppm relative to the amount by weight of laquinimod sodium; d) an amount of MCQ in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; e) an amount of MCQCA in the mixture is no more than 0.15% relative to the amount of laquinimod sodium as measured by HPLC; or f) an amount of MCQME in the mixture is no more than 0.12% relative to the amount of laquinimod sodium as measured by HPLC. The subject invention also provides a pharmaceutical composition comprising an amount of laquinimod and at least one of BH-3-HKAQ, MCQ, MCQCA, MCQME, NEA, and MCQEE. The subject invention also provides processes for preparing BH-3-HLAQ, MCQ, MCQCA, MCQEE, and compounds prepared by said processes. Further provided is a process for testing whether a sample of laquinimod contains an undesirable impurity. Further provided is a process for preparing a validated pharmaceutical composition comprising laquinimod, for preparing a pharmaceutical composition comprising laquinimod, or for distributing a validated batch of a pharmaceutical composition comprising laquinimod, for validating a batch of a pharmaceutical product containing laquinimod and a pharmaceutically acceptable carrier for distribution, and for preparing a packaged pharmaceutical composition comprising laquinimod, each comprising determining the amount of at least one of BH-3-HLAO, MCQ, MCQCA, MCQME02-18-2016 | |
20160050937 | TERMITICIDE AND PREPARATION CONTAINING SAME - Chemical agents are conventionally used to control or prevent termites. Potent agents such as organophosphorus compounds have been used. A termite control agent is provided that is not only high in control effect against termites but also safe to the human body. This is achieved by a termite control agent comprising particles containing two or more kinds of oxide or hydroxide which contain at least one kind of each of a first component and a second component, wherein the first component consists of zinc oxide or zinc hydroxide, and the second component consists of at least one kind of oxide or hydroxide of magnesium, calcium and aluminum. | 02-25-2016 |
20160051473 | TAURINE COMPOSITIONS SUITABLE FOR INHALATION - The invention discloses spray-dried compositions for inhalation and methods for preparing such powder compositions. The compositions of the invention are produced by spray-drying taurine under conditions that (i) retain the physical and chemical stability of the composition during spray drying and upon storage, (ii) protect the powder composition from aggregation and (iii) provide particles suitable for aerosolisation. | 02-25-2016 |
20160051522 | THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME - The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.2 to about 20 weight percent of epothilone, e.g. epothilone B; and about 50 to about 99 weight percent biocompatible polymer. | 02-25-2016 |
20160051576 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS - The present invention provides a crosslinked amine and amide polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritis, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like. | 02-25-2016 |
20160051584 | MICROPOROUS ZIRCONIUM SILICATE AND DIURETICS FOR THE REDUCTION OF POTASSIUM AND TREATMENT OF CHRONIC KIDNEY AND/OR CHRONIC HEART DISEASE - The present invention relates to novel methods of using microporous zirconium silicate to reduce the risk of hyperkalemia and to lower aldosterone levels in the treatment of chronic kidney disease and/or chronic heart disease with therapies comprising diuretics. The invention provides a safe way to reduce the risk of hyperkalemia and to lower aldosterone. The invention also relates to treatment of other conditions that can occur either alone or in connection with hyperkalemia, chronic kidney disease, and/or chronic heart disease. | 02-25-2016 |
20160051725 | BONE GRAFT COMPOSITION AND PREPARATION METHOD THEREOF - The present invention relates to a bone graft composition and a preparation method thereof, and more particularly to bone graft composition having excellent physical properties, which comprises a hydrogel comprising a combination of specific amounts of poloxamer and HPMC, and calcium phosphate compound particles, and a preparation method thereof. | 02-25-2016 |
20160058708 | SUSTAINED RELEASE GUANFACINE HCL FORMULATION - The present invention is directed to a pharmaceutical composition comprising guanfacine or a salt thereof in nano particle form and at least one non-pH dependent sustained release agent. The present invention further is directed to a method of producing said nanoparticles and to nanoparticles obtained by this method. | 03-03-2016 |
20160058727 | Pulmonary Delivery for Levodopa - In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung. | 03-03-2016 |
20160058787 | Therapy and Cure of Ebola - A therapeutic model for the expedient treatment of deadly pathogens involved in pandemics and bioterrorism related events. The immune pathogenesis of deadly pathogens is redefined in the light of Recent advances in the Fundamentals of Immunology by developing three dimensional understandings of deadly pathogens and its interactions with host and its immune system. The immune pathogenesis of deadly pathogens can be treated expediently and globally with NSPS to mitigate the threat of bioterrorism and pandemics. According to a method for treating deadly pathogens having an immune regulatory molecule, the first step is providing a nano-engineered formulation of sodium polystyrene sulfonate (NSPS) having particle size less than 100 nm. A pharmaceutically effective dose of the NSPS is administered to a patient infected with the pathogen. The immune regulatory molecule is targeted with the NSPS for inhibiting serine protease activation. The therapeutic model is further extended for quarantine purposes to facilitate decontamination measures for patients, hospitals and laboratories. | 03-03-2016 |
20160067190 | INJECTABLE NANO-NETWORK GELS FOR DIABETES TREATMENT - A system for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through an injectable nano-network consisting of oppositely-charged dextran nanoparticles encapsulating insulin and glucose-specific enzymes forming a gel-like 3D scaffold. As demonstrated by the examples, the system effectively dissociates to release insulin in a hyperglycemic condition, where the catalytic conversion of glucose into gluconic acid and the subsequent degradation of polymeric matrix are facilitated. This formulation design provides a delivery strategy for both self-regulated and long-term diabetes management. | 03-10-2016 |
20160067218 | SECNIDAZOLE FOR USE IN THE TREATMENT OF BACTERIAL VAGINOSIS - Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV). | 03-10-2016 |
20160067226 | METHODS OF INHIBITING LEUKOTRIENE A4 HYDROLASE - The present invention is directed to methods of inhibiting LTA | 03-10-2016 |
20160067265 | Abiraterone Acetate Formulation - Pharmaceutical compositions, including unit dosage forms, comprising fine particle abiraterone acetate with or without an antioxidant and or a sequesting agent as well as methods for producing and using such compositions are described. | 03-10-2016 |
20160067287 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS WITH OPTIONAL SEALANT AND METHODS OF MAKING AND USING THE SAME - Described herein are compositions composed of micronized placental components and optionally a sealant, and pharmaceutical compositions thereof. Also described are systems, apparatuses, and methods for applying the combination of micronized placental components and adhesives optionally a sealant (e.g., adhesive or gelation agent) for wound care and other medical applications. | 03-10-2016 |
20160067324 | NOVEL VACCINE FORMULATION FOR OCULAR IMMUNIZATION - The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans and animals including mammals and birds. More particularly, it relates to subunit vaccines that are effective against pathogens causing infections thereof for use in humans and animals including mammals and birds. The present invention specifically provides a novel vaccine formulation suitable for ocular immunization comprising a subunit vaccine antigen in an amount to provoke a protective immune response and at least two adjuvants of which one is corpuscular. It further provides a method for inducing a local and systemic immune response and methods for preventing recurrence of ocular infections and/or modulates the occurrence and/or severity of sequels. | 03-10-2016 |
20160074325 | Low-Dimensional Structures of Organic and/or Inorganic Substances and Use Thereof - The object of the present invention is low-dimensional, primarily 2D folded structures of organic and/or inorganic substances and/or their agglomerates, which have folds and faces of irregular shape and exhibit high local electric field strength generated by surface charges on the said folds, faces and edges, and use thereof: as sorbents of organic particles (molecules, bacteria, viruses, proteins, antigens, endotoxins) and inorganic particles (metal ions, colloids); as an agent with wound healing and antibacterial activity; as an agent for tumor cell growth inhibition. | 03-17-2016 |
20160074328 | Drug Particles From Freezing Onto A Surface - The present invention is a method for preparing micron-sized or submicron-sized drug particles comprising contacting a solution comprising a poorly water soluble drug substance and at least one freezable organic solvent with a cold surface so as to freeze the solution; and removing the organic solvent. The resulting particles are also disclosed, as are several embodiments of an apparatus that can be used in performing the method of the present invention. | 03-17-2016 |
20160074398 | PHARMACEUTICAL COMPOSITION CONTAINING CRYSTALLINE MACITENTAN - The present invention relates to an oral solid dosage form, in particular a tablet, comprising macitentan free base polymorphic form I. | 03-17-2016 |
20160074506 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES - Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described. | 03-17-2016 |
20160074526 | SSTR-TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF - Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases. | 03-17-2016 |
20160075677 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS - Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90. | 03-17-2016 |
20160075733 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 03-17-2016 |
20160075776 | Compositions and Methods for Controlled Release of Agents - This invention discloses reservoirs, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies. The reservoirs may comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The reservoir may be used in vitro or in vivo to maintain an equilibrium concentration of a therapeutic agent over an intended period of time such as over multiple days, weeks, months, or years. Additionally, the reservoir may be reloaded with additional therapeutic agent. These reservoirs may be used for treating or preventing conditions of a subject such as chronic diseases. | 03-17-2016 |
20160081902 | PERSONAL CARE COMPOSITIONS - Personal care compositions comprising a dipeptide and methods of using such compositions to treat the condition of keratinous tissue. The C terminal amino acid of said dipeptide is threonine. The personal care composition can be applied topically, ingested orally, injected, or used as part of a combined treatment regimen. | 03-24-2016 |
20160081924 | PHARMACEUTICAL COMPOSITIONS - This invention provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for delivery to the lung by inhalation. This invention also provides a pharmaceutical composition comprising a eutectic composition of two pharmacologically active ingredients for the treatment of respiratory disease. | 03-24-2016 |
20160081931 | POWDER COMPOSITION FOR TREATING A DISORDER IN THE AUDITORY CANAL OF MAMMALS AND USE THEREOF - The invention relates to a new powder composition which comprises in admixture: lactic acid, lactose and kaolin, wherein the amount of lactic acid is such that the pH of the powder composition should be within the range of about 3 to 4. Said powder composition may be use as a veterinary drug and in treating and/or preventing a disorder in the auditory canal of dogs and cats. | 03-24-2016 |
20160082050 | COMPOSITION, USE THEREOF, AND METHODS OF MANUFACTURING - A composition that includes at least two of: echinochrome A (2-ethyl-3,5,6,7,8-pentahydroxy-1,4-naphthoquinone); spinochrome A (2-acetyl-3,5,6,8-tetrahydroxy-1,4-naphthalenedione); spinochrome B (2,3,5,7-tetrahydroxy-1,4-naphthalenedione); spinochrome C (2-acetyl-3,5,6,7,8-pentahydroxy-1,4-naphthalenedione); spinochrome D (2,3,5,6,8-Pentahydroxy-1,4-naphthalenedione); and spinochrome E (hexahydroxy-1,4-naphthalenedione). The composition can include one or more additional active ingredients (e.g., vitamin, tretinoin (alltrans retinoic acid or ATRA), a glycosaminoglycan (GAG), dermal filler, | 03-24-2016 |
20160082415 | GRANULAR FUNCTIONALIZED SILICA, PROCESS FOR PREPARATION THEREOF AND USE THEREOF - The present invention relates to granular functionalized silicas, wherein
| 03-24-2016 |
20160083423 | NEW COMPOUNDS HAVING TRIPLE ACTIVITIES OF THROMBOLYSIS, ANTITHROMBOTIC AND RADICAL SCAVENGING, AND SYNTHESIS, NANO-STRUCTURE AND USE THEREOF - The present invention relates to a compound simultaneously having triple activities of thrombolysis, antithrombosis and free radical scavenging, as well as the preparation method, composition, and applications thereof. The compound is represented by the formula I shown below: | 03-24-2016 |
20160083431 | LYOPHILISATE CONTAINING A CYCLIC PEPTIDE OF FORMULA X1-GQRETPEGAEAKPWY-X2 - Cyclic peptide of formula | 03-24-2016 |
20160089332 | GEL-LIKE COMPOSITION HAVING HIGH UBIQUINOL CONTENT - This invention relates to a gel-like composition in which ubiquinol is dispersed and stabilized in a gel and which contains 0.2 to 5% by weight of ubiquinol, 5 to 15% by weight of gelatin, 55 to 80% by weight of carbohydrate and/or water-soluble dietary fiber, and 9 to 18% by weight of water, and further contains ascorbic acid and/or gallate type catechin. | 03-31-2016 |
20160089334 | POROUS METAL OXIDE PARTICLES, PRODUCTION METHOD THEREOF AND APPLICATION THEREOF - Provided are porous metal oxide particles, in which 50% mean particle size by volume is equal to or larger than 50 nm and equal to or smaller than 300 nm, ratio of 90% mean particle size by volume to 50% mean particle size by volume (D90/D50) is equal to or lower than 2.0, the particles have mesopores having a pore size determined by BJH method of equal to or larger than 5 nm and equal to or smaller than 30 nm, and the structure of the pores is a three-dimensional cubic phase structure. | 03-31-2016 |
20160089369 | AQUEOUS SUSPENSIONS OF TMC278 - This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection. | 03-31-2016 |
20160089403 | TREATMENT OF ATOPIC DERMATITIS AND INFECTIOUS DERMATITIS WITH BIOLOGICAL SPA THERAPY - Provided is a method for treatment of atopic dermatitis and infectious dermatitis with biological spa therapy. The method seeks to cure or alleviate symptoms of atopic dermatitis by bathing in a bathwater containing, as dominant bacteria, not less than 10 | 03-31-2016 |
20160089429 | ORAL VACCINE HAVING IMPROVED CELLULAR IMMUNITY INDUCTION POTENCY - An oral preparation for the prophylaxis or treatment of a disease with infection by a pathogen, containing a killed lactic acid bacterium expressing, on the surface, an antigen of the pathogen, or a microparticulated form thereof, which has an average particle size of 2.68-30 μm. An oral preparation for inducing cellular immunity to a target antigen, containing a killed lactic acid bacterium expressing the target antigen on the surface or a microparticulated form thereof, which has a particle size of 2.68-30 μm. | 03-31-2016 |
20160090354 | SOLID DRUG FORM OF N-(2,6-BIS(1-METHYLETHYL)PHENYL)-N'-((1-(4-(DIMETHYLAMINO)PHENYL)CYCLOPEN- TYL)METHYL)UREA HYDROCHLORIDE AND COMPOSITIONS, METHODS AND KITS RELATED THERETO - A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N′-((1-(4-(dimethylamino)phenyl)cyclopentyl)methyl)urea hydrochloride (also referred to “ATR-101”) suitable for oral dosing, and to compositions, methods and kits relating thereto. ATR-101 has particular utility in the treatment of, for example, aberrant adrenocortical cellular activity, including adrenocortical carcinoma (ACC), congenital adrenal hyperplasia (CAH) and Cushing's syndrome. | 03-31-2016 |
20160090444 | DRUG LOADING PENTABLOCK POLYMERS - Novel pentablock polymers having a PCL-PLA-PEG-PLA-PCL or PCL-PGA-PEG-PGA-PCL configuration, wherein PEG is polyethylene glycol, PCL is poly(8-caprolactone), PGA is poly(glycolic acid), and PLA is poly(lactic acid), and methods of making nanoparticles from the pentablock polymers, are disclosed. The invention is also directed to a method for preparing nanoparticle compositions comprised of polymers with high levels of bioactive or diagnostic agents. | 03-31-2016 |
20160095880 | HYDROXYAPATITE TISSUE FILLER AND ITS PREPARATION AND USE - The invention pertains to a biocompatible composition, suitable for use in soft or hard tissue augmentation, wherein the composition is an aqueous suspension containing a carrier fraction of ceramic particles of less than 15 μm and an augmentation fraction of ceramic particles of at least 20 μm. The ceramics typically comprise calcium phosphate. The composition is a may be used in soft tissue repair as well as hard bone replacement. It advantageously avoids the need for foreign body materials which are conventionally applied to stabilize augmentation suspensions. | 04-07-2016 |
20160095913 | Controlled Release Vaccines and Methods of Treating Brucella Diseases and Disorders - Methods and compositions for the treatment of | 04-07-2016 |
20160101055 | METHOD OF PREPARING DRUG AGGLOMERATE - A method of preparing drug agglomerates includes adding a drug powder to a first solvent to form a first solution, adding a second solvent to the first solution to form a second solution. The drug powder undergoes nucleation to form drug agglomerates. The drug agglomerates are isolated from the second solution. | 04-14-2016 |
20160106108 | METHOD FOR PRODUCING A DOPED OR UNDOPED MIXED OXIDE FOR A COMPOSITE MATERIAL, AND A COMPOSITE MATERIAL COMPRISING SUCH A MIXED OXIDE - The invention relates to a method for producing a doped or undoped mixed oxide for a composite material, wherein the mixed oxide has the chemical formula of Mo | 04-21-2016 |
20160106674 | COLLAGEN POWDER, COMPOSITION AND USE - Collagen powder in which at least 99.5% of the particles have a maximum size of 80 microns 25% to 45% by volume of the particles have a size of more than 30 microns and 35% to 50% by volume of the particles have a size in the range of 20 to 70 microns. | 04-21-2016 |
20160106704 | METHODS FOR DELIVERING CROMOLYN - Methods of delivering cromolyn to a patient in need thereof, methods of treating amyloid-associated conditions and inflammatory or allergic lung diseases, and blister packs and kits comprising cromolyn are described. | 04-21-2016 |
20160107993 | POLYMORPHIC FORMS OF ST-246 AND METHODS OF PREPARATION - Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions. | 04-21-2016 |
20160113944 | Dry Powder For Inhalation - The present invention provides dry powder formulations for inhalation having improved moisture resistance such that the powders maintain a high fine particle dosage or fine particle fraction following storage under relatively extreme temperature and humidity conditions. | 04-28-2016 |
20160113961 | Sachet Formulation for Amine Polymers - A powder formulation comprises a pharmaceutically acceptable anionic stabilizer and an aliphatic amine polymer or a pharmaceutically acceptable salt thereof mixed with the anionic stabilizer. The powder formulation is conveniently packaged in a container, such as a sachet. A method of treating a subject with hyperphosphotemia with the powder formulation is also disclosed. | 04-28-2016 |
20160114038 | SCALABLE, MASSIVELY PARALLEL PROCESS FOR MAKING MICRO-SCALE PARTICLES - A method of fabrication produces one or more functional microparticles using a parallel pore working piece. In one embodiment, the method forms a particle that includes a segment for the oxidation of a biofuel (such as glucose) and the reduction of oxygen. The particle may be synthesized in a structure with defined and parallel, uniform, thin pores that completely penetrate the structure. Further, the functional microparticle may be configured to reside in a human or animal body or cell such that it may be self-contained fuel cell having an anode, a cathode, a separator membrane, and a magnetic component. In other embodiments, the functional microparticles may deliver energy or therapeutic materials in the body. | 04-28-2016 |
20160120815 | MICROSPHERES OF PANCREATIC ENZYMES WITH HIGH STABILITY AND PRODUCTION METHOD THEREOF - The present invention refers to new microspheres including pancreatic enzymes, pharmaceutical compositions containing them, and a process to obtain them. The process here described doesn't involve the use of solvents and proves to be remarkably shorter and efficient than the producing methods of the prior arts. The microspheres obtained, including one or more pancreatic enzymes, one or more hydrophilic low-melting polymers and eventual excipients, have an high enzymatic activity, bio-availability and stability. | 05-05-2016 |
20160120847 | Low Dose Pharmaceutical Composition - This invention provides a low dose pharmaceutical composition comprising deferasirox or a pharmaceutically acceptable derivative thereof and one or more pharmaceutically acceptable excipients. A unit dose of the pharmaceutical composition comprises from about 50 mg to about 100 mg of deferasirox, from about 150 mg to about 200 mg of deferasirox or from about 260 mg to about 350 mg of deferasirox. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox, may be used to treat chronic iron overload or to treat lead toxicity. The pharmaceutical composition of the present invention, wherein the pharmaceutical composition comprises deferasirox and deferiprone, may be used to treat lead toxicity. This invention also provides a process for preparing the low dose pharmaceutical composition, the process comprising: dissolving or adsorbing or blending deferasirox and at least one excipient to produce a dispersion of deferasirox; and processing the dispersion to produce a desired dosage form. | 05-05-2016 |
20160120921 | COMPOSITIONS COMPRISING DEHYDRATED MICRO-ORGANISMS, METHOD OF PREPARATION THEREOF, AND USES THEREOF - The invention relates to a composition comprising revivable dehydrated micro-organisms. The invention is characterised in that it further comprises particles at least 50% of which have a mean diameter greater than 250 μm. The invention is applicable, in particular, to human or veterinary pharmaceuticals, to dietetics or to food products. | 05-05-2016 |
20160120988 | PAZOPANIB FORMULATION - A granulation formulation of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide or pharmaceutically acceptable salt thereof, which is adapted for reconstitution with an aqueous vehicle, and associated oral suspension. | 05-05-2016 |
20160122395 | Immunogenic compositions and a process for producing same - The present invention provides a modified HIV envelope glycoprotein (Env) antigen or a lipid containing vehicle comprising same. The Env antigen comprises one of a second site suppressor mutation in residue 674 of the membrane proximal ectodomain region (MPER) of HIV gp41; a second site suppressor mutation which ablates a glycosylation site in the variable region (V1) region of gp120; or a second site suppressor mutation ablating a glycosylation site in the V1 region of gp120 and a second site suppressor mutation in residue 674 of the MPER of HIV gp41. It is preferred that the lipid containing vehicle is a HIVLP. | 05-05-2016 |
20160122759 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES - Methods, kits and devices for dosing a subject to reduce a hypersensitivity response to a lipid-formulated nucleic acid (e.g., RNA) molecule are disclosed. | 05-05-2016 |
20160128942 | SOLVENT EXTRACTION FROM BIODEGRADABLE MICROPARTICLES - Embodiments may include a method for reducing a solvent concentration in a plurality of microparticles. The method may involve contacting a mixture including the plurality of microparticles and the solvent with water to form an aqueous suspension. A first portion of the solvent may dissolve into the water of the aqueous suspension to reduce the solvent concentration in the plurality of microparticles from a first solvent concentration in the mixture to a second solvent concentration in the aqueous suspension. The method may also include transferring the aqueous suspension to a concentration unit that may further reduce the solvent concentration from the second solvent concentration to a third solvent concentration. The method may further include transferring a microparticle concentrate with the third solvent concentration to a washing unit to form an amalgam of washed microparticles with a fourth solvent concentration. The method may also include drying the amalgam of washed microparticles. | 05-12-2016 |
20160128951 | PHARMACEUTICAL COMPOSITIONS OF FINGOLIMOD - The invention relates to a stable pharmaceutical composition comprising fingolimod, a pharmaceutically acceptable salt thereof or a phosphate derivative as an active ingredient and its preparation. | 05-12-2016 |
20160128972 | METHOD FOR PREVENTING INFLUENZA VIRUS INFECTION BY ADMINISTERING A DRY POWDER PHARMACEUTICAL COMPOSITION - A method for preventing an influenza virus infection by administering by inhalation to a patient a pharmaceutically effective amount of a dry powder composition containing | 05-12-2016 |
20160129019 | COMPOSITIONS, METHODS, AND SYSTEMS RELATING TO CONTROLLED CRYSTALLIZATION AND/OR NUCLEATION OF MOLECULAR SPECIES - The present invention generally relates to compositions, methods, and systems relating to controlled crystallization and/or nucleation of a molecular species. In some embodiments, the crystallization and/or nucleation of the molecular species may be controlled by tuning the surface chemistry and/or the morphology of a crystallization substrate. In some embodiments, the molecular species is a small organic molecule (e.g., pharmaceutically active agent). | 05-12-2016 |
20160129074 | SUSPENSIONS OF CYCLOSPORIN A FORM 2 - Disclosed herein are methods of formulating cyclosporin A Form 2. | 05-12-2016 |
20160129133 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY - The present invention provides compositions and methods for immunotherapy, which include shelf-stable pharmaceutical compositions for inducing antigen-specific T cells. Such compositions are employed as components of an artificial antigen presenting cell (aAPC), to provide a patient with complexes for presentation of an antigen (e.g., a tumor antigen) and/or a T cell co-stimulatory molecule. | 05-12-2016 |
20160129152 | CONSISTENT CALCIUM CONTENT BONE ALLOGRAFT SYSTEMS AND METHODS - Embodiments of the present invention provides bone graft compositions, and methods for their use and manufacture. A bone graft composition may include a first amount of non-demineralized cancellous bone. The composition may further include a second amount of demineralized cancellous bone. The composition may also include a third amount of demineralized cortical bone. The non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone may be obtained from the same cadaveric donor. | 05-12-2016 |
20160136093 | ENGINEERED AEROSOL PARTICLES, AND ASSOCIATED METHODS - An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated nanoparticle body member being non-spherical. The fabricated nanoparticle body member is configured to provide at least one of auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time of the fabricated nanoparticle body member. An associated method is also provided. | 05-19-2016 |
20160136095 | METHODS FOR TREATING EPILEPSY OR SEIZURE DISORDERS - Provided herein are methods for treating epilepsy or seizure disorders comprising administering a composition to a subject, the composition comprising an anticonvulsant agent and a biodegradable carrier, wherein the agent is incorporated within the biodegradable carrier. | 05-19-2016 |
20160136098 | ORALLY DISINTEGRATING EXCIPIENT - The present invention is directed to coprocessed excipient particles comprising a cellulosic material such as microcrystalline cellulose in intimate association with silicon dioxide, a disintegrant and a polyol, sugar or a polyol/sugar blend. The excipient particles display good processing and are useful in prepared compressed solid dosage forms that exhibit rapid disintegration (less than about 60 seconds) when placed on the tongue or when tested according USP disintegration testing, while still providing acceptable mouth feel. | 05-19-2016 |
20160136105 | Compositions and Methods for the Delivery of Therapeutics - The present invention provides compositions and methods for the delivery of antivirals to a cell or subject. | 05-19-2016 |
20160136179 | Compositions For Treating Acute, Post-Operative, Or Chronic Pain and Methods of Using the Same - Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising an anticonvulsant agent and a biodegradable carrier, wherein the agent is incorporated within the biodegradable carrier. Methods of treating pain in a subject and kits for producing compositions for treating acute, chronic or post-operative pain in in a subject are also disclosed herein. | 05-19-2016 |
20160136282 | NOVEL FORMULATION OF CILOSTAZOL, A QUINOLINONE-DERIVATIVE USED FOR ALLEVIATING THE SYMPTOM OF INTERMITTENT CLAUDICATION IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE - A pharmaceutical composition in solid form containing particulate cilostazol or a salt thereof, a cellulose, a diluent, and a lubricant. The pharmaceutical composition features an in vivo plasma profile for cilostazol of C | 05-19-2016 |
20160136291 | POLYMERS FOR DELIVERY OF FACTOR VIII AND/OR FACTOR IX - In some aspects, a composition comprising a pH-sensitive crosslinked copolymer of methacrylic acid and poly(ethylene glycol) monomethyl ether methacrylate and a therapeutic protein is provided. In some embodiments, the therapeutic protein is a high molecular weight protein such as factor VIII or factor IX. In some embodiments, the composition is orally administered to a patient to treat a disease or disorder such as, e.g., hemophilia. | 05-19-2016 |
20160143914 | Nanoparticles for Encapsulation and Delivery of Bioactive Compounds and Compositions Thereof - In certain embodiments, this disclosure relates to nanoparticles for drug-delivery of cytotoxic anti-cancer compounds. In certain embodiments, the nanoparticle comprises a maytansinoid and an acetalated polysaccharide-polyethylene glycol conjugate. This disclosure also relates to methods for treatment of infection and cancer are also claimed, wherein a cytotoxic compound is en capsulated in a nanoparticle is degraded at the intended target, but otherwise stable, releasing the cytotoxic compound. Compositions comprising the nanoparticles and cytotoxic drugs are also considered. | 05-26-2016 |
20160143945 | Methods and Treatment for Certain Demyelination and Dysmyelination-Based Disorders and/or Promoting Remyelination - The invention relates to methods and compositions for treating demyelination and/or dysmyelination and/or promoting remyelination of neurons and/or preventing the development of myelin-related diseases by administering to a subject in need thereof an effective amount (either therapeutic or prophylactic) of an elemental gold crystal nanosuspension. | 05-26-2016 |
20160143972 | METHOD AND APPARATUS FOR PREPARING A SOLID FORM OF CANNABINOID - Disclosed is a method of preparing a solid form of a cannabinoid. The solid form of the Cannabinoid may be substantially soluble in an aqueous solution. The method may include dissolving each of a Cannabinoid and one or more emulsifying agents into one or more solvents to obtain one or more combined solutions. Further, the method may include separating the one or more solvents from the one or more combined solutions to obtain the solid form of the cannabinoid. | 05-26-2016 |
20160143979 | Long Pepper Extract an Effective Anticancer Treatment - In a preferred embodiment, there is provided a method for preparing a medicament for the treatment or prevention of a cancer, the method comprising: grinding a | 05-26-2016 |
20160144021 | Vaccine Composition And Method Of Use - Described herein is a vaccine composition and methods of use. In one embodiment, the vaccine composition includes RSV-F protein in combination with an adjuvant. In a more particular embodiment, the vaccine composition includes RSV soluble F protein in combination with a lipid toll-like receptor (TLR) agonist. In a more particular embodiment, the adjuvant comprises Glucopyraonsyl Lipid A (GLA). In a further embodiment, the adjuvant comprises GLA in a stable oil-in-water emulsion (GLA-SE). | 05-26-2016 |
20160150775 | BAIT COMPOSITIONS AND METHODS FOR CONTROLLING A PEST BY PHYSICAL EFFECTS | 06-02-2016 |
20160151396 | PHARMACEUTICAL COMPOSITION OF DOXYCYCLINE WITH REDUCED FOOD EFFECT | 06-02-2016 |
20160151397 | DOXYCYCLINE COMPOSITION | 06-02-2016 |
20160151510 | PROTEINS AND PROTEIN CONJUGATES WITH INCREASED HYDROPHOBICITY | 06-02-2016 |
20160158216 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF - The subject invention provides a mixture of crystalline laquinimod sodium particles, wherein (i) 90% or more of the total amount by volume of the laquinimod sodium particles have a size of 40 microns or less or (ii) 50% or more of the total amount by volume of the laquinimod sodium particle have a size of 15 microns or less, and wherein:
| 06-09-2016 |
20160158365 | METHODS AND COMPOSITIONS FOR TREATING RECURRENT CANCER - The present invention provides methods of treating recurrent cancer (such as recurrent ovarian, peritoneal, or fallopian tube cancer) in an individual, comprising administering to the individual an effective amount of a composition (such as Nab-paclitaxel or Abraxane®) comprising nanoparticles comprising a taxane and a carrier protein. | 06-09-2016 |
20160158382 | AGENT FOR THE TREATMENT AND PREVENTION OF SLEEP DISORDERS - The invention relates to the fields of pharmaceutics and medicine and describes an agent for the treatment and prevention of sleep disorders, wherein a conjugate of glycine immobilized on detonation nanodiamond particles 2-10 nm in size comprises 21±3 wt. % glycine. Said preparation improves the outcome of pharmacotherapy and prevention of sleep disorders, in particular, insomnia, and leads to the creation of a greater number of effective and safe sedative-hypnotic medications. | 06-09-2016 |
20160159954 | POLYDENDRONS - A method of preparing a pH-responsive non-gelled branched vinyl polymer scaffold carrying dendrons, comprising the living or controlled polymerization of a mono functional vinyl monomer and a difunctional vinyl monomer, using a dendron initiator. | 06-09-2016 |
20160166551 | Solid dispersions comprising tacrolimus | 06-16-2016 |
20160166599 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, CONTAINING ADENOSINE N1-OXIDE AS AN EFFECTIVE INGREDIENT | 06-16-2016 |
20160166654 | COLLAGEN-TARGETED NANOPARTICLES | 06-16-2016 |
20160166655 | HEMOSTATIC COMPOSITIONS | 06-16-2016 |
20160166664 | COMPOSITIONS AND METHODS FOR INDUCTION OF ANTIGEN-SPECIFIC TOLERANCE | 06-16-2016 |
20160166694 | PHARMACEUTICAL COMPOSITION, METHOD OF PREPARATION AND METHODS OF TREATING ACHES/PAINS | 06-16-2016 |
20160168228 | GENERATION OF HEMOGLOBIN-BASED OXYGEN CARRIERS USING ELASTIN-LIKE POLYPEPTIDES | 06-16-2016 |
20160168349 | Microparticles having a Multimodal Pore Distribution | 06-16-2016 |
20160174554 | COMPOSTION AND METHOD FOR THE CONTROL OF PHYTO-PARASITIC NEMATODES | 06-23-2016 |
20160175252 | OXIDIZED CELLULOSE MICROSPHERES | 06-23-2016 |
20160175276 | NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME | 06-23-2016 |
20160175298 | OXYCODONE DOSAGE FORMS | 06-23-2016 |
20160175313 | ENTECAVIR MICROSPHERES AND PHARMACEUTICAL COMPOSITION FOR PARENTERAL ADMINISTRATION CONTAINING SAME | 06-23-2016 |
20160175317 | PHARMACEUTICAL COMPOSITION COMPRISING BRINZOLAMIDE | 06-23-2016 |
20160175342 | CONTINUOUS RELEASE COMPOSITIONS MADE FROM HYALURONIC ACID, AND THERAPEUTIC APPLICATIONS OF SAME | 06-23-2016 |
20160175346 | PHARMACEUTICAL COMPOSITIONS FOR TREATING HYPERKALEMIA | 06-23-2016 |
20160175355 | CURABLE CALCIUM PHOSPHATE COMPOSITION FOR BIOLOGICAL HARD TISSUE REPAIR, BONE REPAIR MATERIAL, AND VARIOUS DENTAL MATERIALS | 06-23-2016 |
20160175432 | AN OIL-IN-WATER EMULSION CONTAINING NO SURFACTANT AND USE THEREOF | 06-23-2016 |
20160175482 | COMPOSITION AND DELIVERY SYSTEM | 06-23-2016 |
20160176986 | HIGH-CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS | 06-23-2016 |
20160184230 | MELT-PROCESSED POLYMERIC CELLULAR DOSAGE FORM - Presented herein are polymeric cellular dosage forms exhibiting improved immediate release properties, while maintaining high uniformity and satisfactory mechanical properties (e.g., to permit necessary handling). An exfoliating polymeric cellular dosage form is described herein that can be cost-effectively manufactured via batch or even non-batch (continuous or semi-continuous) melt processing. The solid dosage forms have a unique cellular microstructure featuring a number of open, interconnected cells. The cell walls contain the active ingredient(s) as well as an excipient that swells in the presence of a physiological fluid such as gastrointestinal fluid and/or saliva under physiological conditions. | 06-30-2016 |
20160184244 | Iron Chelators and Use Thereof for Reducing Transplant Failure During Rejection Episodes - Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. is topically applied to the surface of tissues during episodes of graft rejection. | 06-30-2016 |
20160184296 | COMPOSITIONS COMPRISING BUPRENORPHINE - This disclosure relates to a buprenorphine sustained release delivery system for treatment of conditions ameliorated by buprenorphine compounds. The sustained release delivery system includes a flowable composition containing a suspension of buprenorphine, a metabolite, or a prodrug thereof. | 06-30-2016 |
20160193118 | DENTINAL TUBULE SEALING MATERIAL | 07-07-2016 |
20160193188 | METHODS AND COMPOSITIONS FOR INCREASING THE EFFECTIVENESS OF ANTIVIRAL AGENTS | 07-07-2016 |
20160193249 | TREATMENT OF INFLAMMATORY DISEASES BY CARBON MATERIALS | 07-07-2016 |
20160193253 | METHODS AND MATERIALS FOR TREATING LUNG DISORDERS | 07-07-2016 |
20160193301 | Eye Drop Formulation | 07-07-2016 |
20160193307 | METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS | 07-07-2016 |
20160193342 | Modified Hyaluronic Acid Polymer Compositions and Related Methods | 07-07-2016 |
20160198755 | DRINKING WATER FORMULATION AND METHOD AND ARTICLE RELATING TO SAME | 07-14-2016 |
20160199301 | MICRONIZED AMOXICILLIN | 07-14-2016 |
20160199386 | METHODS OF TREATING THYROID EYE DISEASE | 07-14-2016 |
20160250146 | Hydrophobic Drug-Delivery Material, Method for Manufacturing Thereof and Methods for Delivery of a Drug-Delivery Composition | 09-01-2016 |
20160250150 | CALCIUM CARBONATE GRANULATION | 09-01-2016 |
20160250152 | Nanogel-Mediated Drug Delivery | 09-01-2016 |
20160250159 | COMPOSITION, USE THEREOF, AND METHODS OF MANUFACTURING | 09-01-2016 |
20160250222 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | 09-01-2016 |
20160250297 | Diketopiperazine salts for drug delivery and related methods | 09-01-2016 |
20160250378 | Spray-On Burn Dressing | 09-01-2016 |
20160374938 | TOPICAL WOUND TREATMENT METHOD AND COMPOSITION - A topical wound treatment composition comprises a hydrogen peroxide generator; alkaline powder; not more than 5 percent by weight of water; additional topical active agent if desired, and emollient (preferably hygroscopic emollient) to balance. When topically applied to a wound and water from the surrounding environment diffuses into the composition, the hydrogen peroxide generator and/or the alkaline compound diffuse into one another, causing a chemical reaction that generates treatment-effective amounts of oxygen to occur. The oxygen can then diffuse out of the composition and aid in wound treatment or healing. | 12-29-2016 |
20160374943 | PROCESS FOR PRODUCING INORGANIC PARTICULATE MATERIAL - The present invention relates to a process for producing inorganic particulate material, the material obtainable by such process, a modified release delivery system comprising the material and the use of the material for the administration of a bioactive agent. | 12-29-2016 |
20160374984 | NANOPARTICLE ISOFLAVONE COMPOSITIONS & METHODS OF MAKING AND USING THE SAME - The present invention is directed to formulations of genistein and methods for making and using the same. In particular embodiments, the formulations described herein include suspension formulations of nanoparticulate genistein. | 12-29-2016 |
20160375034 | BISMUTH-THIOLS AS ANTISEPTICS FOR BIOMEDICAL USES, INCLUDING TREATMENT OF BACTERIAL BIOFILMS AND OTHER USES - Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections. | 12-29-2016 |
20160375054 | Microporous Zirconium Silicate for the Treatment of Hyperkalemia - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. These compositions are also useful in the treatment of chronic kidney disease, coronary vascular disease, diabetes mellitus, and transplant rejection. | 12-29-2016 |
20160375063 | COMPOSITIONS AND METHODS FOR TRANSPLANTATION OF COLON MICROBIOTA - The present invention provides compositions that include an extract of human feces, and methods for using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease, pathological condition, and/or iatrogenic condition of the colon. | 12-29-2016 |
20160375064 | AMNION DERIVED THERAPEUTIC COMPOSITIONS AND METHODS OF USE - Therapeutic compositions are described for the treatment of a variety of conditions including heart, eye, lungs, organs, joints, dermal, nerve, and the like. s, A therapeutic composition may be a fluid comprising amniotic fluid or micronized amniotic particles. A therapeutic composite may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. In another embodiment, the therapeutic composite is a mixture of micronized amniotic membrane particles combined with an amniotic rich stem cell fluid. An amniotic rich or concentrated stem cell fluid comprises at least 0.5×10 | 12-29-2016 |
20160375132 | HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF - The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies. | 12-29-2016 |
20160375134 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 12-29-2016 |
20170231934 | COMPOSITIONS INCLUDING ANTHOCYANIN OR ANTHOCYANIDIN METABOLITES FOR THE PREVENTION OR TREATMENT OF ARTICULAR CARTILAGE-ASSOCIATED CONDITIONS | 08-17-2017 |
20170231937 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA, A DOPAMINE DECARBOXYLASE INHIBITOR AND A COMT INHIBITOR AND METHOD OF ADMINISTRATION THEREOF | 08-17-2017 |
20170231981 | COMPOSITIONS OF MULTIPLE ARIPIPRAZOLE PRODRUGS | 08-17-2017 |
20170232054 | Method for economically producing stable and bio-available glutathione | 08-17-2017 |
20170232056 | PHARMACEUTICAL COMPOSITIONS OF WATER SOLUBLE PEPTIDES WITH POOR SOLUBILITY IN ISOTONIC CONDITIONS AND METHODS FOR THEIR USE | 08-17-2017 |
20180021259 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | 01-25-2018 |
20180021261 | Nanoemulsions | 01-25-2018 |
20180021265 | COMPOSITIONS AND METHODS FOR NANOPARTICLE-BASED DRUG DELIVERY AND IMAGING | 01-25-2018 |
20180021271 | Pharmaceutical Compositions | 01-25-2018 |
20180021290 | DIACEREIN OR RHEIN TOPICAL FORMULATIONS AND USES THEREOF | 01-25-2018 |
20180021304 | COMPOSITION COMPRISING CEBRANOPADOL IN A DISSOLVED FORM | 01-25-2018 |
20180021374 | Antibacterial Clay Compositions for Use as a Topical Ointment | 01-25-2018 |
20180021454 | TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF | 01-25-2018 |
20180022615 | TOTALLY-MESOPOROUS ZIRCONIA NANOPARTICLES, USE AND METHOD FOR PRODUCING THEREOF | 01-25-2018 |
20180026186 | NANOPARTICLE WITH PLURAL FUNCTIONALITIES, AND METHOD OF FORMING THE NANOPARTICLE | 01-25-2018 |
20190142055 | GRANULES | 05-16-2019 |
20190142741 | A NOVEL PHARMACEUTICAL COMPOSITION OF A LIPID LOWERING COMPOUND | 05-16-2019 |
20190142744 | NUCLEIC ACID NANOCAGES, COMPOSITIONS, AND USES THEREOF | 05-16-2019 |
20190142758 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | 05-16-2019 |
20190142866 | POROUS CARBON PARTICLES FOR USE IN THE TREATMENT OR PREVENTION OF LIVER DISEASE | 05-16-2019 |
20190142923 | Controlled Release Vaccines and Methods of Treating Brucella Diseases and Disorders | 05-16-2019 |
20190142925 | HPV PARTICLES AND USES THEREOF | 05-16-2019 |
20190143295 | COMPOSITION | 05-16-2019 |
20220133708 | INHALABLE SUSTAINED THERAPEUTIC FORMULATIONS - The present invention is based, in part, on the unexpected discovery that particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that comprise a phospholipid and a sufficient amount of leucine can produce sustained effect of the agent. Specifically, particles for pulmonary delivery of a therapeutic, prophylactic or diagnostic agent that contain a phospholipid or combination of phospholipids, wherein the phospholipid or combination of phospholipids is present in the particles in an amount of about 1 to 46 weight percent; and leucine, wherein leucine is present in the particles in an amount of at least 46 weight percent, can contribute to sustained effect of the agent. Particles that comprise at least 46 weight percent leucine but that do not contain phospholipids do not exhibit these same sustained effect properties. | 05-05-2022 |
20220133905 | METHODS FOR ASSEMBLING SCAVENGING PARTICLES - The disclosure provides, methods for preparing scavenging particles, as well as methods for attaching capture agents to the particles. The disclosure further provides compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles that specifically bind a target, such as a soluble biomolecule or a biomolecule on the surface of a pathogen, to inhibit the target (or pathogen) from interacting with other molecules or cells. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful. | 05-05-2022 |